<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Signal Transduct Target Ther</journal-id><journal-id journal-id-type="iso-abbrev">Signal Transduct Target Ther</journal-id><journal-id journal-id-type="pmc-domain-id">3308</journal-id><journal-id journal-id-type="pmc-domain">sigtrans</journal-id><journal-title-group><journal-title>Signal Transduction and Targeted Therapy</journal-title></journal-title-group><issn pub-type="ppub">2095-9907</issn><issn pub-type="epub">2059-3635</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11564800</article-id><article-id pub-id-type="pmcid-ver">PMC11564800.1</article-id><article-id pub-id-type="pmcaid">11564800</article-id><article-id pub-id-type="pmcaiid">11564800</article-id><article-id pub-id-type="pmid">39543114</article-id><article-id pub-id-type="doi">10.1038/s41392-024-02002-z</article-id><article-id pub-id-type="publisher-id">2002</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>Progress and prospects of mRNA-based drugs in pre-clinical and clinical applications</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Shi</surname><given-names initials="Y">Yingying</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Shi</surname><given-names initials="M">Meixing</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-3676-9183</contrib-id><name name-style="western"><surname>Wang</surname><given-names initials="Y">Yi</given-names></name><address><email>zjuwangyi@zju.edu.cn</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-7114-6299</contrib-id><name name-style="western"><surname>You</surname><given-names initials="J">Jian</given-names></name><address><email>youjiandoc@zju.edu.cn</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00a2xv884</institution-id><institution-id institution-id-type="GRID">grid.13402.34</institution-id><institution-id institution-id-type="ISNI">0000 0004 1759 700X</institution-id><institution>College of Pharmaceutical Sciences, </institution><institution>Zhejiang University, </institution></institution-wrap>866 Yuhangtang Road, Hangzhou, Zhejiang P. R. China </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00325dg83</institution-id><institution>State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, </institution></institution-wrap>79 Qingchun Road, Shangcheng District, Hangzhou, Zhejiang P. R. China </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00a2xv884</institution-id><institution-id institution-id-type="GRID">grid.13402.34</institution-id><institution-id institution-id-type="ISNI">0000 0004 1759 700X</institution-id><institution>The First Affiliated Hospital, College of Medicine, </institution><institution>Zhejiang University, </institution></institution-wrap>79 QingChun Road, Hangzhou, Zhejiang P. R. China </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00a2xv884</institution-id><institution-id institution-id-type="GRID">grid.13402.34</institution-id><institution-id institution-id-type="ISNI">0000 0004 1759 700X</institution-id><institution>Jinhua Institute of Zhejiang University, </institution></institution-wrap>498 Yiwu Street, Jinhua, Zhejiang P. R. China </aff></contrib-group><pub-date pub-type="epub"><day>14</day><month>11</month><year>2024</year></pub-date><pub-date pub-type="collection"><year>2024</year></pub-date><volume>9</volume><issue-id pub-id-type="pmc-issue-id">451959</issue-id><elocation-id>322</elocation-id><history><date date-type="received"><day>2</day><month>6</month><year>2024</year></date><date date-type="rev-recd"><day>3</day><month>9</month><year>2024</year></date><date date-type="accepted"><day>26</day><month>9</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>14</day><month>11</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>15</day><month>11</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-11-16 00:25:15.860"><day>16</day><month>11</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2024</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article&#8217;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#8217;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="41392_2024_Article_2002.pdf"/><abstract id="Abs1"><p id="Par1">In the last decade, messenger ribonucleic acid (mRNA)-based drugs have gained great interest in both immunotherapy and non-immunogenic applications. This surge in interest can be largely attributed to the demonstration of distinct advantages offered by various mRNA molecules, alongside the rapid advancements in nucleic acid delivery systems. It is noteworthy that the immunogenicity of mRNA drugs presents a double-edged sword. In the context of immunotherapy, extra supplementation of adjuvant is generally required for induction of robust immune responses. Conversely, in non-immunotherapeutic scenarios, immune activation is unwanted considering the host tolerability and high expression demand for mRNA-encoded functional proteins. Herein, mainly focused on the linear non-replicating mRNA, we overview the preclinical and clinical progress and prospects of mRNA medicines encompassing vaccines and other therapeutics. We also highlight the importance of focusing on the host-specific variations, including age, gender, pathological condition, and concurrent medication of individual patient, for maximized efficacy and safety upon mRNA administration. Furthermore, we deliberate on the potential challenges that mRNA drugs may encounter in the realm of disease treatment, the current endeavors of improvement, as well as the application prospects for future advancements. Overall, this review aims to present a comprehensive understanding of mRNA-based therapies while illuminating the prospective development and clinical application of mRNA drugs.</p></abstract><kwd-group kwd-group-type="npg-subject"><title>Subject terms</title><kwd>Nucleic-acid therapeutics</kwd><kwd>Preclinical research</kwd><kwd>Translational research</kwd><kwd>Genetics research</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China (National Science Foundation of China)</institution></institution-wrap></funding-source><award-id>82273862</award-id><award-id>82404520</award-id><principal-award-recipient><name name-style="western"><surname>Shi</surname><given-names>Yingying</given-names></name><name name-style="western"><surname>You</surname><given-names>Jian</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution>National Key R&amp;D Program of China (2023YFC340200)</institution></funding-source></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/501100002858</institution-id><institution>China Postdoctoral Science Foundation</institution></institution-wrap></funding-source><award-id>2024M752834</award-id><principal-award-recipient><name name-style="western"><surname>Shi</surname><given-names>Yingying</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution>China National Postdoctoral Program for Innovative Talents (BX20230321)</institution></funding-source></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; West China Hospital, Sichuan University 2024</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p id="Par2">Recently, messenger ribonucleic acid (mRNA) therapy represents a novel approach for treating a wide range of diseases, encompassing both immune-related and non-immune conditions. Amidst the COVID-19 pandemic, mRNA vaccines have achieved remarkable advancements, owing to the unwavering dedication of numerous scientists who have been at the forefront of mRNA research for decades.</p><p id="Par3">However, despite a plethora of preclinical studies conducted, successful translation of mRNA medicines into clinical applications remains limited, probably due to the suboptimal design and administration of mRNA drugs to patients with specific physiological and pathological conditions. Distinct characteristics of mRNA drugs are demanded in different therapeutic indications.<sup><xref ref-type="bibr" rid="CR1">1</xref></sup> Specifically, in immunogenic applications that include cancer immunotherapies and infectious disease vaccines, appropriate incorporation of adjuvants is required for eliciting augmented host immune responses. In contrast, in non-immunotherapies encompassing protein replacement/supplementation therapy, regenerative medicine therapy, and genetic editing, the immunogenicity of mRNA drugs is unfavorable, which may lead to diminished protein expression and even cause adverse reactions. On the other hand, the host individual variations, such as, age, gender, disease and medical history may influence both the efficacy and safety of mRNA medication. For example, compared to healthy adults, immunocompromised patients exhibit inadequate immune responses following initial mRNA vaccine inoculation, where repeated vaccinations are recommended for the establishment of sufficient immune protection.<sup><xref ref-type="bibr" rid="CR2">2</xref></sup> Nevertheless, repeated doses may cause potential risks that exacerbate the pathological burden.<sup><xref ref-type="bibr" rid="CR3">3</xref></sup> To date, there is still a lack of systemic understanding over the fate and outcomes of mRNA drugs in personalized recipient.</p><p id="Par4">In this review, we first summarize the preclinical and clinical applications of mRNA drugs pertaining to immunotherapy and non-immunotherapy, then discuss the impact from patient physiological and pathological characteristics. Finally, we provide insights into the future directions and research priorities of mRNA drugs.</p></sec><sec id="Sec2"><title>Evolution and milestones in mRNA-based drugs</title><sec id="Sec3"><title>Brief history of mRNA drug development</title><p id="Par5">Chronologically (Fig. <xref rid="Fig1" ref-type="fig">1</xref>), mRNA was first discovered by pioneering researches in 1961.<sup><xref ref-type="bibr" rid="CR4">4</xref></sup> However, it was not until 1990 when Wolff et al. successfully expressed proteins by injecting mRNA into the body<sup><xref ref-type="bibr" rid="CR5">5</xref></sup> that mRNA gradually gained recognition as a therapeutic modality.<sup><xref ref-type="bibr" rid="CR1">1</xref></sup> In 1999, mRNA-engineered dendritic cells (DCs) entered clinical trial as antitumor vaccines for the first time (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00004211">NCT00004211</ext-link>).<sup><xref ref-type="bibr" rid="CR6">6</xref>&#8211;<xref ref-type="bibr" rid="CR8">8</xref></sup> In 2004, Weide et al. conducted the initial clinical trial involving the direct injection of protamine-stabilized mRNA into the human body to target metastatic melanoma (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00204607">NCT00204607</ext-link>),<sup><xref ref-type="bibr" rid="CR9">9</xref></sup> wherein the mRNA encoded tumor-associated antigens (TAAs)&#8212;Melan-A, Mage-A1, Mage-A3, Tyrosinase, gp100, and Survivin.<sup><xref ref-type="bibr" rid="CR10">10</xref></sup> In 2005, Karik&#243; et al. demonstrated that RNA could evade immune detection when it was naturally modified with nucleotides such as 5-methylcytosine (m<sup>5</sup>C), 5-methyluridine (m<sup>5</sup>U), <italic toggle="yes">N</italic><sup>6</sup>-methyladenosine (m<sup>6</sup>A), pseudouridine (&#936;), and 2&#8242;-<italic toggle="yes">O</italic>-Methyluridine.<sup><xref ref-type="bibr" rid="CR11">11</xref>,<xref ref-type="bibr" rid="CR12">12</xref></sup> The identification of this approach to mitigate the immunogenicity of mRNA is crucial for broadening the scope of mRNA therapeutics in non-immunological medical fields. In 2013, CureVac conducted an initial evaluation of the safety and immunogenicity of a prophylactic mRNA vaccine coding the rabies virus glycoprotein (CV7201) in a clinical trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02241135">NCT02241135</ext-link>) involving healthy adults.<sup><xref ref-type="bibr" rid="CR13">13</xref></sup> This trial represents the first clinical study utilizing mRNA vaccines to combat infectious diseases.<sup><xref ref-type="bibr" rid="CR12">12</xref></sup> Then, in 2016, the therapeutic potential of mRNA was first unleashed in the field of protein supplementation therapy (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02935712">NCT02935712</ext-link>). Notably, in 2020, two antivirus mRNA vaccines&#8212;mRNA-1273 by Moderna (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04283461">NCT04283461</ext-link>) and BNT162b2 by Pfizer/BioNTech (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04380701">NCT04380701</ext-link>), were quickly approved by the United States (U.S.) Food and Drug Administration (FDA) and put into use during the COVID-19 outbreak, which achieved great success and marked a significant milestone in emergency response against infectious diseases.<sup><xref ref-type="bibr" rid="CR14">14</xref></sup> Since then, mRNA drugs have experienced an explosion of development.<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Chronological development of mRNA drugs. Yellow box, common events of mRNA drugs; green box, mRNA-based non-immunotherapy; red box, mRNA-based immunotherapy. From 1961 to 1990: mRNA discovery and the maturation of IVT mRNA technology, including the discovery of mRNA,<sup><xref ref-type="bibr" rid="CR4">4</xref></sup> purified mRNA could be translated into proteins in the mammalian cell-free system,<sup><xref ref-type="bibr" rid="CR518">518</xref></sup> discovery of mRNA cap,<sup><xref ref-type="bibr" rid="CR519">519</xref></sup> discovery of single-stranded circular RNA,<sup><xref ref-type="bibr" rid="CR520">520</xref></sup> cap analog commercialized,<sup><xref ref-type="bibr" rid="CR18">18</xref></sup> synthetic mRNA was first produced in the laboratory by IVT,<sup><xref ref-type="bibr" rid="CR374">374</xref></sup> T7 RNA polymerases commercialized.<sup><xref ref-type="bibr" rid="CR335">335</xref></sup> From 1990 to 2019: the exploration of mRNA vaccines, particularly for cancer therapy, including IVT mRNA injected into the mouse skeletal muscle achieved protein translation,<sup><xref ref-type="bibr" rid="CR5">5</xref></sup> vasopressin mRNA injected into the hypothalamus of Brattleboro rats was found to successfully express vasopressin,<sup><xref ref-type="bibr" rid="CR357">357</xref></sup> mRNA vaccine encoding tumor antigen in mice,<sup><xref ref-type="bibr" rid="CR171">171</xref></sup> first clinical trial of mRNA-engineered DCs vaccine strategy,<sup><xref ref-type="bibr" rid="CR6">6</xref>&#8211;<xref ref-type="bibr" rid="CR8">8</xref></sup> first DC vaccine with autologous tumor mRNA was used to treat clinical Phase I/II of advanced malignant melanoma trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01278940">NCT01278940</ext-link>),<sup><xref ref-type="bibr" rid="CR332">332</xref>,<xref ref-type="bibr" rid="CR333">333</xref></sup> first attempt was made to inject an mRNA vaccine directly into humans to fight tumors (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00204607">NCT00204607</ext-link>),<sup><xref ref-type="bibr" rid="CR9">9</xref>,<xref ref-type="bibr" rid="CR10">10</xref></sup> nucleotide-modified RNA reduced the potential for immune stimulation,<sup><xref ref-type="bibr" rid="CR11">11</xref></sup> first personalized cancer mRNA vaccine in clinical trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02035956">NCT02035956</ext-link>),<sup><xref ref-type="bibr" rid="CR521">521</xref>,<xref ref-type="bibr" rid="CR522">522</xref></sup> first clinical trial of prophylactic mRNA vaccine (CV7201) against rabies (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02241135">NCT02241135</ext-link>),<sup><xref ref-type="bibr" rid="CR13">13</xref></sup> NIH called for gender to be included in biological variables in preclinical and clinical studies,<sup><xref ref-type="bibr" rid="CR435">435</xref></sup> first mRNA (AZD8601) therapy encoding VEGF-A to enter the clinic (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02935712">NCT02935712</ext-link>),<sup><xref ref-type="bibr" rid="CR523">523</xref></sup> first clinical trial of mRNA-encoding immunostimulant (mRNA-2416, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03323398">NCT03323398</ext-link>).<sup><xref ref-type="bibr" rid="CR524">524</xref></sup> From 2019 to the present: rapid development of mRNA-based therapeutics, including two mRNA vaccines (mRNA-1273<sup><xref ref-type="bibr" rid="CR486">486</xref></sup> and BNT162b2) have been approved for emergency use by the FDA,<sup><xref ref-type="bibr" rid="CR123">123</xref>,<xref ref-type="bibr" rid="CR124">124</xref></sup> first to use unmodified mRNA in regenerative medicine,<sup><xref ref-type="bibr" rid="CR370">370</xref></sup> forty-three COVID-19 mRNA vaccines were in clinical trials,<sup><xref ref-type="bibr" rid="CR125">125</xref></sup> first combining mRNA therapy with photodynamic therapy to fight tumors,<sup><xref ref-type="bibr" rid="CR290">290</xref></sup> Phase III trial of mRNA-4157 plus Pembrolizumab in the treatment of melanoma.<sup><xref ref-type="bibr" rid="CR501">501</xref></sup> IVT in vitro transcription, NIH the National Institutes of Health, DCs dendritic cells, FDA the Food and Drug Administration. The graphic is created with Adobe Illustrator</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e438" position="float" orientation="portrait" xlink:href="41392_2024_2002_Fig1_HTML.jpg"/></fig></p></sec><sec id="Sec4"><title>Classification, advantages, and limitations of mRNA drugs</title><p id="Par6">mRNA, a single-stranded ribonucleic acid, acts as a transient carrier for the genetic information transcribed from DNA to guide protein synthesis.<sup><xref ref-type="bibr" rid="CR15">15</xref></sup> The execution of mRNA function in eukaryotes involves multiple stages, including transcription, post-transcriptional processing, intracellular transport, and translation.<sup><xref ref-type="bibr" rid="CR16">16</xref></sup> Prior to the maturation of mRNA, precursor messenger RNA (pre-mRNA) must undergo three essential processing steps: addition of a 5&#8217; cap structure, cleavage mediated by numerous protein factors, and 3&#8217;-end processing which includes adding a polyadenosine [poly(A)] tail. These pre-mRNA processing steps are crucial for the generation of mature mRNA.<sup><xref ref-type="bibr" rid="CR17">17</xref></sup> With the commercialization of Cap analogs and T7 RNA polymerase in 1983 and 1985, respectively, the technology for in vitro transcription (IVT) of mRNA has steadily matured.<sup><xref ref-type="bibr" rid="CR18">18</xref></sup> The structural characteristics of IVT mRNA closely resemble those of endogenous mRNA found in natural eukaryotic cells.<sup><xref ref-type="bibr" rid="CR19">19</xref></sup></p><p id="Par7">The linear non-replicating mRNA, representative of IVT mRNA, is composed of five segments in the 5&#8217; to 3&#8217; direction: the 5&#8217; cap, the 5&#8217; untranslated region (UTR), an open reading frame (ORF) encoding the target protein, the 3&#8217; UTR, and a poly(A) tail.<sup><xref ref-type="bibr" rid="CR20">20</xref>&#8211;<xref ref-type="bibr" rid="CR22">22</xref></sup> The ORF functions as the coding sequence for protein translation and is an indispensable element of IVT mRNA. The UTR, although non-coding, plays a pivotal role in ribosome recruitment and successful mRNA translation. Furthermore, the 5&#8217; cap and 3&#8217; Poly(A) tail structures significantly contribute to enhancing mRNA stability and translation efficiency.<sup><xref ref-type="bibr" rid="CR23">23</xref>,<xref ref-type="bibr" rid="CR24">24</xref></sup> One of the key attributes of mRNA is its highly customizable nature. The optimization of mRNA involves nucleotide sequence refinement, chemical modifications,<sup><xref ref-type="bibr" rid="CR25">25</xref></sup> and mRNA purification. Various factors must be taken into consideration during mRNA design, including the influence of nucleotide sequence on RNA folding, immunogenicity, enhancement of mRNA stability, and maximization of the expression of the target protein.<sup><xref ref-type="bibr" rid="CR26">26</xref>,<xref ref-type="bibr" rid="CR27">27</xref></sup> The immunogenicity of exogenous mRNA elicits an innate immune response, leading to the suppression of exogenous mRNA translation in the body.<sup><xref ref-type="bibr" rid="CR28">28</xref></sup> Substituting uridine with modified nucleotides such as m<sup>5</sup>U and &#936;, which are not recognized by pattern-recognition receptors, can mitigate the immunogenicity of mRNA.<sup><xref ref-type="bibr" rid="CR26">26</xref></sup> In addition, several studies suggest that &#936; modification may enhance the stability of transcripts.<sup><xref ref-type="bibr" rid="CR29">29</xref></sup> Nevertheless, there have been investigations suggesting that specific circumstances may disrupt the stability of mRNA.<sup><xref ref-type="bibr" rid="CR30">30</xref></sup> It is noteworthy that there are currently more than 170 identified types of RNA modifications.<sup><xref ref-type="bibr" rid="CR31">31</xref></sup> Exploring the optimization of mRNA holds substantial research potential.<sup><xref ref-type="bibr" rid="CR32">32</xref></sup></p><p id="Par8">Compared to recombinant protein drugs, mRNA drugs have a shorter production cycle<sup><xref ref-type="bibr" rid="CR33">33</xref></sup> and are not limited to short peptide sequences.<sup><xref ref-type="bibr" rid="CR34">34</xref></sup> mRNA vaccines can easily deliver numerous tumor antigen fragments simultaneously, thereby increasing the diversity of antigenic epitopes.<sup><xref ref-type="bibr" rid="CR33">33</xref></sup> In contrast to DNA vaccines, mRNA vaccines circumvent the need to enter the nucleus, thereby obviating the potential for gene insertion and subsequent mutations.<sup><xref ref-type="bibr" rid="CR33">33</xref>,<xref ref-type="bibr" rid="CR35">35</xref></sup> In addition, mRNA exhibits modifiable immunogenicity<sup><xref ref-type="bibr" rid="CR36">36</xref></sup> and can be effectively potentiated by adjuvants to efficiently elicit humoral and cellular immunity.<sup><xref ref-type="bibr" rid="CR35">35</xref></sup> Moreover, mRNA vaccines have the potential to become personalized therapeutic drugs, in which they have application prospects for targeting specific tumors<sup><xref ref-type="bibr" rid="CR37">37</xref></sup> and treating rare diseases. Nevertheless, mRNA is susceptible to degradation by nucleases<sup><xref ref-type="bibr" rid="CR33">33</xref></sup> and suffers from thermal instability, necessitating a cold-chain infrastructure for storage and transportation, thereby increasing the overall cost.<sup><xref ref-type="bibr" rid="CR38">38</xref></sup> Furthermore, mRNA, being a large polyanionic structure, presents challenges in traversing cell and tissue barriers.<sup><xref ref-type="bibr" rid="CR33">33</xref></sup> Overcoming these limitations necessitates the development of appropriate delivery strategies.</p><p id="Par9">Two innovative mRNA structures have been developed for specific purposes, namely self-amplifying mRNA (saRNA)<sup><xref ref-type="bibr" rid="CR39">39</xref></sup> and circular mRNA (circRNA).<sup><xref ref-type="bibr" rid="CR40">40</xref></sup> saRNA can confer equivalent vaccine protection effects to those of non-replicating mRNA at a reduced dosage.<sup><xref ref-type="bibr" rid="CR41">41</xref>&#8211;<xref ref-type="bibr" rid="CR43">43</xref></sup> The primary distinction between saRNA and linear non-replicating mRNA is that saRNA contains additional self-amplifying replicon genes that originate from multiple positive-strand RNA viruses,<sup><xref ref-type="bibr" rid="CR44">44</xref>&#8211;<xref ref-type="bibr" rid="CR46">46</xref></sup> resulting in a larger molecular size.<sup><xref ref-type="bibr" rid="CR47">47</xref></sup> Owing to the extensive anionic structure of saRNA, its delivery vehicle often comprises polycations. Nevertheless, the use of such delivery vectors may lead to high charge density that induces cytotoxicity. Hence, it is imperative to optimize a suitable delivery method for enhancing both the loading efficiency and the overall safety of saRNA drugs. Dastgerdi et al.<sup><xref ref-type="bibr" rid="CR48">48</xref></sup> demonstrated that optimizing the ratio of polyanions, such as &#947;-polyglutamic acid, to polycations in RNA formulations is an effective approach for improving the delivery efficiency and safety of saRNA. Furthermore, given the continuous generation of new mRNA within the body by saRNA vaccines, it is important to remain vigilant about safety concerns such as the potential for severe systemic or local inflammatory responses.<sup><xref ref-type="bibr" rid="CR49">49</xref></sup> CircRNA is a class of covalently closed-loop single-stranded RNA molecule that is not initiated by the classical translation pathway due to the absence of a 5&#8217; cap and a 3&#8217; tail.<sup><xref ref-type="bibr" rid="CR50">50</xref></sup> The internal loading of the ribosome may be the sole means for its translation to commence.<sup><xref ref-type="bibr" rid="CR51">51</xref></sup> The capability to encode proteins without the classical pathway is granted by circRNA&#8217;s ability to translate without a 5&#8217; cap.<sup><xref ref-type="bibr" rid="CR50">50</xref></sup> Meanwhile, circRNA exhibits better structural and biochemical stability due to its inherent resistance against exonucleases-mediated degradation.<sup><xref ref-type="bibr" rid="CR52">52</xref></sup> Therefore, the average half-life of circRNA in cells significantly exceeds that of linear mRNA.<sup><xref ref-type="bibr" rid="CR53">53</xref></sup> Hence, cirRNA has the capacity to extend antigen production and sustain enduring immune responses.<sup><xref ref-type="bibr" rid="CR54">54</xref></sup> Nevertheless, despite the more persistent and robust expression of encoded proteins, circRNA seems to perform poorly in targeted delivery.<sup><xref ref-type="bibr" rid="CR55">55</xref></sup> At present, non-replicating IVT mRNA, which has been well-established in production and quality control, is primarily used in preclinical and clinical practice.</p></sec><sec id="Sec5"><title>Delivery system and preparation strategy of mRNA drugs</title><p id="Par10">Due to the susceptibility of IVT mRNA to degradation by nucleases, it is crucial to select an appropriate delivery vehicle to safeguard the integrity of the mRNA prior to its intracellular delivery.<sup><xref ref-type="bibr" rid="CR56">56</xref></sup> An innovation initially not intended for mRNA but crucial for mRNA drug development is the advancement of delivery vectors, particularly the development of lipid nanoparticles (LNPs). At present, mRNA delivery systems can be classified into viral and nonviral systems.<sup><xref ref-type="bibr" rid="CR57">57</xref></sup></p><p id="Par11">Virus-related delivery systems include both viruses and virus-like particles (VLPs).<sup><xref ref-type="bibr" rid="CR58">58</xref></sup> Viral vectors encompass adenoviruses, adeno-associated viruses (AAV), lentiviruses, herpes simplex virus (HSV), and Sendai virus.<sup><xref ref-type="bibr" rid="CR59">59</xref>,<xref ref-type="bibr" rid="CR60">60</xref></sup> The formation of VLPs is facilitated by the structural proteins of a virus, which are viral components devoid of genetic material.<sup><xref ref-type="bibr" rid="CR61">61</xref></sup> In comparison to nonviral vectors, viral vectors possess the inherent advantage of efficiently entering cells and delivering nucleic acid drugs.<sup><xref ref-type="bibr" rid="CR58">58</xref></sup> This approach holds significant promise for vaccine development.<sup><xref ref-type="bibr" rid="CR62">62</xref></sup> Several clinical trials are currently utilizing viral vectors to deliver genetic material for the treatment of diseases. For instance, AAV9-mediated <italic toggle="yes">CLN6</italic> gene therapy (AT-GTX-501) has progressed to clinical stages I/II (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02725580">NCT02725580</ext-link>), and interim findings indicated that AT-GTX-501 demonstrated favorable tolerability and could ameliorate the deterioration in motor and language function among pediatric patients with variant late infantile ceroid lipofuscinosis 6 (vLINCL6).<sup><xref ref-type="bibr" rid="CR63">63</xref></sup> Nevertheless, virus-mediated delivery systems pose potential biosecurity concerns (e.g., tumorgenicity and immunogenicity), exhibit low packaging efficiency, and entail high manufacturing costs.<sup><xref ref-type="bibr" rid="CR59">59</xref></sup> These limitations have driven researchers to investigate alternative delivery methods for mRNA vaccines, such as nonviral delivery systems.<sup><xref ref-type="bibr" rid="CR62">62</xref></sup></p><p id="Par12">Various nonviral delivery vectors, such as LNPs,<sup><xref ref-type="bibr" rid="CR64">64</xref>&#8211;<xref ref-type="bibr" rid="CR68">68</xref></sup> polymeric nanoparticles,<sup><xref ref-type="bibr" rid="CR67">67</xref>,<xref ref-type="bibr" rid="CR69">69</xref>,<xref ref-type="bibr" rid="CR70">70</xref></sup> lipid enveloped hybrid nanoparticles,<sup><xref ref-type="bibr" rid="CR66">66</xref></sup> protein/peptide-based nanoparticles,<sup><xref ref-type="bibr" rid="CR67">67</xref>,<xref ref-type="bibr" rid="CR68">68</xref></sup> lyotropic liquid crystalline lipid nanoparticles (LCNPs),<sup><xref ref-type="bibr" rid="CR71">71</xref>,<xref ref-type="bibr" rid="CR72">72</xref></sup> inorganic nanoparticles,<sup><xref ref-type="bibr" rid="CR65">65</xref></sup> nanoemulsions,<sup><xref ref-type="bibr" rid="CR73">73</xref>,<xref ref-type="bibr" rid="CR74">74</xref></sup> exosomes,<sup><xref ref-type="bibr" rid="CR64">64</xref>,<xref ref-type="bibr" rid="CR75">75</xref></sup> hydrogels,<sup><xref ref-type="bibr" rid="CR76">76</xref>,<xref ref-type="bibr" rid="CR77">77</xref></sup> polymeric nanoparticle gel,<sup><xref ref-type="bibr" rid="CR78">78</xref></sup> and biological membrane-based vesicles,<sup><xref ref-type="bibr" rid="CR79">79</xref></sup> have been developed for efficient and versatile mRNA delivery. Optimizing the route of mRNA drug administration is essential for enhancing therapeutic efficacy, as it can significantly impact the biodistribution of the drug within tissues. Generally, intravenously injected mRNA drugs tend to accumulate in the liver, whereas locally administrated ones often prolong the duration of protein expression at the injection site and deliver sustained therapeutic effects. Subcutaneous and intramuscular injections represent the predominant routes for administering mRNA vaccines.<sup><xref ref-type="bibr" rid="CR80">80</xref></sup> Alternative mRNA drug delivery methods include aerosol inhalation to directly target the lungs,<sup><xref ref-type="bibr" rid="CR81">81</xref>&#8211;<xref ref-type="bibr" rid="CR83">83</xref></sup> eye drops,<sup><xref ref-type="bibr" rid="CR84">84</xref></sup> intravitreal administration, subretinal administration,<sup><xref ref-type="bibr" rid="CR80">80</xref></sup> oral administration,<sup><xref ref-type="bibr" rid="CR85">85</xref>,<xref ref-type="bibr" rid="CR86">86</xref></sup> transcutaneous route,<sup><xref ref-type="bibr" rid="CR87">87</xref></sup> and in utero delivery.<sup><xref ref-type="bibr" rid="CR88">88</xref></sup></p><p id="Par13">Despite the development of various types of delivery vectors in preclinical studies, LNPs remain the established preferred delivery system for mRNA due to its clinical validation.<sup><xref ref-type="bibr" rid="CR89">89</xref></sup> Therefore, a comprehensive understanding of the design strategies employed in LNPs is essential for the effective implementation of mRNA therapies. The current formulation of LNPs for nucleic acid delivery typically comprises four key components: ionizable lipids, helper lipids, cholesterol, and polyethylene glycol (PEG)-lipids,<sup><xref ref-type="bibr" rid="CR90">90</xref>,<xref ref-type="bibr" rid="CR91">91</xref></sup> with the ratio of ~50:10:38.5:1.5&#8201;mol%.<sup><xref ref-type="bibr" rid="CR92">92</xref></sup> Ionizable lipids play a crucial role in encapsulating mRNA and facilitating the successful transfection of mRNA into cells.<sup><xref ref-type="bibr" rid="CR93">93</xref></sup> The incorporation of PEG-lipids serves primarily to evade macrophage phagocytosis and ensure prolonged systemic circulation of LNPs. The inclusion of helper lipids and cholesterol allows for modulation of LNPs rigidity.<sup><xref ref-type="bibr" rid="CR94">94</xref></sup> Kulkarni et al.<sup><xref ref-type="bibr" rid="CR95">95</xref></sup> demonstrated that helper lipids and cholesterol play crucial roles in the formulation of LNPs, aiding in the encapsulation of genetic material.<sup><xref ref-type="bibr" rid="CR96">96</xref></sup> However, Su et al.<sup><xref ref-type="bibr" rid="CR97">97</xref></sup> broke away from the traditional LNPs model and discovered that cholesterol and phospholipids may not be essential for LNPs.</p><p id="Par14">It is essential to elucidate the considerations for designing LNPs delivery systems, encompassing payload efficiency, stability, circulation time, facilitation of endosomal escape, biodegradability, immunogenicity, safety, and targeting capability.<sup><xref ref-type="bibr" rid="CR98">98</xref></sup> The precise structure of cationic lipids is pivotal, typically comprising a positively charged head and multiple hydrophobic tails. Even minor alterations, such as the addition or removal of an atom or a functional group, can significantly impact tissue targeting, cellular uptake, and endosomal escape.<sup><xref ref-type="bibr" rid="CR99">99</xref></sup> The design of ionizable lipids necessitates careful consideration of the pKa values of the headgroup in order to achieve an optimal pH-dependent electrostatic pattern.<sup><xref ref-type="bibr" rid="CR98">98</xref></sup> Ionizable lipids are typically positively charged in acidic pH environments and possess the capability to aggregate negatively charged mRNA into LNPs. At physiological pH, they become neutralized to minimize toxicity and enhance the biocompatibility of mRNA LNPs. Upon uptake by cells into acidic endosomes, they undergo protonation, thereby promoting the translocation of mRNA from endosomes into the cytosol.<sup><xref ref-type="bibr" rid="CR93">93</xref></sup> The pKa values of ionizable lipids can be modified by altering the chemical composition of the headgroup, such as imidazole, ester, and piperazine.<sup><xref ref-type="bibr" rid="CR98">98</xref></sup> The hydrophobic tails of the ionizable lipids play a crucial role in facilitating the assembly of LNPs and ensuring the stable encapsulation of mRNA. The design of the linker region between the headgroup and the lipid tails has a significant impact on the overall pH sensitivity of the ionizable lipids, consequently influencing both the release kinetics and magnitude of mRNA.<sup><xref ref-type="bibr" rid="CR61">61</xref></sup> The shape of ionizable lipids can also impact their functionality. More conical ionizable lipids, with a molecular structure that is not compatible with the lipid bilayer, can facilitate mRNA escape from lysosomes.<sup><xref ref-type="bibr" rid="CR100">100</xref></sup></p><p id="Par15">The safety and stability concerns associated with mRNA therapy encompass various facets. With regard to safety, it is imperative to assess the biocompatibility of mRNA and its delivery system, minimize direct cellular damage, and mitigate the elicitation of unnecessary immune responses.<sup><xref ref-type="bibr" rid="CR101">101</xref></sup> However, the presence of pH-dependent or permanent cationic properties may result in safety concerns, such as disruption of cellular membranes and organelles, release of degradative enzymes from lysosomes, and damage to DNA. As a result, biocompatible molecular components capable of forming covalent ester or amide bonds have been developed for the production of biodegradable ionizable cationic lipids.<sup><xref ref-type="bibr" rid="CR102">102</xref></sup> In terms of stability, the carrier design should ensure protection of the mRNA from enzymatic degradation without impacting its release.<sup><xref ref-type="bibr" rid="CR101">101</xref></sup> In addition, enhancing the thermal stability of mRNA LNPs is crucial for reducing storage costs. For example, in order to enhance the thermostability of mRNA LNPs, researchers developed a novel ionizable lipid DOG-IM4 modified with imidazole.<sup><xref ref-type="bibr" rid="CR103">103</xref></sup></p><p id="Par16">Modifying the physical and chemical characteristics of LNPs, such as their size, surface charge, and surface hydrophobicity, can impact their biological activity.<sup><xref ref-type="bibr" rid="CR104">104</xref></sup> Generally, hydrophilic LNPs with a neutral charge and a size smaller than 100&#8201;nm exhibit prolonged circulation in the bloodstream. LNPs with a positive charge are more conducive to cellular uptake.<sup><xref ref-type="bibr" rid="CR105">105</xref></sup> The morphology and nanostructure of LNPs are correlated with the transfection efficiency of mRNA. Nevertheless, the morphology of mRNA LNPs remains ambiguous, necessitating further research for elucidation.<sup><xref ref-type="bibr" rid="CR106">106</xref></sup> Furthermore, the precise localization of the four components within the LNPs remains unclear, posing certain limitations in molecular design.<sup><xref ref-type="bibr" rid="CR107">107</xref></sup> In order to tackle more demanding tasks for LNPs, such as targeted functionality, cellular penetration, and endosomal escape, the surface of LNPs can be subject to modification. Polymers like PEG-modified lipids are the predominant surface modifiers utilized for LNPs.<sup><xref ref-type="bibr" rid="CR108">108</xref></sup> Nevertheless, surface-modified LNPs may present potential adverse effects, such as allergic responses triggered by lipids modified with PEG.<sup><xref ref-type="bibr" rid="CR61">61</xref></sup> Furthermore, the challenges in scaling up the production of surface-modified LNPs could impede their commercialization.<sup><xref ref-type="bibr" rid="CR108">108</xref></sup></p><p id="Par17">Presently, the commonly utilized methodologies for formulating LNPs encompass the thin-film hydration approach, solvent injection technique, reverse evaporation method, and microfluidic technology.<sup><xref ref-type="bibr" rid="CR109">109</xref></sup> Depending on the specific application, microfluidic chips can be fabricated from a variety of materials such as silicon, glass, polydimethylsiloxane (PDMS), cyclo-olefin polymers and copolymers (COPs/COCs). In addition, various fabrication methods including photolithography, electron beam lithography, wet and dry etching, and embossing can be employed. Microfluidic technology offers numerous advantages in the production of LNPs, facilitating continuous liquid flow within the microfluidic platform to ensure consistent nanoparticle quality over time and mitigate batch-to-batch variations. Furthermore, the design flexibility of microfluidic channels enables adaptation to different rapid mixing modes.<sup><xref ref-type="bibr" rid="CR110">110</xref></sup> Microfluidic technology has not only yielded remarkable results in laboratory research, but also been adopted and integrated into industrial production processes. The microfluidic device utilized in the preparation of BNT162b2 is an impingement jet mixer.<sup><xref ref-type="bibr" rid="CR111">111</xref></sup> Furthermore, ongoing advancements in automated high-throughput preparation techniques are continuously enhancing the production of LNPs<sup><xref ref-type="bibr" rid="CR112">112</xref></sup> and other nanodelivery vectors.<sup><xref ref-type="bibr" rid="CR113">113</xref></sup></p></sec></sec><sec id="Sec6"><title>Preclinical and clinical applications of mRNA-based drugs</title><sec id="Sec7"><title>Immunotherapy</title><p id="Par18">mRNA vaccines outplayed their traditional counterparts in rapid development and cost-effectiveness trait,<sup><xref ref-type="bibr" rid="CR114">114</xref></sup> rendering them a promising tool for immunization against viruses, tumors, bacteria, and parasite. Despite the fact that mRNA was discovered in 1961, the revolutionary breakthrough of using it as a vaccine has only occurred in recent years, due to its susceptibility to enzymatic degradation, inefficient in vivo delivery, and intrinsic immunogenicity.<sup><xref ref-type="bibr" rid="CR115">115</xref></sup></p><p id="Par19">In order to achieve antiviral, antitumor, antibacterial, and antiparasitic effects, mRNA-based immunotherapies must elicit a robust and specific host immune response to eliminate pathogens and confer durable protection.<sup><xref ref-type="bibr" rid="CR28">28</xref></sup> mRNA vaccines encoding disease-specific antigens function by transfecting antigen-presenting cells (APCs). The protein antigen is translated within the cell and released into the extracellular space or degraded by the proteasome to expose the antigenic sites. Intrinsic antigens can be presented by the cell surface major histocompatibility complex I (MHC I) to induce maturation of cluster of differentiation (CD) 8<sup>+</sup> T cells, while extracellular antigen proteins can be recognized by B cells, internalized, degraded by APC cells, and presented through the MHC II class pathway to activate CD4<sup>+</sup> T helper (Th) cells.<sup><xref ref-type="bibr" rid="CR28">28</xref>,<xref ref-type="bibr" rid="CR116">116</xref></sup></p><p id="Par20">In addition to disease-specific antigens, proteins related to immunotherapy encompass antibodies, cytokines, ligands, tumor suppressor proteins, and other functional proteins. It is worth noting that mRNA therapies encoding cytokines could be utilized to either enhance or suppress the immune response. Cytokines are a class of proteins that modulate immune cells by activating downstream cytokine receptors.<sup><xref ref-type="bibr" rid="CR117">117</xref></sup> Stimulatory cytokines are suitable for combating infectious diseases and cancer, while inhibitory cytokines are appropriate for treating autoimmune diseases. It is noteworthy that certain cytokines, such as Interleukin (IL)-2, do not have a fixed function in regulating the immune response; rather, their function changes with variations in concentration.<sup><xref ref-type="bibr" rid="CR118">118</xref>,<xref ref-type="bibr" rid="CR119">119</xref></sup> Moreover, mRNA-based adoptive cell therapies may not be exclusively utilized for immune modulation or suppression, contingent upon the protein encoded by the mRNA. For instance, BNT211 is employed in the treatment of CLDN6-positive advanced solid tumors,<sup><xref ref-type="bibr" rid="CR120">120</xref></sup> while Descartes-08 is designated for autoimmune disorders.<sup><xref ref-type="bibr" rid="CR121">121</xref></sup></p><p id="Par21">In general, mRNA possesses the capacity to encode diverse proteins including antigens, antibodies, ligands, and tumor suppressor proteins. In addition, mRNA can also be harnessed in combination with adoptive cell therapy (Fig. <xref rid="Fig2" ref-type="fig">2</xref>), thus showcasing immense potential within the realm of immunotherapy (Table <xref rid="Tab1" ref-type="table">1</xref>).<fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>mRNA codes for immunotherapy-associated antigen, antibody, cytokine, ligand, tumor suppressor protein, and adoptive cell therapy. RV rotavirus, VZV varicella-zoster virus, RSV respiratory syncytial virus, CMV cytomegalovirus, HPV human papillomavirus, EBV Epstein&#8211;Barr virus, RABV rabies virus, HIV human immunodeficiency virus, MPXV monkeypox virus, anti-VEGF anti-vascular endothelial growth factor. The graphic is created with BioRender.com</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e983" position="float" orientation="portrait" xlink:href="41392_2024_2002_Fig2_HTML.jpg"/></fig><table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>Representative completed and ongoing clinical studies (immunotherapy)</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Therapy</th><th colspan="1" rowspan="1">Subclass</th><th colspan="1" rowspan="1">mRNA drug</th><th colspan="1" rowspan="1">Application</th><th colspan="1" rowspan="1">mRNA-encoded protein</th><th colspan="1" rowspan="1">Delivery system</th><th colspan="1" rowspan="1">Administration route</th><th colspan="1" rowspan="1">Study started</th><th colspan="1" rowspan="1">Phase</th><th colspan="1" rowspan="1">Status</th><th colspan="1" rowspan="1">Result</th><th colspan="1" rowspan="1">NCT number</th><th colspan="1" rowspan="1">Sponsor</th><th colspan="1" rowspan="1">Ref.</th></tr></thead><tbody><tr><td rowspan="30" colspan="1">Disease-specific antigen therapy</td><td rowspan="18" colspan="1">Virus antigen</td><td colspan="1" rowspan="1">mRNA-1273</td><td colspan="1" rowspan="1">COVID-19</td><td colspan="1" rowspan="1">Prefusion stabilized full-length spike protein</td><td colspan="1" rowspan="1">LNPs (SM-102, PEG2000-DMG, DSPC, cholesterol)</td><td colspan="1" rowspan="1">Intramuscular injection</td><td colspan="1" rowspan="1">2020-07-27</td><td colspan="1" rowspan="1">Phase III</td><td colspan="1" rowspan="1">Completed</td><td colspan="1" rowspan="1">Show 94.1% efficacy in preventing COVID-19 disease, with no safety concerns found except for transient local or systemic reactions</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04470427">NCT04470427</ext-link></td><td colspan="1" rowspan="1">ModernaTX, Inc.</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR486">486</xref></sup></td></tr><tr><td colspan="1" rowspan="1">BNT162b2</td><td colspan="1" rowspan="1">COVID-19</td><td colspan="1" rowspan="1">SARS-CoV-2 full-length spike protein</td><td colspan="1" rowspan="1">LNPs (ALC-0315, ALC-0159, DSPC, cholesterol)</td><td colspan="1" rowspan="1">Intramuscular injection</td><td colspan="1" rowspan="1">2020-04-29</td><td colspan="1" rowspan="1">Phase II/III</td><td colspan="1" rowspan="1">Completed</td><td colspan="1" rowspan="1">Good immune efficacy against COVID-19 with a sustained safety profile and acceptable adverse events, but the immune efficacy declines after 6 months</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04368728">NCT04368728</ext-link></td><td colspan="1" rowspan="1">BioNTech SE</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR487">487</xref></sup></td></tr><tr><td colspan="1" rowspan="1">mRNA-1345</td><td colspan="1" rowspan="1">RSV</td><td colspan="1" rowspan="1">RSV prefusion stabilized F (preF) glycoprotein</td><td colspan="1" rowspan="1">LNPs (ionizable lipid, phospholipid, PEG lipid, sterol)</td><td colspan="1" rowspan="1">Intramuscular injection</td><td colspan="1" rowspan="1">2023-10-06</td><td colspan="1" rowspan="1">Phase III</td><td colspan="1" rowspan="1">Recruiting</td><td colspan="1" rowspan="1">/</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06067230">NCT06067230</ext-link></td><td colspan="1" rowspan="1">ModernaTX, Inc.</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR479">479</xref></sup></td></tr><tr><td colspan="1" rowspan="1">mRNA-1010</td><td colspan="1" rowspan="1">Seasonal influenza</td><td colspan="1" rowspan="1">Membrane-bound hemagglutinin (HA) surface glycoproteins of four influenza strains (A/H1N1, A/H3N2, B/Victoria, and B/Yamagata)</td><td colspan="1" rowspan="1">LNPs</td><td colspan="1" rowspan="1">Intramuscular injection</td><td colspan="1" rowspan="1">2022-09-14</td><td colspan="1" rowspan="1">Phase III</td><td colspan="1" rowspan="1">Completed</td><td colspan="1" rowspan="1">Acceptable safety and tolerability support continued study</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05566639">NCT05566639</ext-link></td><td colspan="1" rowspan="1">ModernaTX, Inc.</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR134">134</xref>,<xref ref-type="bibr" rid="CR488">488</xref></sup></td></tr><tr><td colspan="1" rowspan="1">mRNA-1647</td><td colspan="1" rowspan="1">CMV</td><td colspan="1" rowspan="1">Two CMV antigens (glycoprotein B and the pentameric glycoprotein complex)</td><td colspan="1" rowspan="1">LNPs</td><td colspan="1" rowspan="1">Intramuscular injection</td><td colspan="1" rowspan="1">2021-10-26</td><td colspan="1" rowspan="1">Phase III</td><td colspan="1" rowspan="1">Active, not recruiting</td><td colspan="1" rowspan="1">/</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05085366">NCT05085366</ext-link></td><td colspan="1" rowspan="1">ModernaTX, Inc.</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR489">489</xref></sup></td></tr><tr><td colspan="1" rowspan="1">mRNA-1325</td><td colspan="1" rowspan="1">Zika virus</td><td colspan="1" rowspan="1">Premembrane and envelope E structural proteins (prME) from a Micronesia 2007 Zika virus isolate</td><td colspan="1" rowspan="1">LNPs</td><td colspan="1" rowspan="1">Intramuscular injection</td><td colspan="1" rowspan="1">2016-12-21</td><td colspan="1" rowspan="1">Phase I</td><td colspan="1" rowspan="1">Completed</td><td colspan="1" rowspan="1">Well tolerated, but poor Zika virus-specific nAb responses</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03014089">NCT03014089</ext-link></td><td colspan="1" rowspan="1">ModernaTX, Inc.</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR490">490</xref></sup></td></tr><tr><td colspan="1" rowspan="1">mRNA-1893</td><td colspan="1" rowspan="1">Zika virus</td><td colspan="1" rowspan="1">prME from the RIO-U1 Zika virus isolate</td><td colspan="1" rowspan="1">LNPs</td><td colspan="1" rowspan="1">Intramuscular injection</td><td colspan="1" rowspan="1">2019-07-30</td><td colspan="1" rowspan="1">Phase I</td><td colspan="1" rowspan="1">Completed</td><td colspan="1" rowspan="1">Well tolerated, induce strong Zika virus-specific serum nAb responses after two doses that supported the continued study of mRNA-1893</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04064905">NCT04064905</ext-link></td><td colspan="1" rowspan="1">ModernaTX, Inc.</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR490">490</xref></sup></td></tr><tr><td colspan="1" rowspan="1">mRNA-1388</td><td colspan="1" rowspan="1">CHIKV</td><td colspan="1" rowspan="1">Full CHIKV structural polyprotein (capsid and envelope proteins E3, E2, 6 k/TF, and E1) from CHIKV West African strain 37,997</td><td colspan="1" rowspan="1">LNPs (cholesterol, DPSC, ionizable lipid MC3, PEG2000-DMG)</td><td colspan="1" rowspan="1">Intramuscular injection</td><td colspan="1" rowspan="1">2017-08-15</td><td colspan="1" rowspan="1">Phase I</td><td colspan="1" rowspan="1">Completed</td><td colspan="1" rowspan="1">Good safety and immunogenicity</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03325075">NCT03325075</ext-link></td><td colspan="1" rowspan="1">ModernaTX, Inc.</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR491">491</xref></sup></td></tr><tr><td colspan="1" rowspan="1">H10N8 mRNA vaccine (VAL-506440)</td><td colspan="1" rowspan="1">Influenza (H10N8)</td><td colspan="1" rowspan="1">Full-length, membrane-bound form of the HA glycoprotein from the H10N8 influenza strain (A/Jiangxi-Donghu/346/2013)</td><td colspan="1" rowspan="1">LNPs</td><td colspan="1" rowspan="1">Intramuscular injection</td><td colspan="1" rowspan="1">2015-12</td><td colspan="1" rowspan="1">Phase I</td><td colspan="1" rowspan="1">Completed</td><td colspan="1" rowspan="1">Well tolerated, trigger strong humoral immune responses</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03076385">NCT03076385</ext-link></td><td colspan="1" rowspan="1">ModernaTX, Inc.</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR492">492</xref></sup></td></tr><tr><td colspan="1" rowspan="1">H7N9 mRNA vaccine (VAL-339851)</td><td colspan="1" rowspan="1">Influenza (H7N9)</td><td colspan="1" rowspan="1">Full-length, membrane-bound form of the HA glycoprotein from the H7N9 influenza strain (A/Anhui/1/2013)</td><td colspan="1" rowspan="1">LNPs</td><td colspan="1" rowspan="1">Intramuscular injection</td><td colspan="1" rowspan="1">2016-05-11</td><td colspan="1" rowspan="1">Phase I</td><td colspan="1" rowspan="1">Completed</td><td colspan="1" rowspan="1">Well tolerated, trigger strong humoral immune responses</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03345043">NCT03345043</ext-link></td><td colspan="1" rowspan="1">ModernaTX, Inc.</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR492">492</xref></sup></td></tr><tr><td colspan="1" rowspan="1">CV7201</td><td colspan="1" rowspan="1">Rabies</td><td colspan="1" rowspan="1">Rabies virus glycoprotein</td><td colspan="1" rowspan="1">Cationic protein protamine as stabilizer and adjuvant</td><td colspan="1" rowspan="1">Intradermal, intramuscular injection</td><td colspan="1" rowspan="1">2013-10</td><td colspan="1" rowspan="1">Phase I</td><td colspan="1" rowspan="1">Completed</td><td colspan="1" rowspan="1">Generally safe and reasonably tolerated</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02241135">NCT02241135</ext-link></td><td colspan="1" rowspan="1">CureVac</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR13">13</xref></sup></td></tr><tr><td colspan="1" rowspan="1">CV7202</td><td colspan="1" rowspan="1">Rabies</td><td colspan="1" rowspan="1">Rabies virus glycoprotein</td><td colspan="1" rowspan="1">LNPs (cholesterol, DSPC, PEGylated lipid, cationic lipid)</td><td colspan="1" rowspan="1">Intramuscular injection</td><td colspan="1" rowspan="1">2018-10-12</td><td colspan="1" rowspan="1">Phase I</td><td colspan="1" rowspan="1">Completed</td><td colspan="1" rowspan="1">Low doses (1&#8201;&#956;g or 2&#8201;&#956;g) were well-tolerated, whereas the 5&#8201;&#956;g dose exhibited unacceptable reactogenicity</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03713086">NCT03713086</ext-link></td><td colspan="1" rowspan="1">CureVac</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR493">493</xref></sup></td></tr><tr><td colspan="1" rowspan="1">mRNA-1644</td><td colspan="1" rowspan="1">HIV</td><td colspan="1" rowspan="1">eOD-GT8 60mer</td><td colspan="1" rowspan="1">Self-assembling nanoparticles</td><td colspan="1" rowspan="1">Intramuscular injection</td><td colspan="1" rowspan="1">2022-05-25</td><td colspan="1" rowspan="1">Phase I</td><td colspan="1" rowspan="1">Active, not recruiting</td><td colspan="1" rowspan="1">/</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05414786">NCT05414786</ext-link></td><td colspan="1" rowspan="1">International AIDS Vaccine Initiative</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR156">156</xref></sup></td></tr><tr><td colspan="1" rowspan="1">mRNA-1644v2-Core</td><td colspan="1" rowspan="1">HIV</td><td colspan="1" rowspan="1">Core-g28v2 60mer</td><td colspan="1" rowspan="1">LNPs</td><td colspan="1" rowspan="1">Intramuscular injection</td><td colspan="1" rowspan="1">2021-11-12</td><td colspan="1" rowspan="1">Phase I</td><td colspan="1" rowspan="1">Active, not recruiting</td><td colspan="1" rowspan="1">/</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05001373">NCT05001373</ext-link></td><td colspan="1" rowspan="1">International AIDS Vaccine Initiative</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR494">494</xref>,<xref ref-type="bibr" rid="CR495">495</xref></sup></td></tr><tr><td colspan="1" rowspan="1">BNT166a</td><td colspan="1" rowspan="1">MPXV</td><td colspan="1" rowspan="1">MPXV antigens A35, B6, H3, and M1</td><td colspan="1" rowspan="1">LNPs</td><td colspan="1" rowspan="1">Intramuscular injection</td><td colspan="1" rowspan="1">2023-09-21</td><td colspan="1" rowspan="1">Phase I</td><td colspan="1" rowspan="1">Recruiting</td><td colspan="1" rowspan="1">/</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05988203">NCT05988203</ext-link></td><td colspan="1" rowspan="1">BioNTech SE</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR167">167</xref></sup></td></tr><tr><td colspan="1" rowspan="1">EBV mRNA vaccine</td><td colspan="1" rowspan="1">EBV-positive advanced malignant tumors</td><td colspan="1" rowspan="1">Undisclosed</td><td colspan="1" rowspan="1">Undisclosed</td><td colspan="1" rowspan="1">Intramuscular injection</td><td colspan="1" rowspan="1">2022-11-18</td><td colspan="1" rowspan="1">Phase I</td><td colspan="1" rowspan="1">Recruiting</td><td colspan="1" rowspan="1">/</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05714748">NCT05714748</ext-link></td><td colspan="1" rowspan="1">West China Hospital</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR496">496</xref></sup></td></tr><tr><td colspan="1" rowspan="1">BNT113</td><td colspan="1" rowspan="1">HPV16 positive head and neck squamous cell carcinoma (HNSCC) that expresses PD-L1</td><td colspan="1" rowspan="1">HPV16 oncoproteins E6 and E7</td><td colspan="1" rowspan="1">Liposomal</td><td colspan="1" rowspan="1">Intravenous injection</td><td colspan="1" rowspan="1">2021-01-07</td><td colspan="1" rowspan="1">Phase II</td><td colspan="1" rowspan="1">Recruiting</td><td colspan="1" rowspan="1">Acceptable safety profile</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04534205">NCT04534205</ext-link></td><td colspan="1" rowspan="1">BioNTech SE</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR497">497</xref></sup></td></tr><tr><td colspan="1" rowspan="1">HBV mRNA vaccine</td><td colspan="1" rowspan="1">HBV-associated refractory hepatocellular carcinoma</td><td colspan="1" rowspan="1">HBsAg</td><td colspan="1" rowspan="1">LNPs</td><td colspan="1" rowspan="1">Intramuscular injection</td><td colspan="1" rowspan="1">2023-02-15 (estimated)</td><td colspan="1" rowspan="1">Phase I</td><td colspan="1" rowspan="1">Recruiting</td><td colspan="1" rowspan="1">/</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05738447">NCT05738447</ext-link></td><td colspan="1" rowspan="1">West China Hospital</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR498">498</xref></sup></td></tr><tr><td rowspan="9" colspan="1">Tumor antigen</td><td colspan="1" rowspan="1">BNT111</td><td colspan="1" rowspan="1">Melanoma</td><td colspan="1" rowspan="1">Melanoma TAAs: New York esophageal squamous cell carcinoma 1 (NY-ESO-1), tyrosinase, melanoma-associated antigen 3 (MAGE-A3), and transmembrane phosphatase with tensin homology (TPTE)</td><td colspan="1" rowspan="1">Lipoplexes</td><td colspan="1" rowspan="1">Intravenous administration</td><td colspan="1" rowspan="1">2015-03</td><td colspan="1" rowspan="1">Phase I</td><td colspan="1" rowspan="1">Completed</td><td colspan="1" rowspan="1">Strong immunogenicity and promising clinical activity</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02410733">NCT02410733</ext-link></td><td colspan="1" rowspan="1">BioNTech SE</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR174">174</xref></sup></td></tr><tr><td colspan="1" rowspan="1">BNT112</td><td colspan="1" rowspan="1">Prostate cancer</td><td colspan="1" rowspan="1">Prostate cancer TAAs: kallikrein-2, kallikrein-3, acid phosphatase prostate, homeobox B13 (HOXB13), and NK3 homeobox 1</td><td colspan="1" rowspan="1">Lipoplexes</td><td colspan="1" rowspan="1">Intravenous bolus injection</td><td colspan="1" rowspan="1">2019-12-19</td><td colspan="1" rowspan="1">Phase I/II</td><td colspan="1" rowspan="1">Terminated</td><td colspan="1" rowspan="1">Acceptable safety profile, induce robust prostate antigen-specific immune responses in patients with advanced prostate cancer</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04382898">NCT04382898</ext-link></td><td colspan="1" rowspan="1">BioNTech SE</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR499">499</xref></sup></td></tr><tr><td colspan="1" rowspan="1">BNT116</td><td colspan="1" rowspan="1">Non-small cell lung cancer</td><td colspan="1" rowspan="1">Six shared antigens frequently expressed in non-small cell lung cancer</td><td colspan="1" rowspan="1">Undisclosed</td><td colspan="1" rowspan="1">Intravenous injection</td><td colspan="1" rowspan="1">2022-06-17</td><td colspan="1" rowspan="1">Phase I</td><td colspan="1" rowspan="1">Recruiting</td><td colspan="1" rowspan="1">/</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05142189">NCT05142189</ext-link></td><td colspan="1" rowspan="1">BioNTech SE</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR500">500</xref></sup></td></tr><tr><td colspan="1" rowspan="1">mRNA-4157</td><td colspan="1" rowspan="1">Melanoma</td><td colspan="1" rowspan="1">Up to 34 patient-specific tumor neoantigens</td><td colspan="1" rowspan="1">LNPs</td><td colspan="1" rowspan="1">Intramuscular injection</td><td colspan="1" rowspan="1">2019-07-18</td><td colspan="1" rowspan="1">Phase IIb</td><td colspan="1" rowspan="1">Recruiting</td><td colspan="1" rowspan="1">Significantly extended distant metastasis-free survival in patients with resected high-risk melanoma as compared with Pembrolizumab monotherapy</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03897881">NCT03897881</ext-link></td><td colspan="1" rowspan="1">ModernaTX, Inc.</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR481">481</xref></sup></td></tr><tr><td colspan="1" rowspan="1">mRNA-4157</td><td colspan="1" rowspan="1">Melanoma</td><td colspan="1" rowspan="1">Up to 34 patient-specific tumor neoantigens</td><td colspan="1" rowspan="1">LNPs</td><td colspan="1" rowspan="1">Intramuscular injection</td><td colspan="1" rowspan="1">2023-07-19</td><td colspan="1" rowspan="1">Phase III</td><td colspan="1" rowspan="1">Recruiting</td><td colspan="1" rowspan="1">/</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05933577">NCT05933577</ext-link></td><td colspan="1" rowspan="1">Merck Sharp &amp; Dohme LLC</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR501">501</xref></sup></td></tr><tr><td colspan="1" rowspan="1">Autogene cevumeran (RO7198457)</td><td colspan="1" rowspan="1">Pancreatic cancer</td><td colspan="1" rowspan="1">Neoantigen</td><td colspan="1" rowspan="1">Lipoplex nanoparticles</td><td colspan="1" rowspan="1">Intravenous delivery</td><td colspan="1" rowspan="1">2019-12-13</td><td colspan="1" rowspan="1">Phase I</td><td colspan="1" rowspan="1">Active, not recruiting</td><td colspan="1" rowspan="1">Preliminarily shown to be safe in combination with Atezolizumab and mFOLFIRINOX and to delay recurrence in patients with surgically removed pancreatic ductal adenocarcinoma (PDAC)</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04161755">NCT04161755</ext-link></td><td colspan="1" rowspan="1">Memorial Sloan Kettering Cancer Center</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR502">502</xref></sup></td></tr><tr><td colspan="1" rowspan="1">Personalized tumor neoantigen mRNA vaccine</td><td colspan="1" rowspan="1">Liver cancer</td><td colspan="1" rowspan="1">Personalized tumor neoantigen</td><td colspan="1" rowspan="1">LNPs</td><td colspan="1" rowspan="1">Subcutaneous injection</td><td colspan="1" rowspan="1">2023-04-20</td><td colspan="1" rowspan="1">Not applicable</td><td colspan="1" rowspan="1">Not yet recruiting</td><td colspan="1" rowspan="1">/</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05761717">NCT05761717</ext-link></td><td colspan="1" rowspan="1">Shanghai Zhongshan Hospital</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR503">503</xref></sup></td></tr><tr><td colspan="1" rowspan="1">Tumor neoantigen mRNA vaccine</td><td colspan="1" rowspan="1">Advanced esophageal cancer and non-small cell lung cancer</td><td colspan="1" rowspan="1">Tumor neoantigen</td><td colspan="1" rowspan="1">LNPs</td><td colspan="1" rowspan="1">Subcutaneous injection</td><td colspan="1" rowspan="1">2019-10-18</td><td colspan="1" rowspan="1">Not applicable</td><td colspan="1" rowspan="1">Recruiting</td><td colspan="1" rowspan="1">/</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03908671">NCT03908671</ext-link></td><td colspan="1" rowspan="1">Stemirna Therapeutics</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR504">504</xref></sup></td></tr><tr><td colspan="1" rowspan="1">GRT-C901 and GRT-R902</td><td colspan="1" rowspan="1">Solid tumors</td><td colspan="1" rowspan="1">Neoantigen (#samRNA)</td><td colspan="1" rowspan="1">Chimpanzee adenovirus vector</td><td colspan="1" rowspan="1">Intramuscular injection</td><td colspan="1" rowspan="1">2019-02-13</td><td colspan="1" rowspan="1">Phase I/II</td><td colspan="1" rowspan="1">Completed</td><td colspan="1" rowspan="1">Well tolerated, induce neoantigen-specific CD8<sup>+</sup> T-cell response in all patients, subsequent Phase II/III initiated (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05141721">NCT05141721</ext-link>)</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03639714">NCT03639714</ext-link></td><td colspan="1" rowspan="1">Gritstone bio, Inc.</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR505">505</xref></sup></td></tr><tr><td rowspan="2" colspan="1">Bacterial antigen</td><td colspan="1" rowspan="1">mRNA-1975 and mRNA-1982</td><td colspan="1" rowspan="1">Lyme disease</td><td colspan="1" rowspan="1">Undisclosed</td><td colspan="1" rowspan="1">Undisclosed</td><td colspan="1" rowspan="1">Intramuscular injection</td><td colspan="1" rowspan="1">2023-07-26</td><td colspan="1" rowspan="1">Phase I/II</td><td colspan="1" rowspan="1">Active, not recruiting</td><td colspan="1" rowspan="1">/</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05975099">NCT05975099</ext-link></td><td colspan="1" rowspan="1">ModernaTX, Inc</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR188">188</xref></sup></td></tr><tr><td colspan="1" rowspan="1">BNT164a1 and BNT164b1</td><td colspan="1" rowspan="1">Tuberculosis</td><td colspan="1" rowspan="1">Undisclosed</td><td colspan="1" rowspan="1">Undisclosed</td><td colspan="1" rowspan="1">Intramuscular injection</td><td colspan="1" rowspan="1">2023-07-31</td><td colspan="1" rowspan="1">Phase I/II</td><td colspan="1" rowspan="1">Recruiting</td><td colspan="1" rowspan="1">/</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05547464">NCT05547464</ext-link></td><td colspan="1" rowspan="1">BioNTech SE</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR453">453</xref></sup></td></tr><tr><td colspan="1" rowspan="1">Parasite antigen</td><td colspan="1" rowspan="1">BNT165b1</td><td colspan="1" rowspan="1">Malaria</td><td colspan="1" rowspan="1">Part of the Plasmodium falciparum circumsporozoite protein (PfCSP)</td><td colspan="1" rowspan="1">LNPs</td><td colspan="1" rowspan="1">Intramuscular injection</td><td colspan="1" rowspan="1">2022-12-15</td><td colspan="1" rowspan="1">Phase I</td><td colspan="1" rowspan="1">Active, not recruiting</td><td colspan="1" rowspan="1">/</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05581641">NCT05581641</ext-link></td><td colspan="1" rowspan="1">BioNTech SE</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR201">201</xref></sup></td></tr><tr><td rowspan="4" colspan="1">Therapeutic antibody therapy</td><td rowspan="4" colspan="1">Antibody</td><td colspan="1" rowspan="1">mRNA-1944</td><td colspan="1" rowspan="1">CHIKV</td><td colspan="1" rowspan="1">Light and heavy chains of a human monoclonal antibody (CHKV-24 IgG) targeting the CHIKV E2 glycoprotein</td><td colspan="1" rowspan="1">LNPs (a proprietary IAL; a proprietary high-purity PEG-2k-stearate monoester; cholesterol, DOPE)</td><td colspan="1" rowspan="1">Intravenous infusion</td><td colspan="1" rowspan="1">2019-01-22</td><td colspan="1" rowspan="1">Phase I</td><td colspan="1" rowspan="1">Completed</td><td colspan="1" rowspan="1">Acceptable safety profile, produce high levels of functionally neutralizing antibodies</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03829384">NCT03829384</ext-link></td><td colspan="1" rowspan="1">ModernaTX, Inc.</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR506">506</xref></sup></td></tr><tr><td colspan="1" rowspan="1">BNT141</td><td colspan="1" rowspan="1">Unresectable or metastatic CLDN18.2-positive gastric, pancreatic, ovarian and biliary tract tumors</td><td colspan="1" rowspan="1">Anti-CLDN18.2 antibodies</td><td colspan="1" rowspan="1">LNPs</td><td colspan="1" rowspan="1">Intravenous injection</td><td colspan="1" rowspan="1">2022-01-18</td><td colspan="1" rowspan="1">Phase I/II</td><td colspan="1" rowspan="1">Terminated</td><td colspan="1" rowspan="1">/</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04683939">NCT04683939</ext-link></td><td colspan="1" rowspan="1">BioNTech SE</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR507">507</xref></sup></td></tr><tr><td colspan="1" rowspan="1">BNT142</td><td colspan="1" rowspan="1">CLDN6-positive solid tumors</td><td colspan="1" rowspan="1">T-cell-engaging bispecific antibody against CLDN6 and the T-cell receptor&#8211;associated molecule CD3</td><td colspan="1" rowspan="1">LNPs</td><td colspan="1" rowspan="1">Intravenous bolus/infusion</td><td colspan="1" rowspan="1">2022-03-28</td><td colspan="1" rowspan="1">Phase I/II</td><td colspan="1" rowspan="1">Recruiting</td><td colspan="1" rowspan="1">/</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05262530">NCT05262530</ext-link></td><td colspan="1" rowspan="1">BioNTech SE</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR508">508</xref></sup></td></tr><tr><td colspan="1" rowspan="1">RNA-transfected mature autologous DC</td><td colspan="1" rowspan="1">Melanoma</td><td colspan="1" rowspan="1">Anti-CTLA-4 and anti-GITR mAb and melanoma TAAs MART, tyrosinase, and gp100, and MAGE-3</td><td colspan="1" rowspan="1">DCs</td><td colspan="1" rowspan="1">Intranodal injection</td><td colspan="1" rowspan="1">2010-01</td><td colspan="1" rowspan="1">Phase I</td><td colspan="1" rowspan="1">Terminated</td><td colspan="1" rowspan="1">/</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01216436">NCT01216436</ext-link></td><td colspan="1" rowspan="1">Duke University</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR236">236</xref></sup></td></tr><tr><td rowspan="5" colspan="1">Cytokine</td><td rowspan="4" colspan="1">Immune-potentiating</td><td colspan="1" rowspan="1">MEDI1191</td><td colspan="1" rowspan="1">Solid tumors</td><td colspan="1" rowspan="1">IL-12</td><td colspan="1" rowspan="1">LNPs</td><td colspan="1" rowspan="1">Intratumoral injection</td><td colspan="1" rowspan="1">2019-05-08</td><td colspan="1" rowspan="1">Phase I</td><td colspan="1" rowspan="1">Completed</td><td colspan="1" rowspan="1">/</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03946800">NCT03946800</ext-link></td><td colspan="1" rowspan="1">MedImmune LLC</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR259">259</xref></sup></td></tr><tr><td colspan="1" rowspan="1">mRNA-2752</td><td colspan="1" rowspan="1">Advanced solid tumors and lymphoma</td><td colspan="1" rowspan="1">OX40L, IL-23, and IL-36&#947;</td><td colspan="1" rowspan="1">LNPs</td><td colspan="1" rowspan="1">Intratumoral injection</td><td colspan="1" rowspan="1">2018-11-27</td><td colspan="1" rowspan="1">Phase I</td><td colspan="1" rowspan="1">Active, not recruiting</td><td colspan="1" rowspan="1">Tolerated, may be associated with tumor shrinkage</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03739931">NCT03739931</ext-link></td><td colspan="1" rowspan="1">ModernaTX, Inc.</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR509">509</xref></sup></td></tr><tr><td colspan="1" rowspan="1">SAR441000</td><td colspan="1" rowspan="1">Solid tumors</td><td colspan="1" rowspan="1">IL-12 single chain, IFN &#593;-2b, GM-CSF, and IL-15 sushi</td><td colspan="1" rowspan="1">Saline-formulated mixture</td><td colspan="1" rowspan="1">Intratumoral injection</td><td colspan="1" rowspan="1">2019-01-03</td><td colspan="1" rowspan="1">Phase I</td><td colspan="1" rowspan="1">Terminated</td><td colspan="1" rowspan="1">Well tolerated (clinical trial in 17 patients; July 2020), supporting further clinical studies</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03871348">NCT03871348</ext-link></td><td colspan="1" rowspan="1">Sanofi</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR263">263</xref></sup></td></tr><tr><td colspan="1" rowspan="1">BNT153 and BNT152</td><td colspan="1" rowspan="1">Solid tumors</td><td colspan="1" rowspan="1">IL-2, IL-7</td><td colspan="1" rowspan="1">LNPs</td><td colspan="1" rowspan="1">Intravenous</td><td colspan="1" rowspan="1">2021-06-08</td><td colspan="1" rowspan="1">Phase I</td><td colspan="1" rowspan="1">Recruiting</td><td colspan="1" rowspan="1">/</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04710043">NCT04710043</ext-link></td><td colspan="1" rowspan="1">BioNTech SE</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR510">510</xref></sup></td></tr><tr><td colspan="1" rowspan="1">Immune-suppressing</td><td colspan="1" rowspan="1">mRNA-6231</td><td colspan="1" rowspan="1">Healthy volunteers</td><td colspan="1" rowspan="1">Human serum albumin IL-2 mutein fusion protein (HSA-IL2m)</td><td colspan="1" rowspan="1">LNPs</td><td colspan="1" rowspan="1">Subcutaneous injection</td><td colspan="1" rowspan="1">2021-07-28</td><td colspan="1" rowspan="1">Phase I</td><td colspan="1" rowspan="1">Completed</td><td colspan="1" rowspan="1">/</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04916431">NCT04916431</ext-link></td><td colspan="1" rowspan="1">ModernaTX, Inc.</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR511">511</xref></sup></td></tr><tr><td colspan="1" rowspan="1">Ligand</td><td colspan="1" rowspan="1">Ligand</td><td colspan="1" rowspan="1">TriMix</td><td colspan="1" rowspan="1">Breast cancer</td><td colspan="1" rowspan="1">DC-activating [CD40 ligand (CD40L), CD70, and constitutively active Toll-like receptor 4 (TLR4)] proteins</td><td colspan="1" rowspan="1">Undisclosed</td><td colspan="1" rowspan="1">Intratumoral administration</td><td colspan="1" rowspan="1">2018-11-12</td><td colspan="1" rowspan="1">Phase I</td><td colspan="1" rowspan="1">Recruiting</td><td colspan="1" rowspan="1">/</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03788083">NCT03788083</ext-link></td><td colspan="1" rowspan="1">Universitair Ziekenhuis Brussel</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR512">512</xref></sup></td></tr><tr><td rowspan="8" colspan="1">Adoptive cell therapy</td><td colspan="1" rowspan="1">CAR-T</td><td colspan="1" rowspan="1">CLDN6 CAR-T cells +/&#8722; CARVac</td><td colspan="1" rowspan="1">CLDN6-positive advanced solid tumors</td><td colspan="1" rowspan="1">CLDN6</td><td colspan="1" rowspan="1">Lipoplexes</td><td colspan="1" rowspan="1">Intravenous injection</td><td colspan="1" rowspan="1">2020-09-16</td><td colspan="1" rowspan="1">Phase I/II</td><td colspan="1" rowspan="1">Recruiting</td><td colspan="1" rowspan="1">Good safety profile and encouraging efficacy</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04503278">NCT04503278</ext-link></td><td colspan="1" rowspan="1">BioNTech Cell &amp; Gene Therapies GmbH</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR120">120</xref></sup></td></tr><tr><td colspan="1" rowspan="1">CAR-T</td><td colspan="1" rowspan="1">Descartes-08</td><td colspan="1" rowspan="1">Myasthenia gravis</td><td colspan="1" rowspan="1">Anti-BCMA targeting CAR protein</td><td colspan="1" rowspan="1">Autogolous T cells</td><td colspan="1" rowspan="1">Infusion</td><td colspan="1" rowspan="1">2019-12-04</td><td colspan="1" rowspan="1">Phase Ib/IIa</td><td colspan="1" rowspan="1">Recruiting</td><td colspan="1" rowspan="1">Safe and well-tolerated</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04146051">NCT04146051</ext-link></td><td colspan="1" rowspan="1">Cartesian Therapeutics</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR121">121</xref></sup></td></tr><tr><td colspan="1" rowspan="1">TCR-T</td><td colspan="1" rowspan="1">LioCyx-M</td><td colspan="1" rowspan="1">Recurrent hepatocellular carcinoma</td><td colspan="1" rowspan="1">HBV-specific TCR</td><td colspan="1" rowspan="1">Autologous T cells</td><td colspan="1" rowspan="1">Infusion</td><td colspan="1" rowspan="1">2015-07-02</td><td colspan="1" rowspan="1">Phase I</td><td colspan="1" rowspan="1">Unknown status</td><td colspan="1" rowspan="1">Well tolerated, have no adverse effects on the transplanted liver</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02719782">NCT02719782</ext-link></td><td colspan="1" rowspan="1">Lion TCR Pte. Ltd.</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR513">513</xref></sup></td></tr><tr><td colspan="1" rowspan="1">CAR-PBMC</td><td colspan="1" rowspan="1">MCY-M11</td><td colspan="1" rowspan="1">Advanced ovarian cancer and peritoneal mesothelioma</td><td colspan="1" rowspan="1">Anti-mesothelin CAR (Meso-CAR)</td><td colspan="1" rowspan="1">PBMCs</td><td colspan="1" rowspan="1">Intraperitoneal infusion</td><td colspan="1" rowspan="1">2018-08-27</td><td colspan="1" rowspan="1">Phase I</td><td colspan="1" rowspan="1">Terminated</td><td colspan="1" rowspan="1">Mediate effective and long-term antitumor response</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03608618">NCT03608618</ext-link></td><td colspan="1" rowspan="1">MaxCyte, Inc.</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR329">329</xref></sup></td></tr><tr><td rowspan="4" colspan="1">DCs</td><td colspan="1" rowspan="1">AGS-004</td><td colspan="1" rowspan="1">HIV</td><td colspan="1" rowspan="1">CD40L and three or four autologous HIV-1 antigens</td><td colspan="1" rowspan="1">DCs</td><td colspan="1" rowspan="1">Undisclosed</td><td colspan="1" rowspan="1">2008-02</td><td colspan="1" rowspan="1">Phase II</td><td colspan="1" rowspan="1">Completed</td><td colspan="1" rowspan="1">/</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00672191">NCT00672191</ext-link></td><td colspan="1" rowspan="1">Argos Therapeutics</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR514">514</xref></sup></td></tr><tr><td colspan="1" rowspan="1">WT1 antigen-targeted DC vaccine</td><td colspan="1" rowspan="1">Acute myeloid leukemia (AML)</td><td colspan="1" rowspan="1">WT1 antigen mRNA loaded autologous DCs (by electroporation)</td><td colspan="1" rowspan="1">DCs</td><td colspan="1" rowspan="1">Undisclosed</td><td colspan="1" rowspan="1">2012-10</td><td colspan="1" rowspan="1">Phase II</td><td colspan="1" rowspan="1">Active, not recruiting</td><td colspan="1" rowspan="1">/</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01686334">NCT01686334</ext-link></td><td colspan="1" rowspan="1">Zwi Berneman</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR515">515</xref></sup></td></tr><tr><td colspan="1" rowspan="1">DC vaccine (DCs transfected with Survivin, hTERT and p53 mRNA)</td><td colspan="1" rowspan="1">Metastatic breast cancer or malignant melanoma</td><td colspan="1" rowspan="1">Survivin, hTERT and p53</td><td colspan="1" rowspan="1">DCs</td><td colspan="1" rowspan="1">Intradermal injection</td><td colspan="1" rowspan="1">2009-09</td><td colspan="1" rowspan="1">Phase I</td><td colspan="1" rowspan="1">Completed</td><td colspan="1" rowspan="1">/</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00978913">NCT00978913</ext-link></td><td colspan="1" rowspan="1">Inge Marie Svane</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR516">516</xref></sup></td></tr><tr><td colspan="1" rowspan="1">Human CMV pp65-LAMP mRNA-pulsed autologous DCs</td><td colspan="1" rowspan="1">GBM</td><td colspan="1" rowspan="1">CMV protein pp65</td><td colspan="1" rowspan="1">DCs</td><td colspan="1" rowspan="1">Intradermal and bilateral administration at the groin site (divided equally to both inguinal regions)</td><td colspan="1" rowspan="1">2015-10-12</td><td colspan="1" rowspan="1">Phase II</td><td colspan="1" rowspan="1">Completed</td><td colspan="1" rowspan="1">Effective GBM inhibition</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02366728">NCT02366728</ext-link></td><td colspan="1" rowspan="1">Mustafa Khasraw, MBChB, MD, FRCP, FRACP</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR517">517</xref></sup></td></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">LNPs</italic> lipid nanoparticles, <italic toggle="yes">PEG</italic> polyethylene glycol, <italic toggle="yes">DSPC</italic> distearoylphosphatidylcholine, <italic toggle="yes">RSV</italic> respiratory syncytial virus, <italic toggle="yes">CMV</italic> cytomegalovirus, <italic toggle="yes">CHIKV</italic> chikungunya virus, <italic toggle="yes">HIV</italic> human immunodeficiency virus, <italic toggle="yes">MPXV</italic> monkeypox virus, <italic toggle="yes">EBV</italic> Epstein&#8211;Barr virus, <italic toggle="yes">HPV</italic> human papillomavirus, <italic toggle="yes">HBV</italic> hepatitis B virus, <italic toggle="yes">TAAs</italic> tumor-associated antigens, <italic toggle="yes">DOPE</italic> 1,2-dioleyl-sn-glycero-3-phosphoethanolamine, <italic toggle="yes">CLDN6</italic> claudin 6, <italic toggle="yes">DCs</italic> dendritic cells, <italic toggle="yes">IL</italic> interleukin, <italic toggle="yes">IFN</italic> interferon, <italic toggle="yes">GM-CSF</italic> granulocyte-macrophage colony-stimulating factor, <italic toggle="yes">TriMix</italic> mRNA-encoding CD40L, CD70, and TLR4, <italic toggle="yes">CAR</italic> chimeric antigen receptor, <italic toggle="yes">BCMA</italic> B-cell maturation antigen, <italic toggle="yes">TCR</italic> T-cell receptor, <italic toggle="yes">PBMC</italic> peripheral blood mononuclear cells, <italic toggle="yes">WTI</italic> Wilms&#8217; tumor, <italic toggle="yes">GBM</italic> glioblastoma</p></table-wrap-foot></table-wrap></p><sec id="Sec8"><title>Disease-specific antigen therapy</title><sec id="FPar1"><title>Virus antigen mRNA vaccine</title><p id="Par22"><bold>SARS-CoV-2:</bold> In 2019, the novel coronavirus emerged globally, leading to widespread transmission and the tragic loss of numerous lives, thereby posing a huge threat to global health and sanitation. The scarcity of a specific therapeutic agent for post-infection treatment with SARS-CoV-2 caused global panic. In response to this challenge, a variety of SARS-CoV-2 vaccines have been propelled into an intense and accelerated research phase. mRNA vaccines, representing an innovative technology for the prevention of infectious diseases, were initially anticipated to require 5&#8211;6 years to reach the market.<sup><xref ref-type="bibr" rid="CR122">122</xref></sup> Encouragingly, following the public disclosure of the coronavirus RNA sequence in January 2020,<sup><xref ref-type="bibr" rid="CR122">122</xref></sup> it took less than 3 months for the mRNA vaccines, mRNA-1273 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04283461">NCT04283461</ext-link>, Phase I initiated in March 2020) and BNT162b2 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04380701">NCT04380701</ext-link>, Phase I and Phase II initiated in April 2020), to transition from development to clinical trials.<sup><xref ref-type="bibr" rid="CR123">123</xref></sup> Remarkably, within a year, both mRNA vaccines (BNT162b2 and mRNA-1273) rose to prominence, securing emergency approval from the U.S. FDA and were authorized for global mass vaccination against SARS-CoV-2.<sup><xref ref-type="bibr" rid="CR122">122</xref>,<xref ref-type="bibr" rid="CR124">124</xref></sup> According to the consolidated information provided by the World Health Organization (WHO), as of March 30, 2023 (Fig. <xref rid="Fig3" ref-type="fig">3a</xref>), a total of 183 vaccines had entered the clinical stage, with RNA-based vaccines accounting for about 24% (43 in total), ranking second only to protein subunit vaccines which account for around 32% (59 in total).<sup><xref ref-type="bibr" rid="CR125">125</xref></sup><fig id="Fig3" position="float" orientation="portrait"><label>Fig. 3</label><caption><p>Application of mRNA vaccine in immunotherapy. <bold>a</bold> Types of COVID-19 vaccines in clinical trials (from WHO; March 30, 2023). <bold>b</bold> mRNA-based drugs in Phase III/IV trials. On clinicaltrial.gov, search for &#8220;mRNA&#8221; as the only keyword and the search criteria are limited to &#8220;Phase 3&#8221; and &#8220;Phase 4&#8221;. Note that this search method cannot find all mRNA vaccines, and some mRNA vaccines do not contain the word &#8220;mRNA&#8221;, so the figure should be viewed dialectically. PS protein subunit, VVnr viral vector (non-replicating), IV inactivated virus, VVr viral vector (replicating), VLP virus-like particle, VVr + APC VVr + antigen-presenting cell, LAV live attenuated virus, VVnr + APC VVnr + antigen-presenting cell, BacAg-SpV bacterial antigen-spore expression vector</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e2606" position="float" orientation="portrait" xlink:href="41392_2024_2002_Fig3_HTML.jpg"/></fig></p><p id="Par23"><bold>Rotavirus:</bold> The successful application of mRNA vaccines against COVID-19 disease has prompted researchers to swiftly expand them to other antiviral fields. Rotaviruses (RVs) are responsible for causing diarrhea in children worldwide and can result in subsequent gastroenteritis, yet there is no specific treatment for this virus. Lu et al.<sup><xref ref-type="bibr" rid="CR14">14</xref></sup> designed an mRNA vaccine encoding the VP7 protein, which is one of the capsid proteins of RVs and plays an important role in the infection of target cells, for preventing RVs infection. The VP7 mRNA vaccine was inoculated to mice via intramuscular or subcutaneous injection (three doses). The findings demonstrated that the VP7 mRNA vaccine effectively stimulated T-cell immune responses and elicited RV-specific antibodies.</p><p id="Par24"><bold>Varicella-zoster virus:</bold> Varicella-zoster virus (VZV), a member of the alphaherpesvirus subfamily, is a neurotropic human herpesvirus.<sup><xref ref-type="bibr" rid="CR126">126</xref></sup> The initial infection manifests as chickenpox symptoms, after which the virus remains latent in the body. Reactivation of the virus occurs when the immune system weakens due to aging or compromised immunity.<sup><xref ref-type="bibr" rid="CR127">127</xref></sup> In 2024, Huang et al.<sup><xref ref-type="bibr" rid="CR128">128</xref></sup> developed an mRNA-based VZV vaccine called ZOSAL, which employed ionizable LNPs for encapsulating sequence-optimized mRNA encoding the full-length glycoprotein E. In this study, the immunogenicity, safety, and immune mechanisms of ZOSAL were compared with those of the licensed protein-based vaccine Shingrix in mice and rhesus macaques. The findings demonstrated that ZOSAL exhibited superior immunogenicity, safety profile, and capacity to induce virus-specific T-cell immunity when compared to Shingrix.</p><p id="Par25"><bold>Respiratory syncytial virus:</bold> Respiratory syncytial virus (RSV) is an enveloped, single-stranded RNA virus, which can cause respiratory illnesses.<sup><xref ref-type="bibr" rid="CR129">129</xref></sup> RSV can result in fatal outcomes for pediatric, geriatric, and immunocompromised individuals.<sup><xref ref-type="bibr" rid="CR130">130</xref></sup> One of the highly progressive vaccines aimed at combating RSV is mRNA-1345, which is presently being developed by ModernaTX, Inc. This vaccine encodes the membrane-anchored RSV prefusion stabilized F (preF) glycoprotein.<sup><xref ref-type="bibr" rid="CR131">131</xref></sup> Currently, the mRNA-1345 vaccine for RSV is undergoing Phase III trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05330975">NCT05330975</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06067230">NCT06067230</ext-link>), and it has already received FDA approval via fast-track designation for administration in individuals aged 60 years and older.<sup><xref ref-type="bibr" rid="CR132">132</xref></sup></p><p id="Par26"><bold>Influenza virus:</bold> Influenza viruses have the ability to infect a wide range of vertebrates and are responsible for causing seasonal influenza as well as influenza pandemics in humans.<sup><xref ref-type="bibr" rid="CR133">133</xref></sup> ModernaTX, Inc. developed a quadrivalent mRNA vaccine (mRNA-1010) targeting seasonal influenza, encoding the four hemagglutinin (HA) surface glycoproteins of influenza strains (A/H1N1, A/H3N2, B/Victoria, and B/Yamagata). The vaccine has undergone testing in healthy adults during Phase I/II trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04956575">NCT04956575</ext-link>), with interim results demonstrating favorable safety.<sup><xref ref-type="bibr" rid="CR134">134</xref></sup> Further, it has currently enrolled 22,510 adults aged 50 years and older (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05566639">NCT05566639</ext-link>)<sup><xref ref-type="bibr" rid="CR135">135</xref></sup> and 8400 adults aged 18 years and older (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05827978">NCT05827978</ext-link>)<sup><xref ref-type="bibr" rid="CR136">136</xref></sup> to initiate Phase III safety and efficacy studies.</p><p id="Par27"><bold>Cytomegalovirus:</bold> Cytomegalovirus (CMV) is an incredibly prevalent virus, with estimated incidence rates of 60% in developed countries and 90% in developing countries. Although asymptomatic in healthy individuals, infection with CMV can pose a significant risk to immunocompromised patients (such as those undergoing organ transplantation), potentially leading to graft rejection and even life-threatening complications. In addition, it is imperative to acknowledge the issue of vertical transmission of CMV from pregnant women to fetuses, which can result in premature birth and profound permanent disabilities in neonates, encompassing cognitive impairment and visual deficits. In order to tackle this concern, ModernaTX, Inc. developed an mRNA vaccine (mRNA-1647) that encodes two CMV proteins, namely glycoprotein B (gB) and pentameric gH/gL/UL128/UL130/UL131A glycoprotein complex (pentamer). The vaccine has successfully completed Phase I clinical trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03382405">NCT03382405</ext-link>), demonstrating that administration of three doses of mRNA-1647 (180&#8201;&#181;g) could effectively elicit high titers of neutralizing antibodies (nAbs), broad neutralization activity, robust T-cell response, and long-lasting memory B cells in healthy adults,<sup><xref ref-type="bibr" rid="CR137">137</xref></sup> while maintaining an acceptable safety profile.<sup><xref ref-type="bibr" rid="CR138">138</xref></sup> Hu et al.<sup><xref ref-type="bibr" rid="CR139">139</xref></sup> compared mRNA-1647 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03382405">NCT03382405</ext-link>) with MF59-adjuvanted gB subunit (gB/MF59) vaccine (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00133497">NCT00133497</ext-link>), and observed that although the gB-specific IgG responses were lower after inoculation with mRNA-1647 vaccine, it elicited persistent HCMV-specific antibody responses and higher antibody-dependent cellular cytotoxicity responses. In addition, a Phase III trial was conducted in healthy female participants aged 16&#8211;40 years with mRNA-1647 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05085366">NCT05085366</ext-link>).<sup><xref ref-type="bibr" rid="CR140">140</xref></sup></p><p id="Par28"><bold>Human papillomavirus:</bold> The distinctive properties of certain viruses, such as carcinogenicity, render mRNA vaccines encoding viral proteins a promising strategy for combating tumors. HPV infection is widely recognized as the primary factor contributing to cervical cancer.<sup><xref ref-type="bibr" rid="CR141">141</xref>,<xref ref-type="bibr" rid="CR142">142</xref></sup> The E6 and E7 proteins of human papillomavirus (HPV) have been established to modulate cell cycle and exhibit a high association with cervical cancer. In light of this, Lee et al.<sup><xref ref-type="bibr" rid="CR143">143</xref></sup> designed an mRNA vaccine encoding the E6 and E7 proteins, which was subsequently administered to C57BL/6J mice via intramuscular or subcutaneous injection. Their findings revealed that the mRNA vaccine markedly elicited robust T-cell-mediated immune responses in tumor-bearing mice, leading to a significant inhibition of tumor growth. Importantly, the experimental results demonstrated that the vaccine not only exhibited therapeutic potential against existing tumors but also displayed preventive efficacy.</p><p id="Par29"><bold>Epstein&#8211;Barr virus:</bold> Epstein&#8211;Barr virus (EBV), an oncogenic virus in humans, is frequently associated with nasopharyngeal carcinoma (NPC). LMP2 is one of the main viral proteins. Xiang et al.<sup><xref ref-type="bibr" rid="CR144">144</xref></sup> delivered LMP2-mRNA LNPs to tumor-draining lymph nodes (TDLN) for the purpose of inducing activation and cytotoxicity of CD8<sup>+</sup> T cells against tumor cells expressing LMP2. Zhao et al.<sup><xref ref-type="bibr" rid="CR145">145</xref></sup> developed three therapeutic EBV mRNA vaccines that encoded truncated latent EBV protein regions containing abundant T-cell epitopes, including truncated forms of latent membrane protein 2A (LMP2A), EBV nuclear antigen 1 (EBNA1), and EBV nuclear antigen 3A (EBNA3A). Their findings demonstrated that these EBV mRNA vaccines could effectively elicit antigen-specific immune responses, thereby suppressing tumor progression and prolonging the survival time of tumor-bearing mice.</p><p id="Par30"><bold>Rabies virus:</bold> The neurotropic rabies virus (RABV), a member of the Lyssavirus family and a single-stranded RNA virus,<sup><xref ref-type="bibr" rid="CR146">146</xref></sup> has the ability to infect all warm-blooded animals,<sup><xref ref-type="bibr" rid="CR147">147</xref></sup> including humans, leading to the development of rabies. Rabies is a fatal neurological disease, and once the initial symptoms manifest, there is minimal time to pursue treatment options, as the mortality rate approaches 100%.<sup><xref ref-type="bibr" rid="CR146">146</xref></sup> Rabies causes an estimated 59,000 fatalities annually on a global scale.<sup><xref ref-type="bibr" rid="CR148">148</xref></sup> The currently most widely used rabies vaccines are all inactivated, requiring individuals to receive three to five doses for optimal immune protection.<sup><xref ref-type="bibr" rid="CR149">149</xref>,<xref ref-type="bibr" rid="CR150">150</xref></sup> In summary, despite advancements in rabies vaccine development, the current availability of vaccines is constrained by factors such as high costs, limited production capacity and storage requirements, as well as the necessity for multiple doses.<sup><xref ref-type="bibr" rid="CR147">147</xref></sup> The mRNA vaccines represent a promising approach that has the potential to reduce costs and lower the required dosage for achieving effective immune protection.<sup><xref ref-type="bibr" rid="CR150">150</xref></sup> RABV glycoprotein (RABV-G), being the only virion-surface protein of RABV, plays a crucial role as an antigen in vaccine development.<sup><xref ref-type="bibr" rid="CR151">151</xref></sup> In 2013, CureVac conducted the initial Phase I clinical trial for an mRNA-based rabies vaccine in healthy adults (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02241135">NCT02241135</ext-link>). The trial findings indicated that the mRNA vaccine (CV7201) encoding the RABV-G demonstrated a favorable safety profile.<sup><xref ref-type="bibr" rid="CR13">13</xref></sup> Subsequently, CureVac also progressed a mRNA vaccine named CV7202, encoding the RABV-G protein, into Phase I clinical trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03713086">NCT03713086</ext-link>). Currently, research on the mRNA vaccine for RABV-G is ongoing. Cao et al.<sup><xref ref-type="bibr" rid="CR152">152</xref></sup> developed a novel mRNA LNPs that encodes RABV-G with the H270P mutation, which can stabilize the prefusion conformation of RABV-G. Their findings demonstrated that this vaccine elicited superior humoral and cellular immune responses compared to mRNA LNPs encoding RABV-G, indicating that structured-guided vaccine design may be the future direction for vaccine development.</p><p id="Par31"><bold>Human immunodeficiency virus:</bold> Acquired immunodeficiency syndrome (AIDS), resulting from infection with the human immunodeficiency virus (HIV), remains a fatal disease for humans.<sup><xref ref-type="bibr" rid="CR153">153</xref></sup> Although current antiretroviral therapies<sup><xref ref-type="bibr" rid="CR154">154</xref></sup> and therapeutic vaccines can improve HIV-related morbidity and mortality, they are still unable to completely eradicate HIV.<sup><xref ref-type="bibr" rid="CR155">155</xref></sup> At present, the HIV mRNA vaccines that have been developed and entered clinical trials include the eOD-GT8 60mer mRNA vaccine (mRNA-1644, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05414786">NCT05414786</ext-link>)<sup><xref ref-type="bibr" rid="CR156">156</xref></sup> and the Core-g28v2 60mer mRNA vaccine (mRNA-1644v2-Core, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05001373">NCT05001373</ext-link>).<sup><xref ref-type="bibr" rid="CR157">157</xref></sup> As of June 2024, these vaccines are still undergoing Phase I clinical trials. Despite the evaluation of various HIV vaccines in preclinical and clinical studies, the overall outcomes have been unsatisfactory.<sup><xref ref-type="bibr" rid="CR158">158</xref></sup> Further endeavors are imperative for the development of an effective HIV vaccine. Mandal et al.<sup><xref ref-type="bibr" rid="CR159">159</xref></sup> designed LNPs containing mRNA that encoded multiple epitopes of HIV viral protease cleavage sites. The mRNA LNPs exhibited long-term stability at cold-chain temperatures and could elicit potent cellular immunity, making it as a promising candidate for a prophylactic HIV mRNA vaccine. A major obstacle in the eradication of HIV lies in the virus&#8217;s ability to conceal itself within host cells, including myeloid cells and CD4<sup>+</sup> T cells.<sup><xref ref-type="bibr" rid="CR160">160</xref></sup> It appears that vaccines alone may not be sufficient for curing HIV, prompting consideration of combining vaccines with other treatment modalities.<sup><xref ref-type="bibr" rid="CR155">155</xref>,<xref ref-type="bibr" rid="CR160">160</xref></sup> The extensive genetic diversity of HIV and its capacity to integrate into the host cell genome undoubtedly pose significant challenges for the development of HIV vaccines.<sup><xref ref-type="bibr" rid="CR161">161</xref>,<xref ref-type="bibr" rid="CR162">162</xref></sup></p><p id="Par32"><bold>Monkeypox virus:</bold> Monkeypox is a communicable disease caused by the monkeypox virus (MPXV), which can be transmitted between humans and animals.<sup><xref ref-type="bibr" rid="CR163">163</xref>,<xref ref-type="bibr" rid="CR164">164</xref></sup> MPXV is a type of double-stranded DNA virus<sup><xref ref-type="bibr" rid="CR163">163</xref>,<xref ref-type="bibr" rid="CR165">165</xref></sup> that belongs to the <italic toggle="yes">Orthopoxvirus</italic> genus.<sup><xref ref-type="bibr" rid="CR165">165</xref>,<xref ref-type="bibr" rid="CR166">166</xref></sup> Currently, a multivalent mRNA vaccine (BNT166) encoding MPXV antigens A35, B6, H3, and M1 has entered Phase I clinical trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05988203">NCT05988203</ext-link>)<sup><xref ref-type="bibr" rid="CR167">167</xref></sup>. Several preclinical studies are underway to develop novel mRNA vaccines targeting various antigens of the virus. Tian et al.<sup><xref ref-type="bibr" rid="CR168">168</xref></sup> designed an mRNA-based vaccine encoding the MPXV A29L antigen. Su et al.<sup><xref ref-type="bibr" rid="CR169">169</xref></sup> developed a quadrivalent mRNA vaccine that encoded the antigens A27, L1, A33, and B5 of vaccinia virus. It is noteworthy that the sera from mice immunized with this vaccine demonstrated reactivity with the antigens of various orthopoxviruses in vitro. This suggests that the mRNA vaccine holds promise for safeguarding humans against MPXV and other orthopoxvirus infections.</p></sec><sec id="FPar2"><title>Tumor antigen mRNA vaccine</title><p id="Par33">Cancer is a major cause of global mortality.<sup><xref ref-type="bibr" rid="CR170">170</xref></sup> The inception of antitumor mRNA vaccines can be traced back to 1995, when Conry et al.<sup><xref ref-type="bibr" rid="CR171">171</xref></sup> constructed an mRNA encoding the tumor antigen&#8211;human carcinogenic antigen (CEA) that could be directly injected into the skin to combat tumors in mouse models. In 2004, a clinical trial was initiated to intradermally administer mRNA-encoding melanoma-associated antigens to stage III/IV melanoma patients (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00204607">NCT00204607</ext-link>).<sup><xref ref-type="bibr" rid="CR9">9</xref></sup> In 2009, Weide et al.<sup><xref ref-type="bibr" rid="CR10">10</xref></sup> reported the results of the Phase I/II trial, demonstrating that the feasibility and safety of direct injection of protamine-protected mRNA, thereby encouraging further clinical studies on mRNA vaccines.</p><p id="Par34">A critical step in the development of cancer vaccines involves the identification and selection of appropriate tumor antigens, encompassing both TAAs and tumor-specific antigens (TSAs).<sup><xref ref-type="bibr" rid="CR172">172</xref></sup></p><p id="Par35">TAAs are non-mutated proteins that exhibit high expression in tumors while showing no-to-low expression in normal tissues.<sup><xref ref-type="bibr" rid="CR173">173</xref></sup> The RNA-LPX vaccine (BNT111), which has successfully completed Phase I clinical trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02410733">NCT02410733</ext-link>) and is now progressing to Phase II (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04526899">NCT04526899</ext-link>), is a tumor vaccine designed to encode TAAs (New York esophageal squamous cell carcinoma 1, melanoma-associated antigen 3, tyrosinase, and transmembrane phosphatase with tensin homology) for melanoma.<sup><xref ref-type="bibr" rid="CR174">174</xref>,<xref ref-type="bibr" rid="CR175">175</xref></sup> The results of the clinical trial demonstrated that the intravenous administration of BNT111 vaccine in patients can elicit a robust and broad T-cell response against TAAs.<sup><xref ref-type="bibr" rid="CR117">117</xref></sup> However, the use of TAAs as tumor antigens is limited by their expression in normal tissues to some extent, which may hinder the development of effective antitumor immune responses owing to the self-tolerance mechanisms and the potential for off-target effects that may lead to autoimmune toxicity.<sup><xref ref-type="bibr" rid="CR173">173</xref>,<xref ref-type="bibr" rid="CR176">176</xref></sup></p><p id="Par36">TSAs, which result from mutations in somatic cells, hold significant potential for inducing specific T-cell responses against tumors.<sup><xref ref-type="bibr" rid="CR173">173</xref></sup> For instance, Moderna&#8217;s mRNA-4157 is an mRNA vaccine that encodes up to 34 patient-specific tumor neoantigens.<sup><xref ref-type="bibr" rid="CR177">177</xref></sup> It became the first mRNA cancer vaccine to enter Phase III clinical trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05933577">NCT05933577</ext-link>). The clinical IIb trial of mRNA-4157 in combination with Pembrolizumab treatment demonstrated a 49% reduction in the risk of mortality among high-risk melanoma patients.<sup><xref ref-type="bibr" rid="CR176">176</xref></sup> TSAs are promising targets for cancer vaccines.<sup><xref ref-type="bibr" rid="CR178">178</xref></sup> However, only a small fraction of somatic mutations in cancer cells could be recognized by spontaneously occurring T cells, and the efficacy of these neoepitopes in mediating antitumor effects varies, posing challenges for their precise utilization.<sup><xref ref-type="bibr" rid="CR173">173</xref></sup></p><p id="Par37">To address the challenge of limited availability of targetable neoantigens and antigen target loss in tumors, it is imperative to investigate and utilize the full spectrum of tumor antigens, to develop personalized cancer vaccines. Trivedi et al.<sup><xref ref-type="bibr" rid="CR179">179</xref></sup> established an immunogenomics pipeline called &#8220;Open Reading Framework Antigen Network (O.R.A.N.)&#8221; to effectively identify immunogenic antigens with high likelihood of becoming therapeutic targets. In addition, they developed a platform called &#8220;Tumor Open reading Frames that are Unique (TOFU)&#8221; which utilizes IVT mRNA technology for encoding multiple tumor antigens into a single mRNA vaccine, thereby enabling the customization of virtually limitless quantities of antigens specific to each tumor type. Ben-Akiva et al.<sup><xref ref-type="bibr" rid="CR180">180</xref></sup> developed a class of bioreducible nanocarriers utilizing lipophilic poly(beta-amino ester) to encapsulate antigen-encoding mRNA and Toll-like receptor (TLR) agonist adjuvants for the treatment of murine melanoma and colon adenocarcinoma. Due to its mRNA sequence-independent encapsulation capacity, this platform can also be extended to address other cancer diseases.</p><p id="Par38">The standalone mRNA cancer vaccine may serve as an effective treatment option for early-stage cancer. However, in the case of advanced cancer patients, the tumor microenvironment often exhibits a high level of immune suppression, thereby diminishing the efficacy of mRNA monotherapy.<sup><xref ref-type="bibr" rid="CR181">181</xref></sup> Instead, combining therapeutic cancer mRNA vaccines with other immunotherapies,<sup><xref ref-type="bibr" rid="CR182">182</xref></sup> such as the combination of mRNA-4157 and Pembrolizumab to treat high-risk melanoma, holds promise for success.<sup><xref ref-type="bibr" rid="CR183">183</xref></sup></p><p id="Par39">Despite the fact that mRNA vaccines encoding tumor antigens entered Phase I trials earlier than viral mRNA vaccines, it is disappointing that few mRNA vaccines against cancer seem to have advanced to Phase III or IV trials (Fig. <xref rid="Fig3" ref-type="fig">3b</xref>).<sup><xref ref-type="bibr" rid="CR184">184</xref></sup> The reasons are summarized in &#8220;Conclusions and prospects&#8221; section. We anticipate an influx of approved drugs and methodologies for cancer treatment, instilling renewed optimism in patients.</p></sec><sec id="FPar3"><title>Bacterial antigen mRNA vaccine</title><p id="Par40">The conventional approach to eradicating bacteria involves the administration of antibiotics. However, due to the overuse of these drugs, we have been alarmed by the emergence of antibiotic-resistant bacteria and even the development of highly resistant strains. Nevertheless, it is important to note that the research and approval process for creating a new antibiotic is exceedingly time-consuming and necessitates substantial financial resources. Regrettably, bacteria can develop resistance at a much faster rate than new drugs can be developed. Consequently, despite our awareness regarding the imperative need for antibiotics control measures, we may find ourselves in a situation where no effective drug exists to combat bacterial infections. Therefore, it is essential to propose an innovative antimicrobial therapy. Given that mammalian organisms are capable of translating mRNA-encoding bacterial proteins, mRNA vaccines offer a promising and efficacious avenue for preventing bacterial diseases.<sup><xref ref-type="bibr" rid="CR185">185</xref>,<xref ref-type="bibr" rid="CR186">186</xref></sup></p><p id="Par41">Lyme disease is a prevalent infectious ailment in the U.S. that currently lacks a specific vaccine. Among various candidates, outer surface protein A (OspA) that expressed on the pathogen Borrelia burgdorferi has emerged as most promising antigen for developing a platform to combat Lyme disease. Therefore, Pine et al.<sup><xref ref-type="bibr" rid="CR187">187</xref></sup> developed a mRNA LNPs encoding OspA and observed that its protective efficacy surpassed that of the OspA protein subunit vaccine. The treatment regimen of mRNA-1975 and mRNA-1982 developed by ModernaTX, Inc. for Lyme disease is currently in Phase I/II clinical trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05975099">NCT05975099</ext-link>).<sup><xref ref-type="bibr" rid="CR188">188</xref></sup></p><p id="Par42">As a significant infectious disease, Tuberculosis (TB), caused by <italic toggle="yes">Mycobacterium Tuberculosis</italic> (M. TB),<sup><xref ref-type="bibr" rid="CR189">189</xref></sup> continues to present a grave global public health menace. Currently, the only licensed vaccine for TB is Bacillus Calmette&#8211;Guerin (BCG), which exhibits limited efficacy in preventing the disease.<sup><xref ref-type="bibr" rid="CR190">190</xref></sup> The absence of effective vaccine strategies and the emergence and dissemination of multidrug-resistant TB (MDR-TB) bacteria have further complicated endeavors to prevent and treat TB. Similar to COVID-19, TB also represents a respiratory infection. Can the mRNA vaccine strategy successfully employed for COVID-19 be replicated for TB?<sup><xref ref-type="bibr" rid="CR191">191</xref></sup> Fortunately, in 2023, BioNTech SE commenced Phase I/II clinical trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05547464">NCT05547464</ext-link>) for an mRNA approach targeting TB (BNT164a1 and BNT164b1),<sup><xref ref-type="bibr" rid="CR185">185</xref>,<xref ref-type="bibr" rid="CR192">192</xref></sup> and we expect a satisfactory therapeutic efficacy from this strategy.</p><p id="Par43">Currently, the application of antibacterial mRNA vaccines in preclinical and clinical attempts is limited, possibly due to the intricate nature of bacterial infections compared to viral infections. Bacterial infections exhibit distinct molecular expression characteristics at different stages of infection, making it virtually impossible for a single antigen to effectively cover all these stages.<sup><xref ref-type="bibr" rid="CR193">193</xref></sup> Moreover, bacterial pathogens display diversity and the variability in antigen expression while also evolving multiple mechanisms to evade or suppress immune responses.<sup><xref ref-type="bibr" rid="CR185">185</xref></sup> Therefore, if mRNA vaccines are intended for further application in preventing and treating bacterial infections, careful consideration must be given to rational antigen selection along with the incorporation of adjuvants and other optimization strategies.<sup><xref ref-type="bibr" rid="CR193">193</xref></sup> The research conducted by Meulewaeter et al.<sup><xref ref-type="bibr" rid="CR194">194</xref></sup> demonstrated that the incorporation of adjuvant &#945;GC into the <italic toggle="yes">Listeria monocytogenes</italic> mRNA LNPs resulted in a synergistic protective effect against listeriosis, underscoring the therapeutic advantages of co-activating invariant natural killer T (iNKT) cells in antibacterial mRNA vaccines. We are looking forward to the successful development of the first antibacterial mRNA vaccine product.</p></sec><sec id="FPar4"><title>Parasite antigen mRNA vaccine</title><p id="Par44">In addition to viral infections, parasitic diseases are also infectious illnesses that debilitate individuals. Parasitic diseases can be generally categorized into three groups: ectoparasitic, protozoal, and helminthic diseases. These conditions can be managed through proactive vector control, disease monitoring, the use of effective vaccines/medications, and the implementation of appropriate sanitation infrastructure.<sup><xref ref-type="bibr" rid="CR195">195</xref></sup> However, the lack of public awareness and the absence of appropriate treatment options have resulted in widespread parasitic infections.<sup><xref ref-type="bibr" rid="CR196">196</xref></sup></p><p id="Par45">Malaria is the most deadly parasitic vector-borne disease<sup><xref ref-type="bibr" rid="CR197">197</xref></sup> caused by at least five species of <italic toggle="yes">Plasmodium</italic> parasites.<sup><xref ref-type="bibr" rid="CR198">198</xref>&#8211;<xref ref-type="bibr" rid="CR200">200</xref></sup> Over the years, researchers have endeavored to develop vaccines targeting different stages of the malaria parasite&#8217;s life cycle. However, the only approved vaccine to date is Mosquirix, which is based on recombinant proteins. Nevertheless, Mosquirix has encountered several limitations, including suboptimal efficacy in specific age groups and the necessity for multiple booster shots to achieve a satisfactory level of protection. Fortunately, the mRNA vaccine (BNT165b1) developed by BioNTech, which encodes a segment of the <italic toggle="yes">Plasmodium falciparum</italic> circumsporozoite protein (PfCSP), has progressed to Phase I clinical trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05581641">NCT05581641</ext-link>).<sup><xref ref-type="bibr" rid="CR201">201</xref></sup> Kunkeaw et al.<sup><xref ref-type="bibr" rid="CR202">202</xref></sup> developed the LNPs platform to deliver nucleotide-modified mRNA encoding the Pvs25 antigen of Plasmodium vivax, a potential vaccine against malaria transmission. Pvs25 is an antigen candidate for blocking malaria transmission. They discovered that the mRNA LNPs platform could elicit stronger and more enduring functional immunity compared to the Pvs25 recombinant protein vaccine. Additional mRNA vaccines against malaria are currently undergoing preclinical research.<sup><xref ref-type="bibr" rid="CR203">203</xref>&#8211;<xref ref-type="bibr" rid="CR205">205</xref></sup></p><p id="Par46">The lack of interest in the commercial development of parasite vaccines may be attributed to the fact that parasitic diseases primarily affect economically disadvantaged populations, and most parasites cause chronic illnesses that are non-lethal to the host, with the exception of the deadly malaria. Parasite infections are intricate, and the development of conventional vaccines entails high costs.<sup><xref ref-type="bibr" rid="CR206">206</xref></sup> In these regards, mRNA-based vaccines present a promising approach to address these challenges.</p></sec><sec id="FPar5"><title>Autoimmune disease antigen therapy</title><p id="Par47">The immune system plays a critical role in defending the body against infections caused by viruses, bacteria, fungi, and parasites. Additionally, it surveils and eliminates cancerous cells to maintain the body&#8217;s health. Autoimmune disorders arise when the immune system erroneously targets healthy tissues and cells in the body.<sup><xref ref-type="bibr" rid="CR207">207</xref>,<xref ref-type="bibr" rid="CR208">208</xref></sup> An essential characteristic of autoimmune diseases is the presence of autoantibodies that have the ability to specifically bind to the antigens present in the patient&#8217;s healthy cells or tissues.<sup><xref ref-type="bibr" rid="CR207">207</xref>,<xref ref-type="bibr" rid="CR209">209</xref></sup> There are more than 80 autoimmune disorders, including multiple sclerosis (MS),<sup><xref ref-type="bibr" rid="CR210">210</xref></sup> type 1 diabetes (T1D),<sup><xref ref-type="bibr" rid="CR211">211</xref></sup> systemic lupus erythematosus (SLE),<sup><xref ref-type="bibr" rid="CR212">212</xref></sup> inflammatory bowel disease (IBD),<sup><xref ref-type="bibr" rid="CR213">213</xref></sup> and rheumatoid arthritis (RA).<sup><xref ref-type="bibr" rid="CR214">214</xref></sup> The objective of treating autoimmune diseases is to regulate the activity of autoreactive cells in the body without inducing systemic immune suppression.<sup><xref ref-type="bibr" rid="CR215">215</xref></sup></p><p id="Par48">Krienke et al.<sup><xref ref-type="bibr" rid="CR210">210</xref></sup> utilized a non-inflammatory lipid complex carrier to encapsulate <italic toggle="yes">N</italic><sup>1</sup>-methyl-pseudouridine-modified mRNA (m<sup>1</sup>&#936; mRNA) encoding disease-related autoantigens. Their findings indicated that the use of this m<sup>1</sup>&#936; mRNA vaccine could stimulate antigen-specific regulatory T cells (Tregs) and mitigate the severity of multiple sclerosis in a mouse model.<sup><xref ref-type="bibr" rid="CR216">216</xref></sup> This strategy seems capable of inducing cross-tolerance in autoimmune T cells while preserving the normal immune response of the immune system.<sup><xref ref-type="bibr" rid="CR217">217</xref></sup> This also implied that by reducing unnecessary immunogenicity, mRNA vaccines encoding autoantigens can be a means to induce and sustain natural peripheral immune tolerance.<sup><xref ref-type="bibr" rid="CR218">218</xref></sup></p><p id="Par49">Type 1 diabetes is an autoimmune condition in which the immune system mistakenly attacks and destroys the pancreatic islet &#946;-cells, resulting in insufficient insulin production.<sup><xref ref-type="bibr" rid="CR211">211</xref>,<xref ref-type="bibr" rid="CR219">219</xref></sup> Foster et al.<sup><xref ref-type="bibr" rid="CR220">220</xref></sup> discovered that the utilization of a novel mRNA vaccine encoding proinsulin II could transiently delay diabetes symptoms in nonobese diabetic mice. This effect may be attributed to the ability of the mRNA vaccine to restore immune tolerance in nonobese diabetic mice.</p><p id="Par50">The mRNA therapies hold significant promise in the realm of autoimmune diseases.<sup><xref ref-type="bibr" rid="CR221">221</xref>,<xref ref-type="bibr" rid="CR222">222</xref></sup> For instance, the mRNA drugs can be tailored to encode proteins or peptides capable of binding and neutralizing autoantibodies. In addition, mRNA can be engineered to specifically target plasma cells and express pro-apoptotic molecules within them, thereby selectively disrupting or eliminating their function and survival. Furthermore, given the pivotal role of Tregs in suppressing immune responses, mRNA can be designed to bolster the functionality of Treg cells.<sup><xref ref-type="bibr" rid="CR207">207</xref></sup></p></sec></sec><sec id="Sec9"><title>Therapeutic antibody therapy</title><p id="Par51">Antibodies, also referred to as immunoglobulins, are effector molecules generated by the humoral immune responses that can neutralize antigens<sup><xref ref-type="bibr" rid="CR223">223</xref></sup> and play a crucial role in the prevention, control, and elimination of infections.<sup><xref ref-type="bibr" rid="CR224">224</xref></sup> The emergence of the therapeutic antibody can be traced back to 1975, when K&#246;hler and Milstein pioneered the hybridoma technology and laid the foundation for the progress of monoclonal antibodies (mAbs).<sup><xref ref-type="bibr" rid="CR225">225</xref></sup> Currently, therapeutic antibodies have emerged as a potent armamentarium against a variety of diseases,<sup><xref ref-type="bibr" rid="CR223">223</xref></sup> demonstrating remarkable efficacy in treating viral illnesses, solid tumors, hematological malignancies, autoimmune disorders, and other indications. In the last few decades, antibodies have experienced unprecedented growth as new drugs for these indications.<sup><xref ref-type="bibr" rid="CR226">226</xref></sup></p><p id="Par52">However, protein-based drugs such as mAbs encounter challenges in terms of production and cost, including intricate manufacturing process, high purification expenses, and difficulties in post-translational modification of proteins. In addition, the human body harbors a total of 22 distinct amino acids, and due to variations in their types, quantities, and arrangements, proteins can exhibit diverse physicochemical properties. To ensure protein storage stability, specialized buffer solutions optimized for this purpose are indispensable.<sup><xref ref-type="bibr" rid="CR227">227</xref></sup> The nucleic acids, in contrast, carry a negative charge and exhibit similar physicochemical characteristics. Therefore, the production and purification process of nucleic acid drugs does not necessitate specific customization, and it is easy to obtain the natural structure of the desired protein owing to the target cell-endogenous expression mechanisms.<sup><xref ref-type="bibr" rid="CR227">227</xref></sup></p><p id="Par53">Delivering mRNA into the body for translation into antibodies, rather than directly administering the mAbs, circumvents the hassles associated with protein production and purification. Moreover, this approach enables the encoding of proteins that are challenging to synthesize in vitro. Deal et al.<sup><xref ref-type="bibr" rid="CR228">228</xref></sup> engineered an mRNA sequence encoding the pathogen-specific immunoglobulin A (IgA) mAbs, which was encapsulated in LNPs and delivered to mucosal secretions. Intriguingly, the pharmacodynamics of lgA<sub>mRNA</sub> encoded by this mRNA closely resemble those of endogenous human lgA rather than recombinant IgA (IgA<sub>R</sub>). These findings suggested that the mRNA antibody technology held promise for intercepting pathogens on mucosal surfaces, offering a novel and effective approach for the prevention and treatment of diseases.</p><p id="Par54">The intravenous administration of anti-vascular endothelial growth factor (VEGF) antibodies typically results in their predominant distribution in the vasculature and interstitial spaces, with limited accumulation in the target organ&#8212;the lungs. This limited localization impairs their therapeutic efficacy for non-small cell lung cancers (NSCLCs) and may have adverse effects on normal tissues. A team led by Le et al.<sup><xref ref-type="bibr" rid="CR229">229</xref></sup> developed a pulmonary-targeting nanoparticle for delivering mRNA-encoding Bevacizumab, an anti-VEGF antibody widely used in the clinic. These nanoparticles utilized the inherent properties of poly(beta-amino esters) (PBAEs) to achieve their pulmonary-targeting function. This innovative approach effectively suppresses angiogenesis in NSCLCs, offering a promising therapeutic strategy for the treatment of this disease.</p><p id="Par55">The <italic toggle="yes">Orthopoxvirus</italic> genus, including MPXV and variola virus (VARV), constitutes a significant global health threat that causes severe pox diseases in both humans and animals. Chi et al.<sup><xref ref-type="bibr" rid="CR230">230</xref></sup> constructed mRNA combinations encoding four mAbs (mAbs 22, 283, 26, and 301) specifically designed to target and neutralize vaccinia virus (VACV) A33, VACV B5, MPXV M1 and VACV A27 proteins. This was the first application of mRNA antibodies against Orthopoxvirus in vivo. The results indicated that a single injection of LNPs encapsulated with mRNA in mice could rapidly induce the production of corresponding neutralizing antibodies, which demonstrated significant protective effects in the VACV lethal challenge mouse model and reduced mortality rates.</p><p id="Par56">In the last decade, there have been significant advancements in the treatment of advanced cancers with immune checkpoint inhibitors (ICIs). Currently, clinically approved ICIs consist of innovative medications that target programmed cell death protein-1 (PD-1), programmed death ligand-1 (PD-L1), cytotoxic T- lymphocyte-associated protein 4 (CTLA-4), and lymphocyte activation gene-3 (LAG-3).<sup><xref ref-type="bibr" rid="CR231">231</xref>,<xref ref-type="bibr" rid="CR232">232</xref></sup> Nevertheless, ICIs still possess certain limitations, such as the potential for immune-related adverse events.<sup><xref ref-type="bibr" rid="CR233">233</xref>,<xref ref-type="bibr" rid="CR234">234</xref></sup> In order to address these safety concerns, researchers have explored the use of mRNA therapies encoding ICIs.<sup><xref ref-type="bibr" rid="CR235">235</xref></sup> Pruitt et al.<sup><xref ref-type="bibr" rid="CR236">236</xref></sup> transfected DCs with mRNA encoding the heavy and light chains of anti-CTLA-4 and anti-GITR mAbs, as well as mRNA-encoding tumor antigens. Their findings demonstrated that these mRNA-engineered DC cells significantly augmented antitumor immunity in melanoma-bearing mice without eliciting any signs of autoimmunity. Utilizing this technology, a Phase I clinical trial for patients with metastatic melanoma is presently under assessment (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01216436">NCT01216436</ext-link>). The IVT mRNA platform also enables the continuous endogenous synthesis of bispecific antibodies that bind to T cells. Zeng et al.<sup><xref ref-type="bibr" rid="CR237">237</xref></sup> established and optimized an mRNA sequence called Z15-0-2 that codes for a bispecific nanobody of anti-PD-1 and anti-CTLA-4. Moreover, there are mRNA-based therapeutics encoding anti-PD-L1 mAb for cancer treatment<sup><xref ref-type="bibr" rid="CR238">238</xref></sup> and mRNA-6981 encoding PD-L1 for autoimmune diseases.<sup><xref ref-type="bibr" rid="CR239">239</xref></sup></p><p id="Par57">Rituximab is a human/murine chimeric glycosylated IgG1-&#954; mAb with specific affinity for the transmembrane protein CD20 on B lymphocytes.<sup><xref ref-type="bibr" rid="CR240">240</xref></sup> Thran et al.<sup><xref ref-type="bibr" rid="CR241">241</xref></sup> developed LNPs formulations containing mRNA-encoding Rituximab (anti-CD20 mAb) to combat B-cell lymphoma. They observed that the mRNA LNPs treatment exhibited a pronounced and potent antitumor effect comparable to that of recombinant antibody therapy.<sup><xref ref-type="bibr" rid="CR79">79</xref></sup> The mRNA drugs encoding anti-CD20 mAb may also offer promising therapeutic options for autoimmune conditions such as multiple sclerosis and rheumatoid arthritis.<sup><xref ref-type="bibr" rid="CR207">207</xref></sup> Antibody-based mRNA therapies hold significant potential for the treatment of tumors, chronic inflammation, and autoimmune disorders.<sup><xref ref-type="bibr" rid="CR242">242</xref></sup></p></sec><sec id="Sec10"><title>Cytokine</title><p id="Par58">Theoretically, mRNA has the potential to encode any protein, including cytokines that can be used as standalone therapies or in combination with other treatment modalities for disease management.<sup><xref ref-type="bibr" rid="CR243">243</xref></sup></p><p id="Par59">Cytokines play a pivotal role in regulating various biological processes such as cell survival, proliferation, differentiation and immune cell activity by facilitating crucial intercellular communication within short distances.<sup><xref ref-type="bibr" rid="CR244">244</xref></sup> The potential of cytokines in the realm of antitumor research is exemplified by their capacity to impede the proliferation of tumor cells, facilitate the induction of apoptosis, and modulate both innate and adaptive immunity.<sup><xref ref-type="bibr" rid="CR245">245</xref></sup> Furthermore, cytokines may exhibit immunosuppressive effects, offering a potential therapeutic approach for conditions derived from hyperactive immune responses such as autoimmune diseases. The cytokine subgroups commonly encompass IL, interferons (IFNs), chemokines, granulocyte-macrophage colony-stimulating factor (GM-CSF) and so on.<sup><xref ref-type="bibr" rid="CR244">244</xref></sup></p><sec id="FPar6"><title>Immune-potentiating cytokine</title><p id="Par60"><bold>IL-2, IL-21, and IL-15:</bold> The FDA granted approval for the use of recombinant human IL-2 in 1992 for the treatment of metastatic renal cancer, and in 1998 for the management of metastatic melanoma.<sup><xref ref-type="bibr" rid="CR246">246</xref></sup> However, intravenous administration of IL-2 exhibits limited tumor accumulation<sup><xref ref-type="bibr" rid="CR247">247</xref></sup> and possesses a short half-life (only 5 to 7&#8201;min). In order to achieve enhanced antitumor effects, administration of high doses of IL-2 is imperative, leading to elevated concentrations of IL-2 in the bloodstream and subsequent manifestation of adverse reactions in patients, including asthenia, pyrexia, and potentially life-threatening toxicity such as capillary leak syndrome.<sup><xref ref-type="bibr" rid="CR248">248</xref></sup> To mitigate the systemic toxicity associated with IL-2 protein delivery, Shin et al.<sup><xref ref-type="bibr" rid="CR249">249</xref></sup> proposed a novel approach involving intratumoral administration of IL-2 mRNA NPs. These NPs are composed of polyethyleneimine-modified porous silica and effectively minimize off-target translation of mRNA. Jiang et al.<sup><xref ref-type="bibr" rid="CR250">250</xref></sup> developed mRNA sequences encoding fusion proteins consisting of IL-2, CD25 (IL-2R&#945;), and a cleavable linker, which were encapsulated within ionizable lipid U-101&#8211;derived NPs. The designed linker was susceptible to cleavage by tumor-specific matrix metalloproteinase-14 (MMP-14). Furthermore, the researchers observed that U-101&#8211;derived NPs exhibited superior transfection efficacy compared to approved ALC-0315&#8211;LNPs, thereby contributing to the platform&#8217;s ability to achieve enhanced antitumor efficacy with reduced toxicity. Beck et al.<sup><xref ref-type="bibr" rid="CR251">251</xref></sup> combined long-lasting mRNA-encoded IL-2 with tumor-targeting mAb therapy, thereby inducing a highly pro-inflammatory TME and overcoming tumor resistance resulting from the absence of MHC I.</p><p id="Par61">In addition to IL-2, other cytokines that belong to the gamma-chain receptor family include IL-4, IL-7, IL-15, IL-21.<sup><xref ref-type="bibr" rid="CR252">252</xref></sup> The role of IL-21 in the clearance of hepatitis B virus (HBV) is significant. The mRNA LNPs encoding IL-21, delivered by Shen et al.<sup><xref ref-type="bibr" rid="CR253">253</xref></sup>, demonstrated remarkable efficacy in inducing effective clearance of HBV and its covalently closed circular DNA (cccDNA).</p><p id="Par62">IL-15 shares a structural resemblance with IL-2<sup><xref ref-type="bibr" rid="CR254">254</xref></sup> and plays a crucial role in the regulation of both innate and adaptive immunity.<sup><xref ref-type="bibr" rid="CR255">255</xref></sup> IL-15 is widely acknowledged as a T-cell growth factor that governs the activation, proliferation, and cytotoxicity of T cells, B cells, and natural killer (NK) cells, thereby enhancing the production of IFN-&#947; and TNF-&#945;. Moreover, due to its unlikely induction of Treg cell activity during immune stimulation,<sup><xref ref-type="bibr" rid="CR254">254</xref></sup> IL-15 has been regarded as a promising candidate in oncology.<sup><xref ref-type="bibr" rid="CR255">255</xref></sup> Nevertheless, IL-15 is associated with significant drawbacks such as severe toxicities and a short half-life. These challenges can be addressed through efficient delivery of mRNA-encoding IL-15 to the tumor. Wang et al.<sup><xref ref-type="bibr" rid="CR256">256</xref></sup> designed a nanoplatform to specifically target PD-L1 for the delivery of IL-15 mRNA, and integrated it with an ultrasound-targeted microbubble destruction therapy approach. This therapeutic approach not only effectively facilitates the expression of IL-15, but also significantly enhances intracellular reactive oxygen species (ROS) levels, induces immunogenic cell death (ICD), thereby effectively suppressing tumor growth and recurrence. Furthermore, this integrated therapy offers real-time ultrasound imaging guidance. Gavigan et al.<sup><xref ref-type="bibr" rid="CR257">257</xref></sup> developed a combination therapy comprising IFN&#945;, IL-7, IL-15, and a TNF receptor superfamily agonist. Their findings demonstrated that co-delivery of mRNA mixture encoding IFN&#945;, IL-7, a protein fused with IL-15 and its receptor &#945; chain, and OX40L could elicit potent antitumor immune responses in mice.</p><p id="Par63"><bold>IL-12 and IL-27:</bold> Liu et al.<sup><xref ref-type="bibr" rid="CR258">258</xref></sup> endeavored to synergize IL-12 mRNA with Oxaliplatin prodrug for the management of colorectal cancer (CRC). Hewitt et al.<sup><xref ref-type="bibr" rid="CR259">259</xref></sup> discovered in preclinical investigations that intratumoral administration of LNPs loaded with mRNA-encoding IL-12 could augment the antitumor effects by inducing the release of IFN-&#947; and promoting the transformation of Th1 cells within the TME. The Phase I trial of human IL-12 mRNA (MEDI1191) has been successfully completed (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03946800">NCT03946800</ext-link>). To further enhance tumor infiltration of IL-12 and mitigate systemic toxicity caused by its extratumoral presence, Trani et al.<sup><xref ref-type="bibr" rid="CR260">260</xref></sup> engineered mRNAs encoding single-chain IL-12 along with two additional components: a rat anti-mouse AFS98 mAb variable region that targets colony-stimulating factor-1 receptor (CSF1R) and the variable region of Avelumab (anti-PD-L1 antibody), which significantly augment post-transcriptional binding of IL-12 to the tumor.</p><p id="Par64">IL-27, belonging to the IL-12 family, exhibits comparable antitumor effects as IL-12. The activation of T cells and NK cells by IL-12 and IL-27 occurs through distinct mechanisms, whereby IL-12 activates T cells via the signal transducer and activator of transcription (Stat) 4 pathway, while IL-27 engages T cells through both the Stat1 and Stat3 pathways. Liu et al.<sup><xref ref-type="bibr" rid="CR261">261</xref></sup> developed LNPs loaded with mRNA and observed that co-delivering IL-12&#8201;+&#8201;IL-27 mRNAs using the same LNPs carrier resulted in superior tumor suppression compared to the single delivery of IL-12 mRNA. Furthermore, the incorporation of IL-27, an anti-inflammatory cytokine, could mitigate potential toxic inflammation associated with mono-administration of IL-12. This combination not only enhanced efficacy but also reduced systemic toxicity.</p><p id="Par65"><bold>GM-CSF:</bold> GM-CSF is a cytokine that promotes the generation of various myeloid cell subpopulations, such as DCs, monocytes, macrophages, and neutrophils. Excessive or inadequate levels of GM-CSF could enhance the malignancy of cancer.<sup><xref ref-type="bibr" rid="CR262">262</xref></sup> The mRNA mixture (SAR441000) encoding IL-12, IFN alpha-2b, GM-CSF, and IL-15 was administered intratumorally as a monotherapy or in combination with Cemiplimab during the Phase I trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03871348">NCT03871348</ext-link>) conducted in 2019 for the treatment of advanced solid tumors. The results demonstrated favorable tolerability and discernible immunomodulatory effects for both SAR441000 monotherapy and its combination with Cemiplimab.<sup><xref ref-type="bibr" rid="CR263">263</xref></sup></p><p id="Par66">To extend the serum half-life of GM-CSF, it can be conjugated with biologically safe and structurally stable proteins. Yeapuri et al.<sup><xref ref-type="bibr" rid="CR264">264</xref></sup> developed mRNA LNPs encoding the albumin-GM-CSF fusion protein, thereby prolonging the half-life of the target protein and enhancing drug bioavailability to optimize its therapeutic efficacy.</p></sec><sec id="FPar7"><title>Immune-suppressing cytokine</title><p id="Par67"><bold>IL-2:</bold> Although mRNA-based cytokine therapies are commonly employed in the field of antitumor research, their potential applications in the treatment of other diseases should not be underestimated. The IL-2 receptor exists in two forms with varying affinities, the form expressed by Treg cells exhibiting a higher affinity for IL-2. Consequently, at low concentrations, IL-2 preferentially activates Tregs.<sup><xref ref-type="bibr" rid="CR118">118</xref>,<xref ref-type="bibr" rid="CR119">119</xref></sup> However, at higher concentrations, it also triggers the activation of pro-inflammatory T cells and NK cells. Treg cells represent a subset of CD4<sup>+</sup> T lymphocytes with significant immunosuppressive capabilities.<sup><xref ref-type="bibr" rid="CR265">265</xref></sup> Impairments in the function of Treg cells or a deficiency in their numbers can result in the breakdown of immune tolerance and the development of autoimmune diseases within the body.<sup><xref ref-type="bibr" rid="CR266">266</xref></sup> Consequently, induced Treg cells hold promise for the treatment of autoimmune diseases and the restoration of immunological self-tolerance.<sup><xref ref-type="bibr" rid="CR267">267</xref>,<xref ref-type="bibr" rid="CR268">268</xref></sup> Picciotto et al.<sup><xref ref-type="bibr" rid="CR118">118</xref></sup> engineered mRNA to encode a fusion protein of human serum albumin IL-2 mutein (HSA-IL2m) with an extended half-life. Their findings demonstrated that delivering this lipid-encapsulated mRNA could selectively expand Tregs in vivo without activating NK cells or conventional T cells. This approach offers a novel strategy for suppressing autoreactive T cells and restoring immune balance in autoimmune diseases. The mRNA-6231, encoding HSA-IL2m, has already progressed to Phase I clinical trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04916431">NCT04916431</ext-link>).<sup><xref ref-type="bibr" rid="CR221">221</xref></sup></p><p id="Par68"><bold>IL-4:</bold> IL-4 is involved in the regulation of the activation, proliferation, differentiation, and survival of various T-cell subtypes.<sup><xref ref-type="bibr" rid="CR269">269</xref></sup> It supports the differentiation of Th2 cells and antagonizes the function of Th1 cells associated with numerous autoimmune disorders.<sup><xref ref-type="bibr" rid="CR270">270</xref></sup> The modulation of Th-cells subgroups, particularly the balance between Th1 and Th2, exerts a significant influence on the pathogenesis of type 1 diabetes.<sup><xref ref-type="bibr" rid="CR271">271</xref>,<xref ref-type="bibr" rid="CR272">272</xref></sup> Creusot et al.<sup><xref ref-type="bibr" rid="CR270">270</xref></sup> reported a novel therapy that delivered translationally enhanced IL-4 mRNA into DCs using electroporation. They have shown that modified DCs containing mRNA could modulate autoimmune diabetes in nonobese diabetic mice by boosting the functionality of Treg cells and inducing a shift in the proportion of Th cell populations.</p><p id="Par69"><bold>IL-10:</bold> IL-10 is a cytokine with anti-inflammatory properties, capable of suppressing the expression of pro-inflammatory cytokines and inhibiting the presentation of alloantigens by APCs.<sup><xref ref-type="bibr" rid="CR273">273</xref></sup> Chen et al.<sup><xref ref-type="bibr" rid="CR274">274</xref></sup> developed a novel delivery system with self-protection and active targeting capabilities for encapsulating mRNA encoding IL-10. Nucleic acids were combined with polyphenols to mitigate enzymatic degradation. Due to the susceptibility of hyaluronic acid to oxidation in the inflamed colon and subsequent inactivation, it is essential to combine bilirubin, known for its potent antioxidant activity, with hyaluronic acid in order to ensure effective targeting of CD44. They demonstrated that rectal administration of the IL-10 mRNA delivery system could effectively induce therapeutic effects in a murine model of colitis. Atherosclerosis is a chronic inflammatory condition. Bu et al.<sup><xref ref-type="bibr" rid="CR275">275</xref></sup> developed an exosome-based delivery platform for loading engineered IL-10 mRNA. They observed that this platform could effectively mitigate atherosclerosis in ApoE&#8722;/&#8722; (Apolipoprotein E-deficient) mice.</p></sec></sec><sec id="Sec11"><title>Ligand</title><p id="Par70">The mRNA can also encode immune-stimulating ligands, thereby facilitating an immunogenic response. The TriMix therapy consists of a combination of mRNA encoding three distinct immune-stimulating proteins, namely CD40 ligand (CD40L), CD70, and constitutively active TLR4.<sup><xref ref-type="bibr" rid="CR276">276</xref></sup> This innovative mRNA-based vaccine can be administered via intratumoral injection for patients with early-stage, resectable breast cancer, which is currently undergoing Phase I clinical trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03788083">NCT03788083</ext-link>).</p><p id="Par71">The TriMix compound not only serves as a direct mRNA vaccine but also functions as an adjuvant in immunization research due to its capacity to encode DC-activating proteins. The ECI-006 vaccine consists of a combination of mRNA-encoding adjuvant proteins (TriMix) and mRNA-encoding melanoma-specific TAAs (tyrosinase, gp100, MAGE-A3, MAGE-C2, and PRAME). A Phase I clinical trial has been conducted to evaluate this mRNA vaccine in patients with stage IIc/III/IV melanoma who have undergone surgical resection (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03394937">NCT03394937</ext-link>). The results demonstrated favorable tolerability profiles when administering ECI-006 at doses of 600 or 1800&#8201;&#956;g to the patients, and immunogenicity was observed in a subset of patients.<sup><xref ref-type="bibr" rid="CR277">277</xref></sup></p></sec><sec id="Sec12"><title>Tumor suppressor protein</title><p id="Par72">The optimal goal of cancer treatment is to eradicate tumor cells while minimizing the harm to healthy tissues and cells. In pursuit of this objective, suicide gene therapy, a novel approach to cancer treatment, has garnered attention.<sup><xref ref-type="bibr" rid="CR278">278</xref></sup> Cancer suicide gene therapies can be categorized into three groups: enzyme/prodrug systems, pro-apoptotic genes, and toxins.<sup><xref ref-type="bibr" rid="CR279">279</xref></sup> The enzyme/prodrug system involves the transfer of genetic material encoding enzymes to tumor cells, leading to the conversion of nontoxic prodrugs by these enzymes into cytotoxic metabolites that induce apoptosis in tumor cells.<sup><xref ref-type="bibr" rid="CR278">278</xref>,<xref ref-type="bibr" rid="CR280">280</xref></sup> For instance, the innovative human herpes simplex virus&#8211;thymidine kinase (HSV-TK)/ganciclovir suicide gene system shows promise. However, the HSV-TK system is hampered by significant limitations associated with its immunogenicity.<sup><xref ref-type="bibr" rid="CR281">281</xref></sup> Furthermore, enzyme/prodrug systems also encounter the challenge of off-target effects on normal tissues, resulting in toxicity, as well as suboptimal efficacy against slow-dividing tumor cells. To address these challenges, the approach of developing genes encoding pro-apoptotic proteins and bacterial toxins as suicide genes was employed.<sup><xref ref-type="bibr" rid="CR282">282</xref></sup></p><sec id="FPar8"><title>Enzyme-encoding mRNA for enzyme/prodrug systems</title><p id="Par73">The combination of cytosine deaminase and uridine phosphoryltransferase (UPRT)/5-fluorocytosine (5-FC) forms an enzyme/prodrug system. The cytosine deaminase is capable of converting the nontoxic 5-FC into the toxic metabolite 5-fluorouracil (5-FU). The gene encoding cytosine deaminase is commonly fused with the UPRT gene to enhance its efficacy.<sup><xref ref-type="bibr" rid="CR279">279</xref></sup> Mizrak et al.<sup><xref ref-type="bibr" rid="CR283">283</xref></sup> obtained microvesicles (MVs) loaded with cytosine deaminase-UPRT mRNA/protein by transfecting the cytosine deaminase-UPRT-EGFP plasmid into HEK-293T cells. Subsequently, they observed that intratumoral injection of cytosine deaminase-UPRT-mRNA/protein-containing MVs and treatment with 5-FC significantly suppressed tumor growth in tumor-bearing mice.</p><p id="Par74">Inducible caspase-9 (iC9) is an engineered version of caspase-9 that can be dimerized and activated upon exposure to the chemical inducers of dimerization (CID), such as the AP1903 molecule, subsequently triggering downstream apoptotic pathways and leading to cell death.<sup><xref ref-type="bibr" rid="CR284">284</xref></sup> Nakashima et al.<sup><xref ref-type="bibr" rid="CR285">285</xref></sup> developed LNPs carrying iC9 mRNA. They discovered that the combination of iC9 mRNA and CID exhibited cytotoxic effects on three breast cancer cell lines in vitro. On the other hand, Saito et al.<sup><xref ref-type="bibr" rid="CR286">286</xref></sup> engineered liposomes for the delivery of iC9 mRNA and combined them with CID for the treatment of T-cell malignancies. It was found that the treatment regimen exhibited anti-leukemia therapeutic effects both in vitro and in vivo.</p></sec><sec id="FPar9"><title>Pro-apoptotic protein</title><p id="Par75"><bold>p53 and PTEN</bold>: It is widely acknowledged that cancer originates from the mutation of somatic cells, and that oncogenic mutations or abnormal expression of cellular proto-oncogenes can trigger carcinogenesis. A distinct category of tumor suppressor gene can counteract these carcinogenic effects and impede tumor development. Notably, p53, retinoblastoma (Rb), and phosphatase and tensin homolog deleted on chromosome ten (PTEN) are three pivotal tumor suppressor proteins with interconnected functions.<sup><xref ref-type="bibr" rid="CR287">287</xref></sup> The majority of human cancers exhibit loss-of-function mutations in the p53 protein. However, due to the fact that p53 is a transcription factor, it has long been deemed undruggable.<sup><xref ref-type="bibr" rid="CR288">288</xref></sup> Nevertheless, the emergence of mRNA therapies has facilitated the development of numerous p53-based cancer treatments utilizing mRNA.</p><p id="Par76">To augment the therapeutic efficacy of p53 mRNA therapy, it can be synergistically combined with other well-established antitumor modalities. Zhang et al.<sup><xref ref-type="bibr" rid="CR289">289</xref></sup> developed paclitaxel amino fat-derived NPs for encapsulating p53 mRNA and chemotherapy drugs, demonstrating remarkable antitumor effects in an orthotopic triple-negative breast cancer (TNBC) mouse model. Zhou et al.<sup><xref ref-type="bibr" rid="CR290">290</xref></sup> were the pioneers in reporting the integration of mRNA therapy with photodynamic therapy (PDT) for tumor treatment. They developed a ROS-responsive NPs platform encapsulating p53 mRNA and indocyanine green (ICG). These NPs can be triggered by ROS to release p53 mRNA, thereby augmenting p53 expression and inducing apoptosis in lung cancer cell. Simultaneously, laser irradiation could activate the released ICG to facilitate PDT. To enhance the expression of intracellular target proteins, Cao et al.<sup><xref ref-type="bibr" rid="CR291">291</xref></sup> employed a novel strategy by designing the CRISPR/dCasRx-SINEB2 platform to augment the translation of endogenous mRNA-encoding tumor suppressor proteins (including PTEN and p53), thereby inducing suppressed proliferation and increased apoptosis in bladder cancer cells. Liu et al.<sup><xref ref-type="bibr" rid="CR292">292</xref></sup> established a nanoparticle platform to encapsulate PTEN mRNA for brain delivery. The NPs exhibited enhanced capability to cross the blood-brain barrier and target tumor cells, demonstrating the potential of using mRNA-based technologies for treating brain diseases.</p><p id="Par77"><bold>Bim and Bax:</bold> Bim is a significant pro-apoptotic member within the Bcl-2 protein family.<sup><xref ref-type="bibr" rid="CR293">293</xref></sup> Gao et al.<sup><xref ref-type="bibr" rid="CR294">294</xref></sup> developed a delivery system that combined cell-penetrating peptides (CPPs), cRGD-R9, and cationic nano-sized DOTAP-mPEG-PCL scaffolds to deliver mRNA-encoding Bim. The Bim mRNA delivery system exhibited potent inhibitory effects on tumors in various colon cancer models through the induction of mitochondrial apoptosis.</p><p id="Par78">Bax is a pro-apoptotic molecule that can serve as a tumor suppressor protein. Okumura et al.<sup><xref ref-type="bibr" rid="CR295">295</xref></sup> developed liposomes to deliver mRNA-encoding Bax and compared the antitumor effects with those of a Bax plasmid in tumor-bearing mice. Their findings indicated that the use of Bax mRNA therapy via liposomes exhibited stronger antitumor effects than the Bax plasmid.</p><p id="Par79"><bold>TRAIL:</bold> Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) can trigger apoptotic cell death in tumor cells while sparing normal cells. Gu et al.<sup><xref ref-type="bibr" rid="CR296">296</xref></sup> developed mRNA-based LNPs encoding a fusion protein of TRAIL and the receptor-binding domain (RBD) from the SARS-CoV-2 spike protein, which were administered via intratumoral injection in colon cancer mice models. They observed that the RBD-TRAIL mRNA LNPs effectively inhibited tumor growth in mice. Silva et al.<sup><xref ref-type="bibr" rid="CR297">297</xref></sup> discovered that the direct intratumoral injection of LNPs loaded with TRAIL mRNA could effectively induce tumor cell death, particularly when combined with Losartan or angiotensin 1&#8211;7.</p><p id="Par80"><bold>Apoptin:</bold> Apoptin is a protein encoded by the gene of the chicken anemia virus.<sup><xref ref-type="bibr" rid="CR298">298</xref></sup> It is capable of inducing apoptosis in tumor cells through a p53-independent pathway.<sup><xref ref-type="bibr" rid="CR299">299</xref></sup> It is noteworthy that Apoptin can trigger apoptosis in tumor cells while sparing normal diploid cells.<sup><xref ref-type="bibr" rid="CR298">298</xref></sup> Therefore, as a tumor suppressor protein, Apoptin holds promise as a safe anticancer medication.<sup><xref ref-type="bibr" rid="CR300">300</xref></sup> However, the collection and purification process of this protein is highly intricate and costly.<sup><xref ref-type="bibr" rid="CR299">299</xref></sup> Therefore, the gene therapy being developed for antitumor Apoptin primarily relies on DNA<sup><xref ref-type="bibr" rid="CR301">301</xref></sup> or viral vectors.<sup><xref ref-type="bibr" rid="CR298">298</xref></sup> Tang et al.<sup><xref ref-type="bibr" rid="CR299">299</xref></sup> engineered nanospheres with self-assembly capabilities to encapsulate mRNA-encoding Apoptin. The combination of Apoptin mRNA with Doxorubicin exhibited remarkable synergistic antitumor effects.</p><p id="Par81">The mRNA-based therapy that encodes tumor suppressor proteins is currently in its early stages of development. Ongoing explorations are being conducted regarding numerous oncogenes and their corresponding tumor suppressor proteins. Qu et al.<sup><xref ref-type="bibr" rid="CR302">302</xref></sup> proposed that Huntingtin-associated protein-1 (HAP1) may function as a potential tumor suppressor in gastric cancer. Zheng and Song<sup><xref ref-type="bibr" rid="CR303">303</xref></sup> believed that Synaptopodin 2 (SYNPO2) functions as both a structural protein in muscle tissue and an emerging tumor suppressor protein, supported by its positive correlation with favorable cancer prognosis, thereby indicating its crucial role in cancer prevention and treatment. With the identification of additional tumor suppressor proteins, it is anticipated that mRNA-based therapies encoding these proteins will gradually emerge as a promising avenue in cancer research.</p></sec><sec id="FPar10"><title>Immunotoxin</title><p id="Par82">Immunotoxins are typically chimeric proteins composed of a protein toxin conjugated to an antibody fragment,<sup><xref ref-type="bibr" rid="CR304">304</xref></sup> enabling specific targeting and elimination of antigen-bearing cells.<sup><xref ref-type="bibr" rid="CR305">305</xref></sup> The toxic components in immunotoxins typically originate from a variety of sources, including bacteria, plants, and human cells. Bacterial-derived toxins such as diphtheria toxin and pseudomonas exotoxin A (PE), as well as plant-derived toxins like ricin and gelonin, are commonly used. Human-derived toxins include granzymes and RNases. Among these, the application of bacterial and plant toxins is limited due to their potential immunogenicity in humans.<sup><xref ref-type="bibr" rid="CR306">306</xref></sup> Various strategies have been developed to mitigate the immunogenicity of immunotoxins. These include employing immunosuppressive therapy, utilizing human-derived toxin proteins, and modifying toxin moiety to evade detection by the human immune system.<sup><xref ref-type="bibr" rid="CR307">307</xref></sup></p><p id="Par83">The short half-life of the immunotoxin in the circulatory system may limit its therapeutic activity. To extend the half-life of immunotoxin in circulation, Guo et al.<sup><xref ref-type="bibr" rid="CR308">308</xref></sup> fused it with the albumin-binding domain. The production of recombinant immunotoxins is typically conducted in bacteria. However, it is generally challenging to produce soluble proteins with molecular weights exceeding 80&#8201;kDa in bacterial systems.<sup><xref ref-type="bibr" rid="CR309">309</xref></sup> mRNA-based immunotoxin therapy presents a promising alternative.</p><p id="Par84">The application of immunotoxins for the treatment of cancer is currently under investigation, which is, however, constrained by their large molecular weight, limited tumor penetration, and the presence of cellular resistance. Consequently, immunotoxins have not yet received approval for clinical use against solid tumors. To address these challenges, Granot-Matok et al.<sup><xref ref-type="bibr" rid="CR310">310</xref></sup> developed a LNPs system that delivered modified mRNA encoding the PE domain. This innovative approach employed toxin-encoding mRNA to overcome the limitations associated with immunotoxin therapy, offering improved safety and enhanced therapeutic efficacy.</p><p id="Par85">PE38, a derivative of the potent toxin PE produced by <italic toggle="yes">Pseudomonas aeruginosa</italic>, has been engineered to remove its targeting domain while retaining its toxicity. The toxicity of PE lies in its specific inhibition of elongation factor 2 (EF-2) in the cytosol of eukaryotes. Eggers et al.<sup><xref ref-type="bibr" rid="CR311">311</xref></sup> utilized PE38 in the development of immunotoxins by fusing it with human VEGF and an anti-human epidermal growth factor receptor-2 (HER2)/neu single-chain variable fragment (scFv). They transfected human primary T cells with mRNA-encoding immunotoxins and demonstrated that the engineered T cells displayed significantly enhanced cytotoxicity against cancer cells in vitro when combined with bispecific antibodies.</p><p id="Par86">The subtilase cytotoxin, diphtheria toxin, and abrin-a belong to the AB toxin family. Their B-subunit initially binds to the target cell, followed by the entry of the A-subunit into the cell, where it exerts toxicity by inhibiting protein synthesis, ultimately leading to the demise of the target cell. Hirschberger et al.<sup><xref ref-type="bibr" rid="CR312">312</xref></sup> developed three chemically modified mRNAs encoding subtilase cytotoxin, diphtheria toxin, and abrin-a. They demonstrated that the mRNA therapy encoding abrin-a exhibited superior efficacy in reducing the viability of tumor cells in vitro compared to the other two mRNA therapies.</p><p id="Par87">Furthermore, immunotoxins offer a promising therapeutic approach for antiviral treatment. Their mechanism involves targeting and eradicating infected cells, rather than the inhibition of viral or cellular pathways essential for virus replication and spread.<sup><xref ref-type="bibr" rid="CR313">313</xref></sup> There is great potential for achieving significant advancements in the fields of antitumor and antiviral researches, among others, through the application of immunotoxins.</p></sec></sec><sec id="Sec13"><title>Adoptive cell therapy</title><p id="Par88">Adoptive cell therapy involves the extraction of the patient&#8217;s immune cells, followed by ex vivo editing and activation, and subsequent reintroduction into the patient for disease treatment. This approach aims to enhance the identification and elimination of tumor cells. Additionally, there is ongoing development of in situ adoptive cell therapy.<sup><xref ref-type="bibr" rid="CR314">314</xref></sup> It is noteworthy that the subsequent adoptive cell therapies are founded upon RNA methods, as opposed to conventional DNA methodologies. Specifically, CAR-T therapy should be further subdivided into RNA chimeric antigen receptor T cells (rCAR-T).</p><sec id="FPar11"><title>CAR-T</title><p id="Par89">In the past decade, chimeric antigen receptor (CAR)-expressing T-cell (CAR-T-cell) therapy has made major breakthroughs in the treatment of hematological cancers. Disappointingly, its effectiveness in treating solid tumors is still limited due to a lack of comprehensive understanding of tumor-specific antigens, the suppression of T-cell infiltration and killing ability by the TME, and limited expansion potential of T cells.<sup><xref ref-type="bibr" rid="CR315">315</xref></sup> Therefore, Mackensen et al. designed CAR-T cells targeting the tumor-specific antigen Claudin 6 (CLDN6) and demonstrated potential clinical activity. However, due to the limited durability of a single dose, they integrated it with a CAR-T-cell Amplifying RNA Vaccine (CARVac) for administration. This combination approach exhibited good tolerability in subjects and showed promise of enhancing CAR-T-cell expansion and improving tumor treatment efficacy. Currently, the study is in Phase I/II clinical trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04503278">NCT04503278</ext-link>).<sup><xref ref-type="bibr" rid="CR120">120</xref>,<xref ref-type="bibr" rid="CR316">316</xref></sup> Despite promising results observed in clinical trial, the findings fell short of meeting expectations, underscoring the urgent challenges that still need to be addressed in targeting CLDN6 CAR-T therapy combined with CARVac administration.<sup><xref ref-type="bibr" rid="CR315">315</xref></sup> The methodology employed in this study for CAR-T-cell production aligns with clinical practice, encompassing ex vivo culturing of CAR-T cells followed by their infusion into patients. This approach entails significant expenditures for manufacturing. Hence, there is an urgent imperative to develop a swift, robust, and economically efficient alternative strategy for manufacturing CAR-T cells. A promising avenue involves the direct delivery of mRNA into the body to induce in situ formation of CAR-T cells.</p><p id="Par90">Despite the challenges associated with transfecting exogenous mRNA into T cells, Tomb&#225;cz et al.<sup><xref ref-type="bibr" rid="CR317">317</xref></sup> discovered that the application of CD4 antibody-conjugated mRNA LNPs encoding Cre recombinase or firefly luciferase significantly augmented the signal of mRNA by ~30-fold in spleen T cells and increased the expression of reporter genes in CD4<sup>+</sup> T cells in vivo when compared to non-targeted mRNA LNPs. Zhou et al.<sup><xref ref-type="bibr" rid="CR318">318</xref></sup> used CD3 antibody-modified LNPs loaded with IL-6 short hairpin RNA (IL-6 shRNA) and CD19-CAR (based on plasmid DNA) for targeted delivery to CD3<sup>+</sup> T cells, which resulted in the downregulation of IL-6 within CAR-T cells and a reduction in cytokine release syndrome (CRS), thereby enhancing the safety profile of leukemia treatment. Rurik et al.<sup><xref ref-type="bibr" rid="CR319">319</xref></sup> developed CD5-targeted LNPs encapsulating mRNA encoding a CAR against fibroblast activation protein (FAP). By administering these CD5-targeted LNPs, potent anti-fibrotic CAR-T cells could be generated in vivo, which mitigated cardiac fibrosis and restored cardiac function.<sup><xref ref-type="bibr" rid="CR320">320</xref></sup></p><p id="Par91">Given the pivotal role played by autoreactive T and B cells in autoimmune disorders, CAR-T-cell therapy has also become a therapeutic option within the realm of autoimmune diseases.<sup><xref ref-type="bibr" rid="CR321">321</xref></sup> The pathogenesis of myasthenia gravis (MG) involves the presence of pathogenic plasma cells and autoantibodies, making it a prototypical autoimmune disorder. The ongoing Phase Ib/IIa trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04146051">NCT04146051</ext-link>) involving Descartes-08 rCAR-T cells for the treatment of generalized MG entailed transfecting mRNA-encoding anti-BCMA (B-cell maturation antigen) into CD8<sup>+</sup> T cells. The findings demonstrated that Descartes-08, which expressed anti-BCMA targeting CAR protein on autologous CD8<sup>+</sup> T cells, exhibited favorable safety and tolerability profiles in MG patients. Furthermore, sustained reduction in MG severity was observed with continued administration of Descartes-08 infusions over a follow-up period of up to 9 months. These promising outcomes warranted further investigation into the potential therapeutic efficacy of this approach in other autoimmune disorders.<sup><xref ref-type="bibr" rid="CR121">121</xref></sup> Excitingly, the Descartes-08 anti-BCMA rCAR-T therapy for systemic lupus erythematosus (SLE-001) has successfully progressed into Phase II as of February 2024 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06038474">NCT06038474</ext-link>).<sup><xref ref-type="bibr" rid="CR322">322</xref></sup> On the other hand, Thatte et al.<sup><xref ref-type="bibr" rid="CR323">323</xref></sup> administered Foxp3 mRNA LNPs to CD4<sup>+</sup> T cells in order to generate immunosuppressive Foxp3-T cells. These cells have the capacity to suppress the proliferation of effector T cells, highlighting the potential of mRNA-engineered immunosuppressive T cells in the management of autoimmune disorders.</p></sec><sec id="FPar12"><title>TCR-T</title><p id="Par92">In addition to CAR-T-cell therapy, there also exist targeted adoptive cell therapies employing T-cell receptor (TCR) engineered T cell (TCR-T cell). To address hepatocellular carcinoma (HCC) associated with HBV following liver transplantation, Yang et al.<sup><xref ref-type="bibr" rid="CR324">324</xref></sup> employed electroporation to introduce mRNA-encoding HBV-specific TCR into ex vivo T cells, which were subsequently transferred to the patients. Currently in Phase I clinical trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02719782">NCT02719782</ext-link>), the study demonstrated favorable tolerability of this treatment approach.</p><p id="Par93">Maggadottir et al.<sup><xref ref-type="bibr" rid="CR325">325</xref></sup> conducted a study on the treatment of metastatic microsatellite instability-high (MSI-H) CRC, wherein they employed an mRNA TCR-modified T-cell therapy approach. This involved administering autologous T cells electroporated with IVT Radium-1 TCR mRNA, specifically targeting the -1A frameshift mutation in the <italic toggle="yes">TGF&#946;RII</italic> gene, to patients with advanced MSI-H CRC. The results demonstrated a favorable safety profile for this TCR-T-cell therapy (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03431311">NCT03431311</ext-link>).</p><p id="Par94">In addition, also for the treatment of viral-associated tumor diseases, such as HPV-associated cervical cancer, Ling et al.<sup><xref ref-type="bibr" rid="CR326">326</xref></sup> designed a pH-responsive nonviral nano-carrier to deliver Cas9 mRNA and the guide RNAs (gRNAs) of oncogenes E6 and E7 that target HPV, which can effectively knock out the E6/E7 oncogenes, reverse the tumor&#8217;s immunosuppressive environment, and promote CD8<sup>+</sup> T-cell survival. Therefore, genome editing therapies co-delivering Cas9 mRNA and gRNAs that target oncogenes can also be combined with adoptive T-cell transfer to improve cancer treatment outcomes.</p></sec><sec id="FPar13"><title>CAR-M</title><p id="Par95">The therapeutic efficacy of CAR-T therapy in treating solid tumors is limited, which is greatly derived from the limited infiltration capacity of T cells within the TME. Conversely, macrophages possess the ability to infiltrate solid tumor tissue and engage with almost all cells in the TME, including tumor cells and diverse immune cells. Consequently, exploring the potential of CAR-expressing macrophages (CAR-M) represents a novel avenue for immunotherapy.<sup><xref ref-type="bibr" rid="CR327">327</xref></sup> The investigational agent CT-0058, a pro-inflammatory macrophage cell product, is currently undergoing Phase I clinical trial for the treatment of solid tumors (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04660929">NCT04660929</ext-link>). The anti-HER2 CAR expressed in CAR-M cells was obtained via adenoviral vectors rather than mRNA transfection.<sup><xref ref-type="bibr" rid="CR328">328</xref></sup> Meanwhile, the MCY-M11, currently undergoing clinical Phase I for advanced ovarian cancer and peritoneal mesothelioma treatment, is derived from the transfection of anti-mesothelin CAR (Meso-CAR) mRNA into peripheral blood mononuclear cells (PBMCs) (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03608618">NCT03608618</ext-link>).<sup><xref ref-type="bibr" rid="CR329">329</xref></sup></p><p id="Par96">CAR-M therapy not only holds immense potential in combating cancer, but also exhibits promising applications in conducting cutting-edge research on bacterial eradication. Tang et al.<sup><xref ref-type="bibr" rid="CR330">330</xref></sup> developed LNPs system encapsulating mRNA that encoded a CAR specifically targeting methicillin-resistant <italic toggle="yes">Staphylococcus aureus</italic> (MRSA). The LNPs surface was modified with the CRV peptide (sequence CRVLRSGSC) to facilitate macrophages targeting. This antibacterial CAR-M therapy demonstrated promising potential in eradicating MRSA.</p></sec><sec id="FPar14"><title>mRNA-engineered DCs</title><p id="Par97">DCs are a crucial subset of APCs responsible for presenting TAAs to T cells, and their functionality can be compromised by TME. Although engineered DCs therapy has gained attention, its standalone efficacy remains unsatisfactory, necessitating combination with other therapies to counteract the inhibitory effects of the TME.<sup><xref ref-type="bibr" rid="CR331">331</xref></sup> The year 2002 witnessed a clinical trial evaluating the efficacy a IVT mRNA DC vaccine against melanoma (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01278940">NCT01278940</ext-link>).<sup><xref ref-type="bibr" rid="CR332">332</xref></sup> In 2006, Kyte et al.<sup><xref ref-type="bibr" rid="CR333">333</xref></sup> reported the results of this Phase I/II trial, indicating that the treatment of tumor-mRNA transfected DCs was safe and feasible, and that the DC vaccine was able to induce antigen-specific T-cell responses in ~50% of patients.</p><p id="Par98">To reprogram the TME and initiate tumor-specific T-cell responses, Zhang et al.<sup><xref ref-type="bibr" rid="CR331">331</xref></sup> designed two mRNA LNPs. One of these mRNA LNPs encoded CD40 ligand, which elicited potent ICD in tumor tissues, resulting in the expression of TAAs and CD40 ligand on the surface of tumor cells. The other LNPs carried CD40 mRNA with the aim to be internalized by DCs for generating in situ engineered DCs, leading to increased expression of CD40 protein and activation upon interaction with CD40 ligand on tumor cells.</p><p id="Par99">The majority of patients diagnosed with acute myeloid leukemia (AML) exhibit a persistent and recurrent manifestation of the disease attributed to residual leukemic cells, even following standard chemotherapy, resulting in a survival rate of less than 5 years. Consequently, supplementary therapeutic interventions are imperative for eradicating minimal residual disease (MRD). The significant overexpression of Wilms tumor 1 (WT1) in AML and its association with the pathogenesis of the disease render it a promising target for T cells. In light of this, a Phase II clinical trial was conducted in 2010 to evaluate the efficacy of loading autologous DCs with WT1 antigen via mRNA electroporation as an adjunctive treatment strategy for AML patients who had completed chemotherapy (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00965224">NCT00965224</ext-link>). The findings reported by Anguille et al.<sup><xref ref-type="bibr" rid="CR334">334</xref></sup> demonstrated that this vaccination approach effectively elicits robust T-cell immune responses in AML patients at high risk of relapse, thereby establishing both the safety and potential utility of autologous <italic toggle="yes">WT1</italic> mRNA-electroporated DC vaccine following chemotherapy.</p></sec></sec></sec><sec id="Sec14"><title>Non-immunotherapy</title><p id="Par100">The emergence of mRNA therapies has infused considerable hope into the battle against previously incurable diseases. Theoretically, optimally designed IVT mRNA can be introduced into cells either through in vivo or ex vivo transfection and subsequently translated into biologically active peptide/protein.<sup><xref ref-type="bibr" rid="CR335">335</xref></sup> The non-immunotherapy described in this article entails directly transcription of mRNA to complement deficient or aberrant proteins within the organism, as well as for gene editing technology, while evading any immune response from the recipient (Fig. <xref rid="Fig4" ref-type="fig">4</xref>).<fig id="Fig4" position="float" orientation="portrait"><label>Fig. 4</label><caption><p>Overview diagram of mRNA-based non-immunotherapy. BDNF brain-derived neurotrophic factor, NEP neprilysin, CFTR cystic fibrosis transmembrane conductance regulator, HNF4A human hepatocyte nuclear factor &#945;, COL1A1 extracellular-matrix &#945;1 type-I collagen, VEGF-A vascular endothelial growth factor-A, TE tropoelastin, BMP-2 bone morphogenetic protein-2, RUNX1 runt-related transcription factor 1, OTC ornithine transcarbamylase, G6Pase-&#945; glucose-6-phosphatase-alpha, AGL amylo-&#945;-1,6-glucosidase 4-alpha-glucanotransferase, IGF-1 insulin-like growth factor 1, ZFNs Zinc finger nucleases, CRISPR/Cas9 clustered regularly interspaced short palindromic repeats/associated protein 9. The graphic is created with BioRender.com</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e3888" position="float" orientation="portrait" xlink:href="41392_2024_2002_Fig4_HTML.jpg"/></fig></p><p id="Par101">The effective treatment of genetic defect diseases with IVT mRNA relies on multiple factors, encompassing the stability and translational potency of the mRNA, the efficacy and biological activity of the encoded protein, as well as its circulation half-life. Importantly, it is worth noting that the therapeutic threshold necessitates an active protein quantity ranging from milligrams to grams, whereas even at the milligram or nanogram level, antigens can provoke an immune response in the body.<sup><xref ref-type="bibr" rid="CR336">336</xref></sup> To mitigate the immunogenicity of mRNA therapies, several optimizations can be implemented for IVT mRNA, including refining the nucleotide sequence, employing diverse mRNA nucleoside modifications, optimizing reaction conditions of the IVT conditions to minimize byproducts generation, and purifying the synthesized mRNA.<sup><xref ref-type="bibr" rid="CR337">337</xref></sup></p><p id="Par102">The repeated administration remains effective in maintaining high protein expression and ensuring in vivo safety, which is crucial for the transformation of mRNA vaccines into mRNA therapeutics. Long-term or even lifelong repeated administration is necessary for treating chronic diseases.<sup><xref ref-type="bibr" rid="CR338">338</xref></sup> However, delivery vectors, such as LNPs, constitute a crucial component in mRNA-based therapeutics, necessitating careful consideration of their immunogenic potential.</p><p id="Par103">The pattern-recognition receptor family on the cell membrane includes TLR4, which is a crucial member known to be activated by damage- and pathogen-associated molecular patterns (DAMPs and PAMPs). PAMPs encompass lipopolysaccharide (LPS)<sup><xref ref-type="bibr" rid="CR339">339</xref></sup> and monophosphoryl lipid A (MPLA; a nontoxic TLR4 agonist approved for clinical use).<sup><xref ref-type="bibr" rid="CR340">340</xref></sup> Kedmi et al.<sup><xref ref-type="bibr" rid="CR341">341</xref></sup> discovered that the systemic administration of positively charged NPs carrying small interfering RNA (siRNA) could trigger TLR4-dependent immune responses, leading to toxicity. Furthermore, they demonstrated that the inflammatory reaction was primarily caused by cationic components rather than the siRNA. The cationic lipid DiC14-amidine, synthesized by Lonez et al.,<sup><xref ref-type="bibr" rid="CR339">339</xref></sup> was shown to activate TLR4. Moreover, competition experiments confirmed that the binding site of this cationic lipid to TLR4 differed from that of LPS. Lonez et al.<sup><xref ref-type="bibr" rid="CR342">342</xref></sup> synthesized a cationic lipid, RPR206252, which effectively triggered the NF-&#954;B pathway and elicited TNF-&#945;, IL-1&#946;, IL-6, and IFN-&#947; production in human or mouse macrophages. These cascades were reliant on TLR2/CD14 and NOD-like receptor protein 3 (NLRP3) signaling.</p><p id="Par104">Therefore, it is imperative to develop low-immunogenic LNPs with diverse compositions and enhanced organ-selectivity, or explore alternative delivery vehicles to amplify the therapeutic efficacy of mRNA therapies for non-immune diseases.<sup><xref ref-type="bibr" rid="CR343">343</xref></sup> In addition, the combination of mRNA therapy with immunosuppressants such as Dexamethasone (a steroidal anti-inflammatory drug) not only holds the potential to enhance mRNA transfection efficiency<sup><xref ref-type="bibr" rid="CR344">344</xref></sup> but also exhibits promise in augmenting the safety and efficacy of non-immunotherapy.</p><p id="Par105">In consideration of the safety of mRNA drugs, it is recommended that preclinical studies encompass the following areas: (1) investigating the correlation between mRNA dosage, carrier properties, and in vivo levels of cytokine secretion as well as complement activation; (2) assessing the potential development of anti-drug antibodies upon repeated administration; (3) evaluating risk of organ damage, particularly focusing on target organs and concerns related to liver toxicity, along with potential accumulation risks associated with carriers.<sup><xref ref-type="bibr" rid="CR337">337</xref></sup></p><sec id="Sec15"><title>Protein replacement therapy</title><p id="Par106">Protein replacement therapy is a broad term encompassing the supplementation of proteins with functional defects or the substitution of deficient proteins to achieve therapeutic efficacy.<sup><xref ref-type="bibr" rid="CR345">345</xref></sup> The delivery of therapeutic proteins directly to the target tissue is significantly impeded by factors such as protein size and biochemical properties.<sup><xref ref-type="bibr" rid="CR346">346</xref></sup> In contrast, mRNA therapies are more likely to bypass these challenges. At present, the use of mRNA translation in vivo to replace the direct delivery of proteins has become a new pillar of protein replacement therapy, and has been extensively studied in various disease areas, including blood diseases (such as Hemophilia A, HemA), and metabolic diseases (such as ornithine transcarbamylase deficiency, OTCD; Fabry disease, FD; Propionic acidaemia, PA).<sup><xref ref-type="bibr" rid="CR335">335</xref></sup></p><p id="Par107">mRNA therapy provides a promising treatment option for refractory genetic diseases. HemA, a form of hemophilia caused by insufficient expression or gene mutation of coagulation factor VIII (FVIII), results in impaired blood clotting ability and can lead to life-threatening bleeding episodes, including intracranial hemorrhage. Current protein replacement therapies are costly and require frequent administration due to the short half-life of FVIII protein.<sup><xref ref-type="bibr" rid="CR347">347</xref></sup> In 2023, the FDA approved Roctavian as the first gene therapy drug for severe HemA in adults, utilizing adeno-associated virus vectors; however, concerns arise regarding potential risks such as liver cancer associated with the introduction of DNA sequences from Roctavian products.<sup><xref ref-type="bibr" rid="CR348">348</xref></sup> mRNA therapy can express the target protein in the cytoplasm without entering the nucleus or inserting the target cell genome, which is much safer than viral vector and DNA therapy.<sup><xref ref-type="bibr" rid="CR1">1</xref></sup> Chen et al.<sup><xref ref-type="bibr" rid="CR347">347</xref></sup> designed an LNPs encapsulating mRNA-encoding FVIII protein, which effectively prolonged the duration of FVIII protein expression.</p><p id="Par108">Low levels of key enzyme proteins or lack of enzyme activity resulting from genetic defects can give rise to inherited metabolic disorders (IMDs). Among these, OTCD is caused by the loss of crucial enzymes involved in the urea cycle within the liver, leading to impaired ammonia metabolism. Elevated levels of ammonia in the bloodstream can result in nerve damage and even fatality. Existing approaches, including dietary controls and ammonia scavengers, fail to address the root cause.<sup><xref ref-type="bibr" rid="CR349">349</xref></sup> Based on this, Prieve et al.<sup><xref ref-type="bibr" rid="CR349">349</xref></sup> designed a Hybrid mRNA Technology delivery system (HMT) that protected OTC-encoding mRNA against degradation by nucleases while exhibiting hepatocellular-specific targeting capabilities. HMT consists of two types of nanoparticles: di-block polymer micelles and inert LNPs. The polymer comprises three functional domains: (1) GalNAc, which serves as a targeting ligand for liver-specific uptake by binding to the asialoglycoprotein receptor abundantly expressed in liver cells; (2) hydrophilic polymer segments that maintain the solubility of the polymer; (3) polymer segments containing butyl methacrylate (hydrophobic monomer), 2-propylacrylic acid, and 2-(dimethylamino)ethyl methacrylate. This polymeric vesicle was designed to achieve liver-specific targeting and further facilitate the pH-dependent release of mRNA from endosomal organelles to the cytosol. The inert LNPs can shield mRNA from nucleases. This platform is not only safe but also extends the therapeutic effects for OTCD treatment. Currently, ARCT-810 (OTC mRNA LNPs) has entered a Phase II clinical trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05526066">NCT05526066</ext-link>) in OCT patients aged 12 years and older.<sup><xref ref-type="bibr" rid="CR350">350</xref></sup></p><p id="Par109">FD is an X-linked lysosomal storage disorder (LSD).<sup><xref ref-type="bibr" rid="CR351">351</xref></sup> Its root cause lies in the pathogenic mutation of the GLA gene (Xq21.3-q22), which leads to a loss of enzyme activity encoding lysosomal enzyme &#945;-galactosidase A. This results in abnormal metabolism of related glycolipids and the subsequent accumulation of glycolipids throughout the body, causing structural damage and functional loss in various tissues and organs, particularly affecting the heart, kidney, and nervous system. The resulting cardiac dysfunction and cerebrovascular events pose life-threatening risks. Although there are clinically approved enzyme replacement therapies (ERTs), they fail to meet medical needs due to their inability to penetrate the blood-brain barrier.<sup><xref ref-type="bibr" rid="CR352">352</xref></sup> To this end, in 2019, DeRosa et al.<sup><xref ref-type="bibr" rid="CR351">351</xref></sup> and Zhu et al.<sup><xref ref-type="bibr" rid="CR353">353</xref></sup>, respectively, reported systemically delivery of mRNA-encoding human alpha-galactosidase A (H-&#945;-gal A) using LNPs, both of which indicated that mRNA LNPs was a potential treatment modality for FD.</p><p id="Par110">PA is a life-threatening IMDs caused by a pathogenic mutation in the propionyl-coenzyme A carboxylase &#945; or &#946; (PCCA or PCCB) subunits gene, and there are currently no approved drugs to address this enzyme deficiency. An innovative approach involving two mRNAs encoding normal human PCCA and PCCB protein subunits has entered Phase I/II clinical trials (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04159103">NCT04159103</ext-link>). Encapsulated within LNPs, these mRNAs are specifically designed for targeted delivery to the liver to restore PCC enzymes. Promising interim results from this trial have demonstrated a favorable safety profile of mRNA-3927 in PA patients. Notably, dose-optimization studies have revealed a remarkable 70% reduction in relative risk associated with metabolic decompensation events (MDEs), highlighting the therapeutic efficacy.<sup><xref ref-type="bibr" rid="CR354">354</xref></sup></p></sec><sec id="Sec16"><title>Hormone replacement therapy</title><p id="Par111">Hormones produced by various glands in the body serve as crucial signaling molecules that are transported through the bloodstream to target organs, tissues, and cells, playing a pivotal role in maintaining physiological balance. Disruptions in hormonal regulation can give rise to diverse diseases.<sup><xref ref-type="bibr" rid="CR355">355</xref></sup> During menopause, hormonal fluctuations lead to the manifestation of menopausal symptoms and an increased risk of cardiovascular disorders. To alleviate these symptoms and slow down the progression of cardiovascular diseases, non-protein hormones like estrogen can be administered orally or topically via gel application. Similarly, for conditions such as androgen deficit in aging men (ADAM) or male hypogonadism, supplementation through similar means may also be considered.<sup><xref ref-type="bibr" rid="CR356">356</xref></sup> However, due to their size and spatial structure, protein hormones cannot be effectively administered orally as they would undergo degradation within the digestive system. Surprisingly, in 1992, Jirikowski et al.<sup><xref ref-type="bibr" rid="CR357">357</xref></sup> injected mRNA-encoding vasopressin into Brattleboro rats with successful expression of vasopressin in the hypothalamus and showed therapeutic effect (temporary reversal of diabetes insipidus for up to 5 days).</p><p id="Par112">Insulin-like growth factor 1 (IGF-1) is a versatile growth factor primarily synthesized in the liver.<sup><xref ref-type="bibr" rid="CR358">358</xref></sup> It can regulate the chondrogenesis of mesenchymal stem cells (MSCs) by stimulating their proliferation and facilitating cartilage differentiation. Wu et al.<sup><xref ref-type="bibr" rid="CR359">359</xref></sup> used modified mRNA (modRNA) encoding IGF-1 to engineer adipose-derived stem cells (ADSCs). The therapeutic effect of engineered ADSCs on Osteoarthritis (OA) is superior to that of natural ADSCs.</p><p id="Par113">Although there have been limited preclinical investigations on mRNA-encoded protein-like hormones, it is exciting that that mRNA-0184 (encoding the Relaxin-2-variable Light Chain Kappa) developed by ModernaTX, Inc. for the treatment of chronic heart failure has entered Phase I clinical trials in 2023 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05659264">NCT05659264</ext-link>).</p></sec><sec id="Sec17"><title>Regenerative medicine application</title><sec id="FPar15"><title>Myocardial infarction</title><p id="Par114">In humans, myocardial infarction results in the occlusion of a portion of the heart&#8217;s blood supply and the subsequent death of billions of cardiomyocytes, leading to a high mortality rate due to the challenging regeneration of lost cardiomyocytes. This difficulty hinders the repair of damaged heart function. The vascular endothelial growth factor (VEGF-A) has been identified as having angiogenic properties,<sup><xref ref-type="bibr" rid="CR360">360</xref></sup> making it a potential therapeutic agent for patients with ischemic heart disease. However, its systemic administration is associated with long-term side effects and poses challenges in specifically targeting the heart.<sup><xref ref-type="bibr" rid="CR361">361</xref></sup> In 2013, Zangi et al.<sup><xref ref-type="bibr" rid="CR360">360</xref></sup> designed modRNA encoding VEGF-A and found that a single intracardial infusion of VEGF-A modRNA could increase the density of blood vessels around infarction, reduce infarct size and cell death. In addition, compared to mice treated with VEGF-A DNA, those receiving VEGF-A modRNA showed improved survival rates. This improvement can be attributed to careful consideration regarding timing and dosage since prolonged exposure to VEGF-A in the DNA group resulted in increased vascular permeability and cardiac edema. Furthermore, they discussed how mobilization of epicardial progenitor cells played a crucial role in enhancing cardiac function through expansion and differentiation into cardiovascular lineages.</p><p id="Par115">The VEGF-A<sub>165</sub> mRNA (AZD8601), dissolved in biocompatible citrate saline, has commenced clinical trials. Specifically, the Phase IIa clinical trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03370887">NCT03370887</ext-link>) aims to enhance outcomes in coronary artery bypass graft patients through endocardial injection of AZD8601.<sup><xref ref-type="bibr" rid="CR362">362</xref></sup> In addition, AZD8601 exhibits promise for treating type 2 diabetes mellitus (T2DM) and is currently undergoing Phase I clinical trials (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02935712">NCT02935712</ext-link>).<sup><xref ref-type="bibr" rid="CR363">363</xref></sup> Nawaz et al.<sup><xref ref-type="bibr" rid="CR364">364</xref></sup> compared VEGF-A protein production in LNPs containing the same amount of VEGF-A mRNA or in extracellular vesicles (EVs) secreted by three different types of cells (cardiac progenitor cells, CPCs; human lung epithelial HTB-177 cells; human umbilical vein endothelial cells, HUVECs) treated with VEGF-A mRNA LNPs. Their findings revealed that when delivered to endothelial cells in vitro, the LNPs carrier produced the highest level of VEGF-A while CPC-EVs demonstrated the lowest protein yield. However, CPC-EVs was the most effective in promoting angiogenesis per given amount of VEGF-A produced. Intriguingly, during intramyocardial injection, EVs-based carriers displayed the highest expression of VEDF-A. Considering that CPC-EVs induce minimal inflammatory cytokine expression compared to other vectors, they are better suited for delivering mRNA to the heart.</p><p id="Par116">The T-box transcription factor 18 (TBX18) plays a pivotal role in the formation and differentiation of the sinoatrial node (SAN).<sup><xref ref-type="bibr" rid="CR365">365</xref></sup> Wolfson et al.<sup><xref ref-type="bibr" rid="CR366">366</xref></sup> discovered that direct injection of naked TBX18 mRNA into the myocardium of rats could effectively transfect cardiomyocytes, leading to transient expression of TBX18 and subsequent reprogramming of the cardiomyocytes into pacemaker cells. Furthermore, they observed that compared to adenoviral vectors, mRNA transfection exhibited a significant reduction in off-target gene expression and lower immunogenicity.</p></sec><sec id="FPar16"><title>Liver fibrosis and cirrhosis</title><p id="Par117">In the context of liver diseases, human hepatocyte nuclear factor &#945; (HNF4A) has been recognized as a pivotal regulator of liver cell phenotype, exerting its influence on hepatic stellate cells and liver macrophages by targeting paraoxoase-1. This targeted regulation effectively mitigates liver fibrosis. Yang et al.<sup><xref ref-type="bibr" rid="CR367">367</xref></sup> designed HNF4A mRNA-loaded LNPs to improve liver fibrosis and cirrhosis in vivo. It was noteworthy that the use of human HNF4A mRNA not only restored the expression of <italic toggle="yes">HNF4A</italic> in mouse liver but also avoided adverse immune reactions, thereby further enhancing its anti-fibrotic efficacy.</p></sec><sec id="FPar17"><title>Cystic fibrosis</title><p id="Par118">The cystic fibrosis transmembrane conductance regulator (CFTR) gene encodes epithelial ion channels responsible for the transport of chloride and bicarbonate, playing a crucial role in maintaining normal physiological functions. Cystic fibrosis is a monogenic disease caused by mutations in the CFTR gene that causes the lungs and other organs to produce thick mucus that blocks the airways of the lungs and makes breathing difficult, leading to lung damage, respiratory failure and chronic lung infections. In addition, cystic fibrosis also affects other organs such as the pancreas resulting in digestive problems and malnutrition. Furthermore, cystic fibrosis can give rise to various complications including diabetes, liver disease, and infertility. Unfortunately, there is currently no cure for this lifelong condition.<sup><xref ref-type="bibr" rid="CR276">276</xref>,<xref ref-type="bibr" rid="CR368">368</xref></sup></p><p id="Par119">In 2018, Translate Bio, Inc. conducted a Phase II trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03375047">NCT03375047</ext-link>) involving adults and seniors aged 18 years or older with cystic fibrosis to investigate the safety and therapeutic efficacy of MRT5005&#8212;an aerosol containing codon-optimized CFTR mRNA. It was found that the overall safety of patients receiving MRT5005 was good, but fever and allergic reactions occurred. The etiology and mechanism of fever remain unclear, necessitating further research.<sup><xref ref-type="bibr" rid="CR369">369</xref></sup> Additionally, two more mRNA therapies, namely ARCT-032 (encoding CFTR protein, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05712538">NCT05712538</ext-link>) and VX-522 mRNA therapy (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05668741">NCT05668741</ext-link>), have commenced clinical trials in 2023, with the outcomes yet to be disclosed.</p></sec><sec id="FPar18"><title>Degenerative disease</title><p id="Par120">The treatment of bone defects resulting from nonunion, trauma, or craniofacial malformations is challenging and affects millions of individuals. Currently, the delivery of bone morphogenetic protein-2 (BMP-2) shows promise as a treatment approach to address these defects. However, it has been observed that excessive administration of BMP-2 can lead to severe side effects such as significant inflammation and swelling. For heterotopic ossification, local delivery and precise translation of BMP-2 mRNA to produce functional proteins can be achieved. Wang et al.<sup><xref ref-type="bibr" rid="CR370">370</xref></sup> employed a dual delivery strategy by simultaneously administering BMP-2 mRNA and non-structural protein-1 (NS1) mRNA in a mass ratio of 3:1. Remarkably, their findings demonstrated that this approach induced high expression levels of BMP-2 surpassing previously reported yields. Notably, they are the first to use unmodified mRNA in the field of regenerative medicine since the co-delivered NS1 mRNA encodes an immune evasion protein originally expressed by <italic toggle="yes">influenza A</italic> viruses (A/Texas/36/1991), which effectively inhibits RNA sensors while reducing the production of immune factors to prevent activation of harmful immune responses.</p><p id="Par121">Wang et al.<sup><xref ref-type="bibr" rid="CR371">371</xref></sup> further explored the delivery platform of BMP-2/NS1 mRNA by incorporating a lipopolyplex (Lip100/His-lPEI/RNA ternary complex, LPR) loaded with BMP-2/NS1 mRNA into a collagen-nanohydroxyapatite scaffolds. The resulting ready-to-use mRNA-activated matrices (RAMs), obtained through freeze&#8211;drying, exhibit a remarkable enhancement in the release time of mRNA, extending up to 16 days. This approach enables in situ expression and continuous production of BMP-2 protein, thereby promoting bone formation. Geng et al.<sup><xref ref-type="bibr" rid="CR372">372</xref></sup> found that compared with the delivery of recombinant protein or single modRNA alone, the co-delivery of human BMP-2 (hBMP-2) and VEGF-A modRNA-modified bone marrow stem cells (BMSCs) increased the expression level of osteogenic-related gene and enhanced the formation of new bone in rats undergoing skull defect surgery. These findings offer a promising therapeutic option for regenerating bone tissue.</p><p id="Par122">Runt-related transcription factor 1 (RUNX1) is a cartilage-anabolic factor, which promotes the proliferation of chondrocytes and increases the expression of cartilage-anabolic markers of chondrocytes. Furthermore, RUNX1 enhances coccygeal disc hydration content while mitigating disc degeneration by minimizing loss of disc cartilage and other constituents. In this regard, Lin et al.<sup><xref ref-type="bibr" rid="CR373">373</xref></sup> developed RUNX1 mRNA nanomicelles for the treatment of intervertebral disc (IVD) degeneration. Compared to the control group, administration of RUNX1 mRNA nanomicelles significantly maintained a higher disc height in rats with coccygeal disc degeneration and prevented fibrosis of the disc tissue.</p><p id="Par123">Alzheimer&#8217;s disease is a degenerative disorder resulting from an imbalance in the metabolic processes of amyloid-beta (A&#946;) synthesis and clearance.<sup><xref ref-type="bibr" rid="CR374">374</xref></sup> Neprilysin (NEP) is known to play an important role in the clearance process of A&#946;. Therefore, Lin et al.<sup><xref ref-type="bibr" rid="CR375">375</xref></sup> designed polyplex nanomicelles based on NEP-encoding mRNA, which significantly reduced the concentration of A&#946; in the brain, demonstrating the potential of mRNA-based therapy in brain therapy. In addition, Li et al.<sup><xref ref-type="bibr" rid="CR376">376</xref></sup> engineered an mRNA encoding brain-derived neurotrophic factor (BDNF) for AD that was packaged on a poly (&#946; amino esters) (PBAE) nanoplatform and delivered directly to the central nervous system. To prevent excessive neuronal activation caused by high translation of BDNF mRNA, they modified the 3&#8217;UTR of this mRNA with neuron-specific miRNA-124 target sequences, ensuring degradation by miRNA upon delivery to neurons. By expressing and releasing BDNF in astrocytes to support neurons, the BDNF mRNA effectively enhanced memory function in AD model mice, thus highlighting the potential of mRNA therapy in the treatment of neurological diseases.</p></sec><sec id="FPar19"><title>Connective tissue disorder</title><p id="Par124">Elastin, one of the most enduring proteins (with a half-life of approximately 74 years), is predominantly expressed during the neonatal period. However, with age, elastin synthesis gradually diminishes and eventually ceases in adults. Elastin plays a pivotal role in endowing tissues and organs with elasticity, thereby contributing significantly to the normal functioning of elastic connective tissue. Unfortunately, genetic disorders like Williams&#8211;Beuren syndrome (WBS) can lead to mutations in elastin-related genes, resulting in a reduction of over 50% in elastin synthesis. Homozygous elastin null mutants (ELN&#8722;/&#8722;) succumb shortly after birth. In addition, factors such as aging and sunburn can also lead to elastin reduction. Lescan et al.<sup><xref ref-type="bibr" rid="CR377">377</xref></sup> synthesized and modified the mRNA-encoding human tropoelastin (TE). Their findings demonstrated that delivery of TE mRNA increased the synthesis of elastin in pig skin by 20%. Furthermore, Golombek et al.<sup><xref ref-type="bibr" rid="CR378">378</xref></sup> carried out codon optimization and natural nucleotide modification on TE mRNA to improve the translation efficiency and stability of mRNA, thus improving the expression level of TE protein in vivo and in vitro. This study not only provides valuable insights for other conditions necessitating de novo elastin synthesis but also holds promise for diseases like myocardial infarction.</p><p id="Par125">Another key protein in connective tissue is collagen.<sup><xref ref-type="bibr" rid="CR379">379</xref></sup> You et al.<sup><xref ref-type="bibr" rid="CR380">380</xref></sup> designed an exosome-based extracellular-matrix &#945;1 type-I collagen (COL1A1) mRNA for anti-aging and treatment of photoaging skin that successfully alleviated UV-induced skin aging through intradermal delivery via microneedle arrays.</p></sec></sec><sec id="Sec18"><title>Targeted genome engineering</title><p id="Par126">Targeted genome engineering is the use of gene editing technology to knock out, insert and replace the target genome sequence to achieve changes in genetic information,<sup><xref ref-type="bibr" rid="CR381">381</xref></sup> which brings a new way for the treatment of diseases (especially genetic diseases caused by gene defects).<sup><xref ref-type="bibr" rid="CR382">382</xref></sup> Zinc finger nucleases (ZFNs) and transcriptional activator-like effector nucleases (TALENs) are widely employed in gene editing techniques over a decade ago.<sup><xref ref-type="bibr" rid="CR383">383</xref></sup> However, their application is complexed and necessitates the design of proteins that specifically bind to target genes.<sup><xref ref-type="bibr" rid="CR384">384</xref></sup> The advent of clustered regularly interspaced short palindromic repeats (CRISPR)/associated protein 9 (CRISPR/Cas9) systems has significantly propelled the advancement of gene editing technology. CRISPR/Cas9 obviates the need for altering the protein sequences and only requires the design of alternative gRNAs for customization purposes.<sup><xref ref-type="bibr" rid="CR385">385</xref></sup> There are three typical forms of the CRISPR/Cas9 system: plasmid DNA (pDNA), Cas9 mRNA/sgRNA, and ribonucleoprotein (RNP, Cas9 protein complexed with gRNA). CRISPR/Cas9 pDNA faces the challenge of nuclear localization and has the risks of off-target repeat expression and genome integration; Cas9 RNP delivery has to surmount obstacles related to macromolecular size and instability; while Cas9 mRNA/sgRNA needs to address the instability of single-stranded nucleic acid.<sup><xref ref-type="bibr" rid="CR386">386</xref></sup></p><p id="Par127">The CRISPR/Cas9 technology can treat diseases by knocking out abnormal genes. The hallmark of wet age-related macular degeneration (wAMD) is vascular dysplasia. At present, anti-VEGF reagents, the first-line drug for the treatment of wAMD, are expensive and require repeated or even lifelong injection. In light of this, Ling et al.<sup><xref ref-type="bibr" rid="CR387">387</xref></sup> designed a platform that used a lentiviral system to package Cas9 mRNA and VEGF-A-targeting gRNA. The area of choroidal neovascularization (CNV) was reduced by 63% with no detectable off-target effect. Legumain, encoded by the LGMN gene located on human chromosome 14, has been identified in various tumors such as breast and gastric cancers where it is associated with tumor aggressiveness, migratory behavior, and poor prognosis. Wang et al.<sup><xref ref-type="bibr" rid="CR388">388</xref></sup> used LNPs to co-deliver Cas9 mRNA and LGMN gene-targeting gRNA, and found that this platform held promise as a therapeutic approach to inhibit breast tumor metastasis.</p><p id="Par128">The CRISPR/Cas9 technology can also remove viral DNA from the body. There are 296 million patients with chronic HBV infection in the world, and current clinical treatment can slow the replication of the virus to a certain extent and delay the progression of the disease, but the viral DNA in infected cells cannot be cleared, and HBV DNA integrated into the host body is considered to be a significant source of cancer risk. Moreover, the formation of cccDNA in the liver nucleus and continuous production of progeny virus posed a challenge to the radical treatment of HBV. To address this issue, Yi et al.<sup><xref ref-type="bibr" rid="CR389">389</xref></sup> used SM-102-based LNPs to deliver Cas9 mRNA and gRNAs together, and employed this CRISPR/Cas9 gene editing technology to achieve targeted site-specific editing. This approach provided an opportunity for continuous elimination of cccDNA and integrated HBV DNA, thereby facilitating a radical treatment strategy against HBV. In addition, to treat HPV-related cervical cancer, Ling et al.<sup><xref ref-type="bibr" rid="CR326">326</xref></sup> designed a pH-responsive nonviral nanonucleus for co-delivery of Cas9 mRNA and gRNAs targeting HPV oncogenes E6 and E7. This platform allowed for combining Cas9 mRNA/gRNA with adoptive cell therapy to effectively treat cancer diseases.</p><p id="Par129">Although CRISPR/Cas9 technology holds immense potential for the treatment of genetically related diseases and virus clearance, its development has been hindered by the challenges associated with delivering mRNA/gRNA. Currently, CRISPR/Cas9 is predominantly used in the form of Cas9 RNP or pDNA and delivered via viral vectors or electroporation in clinical trials.<sup><xref ref-type="bibr" rid="CR386">386</xref></sup> However, there are active efforts to develop mRNA/gRNA delivery strategies such as LNPs,<sup><xref ref-type="bibr" rid="CR388">388</xref>&#8211;<xref ref-type="bibr" rid="CR390">390</xref></sup> lentivirus, and retroviral vectors.<sup><xref ref-type="bibr" rid="CR387">387</xref>,<xref ref-type="bibr" rid="CR391">391</xref></sup> We look forward to developing various delivery vectors to advance the clinical application of mRNA/gRNA.</p><p id="Par130">Clinical trials based on Cas9 mRNA/gRNA have been conducted. Transthyretin (TTR) amyloidosis (abbreviated ATTR amyloidosis) is a life-threatening disease caused by the accumulation of misfolded TTR proteins in tissues, particularly in the heart and nerves. NTLA-2001 represents a gene editing therapy based on the CRISPR-Cas9 system that includes LNPs encapsulated with mRNA-encoding Cas9 protein and TTR-targeting gRNA. The interim trial results from Phase I study (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04601051">NCT04601051</ext-link>) demonstrated that NTLA-2001 effectively reduced serum TTR concentration with only mild adverse events.<sup><xref ref-type="bibr" rid="CR392">392</xref></sup> Other examples can be found in Tables <xref rid="Tab2" ref-type="table">2</xref> and <xref rid="Tab3" ref-type="table">3</xref>. Currently, mRNA-based therapies for encoding ZFN, TALEN, and Cas9 are generally in the developmental stage and have the potential to play a crucial role in disease treatment.<sup><xref ref-type="bibr" rid="CR393">393</xref></sup><table-wrap id="Tab2" position="float" orientation="portrait"><label>Table 2</label><caption><p>Representative completed and ongoing clinical studies (non-immunotherapy)</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Therapy</th><th colspan="1" rowspan="1">Disease</th><th colspan="1" rowspan="1">mRNA</th><th colspan="1" rowspan="1">mRNA-encoded protein</th><th colspan="1" rowspan="1">Delivery system</th><th colspan="1" rowspan="1">Administration route</th><th colspan="1" rowspan="1">Study started</th><th colspan="1" rowspan="1">Phase</th><th colspan="1" rowspan="1">Status</th><th colspan="1" rowspan="1">Sponsor</th><th colspan="1" rowspan="1">NCT number</th></tr></thead><tbody><tr><td rowspan="8" colspan="1">Protein replacement therapy</td><td rowspan="2" colspan="1">Ornithine transcarbamylase deficiency (OTCD)</td><td colspan="1" rowspan="1">ARCT-810</td><td rowspan="2" colspan="1">Ornithine transcarbamylase (OTC)</td><td colspan="1" rowspan="1">LNPs</td><td colspan="1" rowspan="1">Intravenous infusion</td><td colspan="1" rowspan="1">2022-07-06</td><td colspan="1" rowspan="1">Phase II</td><td colspan="1" rowspan="1">Recruiting</td><td colspan="1" rowspan="1">Arcturus Therapeutics, Inc.</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05526066">NCT05526066</ext-link></td></tr><tr><td colspan="1" rowspan="1">MRT5201</td><td colspan="1" rowspan="1">LNPs</td><td colspan="1" rowspan="1">Intravenous administration</td><td colspan="1" rowspan="1">2019-12</td><td colspan="1" rowspan="1">Phase I/II</td><td colspan="1" rowspan="1">Withdrawn</td><td colspan="1" rowspan="1">Translate Bio, Inc.</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03767270">NCT03767270</ext-link></td></tr><tr><td colspan="1" rowspan="1">Propionic acidaemia (PA)</td><td colspan="1" rowspan="1">mRNA-3927</td><td colspan="1" rowspan="1">Propionyl-coenzyme A carboxylase &#945; or &#946; (PCCA or PCCB) subunits</td><td colspan="1" rowspan="1">LNPs (SM-86, DSPC, cholesterol, and PEG lipid)</td><td colspan="1" rowspan="1">Intravenous infusion</td><td colspan="1" rowspan="1">2021-04-15</td><td colspan="1" rowspan="1">Phase I/II</td><td colspan="1" rowspan="1">Recruiting</td><td colspan="1" rowspan="1">ModernaTX, Inc.</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04159103">NCT04159103</ext-link></td></tr><tr><td colspan="1" rowspan="1">Glycogen storage disease 1a (GSD1a)</td><td colspan="1" rowspan="1">mRNA-3745</td><td colspan="1" rowspan="1">Glucose-6-phosphatase-alpha (G6Pase-&#945;)</td><td colspan="1" rowspan="1">LNPs</td><td colspan="1" rowspan="1">Intravenous infusion</td><td colspan="1" rowspan="1">2022-06-01</td><td colspan="1" rowspan="1">Phase I/II</td><td colspan="1" rowspan="1">Recruiting</td><td colspan="1" rowspan="1">ModernaTX, Inc.</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05095727">NCT05095727</ext-link></td></tr><tr><td colspan="1" rowspan="1">Glycogen storage disease type III</td><td colspan="1" rowspan="1">UX053</td><td colspan="1" rowspan="1">Amylo-&#945;-1,6-glucosidase 4-alpha-glucanotransferase (AGL)</td><td colspan="1" rowspan="1">LNPs</td><td colspan="1" rowspan="1">Intravenous infusion</td><td colspan="1" rowspan="1">2021-10-18</td><td colspan="1" rowspan="1">Phase I/II</td><td colspan="1" rowspan="1">Terminated</td><td colspan="1" rowspan="1">Ultragenyx Pharmaceutical Inc</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04990388">NCT04990388</ext-link></td></tr><tr><td rowspan="3" colspan="1">Methylmalonic acidemia (MMA)</td><td colspan="1" rowspan="1">mRNA-3704</td><td colspan="1" rowspan="1">Undisclosed</td><td colspan="1" rowspan="1">LNPs</td><td colspan="1" rowspan="1">Intravenous infusion</td><td colspan="1" rowspan="1">2019-05-28</td><td colspan="1" rowspan="1">Phase I/II</td><td colspan="1" rowspan="1">Withdrawn</td><td colspan="1" rowspan="1">ModernaTX, Inc.</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03810690">NCT03810690</ext-link></td></tr><tr><td rowspan="2" colspan="1">mRNA-3705</td><td rowspan="2" colspan="1">Methylmalonyl-coenzyme A mutase</td><td rowspan="2" colspan="1">LNPs (SM-86, DSPC, cholesterol, and PEG lipid)</td><td colspan="1" rowspan="1">Intravenous injection</td><td colspan="1" rowspan="1">2021-08-06</td><td colspan="1" rowspan="1">Phase I/II</td><td colspan="1" rowspan="1">Recruiting</td><td colspan="1" rowspan="1">ModernaTX, Inc.</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04899310">NCT04899310</ext-link></td></tr><tr><td colspan="1" rowspan="1">Injection</td><td colspan="1" rowspan="1">2022-03-08</td><td colspan="1" rowspan="1">Phase I/II</td><td colspan="1" rowspan="1">Recruiting</td><td colspan="1" rowspan="1">ModernaTX, Inc.</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05295433">NCT05295433</ext-link></td></tr><tr><td rowspan="2" colspan="1">Hormone replacement therapy</td><td colspan="1" rowspan="1">Chronic heart failure</td><td rowspan="2" colspan="1">mRNA-0184</td><td rowspan="2" colspan="1">Relaxin-2-variable light chain kappa</td><td colspan="1" rowspan="1">Undisclosed</td><td colspan="1" rowspan="1">Intravenous infusion</td><td colspan="1" rowspan="1">2022-12-05</td><td colspan="1" rowspan="1">Phase I</td><td colspan="1" rowspan="1">Recruiting</td><td colspan="1" rowspan="1">ModernaTX, Inc.</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05659264">NCT05659264</ext-link></td></tr><tr><td colspan="1" rowspan="1">Healthy participants</td><td colspan="1" rowspan="1">Undisclosed</td><td colspan="1" rowspan="1">Intravenous infusion</td><td colspan="1" rowspan="1">2024-02-16</td><td colspan="1" rowspan="1">Phase I</td><td colspan="1" rowspan="1">Recruiting</td><td colspan="1" rowspan="1">ModernaTX, Inc.</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06243770">NCT06243770</ext-link></td></tr><tr><td rowspan="5" colspan="1">Regenerative medicine application</td><td colspan="1" rowspan="1">Myocardial infarction</td><td rowspan="2" colspan="1">AZD8601</td><td rowspan="2" colspan="1">Vascular endothelial growth factor-A (VEGF-A)</td><td colspan="1" rowspan="1">None</td><td colspan="1" rowspan="1">Epicardial injection</td><td colspan="1" rowspan="1">2018-02-05</td><td colspan="1" rowspan="1">Phase IIa</td><td colspan="1" rowspan="1">Completed</td><td colspan="1" rowspan="1">AstraZeneca</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03370887">NCT03370887</ext-link></td></tr><tr><td colspan="1" rowspan="1">Type 2 diabetes mellitus (T2DM)</td><td colspan="1" rowspan="1">None</td><td colspan="1" rowspan="1">Intradermal injection</td><td colspan="1" rowspan="1">2016-12-16</td><td colspan="1" rowspan="1">Phase I</td><td colspan="1" rowspan="1">Completed</td><td colspan="1" rowspan="1">AstraZeneca</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02935712">NCT02935712</ext-link></td></tr><tr><td rowspan="3" colspan="1">Cystic fibrosis</td><td colspan="1" rowspan="1">MRT5005</td><td rowspan="2" colspan="1">Cystic fibrosis transmembrane conductance regulator (CFTR) protein</td><td colspan="1" rowspan="1">LNPs</td><td colspan="1" rowspan="1">Inhalation</td><td colspan="1" rowspan="1">2018-05-10</td><td colspan="1" rowspan="1">Phase I/II</td><td colspan="1" rowspan="1">Unknown status</td><td colspan="1" rowspan="1">Translate Bio, Inc.</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03375047">NCT03375047</ext-link></td></tr><tr><td colspan="1" rowspan="1">ARCT-032</td><td colspan="1" rowspan="1">LNPs</td><td colspan="1" rowspan="1">Inhalation</td><td colspan="1" rowspan="1">2023-02-15</td><td colspan="1" rowspan="1">Phase I</td><td colspan="1" rowspan="1">Recruiting</td><td colspan="1" rowspan="1">Arcturus Therapeutics, Inc.</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05712538">NCT05712538</ext-link></td></tr><tr><td colspan="1" rowspan="1">VX-522 mRNA therapy</td><td colspan="1" rowspan="1">Undisclosed</td><td colspan="1" rowspan="1">LNPs</td><td colspan="1" rowspan="1">Oral inhalation using nebulizer</td><td colspan="1" rowspan="1">2023-02-27</td><td colspan="1" rowspan="1">Phase I/II</td><td colspan="1" rowspan="1">Recruiting</td><td colspan="1" rowspan="1">Vertex Pharmaceuticals Incorporated</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05668741">NCT05668741</ext-link></td></tr><tr><td rowspan="5" colspan="1">Targeted genome engineering</td><td colspan="1" rowspan="1">Transthyretin amyloidosis (ATTR) with cardiomyopathy</td><td colspan="1" rowspan="1">NTLA-2001</td><td rowspan="2" colspan="1">Cas9 protein</td><td colspan="1" rowspan="1">LNPs (ionizable lipid, DSPC, cholesterol, PEG2000-DMG)</td><td colspan="1" rowspan="1">Intravenous infusion</td><td colspan="1" rowspan="1">2023-12-13</td><td colspan="1" rowspan="1">Phase III</td><td colspan="1" rowspan="1">Recruiting</td><td colspan="1" rowspan="1">Intellia Therapeutics</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06128629">NCT06128629</ext-link></td></tr><tr><td colspan="1" rowspan="1">Hereditary angioedema (HAE)</td><td colspan="1" rowspan="1">NTLA-2002</td><td colspan="1" rowspan="1">LNPs</td><td colspan="1" rowspan="1">Intravenous injection</td><td colspan="1" rowspan="1">2021-12-10</td><td colspan="1" rowspan="1">Phase I/II</td><td colspan="1" rowspan="1">Active, not recruiting</td><td colspan="1" rowspan="1">Intellia Therapeutics</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05120830">NCT05120830</ext-link></td></tr><tr><td colspan="1" rowspan="1">Refractory viral keratitis</td><td colspan="1" rowspan="1">BD111 CRISPR/Cas9 mRNA</td><td colspan="1" rowspan="1">SpCas9</td><td colspan="1" rowspan="1">Lentiviral particles</td><td colspan="1" rowspan="1">Corneal injection</td><td colspan="1" rowspan="1">2020-11-04</td><td colspan="1" rowspan="1">Not applicable</td><td colspan="1" rowspan="1">Completed</td><td colspan="1" rowspan="1">Shanghai BDgene Co., Ltd.</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04560790">NCT04560790</ext-link></td></tr><tr><td colspan="1" rowspan="1">HIV</td><td colspan="1" rowspan="1">SB-728mR-HSPC</td><td colspan="1" rowspan="1">C-C motif chemokine receptor 5 (CCR5) -specific zinc finger nucleases</td><td colspan="1" rowspan="1">Autologous hematopoietic stem and progenitor cells (HSPCs)</td><td colspan="1" rowspan="1">Infusion</td><td colspan="1" rowspan="1">2016-03-10</td><td colspan="1" rowspan="1">Phase I</td><td colspan="1" rowspan="1">Active, not recruiting</td><td colspan="1" rowspan="1">City of Hope Medical Center</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02500849">NCT02500849</ext-link></td></tr><tr><td colspan="1" rowspan="1">Transfusion-dependent beta-thalassemia (TDT)</td><td colspan="1" rowspan="1">ST-400 investigational product</td><td colspan="1" rowspan="1">ZFNs</td><td colspan="1" rowspan="1">Autologous hematopoietic stem and progenitor cells (HSPCs)</td><td colspan="1" rowspan="1">Infusion</td><td colspan="1" rowspan="1">2018-03-29</td><td colspan="1" rowspan="1">Phase I/II</td><td colspan="1" rowspan="1">Completed</td><td colspan="1" rowspan="1">Sangamo Therapeutics</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03432364">NCT03432364</ext-link></td></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">LNPs</italic> lipid nanoparticles, <italic toggle="yes">DSPC</italic> distearoylphosphatidylcholine, <italic toggle="yes">PEG</italic> polyethylene glycol, <italic toggle="yes">CRISPR/Cas9</italic> clustered regularly interspaced short palindromic repeats/associated protein 9, <italic toggle="yes">HIV</italic> human immunodeficiency virus, <italic toggle="yes">ZFNs</italic> Zinc finger nucleases</p></table-wrap-foot></table-wrap><table-wrap id="Tab3" position="float" orientation="portrait"><label>Table 3</label><caption><p>Representative preclinical studies (non-immunotherapy)</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Therapy</th><th colspan="1" rowspan="1">Target organ/tissue</th><th colspan="1" rowspan="1">Disease</th><th colspan="1" rowspan="1">mRNA-encoded protein</th><th colspan="1" rowspan="1">Delivery system</th><th colspan="1" rowspan="1">Administration route</th><th colspan="1" rowspan="1">Ref.</th></tr></thead><tbody><tr><td rowspan="4" colspan="1">Protein replacement therapy</td><td colspan="1" rowspan="1">Blood</td><td colspan="1" rowspan="1">Hemophilia A</td><td colspan="1" rowspan="1">Coagulation factor VIII</td><td colspan="1" rowspan="1">LNPs (ionizable lipid: DSPC: cholesterol: PEG lipid, 50:10:38.5:1.5)</td><td colspan="1" rowspan="1">Intravenous injection</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR347">347</xref></sup></td></tr><tr><td colspan="1" rowspan="1">Liver</td><td colspan="1" rowspan="1">Ornithine transcarbamylase deficiency (OTCD)</td><td colspan="1" rowspan="1">Ornithine transcarbamylase (OTC)</td><td colspan="1" rowspan="1">LNPs (DOTAP, cholesteryl hemisuccinate, cholesterol, PEG lipid); di-block polymer micelle</td><td colspan="1" rowspan="1">Intrahepatic delivery</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR349">349</xref></sup></td></tr><tr><td colspan="1" rowspan="1">Whole body (especially heart, kidneys, and brain)</td><td colspan="1" rowspan="1">Fabry disease (FD)</td><td colspan="1" rowspan="1">&#945;-galactosidase A</td><td colspan="1" rowspan="1">LNPs (C12-200, DOPE, cholesterol, dimyristoyl glycerol-polyethylene glycol analog)</td><td colspan="1" rowspan="1">Intravenous injection</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR351">351</xref></sup></td></tr><tr><td colspan="1" rowspan="1">Whole body (especially heart, kidneys, and brain)</td><td colspan="1" rowspan="1">FD</td><td colspan="1" rowspan="1">&#945;-galactosidase A</td><td colspan="1" rowspan="1">LNPs (ionizable: helper: structural: PEG, 50:10:38.5:1.5)</td><td colspan="1" rowspan="1">Intravenous injection</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR353">353</xref></sup></td></tr><tr><td rowspan="2" colspan="1">Hormone replacement therapy</td><td colspan="1" rowspan="1">Brain</td><td colspan="1" rowspan="1">Diabetes insipidus</td><td colspan="1" rowspan="1">Vasopressin</td><td colspan="1" rowspan="1">None</td><td colspan="1" rowspan="1">Injection into the hypothalamus</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR357">357</xref></sup></td></tr><tr><td colspan="1" rowspan="1">Bone</td><td colspan="1" rowspan="1">Osteoarthritis (OA)</td><td colspan="1" rowspan="1">Insulin-like growth factor 1 (IGF-1)</td><td colspan="1" rowspan="1">ADSCs</td><td colspan="1" rowspan="1">Intraarticular injection</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR359">359</xref></sup></td></tr><tr><td rowspan="8" colspan="1">Regenerative medicine application</td><td colspan="1" rowspan="1">Heart</td><td colspan="1" rowspan="1">Myocardial infarction</td><td colspan="1" rowspan="1">Vascular endothelial growth factor-A (VEGF-A)</td><td colspan="1" rowspan="1">None</td><td colspan="1" rowspan="1">Intramyocardial injection</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR360">360</xref></sup></td></tr><tr><td colspan="1" rowspan="1">Liver</td><td colspan="1" rowspan="1">Liver fibrosis and cirrhosis</td><td colspan="1" rowspan="1">Hepatocyte nuclear factor alpha (HNF4A)</td><td colspan="1" rowspan="1">LNPs</td><td colspan="1" rowspan="1">Intravenous injection</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR367">367</xref></sup></td></tr><tr><td colspan="1" rowspan="1">Bone</td><td colspan="1" rowspan="1">Bone defects</td><td colspan="1" rowspan="1">Bone morphogenetic protein-2 (BMP-2)</td><td colspan="1" rowspan="1">Lipopolyplex</td><td colspan="1" rowspan="1">Subcutaneously implant</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR371">371</xref></sup></td></tr><tr><td colspan="1" rowspan="1">Intervertebral disk (IVD)</td><td colspan="1" rowspan="1">IVD degeneration</td><td colspan="1" rowspan="1">Runt-related transcription factor 1 (RUNX1)</td><td colspan="1" rowspan="1">Polyplex nanomicelles (PEG-polyamino acid block copolymers)</td><td colspan="1" rowspan="1">Administered into rat coccygeal disks</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR373">373</xref></sup></td></tr><tr><td colspan="1" rowspan="1">Brain</td><td colspan="1" rowspan="1">Alzheimer&#8217;s disease</td><td colspan="1" rowspan="1">Neprilysin (NEP)</td><td colspan="1" rowspan="1">Polyplex nanomicelles (PEG-polyamino acid block catiomer)</td><td colspan="1" rowspan="1">Intracerebrovetricular administration</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR375">375</xref></sup></td></tr><tr><td colspan="1" rowspan="1">Nervous system</td><td colspan="1" rowspan="1">Alzheimer&#8217;s disease</td><td colspan="1" rowspan="1">Brain-derived neurotrophic factor (BDNF)</td><td colspan="1" rowspan="1">PBAE polymers</td><td colspan="1" rowspan="1">Delivery to the central nervous system by brain ventricle pumping</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR376">376</xref></sup></td></tr><tr><td colspan="1" rowspan="1">Skin</td><td colspan="1" rowspan="1">Photoaged skin</td><td colspan="1" rowspan="1">Extracellular-matrix &#945;1 type-I collagen (COL1A1)</td><td colspan="1" rowspan="1">EVs</td><td colspan="1" rowspan="1">Intradermal delivery (microneedle array)</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR380">380</xref></sup></td></tr><tr><td colspan="1" rowspan="1">Connective tissue</td><td colspan="1" rowspan="1">Williams&#8211;Beuren syndrome (WBS)</td><td colspan="1" rowspan="1">Tropoelastin (TE)</td><td colspan="1" rowspan="1">None</td><td colspan="1" rowspan="1">Intradermal injection</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR377">377</xref></sup></td></tr><tr><td rowspan="3" colspan="1">Targeted genome engineering</td><td colspan="1" rowspan="1">Eye</td><td colspan="1" rowspan="1">Wet age-related macular degeneration</td><td colspan="1" rowspan="1">Cas9</td><td colspan="1" rowspan="1">Lentiviral system</td><td colspan="1" rowspan="1">Subretinal injection</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR387">387</xref></sup></td></tr><tr><td colspan="1" rowspan="1">Tumor</td><td colspan="1" rowspan="1">Breast cancer</td><td colspan="1" rowspan="1">Cas9</td><td colspan="1" rowspan="1">LNPs</td><td colspan="1" rowspan="1">Intravenous injection</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR388">388</xref></sup></td></tr><tr><td colspan="1" rowspan="1">Viral carcinogenesis</td><td colspan="1" rowspan="1">HBV</td><td colspan="1" rowspan="1">Cas9</td><td colspan="1" rowspan="1">LNPs (SM-102: DSPC: cholesterol: PEG lipid, 50:10:38.5:1.5)</td><td colspan="1" rowspan="1">Intravenous injection</td><td colspan="1" rowspan="1"><sup><xref ref-type="bibr" rid="CR389">389</xref></sup></td></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">LNPs</italic> lipid nanoparticles, <italic toggle="yes">DSPC</italic> distearoylphosphatidylcholine, <italic toggle="yes">PEG</italic> polyethylene glycol, <italic toggle="yes">DOTAP</italic> (2,3-dioleoyloxy-propyl)-trimethylammonium chloride, <italic toggle="yes">DOPE</italic> 1,2-dioleyl-sn-glycero-3-phosphoethanolamine, <italic toggle="yes">ADSCs</italic> adipose-derived stem cells, <italic toggle="yes">EVs</italic> extracellular vesicles, <italic toggle="yes">HBV</italic> hepatitis B virus</p></table-wrap-foot></table-wrap></p></sec></sec></sec><sec id="Sec19"><title>The impacts from individual physiological and pathological characteristics</title><p id="Par131">Beginning in late 2019, patients infected with SARS-CoV-2 virus will progress to COVID-19 disease, ranging from asymptomatic infection to life-threatening disease, with particularly high mortality among vulnerable populations (such as the elderly with compromised immunity, individuals with chronic diseases, those use immunosuppressants, and cancer patients).<sup><xref ref-type="bibr" rid="CR394">394</xref></sup> The U.S. FDA and the European Medicines Agency (EMA) approved mRNA-1273 (Moderna) and BNT162b2 (Pfizer/BioNTech) for eliciting potent B-cell and T-cell immune responses in healthy people to prevent SARS-CoV-2 infection.<sup><xref ref-type="bibr" rid="CR395">395</xref>,<xref ref-type="bibr" rid="CR396">396</xref></sup> However, the protective effect of the vaccine wanes over time, which can be observed in healthy subjects and is more pronounced in immunocompromised subjects. Therefore, it becomes imperative to consider administering a third or even fourth dose of the vaccine.</p><p id="Par132">Specifically, Rizzi et al.<sup><xref ref-type="bibr" rid="CR394">394</xref></sup> recruited patients receiving immunosuppressive therapy for a follow-up trial. They found an absence of protective antibody response after two primary vaccinations, and detectable antibody titers were not produced until a third vaccination. Moreover, given that the induced immune response diminishes gradually after the third vaccination, depending on the patient&#8217;s condition, even a fourth immunization was necessary. Nugent et al.<sup><xref ref-type="bibr" rid="CR397">397</xref></sup> studied the antibody response and pseudovirus neutralization against SARS-CoV-2 wild-type strain, Omicron BA.1, and BA.5 variants in nursing home residents and healthcare workers after primary mRNA vaccination, first and second boosters. They found that antibody titers and neutralizing ability were progressively increasing with each booster, but subsequently diminished over 3&#8211;6 months. Considering that individuals with human immunodeficiency virus (HIV) have significantly compromised immunity, many countries have prioritized SARS-CoV-2 mRNA vaccines for this population. It has been observed that after receiving two doses of BNT162b2 vaccine, HIV-infected ones exhibit a more pronounced weakening in the antibody responses than their healthy counterparts, therefore, a third vaccination is recommended. Heftdal et al.<sup><xref ref-type="bibr" rid="CR398">398</xref></sup> investigated the persistence of cellular and humoral immunity in HIV patients and controls after the third dose of vaccine and found no significant differences in antibody titers and cellular responses between HIV patients and controls at 4 months after the third dose of BNT162b2 vaccine. In conclusion, repeated vaccination is more imperative in susceptible individuals than in their healthy counterparts for the establishment of enduring immune protection.<sup><xref ref-type="bibr" rid="CR394">394</xref></sup></p><p id="Par133">The above results are consistent with the results of epidemiological studies on hospitalized patients with severe and high-risk COVID-19 (including the elderly and patients with other diseases). However, there still exist significant variations in clinical outcomes among epidemiological patients, suggesting that the underlying cause for symptom disparities between severe COVID-19 patients and asymptomatic carriers may be more profound. Through differential gene screening, Zhang et al.<sup><xref ref-type="bibr" rid="CR399">399</xref></sup> identified mutations in type-I IFN genes among severe COVID-19 patients, and they found that at least 3.5% of patients with severe COVID-19 had genetic defects in genes associated with TLR3- and regulatory factor 7 (IRF7)-dependent induction and amplification of type-I IFN.</p><p id="Par134">Furthermore, Bastard et al.<sup><xref ref-type="bibr" rid="CR400">400</xref></sup> found that some individuals who remained severely affected by COVID-19 even after receiving two doses of SARS-CoV-2 mRNA vaccine exhibited not only neutralizing antibodies to the virus but also autoantibodies targeting type-I IFN. The lack of type-I IFN may be the cause of severe hypoxemic pneumonia of COVID-19. The aforementioned evidence implies that it is imperative to focus more on the distinct genetic immune characteristics of vulnerable populations (Fig. <xref rid="Fig5" ref-type="fig">5</xref>).<fig id="Fig5" position="float" orientation="portrait"><label>Fig. 5</label><caption><p>Immunization background map. The variations in individuals&#8217; immunological backgrounds may serve as a potential mechanism for the diversity in vaccine efficacy and adverse reactions following mRNA vaccination. An individual&#8217;s immune background is shaped by a multitude of factors, encompassing both physiological conditions and pathological conditions. Moreover, it is crucial to consider the potential adverse effects of repeated or intensive vaccination using the same or multiple vaccines. The graphic is created with BioRender.com</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e5108" position="float" orientation="portrait" xlink:href="41392_2024_2002_Fig5_HTML.jpg"/></fig></p><sec id="Sec20"><title>Age</title><p id="Par135">Vaccination, as a powerful weapon in the prevention and treatment of deadly infectious diseases, can save hundreds of millions of lives by harnessing the human immune response.<sup><xref ref-type="bibr" rid="CR401">401</xref></sup> However, human immune system is not static, rather, it undergoes profound changes with age.<sup><xref ref-type="bibr" rid="CR402">402</xref></sup> Age-dependent immune system alterations in the elderly include immune senescence in innate immune responses (i.e., changes in the number, function, and distribution of neutrophils, NK cells, monocytes, and DCs),<sup><xref ref-type="bibr" rid="CR403">403</xref></sup> and adaptive immune responses (e.g., decreased TCR diversity of aging na&#239;ve T cells, shortened telomeres of memory T cells, decreased B-cell pool diversity, and decreased response to foreign antigens).<sup><xref ref-type="bibr" rid="CR404">404</xref></sup></p><p id="Par136">However, the reasons for decreased vaccine effectiveness in the elderly go far beyond this, that is, it is not only associated with impaired antibody response, decreased T-cell response, and altered antigen presentation of the immune system, but also related to the chronic and systemic aseptic inflammatory state accompanies aging.<sup><xref ref-type="bibr" rid="CR405">405</xref></sup> Research conducted by Puzianowska-Ku&#378;nicka et al.<sup><xref ref-type="bibr" rid="CR406">406</xref></sup> has shown that two pro-inflammatory cytokines&#8212;IL-6 and C-reactive protein (CRP), increase in the elderly in an age-dependent manner, highlighting the connection between chronic inflammation and aging. Nakaya et al.<sup><xref ref-type="bibr" rid="CR407">407</xref></sup> conducted studies that revealed an age-related disparity in antibody response following influenza vaccination, irrespective of race or gender, and found that older adults (&gt;65 years) had a relatively reduced B-cell response after vaccination compared to that of younger adults (&lt;65 years). However, these older adults displayed increased monocytes and activated cytotoxic NK cells. Notably, monocytes were also increased in older adults prior to vaccination, suggesting that the baseline state of the immune system in older adults (characterized by age-related low inflammation) is a potential mechanism for the reduced vaccine response.</p><p id="Par137">Age-dependent low-grade chronic inflammation can arise from various potential sources. First, with age, the accumulation of damaged cells and the release of macromolecules such as advanced glycation end-products (AGE) continue to activate the innate immune system and trigger the release of diverse pro-inflammatory factors. Second, immune aging in the elderly may also increase the burden of antigen exposure. For instance, chronic CMV infection not only continuously stimulate the immune system, but also exacerbate both immune aging and inflammation.<sup><xref ref-type="bibr" rid="CR408">408</xref></sup> Compared to younger individuals, the elderly and the patients with chronic diseases have a pro-inflammatory status and are more prone to triggering cytokine storms following COVID-19 infection, leading to severe COVID-19 clinical symptoms.<sup><xref ref-type="bibr" rid="CR408">408</xref></sup> Immune aging is an inevitable major risk factor in various chronic diseases, particularly chronic inflammatory conditions including neurodegenerative diseases, cardiovascular diseases, and chronic kidney diseases. In addition, chronic inflammation plays a crucial role in the pathogenesis of various cancers that share a common factor&#8212;immune aging. The incidence of these pathological conditions significantly increases with age.<sup><xref ref-type="bibr" rid="CR409">409</xref></sup> Moreover, immune aging can explain the higher mortality rate observed in older COVID-19 patients due to ineffective T-cell responses and the inability to produce antibodies against SARS-CoV-2. Therefore, identifying markers that reshape immune response in older adults could serve as potential targets for patients with COVID-19 and other age-related ailments.<sup><xref ref-type="bibr" rid="CR410">410</xref></sup> Immune senescence leads to the disruption of immune checkpoint molecules, such as PD-1 and CTLA-4, and cytokines such as IL-6 and IL-1&#946;.<sup><xref ref-type="bibr" rid="CR411">411</xref>,<xref ref-type="bibr" rid="CR412">412</xref></sup> Furthermore, immune senescence is also closely associated with many autoimmune diseases. The incidence of autoimmune diseases appears to rise with age. In turn, autoimmune diseases such as rheumatoid arthritis may also accelerate the process of aging. On one hand, aging induces a state of age-dependent low-grade chronic inflammation, which in turn triggers immune suppression. This exacerbates immune senescence and increases the prevalence of various ailments among older individuals, including chronic inflammatory conditions that further hasten human aging.<sup><xref ref-type="bibr" rid="CR409">409</xref></sup></p><p id="Par138">Age-related immune senescence and the presence of chronic inflammation in older individuals present significant challenges for disease treatment. Despite the availability of vaccines specifically designed for this population, their overall effectiveness remains inadequate, particularly in infectious diseases such as influenza. Researchers are exploring various therapeutic approaches targeting the pre-vaccination aging characteristics such as inflammation, immune senescence, and mitochondrial dysfunction. Notably, mRNA vaccines have demonstrated promising benefits during the COVID-19 pandemic, including enhanced efficacy among elderly individuals.<sup><xref ref-type="bibr" rid="CR413">413</xref></sup></p><p id="Par139">During early childhood, the thymus predominantly harbors a substantial population of naive T cells, which subsequently undergo maturation processes. During this period, when encountering pathogens, memory T cells gradually accumulate and overtake the original T cells.<sup><xref ref-type="bibr" rid="CR404">404</xref></sup> Throughout the process of maturation from infancy to adulthood, a gradual decline is observed in the overall percentage of lymphocytes, as well as in the absolute count of T and B cells. In addition, there is a decrease in the number of NK cells. Interestingly, elderly individuals exhibit significantly higher levels of NK cells, pro-inflammatory cytokines (INF-&#945;, IL-6), and monocyte chemoattractant protein-1 (MCP-1), while demonstrating lower levels of epidermal growth factor (EGF).<sup><xref ref-type="bibr" rid="CR414">414</xref></sup></p><p id="Par140">The clinical trials of mRNA vaccines are typically conducted across diverse age cohorts, including pediatric, adult, and geriatric populations (Table <xref rid="Tab4" ref-type="table">4</xref>). This may be attributed to variations in their distinct immunological profiles. For instance, mRNA-1273 developed by ModernaTX, Inc. underwent clinical trials in different phases. Initially, it was tested in Phase I (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04283461">NCT04283461</ext-link>) and Phase III clinical trials (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04470427">NCT04470427</ext-link>) for individuals aged 18 years and older. Subsequently, it underwent Phase II and III trials for adolescents aged 12 to 18 years (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04649151">NCT04649151</ext-link>), as well as children aged 6 months to 11 years (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04796896">NCT04796896</ext-link>). Encouragingly, older adults including participants aged 71 years and older exhibited comparable immune responses to younger adults upon receiving the second dose of the mRNA-1273 vaccine (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04283461">NCT04283461</ext-link>).<sup><xref ref-type="bibr" rid="CR415">415</xref></sup> BNT162b2, developed by BioNTech SE, has encompassed age groups and has completed several clinical trials (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04368728">NCT04368728</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04754594">NCT04754594</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04816643">NCT04816643</ext-link>). The findings revealed a decrease in immunogenicity of BNT162b1 or BNT162b2 with advancing age, resulting in a comparatively attenuated overall humoral response among older adults (aged 65&#8211;85 years) compared to their younger counterparts (aged 8 to 55 years). Encouragingly, the administration of the second dose of these vaccines could enhance antibody responses in both young and elderly adults (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04368728">NCT04368728</ext-link>).<sup><xref ref-type="bibr" rid="CR416">416</xref></sup><table-wrap id="Tab4" position="float" orientation="portrait"><label>Table 4</label><caption><p>Clinical trials were conducted according to different age groups</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">mRNA</th><th colspan="1" rowspan="1">Disease</th><th colspan="1" rowspan="1">mRNA encoded protein</th><th colspan="1" rowspan="1">Enrollment (actual)</th><th colspan="1" rowspan="1">Ages</th><th colspan="1" rowspan="1">Sex/gender</th><th colspan="1" rowspan="1">Phase</th><th colspan="1" rowspan="1">NCT number</th><th colspan="1" rowspan="1">Study started (actual)</th><th colspan="1" rowspan="1">Status</th><th colspan="1" rowspan="1">Sponsor</th></tr></thead><tbody><tr><td rowspan="3" colspan="1">mRNA-1273</td><td rowspan="3" colspan="1">COVID-19</td><td rowspan="3" colspan="1">SARS-CoV-2 spike protein</td><td colspan="1" rowspan="1">30415</td><td colspan="1" rowspan="1">18 years and older (adult, older adult)</td><td colspan="1" rowspan="1">All</td><td colspan="1" rowspan="1">Phase III</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04470427">NCT04470427</ext-link></td><td colspan="1" rowspan="1">2020-07-27</td><td colspan="1" rowspan="1">Completed</td><td rowspan="3" colspan="1">ModernaTX, Inc.</td></tr><tr><td colspan="1" rowspan="1">4331</td><td colspan="1" rowspan="1">12 years to 18 years (child, adult)</td><td colspan="1" rowspan="1">All</td><td colspan="1" rowspan="1">Phase II/III</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04649151">NCT04649151</ext-link></td><td colspan="1" rowspan="1">2020-12-09</td><td colspan="1" rowspan="1">Active, not recruiting</td></tr><tr><td colspan="1" rowspan="1">11950</td><td colspan="1" rowspan="1">6 months to 11 years (child)</td><td colspan="1" rowspan="1">All</td><td colspan="1" rowspan="1">Phase II/III</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04796896">NCT04796896</ext-link></td><td colspan="1" rowspan="1">2021-03-15</td><td colspan="1" rowspan="1">Completed</td></tr><tr><td colspan="1" rowspan="1">BNT162b1, BNT162b2</td><td rowspan="5" colspan="1">COVID-19</td><td colspan="1" rowspan="1">SARS-CoV-2 receptor-binding domain, SARS-CoV-2 spike protein</td><td colspan="1" rowspan="1">47079</td><td colspan="1" rowspan="1">12 years and older (child, adult, older adult)</td><td colspan="1" rowspan="1">All</td><td colspan="1" rowspan="1">Phase II/III</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04368728">NCT04368728</ext-link></td><td colspan="1" rowspan="1">2020-04-29</td><td colspan="1" rowspan="1">Completed</td><td rowspan="5" colspan="1">BioNTech SE</td></tr><tr><td rowspan="4" colspan="1">BNT162b2</td><td rowspan="4" colspan="1">SARS-CoV-2 spike protein</td><td colspan="1" rowspan="1">16385</td><td colspan="1" rowspan="1">12 years and older (child, adult, older adult)</td><td colspan="1" rowspan="1">All</td><td colspan="1" rowspan="1">Phase III</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04955626">NCT04955626</ext-link></td><td colspan="1" rowspan="1">2021-07-01</td><td colspan="1" rowspan="1">Completed</td></tr><tr><td colspan="1" rowspan="1">683</td><td colspan="1" rowspan="1">18 years and older (adult, older adult, healthy pregnant women)</td><td colspan="1" rowspan="1">Female</td><td colspan="1" rowspan="1">Phase III</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04754594">NCT04754594</ext-link></td><td colspan="1" rowspan="1">2021-02-16</td><td colspan="1" rowspan="1">Completed</td></tr><tr><td colspan="1" rowspan="1">11837</td><td colspan="1" rowspan="1">6 months to 15 years (child)</td><td colspan="1" rowspan="1">All</td><td colspan="1" rowspan="1">Phase II/III</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04816643">NCT04816643</ext-link></td><td colspan="1" rowspan="1">2021-03-24</td><td colspan="1" rowspan="1">Completed</td></tr><tr><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">72 days to 102 days (child)</td><td colspan="1" rowspan="1">All</td><td colspan="1" rowspan="1">Phase I</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05630352">NCT05630352</ext-link></td><td colspan="1" rowspan="1">2025-01-06 (estimated)</td><td colspan="1" rowspan="1">Withdrawn</td></tr><tr><td rowspan="6" colspan="1">mRNA-1345</td><td rowspan="6" colspan="1">RSV</td><td rowspan="6" colspan="1">RSV prefusion stabilized F (preF) glycoprotein</td><td colspan="1" rowspan="1">36557</td><td colspan="1" rowspan="1">60 years and older (adult, older adult)</td><td colspan="1" rowspan="1">All</td><td colspan="1" rowspan="1">Phase II/III</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05127434">NCT05127434</ext-link></td><td colspan="1" rowspan="1">2021-11-17</td><td colspan="1" rowspan="1">Active, not recruiting</td><td rowspan="6" colspan="1">ModernaTX, Inc.</td></tr><tr><td colspan="1" rowspan="1">3800</td><td colspan="1" rowspan="1">50 years and older (adult, older adult)</td><td colspan="1" rowspan="1">All</td><td colspan="1" rowspan="1">Phase III</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05330975">NCT05330975</ext-link></td><td colspan="1" rowspan="1">2022-04-01</td><td colspan="1" rowspan="1">Active, not recruiting</td></tr><tr><td colspan="1" rowspan="1">210 (estimated)</td><td colspan="1" rowspan="1">5 months to 24 months (child)</td><td colspan="1" rowspan="1">All</td><td colspan="1" rowspan="1">Phase I</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05743881">NCT05743881</ext-link></td><td colspan="1" rowspan="1">2023-02-15</td><td colspan="1" rowspan="1">Active, not recruiting</td></tr><tr><td colspan="1" rowspan="1">1150 (estimated)</td><td colspan="1" rowspan="1">18 years and older (adult, older adult)</td><td colspan="1" rowspan="1">All</td><td colspan="1" rowspan="1">Phase III</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06067230">NCT06067230</ext-link></td><td colspan="1" rowspan="1">2023-10-06</td><td colspan="1" rowspan="1">Recruiting</td></tr><tr><td colspan="1" rowspan="1">340 (estimated)</td><td colspan="1" rowspan="1">2 years to 17 years (child)</td><td colspan="1" rowspan="1">All</td><td colspan="1" rowspan="1">Phase II</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06097299">NCT06097299</ext-link></td><td colspan="1" rowspan="1">2023-10-24</td><td colspan="1" rowspan="1">Active, not recruiting</td></tr><tr><td colspan="1" rowspan="1">360 (estimated)</td><td colspan="1" rowspan="1">18 years to 40 years (adult, pregnant women and infants)</td><td colspan="1" rowspan="1">All</td><td colspan="1" rowspan="1">Phase II</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06143046">NCT06143046</ext-link></td><td colspan="1" rowspan="1">2023-11-15</td><td colspan="1" rowspan="1">Recruiting</td></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">RSV</italic> respiratory syncytial virus</p><p>Note: Vaccination safety and immunogenicity are closely related to age, and clinical trials at different ages are needed to determine efficacy</p></table-wrap-foot></table-wrap></p><p id="Par141">Epidemiological data indicates that individuals aged 60 years and above exhibit a disproportionately higher propensity for severe clinical symptoms and increased rates of hospitalization following SARS-CoV-2 infection during the COVID-19 pandemic. While current vaccines have demonstrated favorable efficacy in younger cohorts, they fail to elicit sustained immunity in the elderly population. Despite previous discussions on potential reasons for this phenomenon, further exploration is warranted to uncover deeper underlying factors. The objective of such investigation is to ultimately develop highly effective vaccines with minimal adverse reactions specifically tailored for older adults. To further enhance the efficacy of the vaccine, in addition to exploring novel strategies against immunosenescence and inflammation, it is also imperative to develop and employ more potent adjuvants.<sup><xref ref-type="bibr" rid="CR405">405</xref></sup> During the COVID-19 pandemic, mRNA vaccines have accumulated valuable insights into age-related efficacy and adverse reactions of vaccination, thus paving the way for their extensive application in other infectious diseases, tumors, and beyond.</p></sec><sec id="Sec21"><title>Gender</title><p id="Par142">Gender dimorphisms are pervasive in human development and physiology. The phenotypic discrepancies of gender derive from a complexed mixture of endogenous and exogenous factors, particularly hormones such as estrogen and androgen. In the era of precision medicine, it becomes crucial to consider the relationship between gender and immune responses for disease prevention and treatment.<sup><xref ref-type="bibr" rid="CR417">417</xref></sup> The existing literature suggests that male patients demonstrate a higher propensity for developing severe clinical symptoms of SARS-CoV-2 compared to their female counterparts.<sup><xref ref-type="bibr" rid="CR418">418</xref></sup> This phenomenon may be attributed to the immunomodulatory effects of estrogen, whereas androgen and progesterone exert immunosuppressive actions.<sup><xref ref-type="bibr" rid="CR404">404</xref></sup> However, the relationship between gender and disease severity is intricate, encompassing the influence of sex hormones, expression of X-linked genes, and other immune regulatory factors. Therefore, a comprehensive understanding of the COVID-19 infection and symptom severity can be achieved by investigating genetic, hormonal, and specific behavioral factors associated with gender and age. Moreover, such researches can contribute to the future development of mRNA vaccines.<sup><xref ref-type="bibr" rid="CR418">418</xref></sup></p><p id="Par143">Gender plays a pivotal role in determining the risk of HIV infection and its pathogenic progression. Reproductive disparities between genders contribute to an augmented susceptibility of women toward HIV infection. However, during the early stages of HIV infection, women exhibit heightened activation of CD8<sup>+</sup> T cells and increased expression of interferon-stimulated genes. Nonetheless, post-HIV infection, women face an elevated risk of non-acquired immunodeficiency syndrome (AIDS) morbidity such as cerebrovascular events.<sup><xref ref-type="bibr" rid="CR419">419</xref></sup></p><p id="Par144">Compared to female mice, male mice demonstrate a higher susceptibility to influenza B virus (FLUBV), mirroring the epidemiological features observed in humans. Cardenas-Garcia et al.<sup><xref ref-type="bibr" rid="CR420">420</xref></sup> conducted a study encompassing various vaccine designs and found that female mice exhibited more robust lgG and lgA responses and increased CD4<sup>+</sup> T cells compared to their male counterparts. Furthermore, they reported that both the quality and quantity of immune response were influenced by factors such as vaccine platform, gender, and inclusion of adjuvants, thereby impacting the vaccine efficacy against FLUBV. The findings suggest that, in general, males demonstrate higher morbidity and mortality rates from viral infectious diseases.<sup><xref ref-type="bibr" rid="CR421">421</xref></sup> However, it is noteworthy that in certain infectious diseases such as measles and dengue, females actually exhibit higher morbidity and mortality rates.<sup><xref ref-type="bibr" rid="CR404">404</xref></sup></p><p id="Par145">For cardiovascular disease, there are well-established modifiable risk factors such as smoking, obesity, diabetes, hypertension, and hyperlipidemia. In addition to these factors, non-modifiable risk factors such as genetics, age, and gender play a significant role in cardiovascular disease development. The risk of cardiovascular disease significantly increases for males aged 45 years and above, as well as for females who undergo oophorectomy or experience natural menopause.<sup><xref ref-type="bibr" rid="CR422">422</xref></sup></p><p id="Par146">It is widely acknowledged that sex hormones play a pivotal role in hormone-dependent organ diseases, such as breast and ovarian cancers in females, as well as prostate and testicular cancers in males. The incidence rates of various non-reproductive organ cancers may also exhibit a significant association with gender.<sup><xref ref-type="bibr" rid="CR423">423</xref></sup> Li et al.<sup><xref ref-type="bibr" rid="CR417">417</xref></sup> conducted an analysis utilizing data from the UK Biobank and identified 119 diseases exhibiting a gender bias (<italic toggle="yes">P</italic> adjusted&#8201;&lt;&#8201;0.05). Notably, stomach, kidney and lung malignancies demonstrated higher incidence rates in men, while asthma displayed a higher incidence rate in women.</p><p id="Par147">The immune system is intricately interconnected with cancer treatment, and variations in hormonal and X chromosome gene expression can lead to different immune responses among distinct populations of innate and adaptive immune cells.<sup><xref ref-type="bibr" rid="CR424">424</xref></sup> For example, in patients with KRAS mutations in lung adenocarcinoma, females demonstrate a greater abundance of CD4<sup>+</sup> T and CD8<sup>+</sup> T cells compared to males.<sup><xref ref-type="bibr" rid="CR425">425</xref></sup> The study conducted by Thompson et al.<sup><xref ref-type="bibr" rid="CR426">426</xref></sup> revealed variations in the functionality of the transcription factor FOXO3, which is associated with tumor-infiltrating DCs tolerance, between genders. These disparities may serve as crucial considerations for augmenting cancer immunotherapy. Observations from clinical trial indicate that immune checkpoint blockade confers greater benefits in the treatment of male cancer patients.<sup><xref ref-type="bibr" rid="CR427">427</xref></sup> However, certain studies have reported no statistically significant gender-based differences in the efficacy of ICIs.<sup><xref ref-type="bibr" rid="CR428">428</xref></sup> Additionally, clinical investigations have demonstrated that ICIs amplified therapeutic outcomes in female patients when combined with Cisplatin and/or radiotherapy.<sup><xref ref-type="bibr" rid="CR429">429</xref></sup> These conflicting experimental findings suggest that the underlying mechanism influencing gender disparities in cancer incidence rates and treatment options are multifaceted and complex.</p><p id="Par148">In summary, women usually exhibit stronger immune responses against infectious diseases and malignant tumors than man. In addition, following vaccination, women demonstrate superior antibody responses, thereby reducing their susceptibility to infections and lowering the mortality rates. However, the better immune response of women also predisposes them to a fourfold increased risk of developing autoimmune diseases.<sup><xref ref-type="bibr" rid="CR430">430</xref>,<xref ref-type="bibr" rid="CR431">431</xref></sup> For example, the incidence ratios of multiple sclerosis, scleroderma, and rheumatoid arthritis in females compared to males range from 2:1 to 3:1. However, the gender distribution of systemic lupus erythematosus is remarkably skewed with a ratio of 9:1, representing the most pronounced gender-based disparity among autoimmune diseases.<sup><xref ref-type="bibr" rid="CR432">432</xref></sup> The etiology of the gender disparity in autoimmune disease incidence is multifaceted and intricate. For instance, the potential exacerbating effect of estrogen on systemic lupus erythematosus, does not preclude its potential immune-protective effect on rheumatoid arthritis.<sup><xref ref-type="bibr" rid="CR433">433</xref></sup> It is noteworthy that the gender-specific variations in intestinal microbiota may underpin certain gender-related physiological and pathological conditions, thus providing a biological basis for such disparities.<sup><xref ref-type="bibr" rid="CR434">434</xref></sup></p><p id="Par149">Despite the higher prevalence of autoimmune diseases in women, there is no significant gender disparity in the incidence of immune-related adverse events (IrAEs) among patients receiving ICIs for skin, gastrointestinal, and lacrimal gland-related conditions. However, notable gender differences exist in specific endocrine-related IrAEs. For example, thyroid dysfunction is more commonly seen in women, whereas hypophysitis is more frequently observed in men.<sup><xref ref-type="bibr" rid="CR432">432</xref></sup></p><p id="Par150">Previously, the role of gender in the development and treatment of diseases was overlooked. For instance, in 1977, the U.S. FDA recommended excluding women of reproductive age from Phase I and early Phase II trials under the guise of safeguarding women and children. Nevertheless, it led to a lack of research and insufficient awareness.<sup><xref ref-type="bibr" rid="CR432">432</xref></sup> Fortunately, in 2015, the National Institutes of Health (NIH) issued a directive urging researchers to incorporate gender as a biological variable into their research designs, data collection protocols, and outcome analysis.<sup><xref ref-type="bibr" rid="CR435">435</xref></sup></p><p id="Par151">Currently, there are relatively few mRNA vaccines designed specifically for gender differences. However, the disparities in immune responses resulting from differences in X-linked genes and sex-based hormonal variations do indeed exist, leading to variations in disease susceptibility and clinical manifestations as well as vaccine efficacy. These differences are increasingly being recognized.<sup><xref ref-type="bibr" rid="CR436">436</xref></sup> Research into the interactions of age and gender may aid in the design of personalized mRNA vaccine treatment strategies tailored to individual patient.<sup><xref ref-type="bibr" rid="CR422">422</xref></sup></p></sec><sec id="Sec22"><title>Pathological condition and vulnerable population</title><p id="Par152">In addition to age and gender, there are other intricate factors affect the efficacy of vaccination. Levin et al.<sup><xref ref-type="bibr" rid="CR437">437</xref></sup> found that individuals aged over 65 years, males, and groups with immunosuppression-related conditions exhibited significantly lower levels of humoral immunity 6 months after receiving the second dose of BNT162b2. Furer et al.<sup><xref ref-type="bibr" rid="CR438">438</xref></sup> revealed that patients with autoimmune inflammatory rheumatic disorders displayed a lower humoral response to the two-dose BNT162b2 mRNA vaccine regimen compared to immunocompetent individuals. Although seropositive levels were restored in immunocompetent individuals after receiving the third vaccine dose, only 80.47% of patients experienced restoration of their humoral response. Notably, all patients who received anti-cytokine biologics, Methotrexate monotherapy, Abatacept and Janus kinase inhibitors had their humoral immunity restored. However, only one-third of patients who received Rituximab were able to regain immune protection. The clinical trials regarding vaccine administration in patients receiving immunosuppressants are listed in Table <xref rid="Tab5" ref-type="table">5</xref>.<table-wrap id="Tab5" position="float" orientation="portrait"><label>Table 5</label><caption><p>Ongoing and completed clinical trials of mRNA vaccines for the treatment of immunosuppressant patients/patients with autoimmune diseases</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Background disease</th><th colspan="1" rowspan="1">Trial population</th><th colspan="1" rowspan="1">mRNA vaccine</th><th colspan="1" rowspan="1">Immunosuppressant</th><th colspan="1" rowspan="1">Phase</th><th colspan="1" rowspan="1">NCT number</th><th colspan="1" rowspan="1">Sponsor</th><th colspan="1" rowspan="1">Last update posted</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">Kidney transplant</td><td colspan="1" rowspan="1">Recipients who had a kidney transplant at least 6 months ago</td><td colspan="1" rowspan="1">Omicron XBB.1.5 vaccine</td><td colspan="1" rowspan="1">Everolimus</td><td colspan="1" rowspan="1">Phase IV</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05924685">NCT05924685</ext-link></td><td colspan="1" rowspan="1">University Medical Center Groningen</td><td colspan="1" rowspan="1">2024-03-04</td></tr><tr><td colspan="1" rowspan="1">Relapsing multiple sclerosis (MS)</td><td colspan="1" rowspan="1">Ofatumumab treated participants</td><td colspan="1" rowspan="1">Pfizer or Moderna mRNA COVID-19 vaccine</td><td colspan="1" rowspan="1">Ofatumumab</td><td colspan="1" rowspan="1">Phase IV</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04878211">NCT04878211</ext-link></td><td colspan="1" rowspan="1">Novartis Pharmaceuticals</td><td colspan="1" rowspan="1">2024-02-08</td></tr><tr><td colspan="1" rowspan="1">Secondary progressive MS</td><td colspan="1" rowspan="1">Patients with secondary progressive MS</td><td colspan="1" rowspan="1">COVID-19 modRNA vaccine</td><td colspan="1" rowspan="1">Siponimod</td><td colspan="1" rowspan="1">Phase IV</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04792567">NCT04792567</ext-link></td><td colspan="1" rowspan="1">Novartis Pharmaceuticals</td><td colspan="1" rowspan="1">2022-12-14</td></tr><tr><td colspan="1" rowspan="1">Malignant neoplasms brain</td><td colspan="1" rowspan="1">Glioblastoma multiforme patients treated with Temozolomide</td><td colspan="1" rowspan="1">Cytomegalovirus (CMV) pp65-LAMP mRNA-loaded dendritic cell (DC) vaccine</td><td colspan="1" rowspan="1">Basiliximab</td><td colspan="1" rowspan="1">Phase I</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00626483">NCT00626483</ext-link></td><td colspan="1" rowspan="1">Gary Archer Ph.D.</td><td colspan="1" rowspan="1">2021-03-09</td></tr><tr><td colspan="1" rowspan="1">Inflammatory bowel disease (IBD)</td><td colspan="1" rowspan="1">Patients with IBD</td><td colspan="1" rowspan="1">COVID-19 vaccine</td><td colspan="1" rowspan="1">Non-systemic immunosuppressive therapy (Mesalamine/Vedolizumab/Vedolizumab combination therapy with Methotrexate or Azathioprine); systemic immunosuppression (Azathioprine/Infliximab/Golimumab/Adalimumab/Certolizumab/Ustekinumab/Tofacitinib/Corticosteroid)</td><td colspan="1" rowspan="1">Observational</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04818892">NCT04818892</ext-link></td><td colspan="1" rowspan="1">University of Wisconsin, Madison</td><td colspan="1" rowspan="1">2022-12-07</td></tr><tr><td colspan="1" rowspan="1">Glioblastoma (GBM)</td><td colspan="1" rowspan="1">GBM patients who underwent resection, Temozolomide (TMZ) therapy, and radiation therapy were also pre-treated with tetanus and given Basiliximab</td><td colspan="1" rowspan="1">CMV-specific DC vaccine</td><td colspan="1" rowspan="1">Basiliximab</td><td colspan="1" rowspan="1">Phase II</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02366728">NCT02366728</ext-link></td><td colspan="1" rowspan="1">Mustafa Khasraw, MBChB, MD, FRCP, FRACP</td><td colspan="1" rowspan="1">2023-06-08</td></tr><tr><td colspan="1" rowspan="1">Autoimmune disease</td><td colspan="1" rowspan="1">5 autoimmune diseases in adults [systemic lupus erythematosus (SLE)/rheumatoid arthritis (RA)/MS/systemic sclerosis/pemphigus], 4 autoimmune diseases in pediatric participants [systemic lupus erythematosus (SLE)/juvenile idiopathic arthritis (JIA)/pediatric-onset multiple sclerosis (POMS)/juvenile dermatomyositis (JDM)]</td><td colspan="1" rowspan="1">COVID-19 vaccine</td><td colspan="1" rowspan="1">/</td><td colspan="1" rowspan="1">Phase II</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05000216">NCT05000216</ext-link></td><td colspan="1" rowspan="1">National Institute of Allergy and Infectious Diseases (NIAID)</td><td colspan="1" rowspan="1">2024-03-26</td></tr><tr><td colspan="1" rowspan="1">Immunosuppress/systematic autoimmunity</td><td colspan="1" rowspan="1">Hematological malignancy + immunosuppressant/systematic autoimmunity</td><td colspan="1" rowspan="1">COVID-19 vaccine, diphtheria/tetanus toxoids vaccine</td><td colspan="1" rowspan="1">e.g., Rituximab, Ocrelizumab, Ofatumumab</td><td colspan="1" rowspan="1">Phase III</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05415267">NCT05415267</ext-link></td><td colspan="1" rowspan="1">Kirby Institute</td><td colspan="1" rowspan="1">2024-03-15</td></tr><tr><td colspan="1" rowspan="1">Solid organ transplant</td><td colspan="1" rowspan="1">Kidney transplant recipients, liver transplant recipients</td><td colspan="1" rowspan="1">COVID-19 vaccine</td><td colspan="1" rowspan="1">Tacrolimus</td><td colspan="1" rowspan="1">Phase II</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05077254">NCT05077254</ext-link></td><td colspan="1" rowspan="1">NIAID</td><td colspan="1" rowspan="1">2024-03-29</td></tr><tr><td colspan="1" rowspan="1">MS</td><td colspan="1" rowspan="1">MS patients on immunotherapy</td><td colspan="1" rowspan="1">COVID-19 vaccine</td><td colspan="1" rowspan="1">Ofatumumab, Ocrelizumab, Fingolimod, Siponimod</td><td colspan="1" rowspan="1">Observational</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05060354">NCT05060354</ext-link></td><td colspan="1" rowspan="1">Brigham and Women&#8217;s Hospital</td><td colspan="1" rowspan="1">2024-01-25</td></tr><tr><td colspan="1" rowspan="1">Breast cancer, malignant melanoma</td><td colspan="1" rowspan="1">Patients with metastatic breast cancer or malignant melanoma</td><td colspan="1" rowspan="1">DC vaccine</td><td colspan="1" rowspan="1">Cyclophosphamide (background drugs, as vaccine adjuvants, commonly used as anticancer drugs)</td><td colspan="1" rowspan="1">Phase I</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00978913">NCT00978913</ext-link></td><td colspan="1" rowspan="1">Inge Marie Svane</td><td colspan="1" rowspan="1">2015-08-19</td></tr><tr><td colspan="1" rowspan="1">Immunocompromised, immunosuppressed</td><td colspan="1" rowspan="1">Patients with immunocompromising conditions in the United States</td><td colspan="1" rowspan="1">COVID-19 vaccine (BNT162b2)</td><td colspan="1" rowspan="1">/</td><td colspan="1" rowspan="1">Observational</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05020145">NCT05020145</ext-link></td><td colspan="1" rowspan="1">Pfizer</td><td colspan="1" rowspan="1">2024-02-12</td></tr><tr><td colspan="1" rowspan="1">Brain stem glioma</td><td colspan="1" rowspan="1">Brain stem glioma patients treated with radiotherapy and Temozolomide</td><td colspan="1" rowspan="1">DC vaccine</td><td colspan="1" rowspan="1">/</td><td colspan="1" rowspan="1">Phase I</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03396575">NCT03396575</ext-link></td><td colspan="1" rowspan="1">University of Florida</td><td colspan="1" rowspan="1">2023-11-18</td></tr></tbody></table><table-wrap-foot><p>Note: Follow all entries found under &#8220;Search for: mRNA vaccine, immunosuppressant |Card Results| ClinicalTrials.gov&#8221;</p></table-wrap-foot></table-wrap></p><p id="Par153">Leston et al.<sup><xref ref-type="bibr" rid="CR439">439</xref></sup> classified immunosuppression and correlated it with the mortality rate of COVID-19. Their findings revealed that patients with solid organ transplants and malignant tumors exhibited a significantly higher mortality risk following COVID-19 infection compared to that of immunocompetent individuals. Furthermore, in comparison to immunocompetent individuals, patients with rheumatological conditions and HIV demonstrated a slightly elevated mortality risk. The study established a close association between specific subgroups of immunosuppression and the mortality risk associated with COVID-19 infection. This categorization method holds substantial reference value for targeted treatment strategies and focused vaccination prevention. Meeraus et al.<sup><xref ref-type="bibr" rid="CR440">440</xref></sup> discovered that individuals with comorbidities and vulnerable populations exhibited reduced vaccine effectiveness following administration of AZD1222 (ChAdOx1 nCov-19) in comparison to those with normal immune systems, while immunosuppressed individuals demonstrated the lowest vaccine effectiveness after the initial dose of AZD1222. Obeid et al.<sup><xref ref-type="bibr" rid="CR441">441</xref></sup> conducted a comparative analysis on the persistence of humoral responses against SARS-CoV-2 and its variants of concern (VOCs) in immunocompromised patients who received two doses of BNT162b2 or mRNA-1273 vaccines, as well as in healthy individuals. The findings revealed that approximately 50% of patients with solid tumors and hematological malignancies, about 70% of autoimmune disease patients and solid organ transplant recipients, and 40% of healthy individuals had lost protective nAbs 6 months after vaccination. Moreover, it was observed that the durability of binding IgG anti-spike antibodies against SARS-CoV-2 was four to nine times greater than that of nAbs. Furthermore, variations were noted in the immune efficacy between different mRNA vaccines, with BNT162b2 inducing lower magnitude and shorter duration of nAbs compared to mRNA-1273. Therefore, it is imperative to select appropriate mRNA vaccines for diverse vulnerable populations in order to ensure effective administration of vaccinations.</p><p id="Par154">In addition to COVID-19 virus infection, similar scenarios seem to arise in other infectious viruses as well. A study conducted by Mbonde et al.<sup><xref ref-type="bibr" rid="CR442">442</xref></sup> revealed that immunosuppressed individuals with neuroinvasive West Nile virus (NWNV) exhibited more severe clinical manifestations compared to immunocompetent populations, thereby indicating a worse prognosis and higher risk of adverse reactions. The survival rate of sepsis survivors is significantly diminished following secondary infection, primarily due to the prolonged state of immunosuppression that ensues after acute infection. A comprehensive study conducted by Liao et al.<sup><xref ref-type="bibr" rid="CR443">443</xref></sup> revealed a close association between IL-10 production by Siglec-F<sup>+</sup> neutrophils and the suppression of T-lymphocyte activity in this phenomenon. Furthermore, their findings indicated that depletion of neutrophils could enhance T-lymphocyte proliferation and improve T-lymphocyte activity, thereby ameliorating the survival rate among immunosuppressed mice subjected to secondary infection. However, further investigation is required to assess the systemic effects associated with neutrophils depletion.</p><p id="Par155">Persistent immune suppression is observed in people with HIV, which is closely associated with low CD4 counts or abnormal CD4/CD8 ratios. The prevention and treatment of cancer in HIV-infected individuals face challenges due to disparities in health status.<sup><xref ref-type="bibr" rid="CR444">444</xref></sup> Evidences suggested that individuals infected with HIV might undergo premature aging. The research conducted by Gianesin et al.<sup><xref ref-type="bibr" rid="CR445">445</xref></sup> further demonstrated that this phenomenon extended to HIV-infected children, resulting in accelerated biological and immunological senescence, particularly affecting the CD8<sup>+</sup> cell subpopulation. Vergori et al.<sup><xref ref-type="bibr" rid="CR446">446</xref></sup> discovered that the administration of a third dose of the COVID-19 mRNA vaccine to individuals with HIV could elicit a robust immune response. However, the magnitude of the SARS-CoV-2-specific T-cell response in HIV-positive subjects was comparatively lower than that observed in the HIV-negative control group. In addition, they provided quantitative analysis regarding the potential augmentation of immune levels through extra booster doses for individuals with HIV.</p><p id="Par156">Pregnant women and infants are also considered vulnerable populations. Antibodies derived from COVID-19 vaccines can offer protection against severe virus infections in newborns through the transfer of placental antibodies. There is limited data on the antibody levels of infants, particularly preterm infants, following maternal vaccination. Therefore, Kachikis et al.<sup><xref ref-type="bibr" rid="CR447">447</xref></sup> conducted a study which revealed that there was no disparity in maternally derived SARS-CoV-2 anti-spike IgG levels between full-term and preterm infants. However, these levels were closely associated with the concentration of the maternal anti-spike antibodies. In addition, it was observed that receiving two or fewer doses of the COVID-19 vaccine might not provide optimal immune protection for pregnant women, nor for infants via cord blood. Consequently, careful consideration should be given to the timing of vaccination for pregnant women.</p></sec><sec id="Sec23"><title>Adverse reaction</title><p id="Par157">Johnston et al.<sup><xref ref-type="bibr" rid="CR448">448</xref></sup> discovered an adverse reaction manifested as a delayed hypersensitivity at the injection site subsequent to administration of the Moderna COVID-19 vaccine. Cappelletti-Montano et al.<sup><xref ref-type="bibr" rid="CR449">449</xref></sup> discovered that the majority of severe adverse reactions reported after COVID-19 vaccination were associated with cardiac complications, particularly among male adolescents. In addition, thrombosis and dyspnea emerged as prevalent serious symptoms following COVID-19 vaccination. In contrast, the adverse reactions after vaccination with HPV and influenza seemed to be more diverse. Dizziness, loss of consciousness, dyspnea, and convulsions occurred after HPV vaccination, and Guillain-Barr&#233; syndrome occurred after influenza vaccination. Vaccination with COVID-19 vaccine (BNT162b2 mRNA or mRNA-1273) can also be associated with the development of various autoimmune diseases, such as autoimmune hepatitis or nephritis, rheumatoid arthritis, and new-onset systemic lupus erythematosus. Heil<sup><xref ref-type="bibr" rid="CR450">450</xref></sup> endeavored to investigate the underlying factors contributing to a diverse range of life-threatening complications in patients infected with SARS-CoV-2. Although the COVID-19 pandemic seems to be receding, the lessons learned from the development of COVID-19 mRNA vaccines are expected to have implications for non-COVID-19 diseases.</p><p id="Par158">The study conducted by Pettini et al.<sup><xref ref-type="bibr" rid="CR451">451</xref></sup> demonstrated that multiple administration of mRNA-1273 vaccine effectively enhanced the specific memory B-cell and antibody responses against SARS-CoV-2 in allogeneic hematopoietic cell transplantation patients. Furthermore, they emphasized the significance of repeated vaccination. The phenomenon of extensive and consecutive immunization has become apparent owing to repetitive vaccinations intended to augment vaccine efficacy, along with advancements in vaccines designed for diverse diseases. Nonetheless, this intricacy presents difficulties in evaluating vaccine safety accurately. Interactions between vaccines have the potential to produce favorable or detrimental outcomes alike. Mawson and Croft<sup><xref ref-type="bibr" rid="CR452">452</xref></sup> postulated that multiple vaccinations might induce activation of the retinoid cascade, resulting in a sequence of unfavorable reactions. The uncertainties of the risks associated with vaccination necessitate further research to optimize vaccine safety.</p><p id="Par159">The safety and immunogenicity profiles following vaccination were assessed in clinical trials through the administration of two distinct vaccine formulations in a predetermined sequence. For example, the Phase I trials of the investigational vaccines BNT164a1 and BNT164b1 have recently commenced with volunteers who have previously received the BCG vaccine (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05547464">NCT05547464</ext-link>).<sup><xref ref-type="bibr" rid="CR453">453</xref></sup> Several clinical trials are currently underway to assess the safety and immunogenicity of co-administering two vaccines simultaneously (Table <xref rid="Tab6" ref-type="table">6</xref>). Moreover, mRNA vaccines can be engineered to encode several epitopes from multiple pathogens simultaneously.<sup><xref ref-type="bibr" rid="CR454">454</xref></sup> Currently, there is ongoing development of multi-component vaccines aimed at achieving progressively more comprehensive disease prevention (Table <xref rid="Tab7" ref-type="table">7</xref>).<table-wrap id="Tab6" position="float" orientation="portrait"><label>Table 6</label><caption><p>Concurrently administered vaccines</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Vaccine</th><th colspan="1" rowspan="1">Disease</th><th colspan="1" rowspan="1">Study started (actual)</th><th colspan="1" rowspan="1">Phase</th><th colspan="1" rowspan="1">Status</th><th colspan="1" rowspan="1">Sponsor</th><th colspan="1" rowspan="1">NCT number</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">9vHPV + mRNA-1273</td><td colspan="1" rowspan="1">Papillomavirus infection and COVID-19</td><td colspan="1" rowspan="1">2022-03-28</td><td colspan="1" rowspan="1">Phase III</td><td colspan="1" rowspan="1">Completed</td><td colspan="1" rowspan="1">Merck Sharp &amp; Dohme LLC</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05119855">NCT05119855</ext-link></td></tr><tr><td colspan="1" rowspan="1">mRNA-1345 + influenza vaccine</td><td colspan="1" rowspan="1">RSV and influenza</td><td colspan="1" rowspan="1">2023-09-25</td><td colspan="1" rowspan="1">Phase III</td><td colspan="1" rowspan="1">Active, not recruiting</td><td colspan="1" rowspan="1">ModernaTX, Inc.</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06060457">NCT06060457</ext-link></td></tr><tr><td colspan="1" rowspan="1">V110/V114 + mRNA-1273</td><td colspan="1" rowspan="1">Pneumococcal infection and COVID-19</td><td colspan="1" rowspan="1">2022-01-12</td><td colspan="1" rowspan="1">Phase III</td><td colspan="1" rowspan="1">Completed</td><td colspan="1" rowspan="1">Merck Sharp &amp; Dohme LLC</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05158140">NCT05158140</ext-link></td></tr><tr><td colspan="1" rowspan="1">ARCT-2303 + influenza vaccine</td><td colspan="1" rowspan="1">COVID-19 and influenza</td><td colspan="1" rowspan="1">2024-03 (estimated)</td><td colspan="1" rowspan="1">Phase III</td><td colspan="1" rowspan="1">Not yet recruiting</td><td colspan="1" rowspan="1">Arcturus Therapeutics, Inc.</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06279871">NCT06279871</ext-link></td></tr><tr><td colspan="1" rowspan="1">BNT162b2 (Omi XBB.1.5)&#8201;+&#8201;RIV</td><td colspan="1" rowspan="1">COVID-19 and influenza</td><td colspan="1" rowspan="1">2024-01-31</td><td colspan="1" rowspan="1">Phase II</td><td colspan="1" rowspan="1">Active, not recruiting</td><td colspan="1" rowspan="1">Pfizer</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06237049">NCT06237049</ext-link></td></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">HPV</italic> human papillomavirus, <italic toggle="yes">RSV</italic> respiratory syncytial virus</p></table-wrap-foot></table-wrap><table-wrap id="Tab7" position="float" orientation="portrait"><label>Table 7</label><caption><p>Multi-component vaccines</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Vaccine</th><th colspan="1" rowspan="1">Disease</th><th colspan="1" rowspan="1">Study started (actual)</th><th colspan="1" rowspan="1">Phase</th><th colspan="1" rowspan="1">Status</th><th colspan="1" rowspan="1">Sponsor</th><th colspan="1" rowspan="1">NCT number</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">mRNA-1045</td><td colspan="1" rowspan="1">Influenza and RSV</td><td colspan="1" rowspan="1">2022-10-14</td><td colspan="1" rowspan="1">Phase I</td><td colspan="1" rowspan="1">Completed</td><td colspan="1" rowspan="1">ModernaTX, Inc.</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05585632">NCT05585632</ext-link></td></tr><tr><td colspan="1" rowspan="1">mRNA-1230</td><td colspan="1" rowspan="1">Influenza, RSV and COVID-19</td><td colspan="1" rowspan="1">2022-10-14</td><td colspan="1" rowspan="1">Phase II</td><td colspan="1" rowspan="1">Completed</td><td colspan="1" rowspan="1">ModernaTX, Inc.</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05585632">NCT05585632</ext-link></td></tr><tr><td colspan="1" rowspan="1">mRNA-1083</td><td colspan="1" rowspan="1">Influenza and COVID-19</td><td colspan="1" rowspan="1">2023-04-14</td><td colspan="1" rowspan="1">Phase I/II</td><td colspan="1" rowspan="1">Active, not recruiting</td><td colspan="1" rowspan="1">ModernaTX, Inc.</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05827926">NCT05827926</ext-link></td></tr><tr><td colspan="1" rowspan="1">mRNA-1073</td><td colspan="1" rowspan="1">Influenza and COVID-19</td><td colspan="1" rowspan="1">2022-05-13</td><td colspan="1" rowspan="1">Phase I/II</td><td colspan="1" rowspan="1">Completed</td><td colspan="1" rowspan="1">ModernaTX, Inc.</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05375838">NCT05375838</ext-link></td></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">RSV</italic> respiratory syncytial virus</p></table-wrap-foot></table-wrap></p></sec></sec><sec id="Sec24"><title>Conclusions and prospects</title><sec id="Sec25"><title>Challenges in mRNA drug application</title><p id="Par160">Despite substantial advancements in the field, effectively and safely delivering mRNA therapeutics to the target site remains a significant challenge. The half-life of direct intravenous administration of mRNA is very short due to their susceptibility to degradation by nucleases. The negative charge and high molecular weight of mRNA hinder cellular transcytosis across the biological membrane. Additional barriers include high renal clearance, non-specific tissue distribution, and off-target effects. In addition, mRNA that enter cells face the challenge of escaping from endosomes.<sup><xref ref-type="bibr" rid="CR455">455</xref></sup> Furthermore, exogenously introduced mRNA can be recognized by the TLRs and cytosolic nucleic acid receptors, triggering innate immune responses and accelerating the deactivation of IVT mRNA within the body.<sup><xref ref-type="bibr" rid="CR181">181</xref></sup></p><p id="Par161">Although the application of mRNA delivery systems, LNPs in particular, mitigates certain of the above obstacles, it is important to remain cautious of the potential hazards associated with delivery vehicles, such as inflammation, immunogenicity, and cytotoxicity.<sup><xref ref-type="bibr" rid="CR105">105</xref></sup> In addition to the toxicity caused by the delivery system, it has been discovered that the production methods, routes of administration, and even proteins generated by the complexed mRNA drugs present toxicity concerns.<sup><xref ref-type="bibr" rid="CR456">456</xref></sup></p></sec><sec id="Sec26"><title>Main reasons for failed mRNA application</title><p id="Par162">Following intravenous or intramuscular administration, mRNA LNPs are extensively distributed in the liver and spleen, potentially resulting in pathological alterations within these organs, such as the disruption of hepatic cell regulation of fatty acid metabolism. In addition, mRNA nanomedicines may elicit adverse immune reactions, such as systemic complement activation, hypersensitivity responses, and cytokine-mediated effects post-vaccination.<sup><xref ref-type="bibr" rid="CR98">98</xref>,<xref ref-type="bibr" rid="CR456">456</xref></sup> The adverse immunogenicity caused by LNPs, besides the lipid components, is closely associated with their size, charge, and aggregation characteristics. Smaller LNPs are more advantageous in mitigating the activation of undesired immune responses. On the other hand, it is important to investigate the translation accuracy of nucleotide-modified mRNA therapeutics, as unintended protein synthesis may result in unforeseen outcomes.<sup><xref ref-type="bibr" rid="CR457">457</xref></sup> Mulroney et al.<sup><xref ref-type="bibr" rid="CR458">458</xref></sup> discovered that the use of m<sup>1</sup>&#936;-modified IVT mRNA led to a notable increase in the +1 ribosomal frameshift during translation. Understanding the translation process of nucleotide-modified mRNA is essential for future mRNA design and optimization to mitigate potential reductions in efficacy and increases in toxicity.</p><p id="Par163">The success application of mRNA therapies is intricately linked to the complexity and public understanding of targeted disease. Take the extensively studied cancer mRNA vaccine as an example. To date, there is few Phase III mRNA vaccine available for tumors, which may be due to the following reasons: (1) The mRNA encoding a single tumor antigen may inadvertently induce mutations in tumors to evade immune response, necessitating the need for developing mRNA vaccines capable of simultaneously targeting multiple TAAs or TSAs; (2) The surface antigens are distinct across different tumor types, calling for personalized tumor-mRNA vaccines for individual patient. However, the production and implementation of personalized vaccines are often associated with high costs and pose challenges to their widespread clinical application; (3) Tumors exert immunosuppressive effects by impeding the recognition of neoantigens and suppressing the viability of antitumor immune cells, emphasizing the importance of meticulous selection and application of adjuvants for potentiated immune responses; (4) The efficacy of mRNA vaccines is largely limited by its instability, inefficient delivery, and poor transfection efficiency. In these cases, iterative optimization of the mRNA molecule and delivery vehicle is needed; (5) Tumor patients often exhibit compromised immune responses due to a multitude of factors, including advanced age, concurrent medication (e.g., chemotherapy), and comorbidity (e.g., HIV). Hence, in addition to bolstering the immune response with adjuvants, vigilance against potential adverse reactions should be taken into serious consideration; (6) The formidable challenge of eradicating advanced tumors using mRNA vaccines alone necessitates the integration of multiple therapies for synergistic therapeutic effects, such as adoptive cell therapy.<sup><xref ref-type="bibr" rid="CR459">459</xref></sup></p></sec><sec id="Sec27"><title>Efforts and improvements made to address these challenges</title><p id="Par164">The current landscape of mRNA vaccines with promising clinical prospects often comprises three components: the mRNA sequence encoding target protein, delivery vector, and adjuvant.<sup><xref ref-type="bibr" rid="CR460">460</xref></sup> In certain cases, the mRNA carrier itself functions as vaccine adjuvant.<sup><xref ref-type="bibr" rid="CR460">460</xref></sup> Notably, although the increased immunogenicity of mRNA drugs boosts immune response, it hampers mRNA translation and suppresses target protein production. In this consideration, the technology of immune-silencing IVT mRNA by replacing naturally occurring nucleosides into the mRNA sequence has been developed.<sup><xref ref-type="bibr" rid="CR461">461</xref></sup> Employing modified mRNA represents a strategic approach to both enhance protein expression and mitigate aberrant immunogenicity.<sup><xref ref-type="bibr" rid="CR462">462</xref></sup> In addition, by optimizing the mRNA sequence, such as introducing multiple adenines at the Poly (A) tail, mRNA stability can be further enhanced with the protein translation efficiency improved. Moreover, purification methods including cellulose and fast protein liquid chromatography can be employed to eliminate the immunogenic double-stranded RNA generated during mRNA manufacturing, thereby reducing the inflammatory responses unfavorable to mRNA stability.<sup><xref ref-type="bibr" rid="CR463">463</xref></sup></p><p id="Par165">In the context of immunotherapy, to avoid the insufficient activation of APCs, especially DCs, with nucleoside-modified immune-silenced mRNA following vaccination,<sup><xref ref-type="bibr" rid="CR115">115</xref></sup> adjuvants can be incorporated into the delivery system. An ideal adjuvant can lower the dose of antigen-encoding mRNA per vaccine dose, reduce the frequency of vaccination, enhance the robustness and specificity of immune responses, and in certain cases, assume the role of a carrier for the efficient delivery of mRNA and contribute to the stabilization of the vaccine formulation.<sup><xref ref-type="bibr" rid="CR464">464</xref>,<xref ref-type="bibr" rid="CR465">465</xref></sup> Gu et al.<sup><xref ref-type="bibr" rid="CR466">466</xref></sup> used TLR2/6 agonist Pam2Cys (a simple synthetic metabolizable lipoamino acid) as an adjuvant to facilitate mRNA encoding CT26 neoantigen peptide or SARS-CoV-2 spike protein antigen for induction of effective immune responses against cancer or infectious diseases. On the other hand, the adjuvant can be incorporated directly into the mRNA sequence. Li et al.<sup><xref ref-type="bibr" rid="CR395">395</xref></sup> developed a multiply adjuvanted mRNA vaccine by fusing antigen-encoding mRNA with C3d (the terminal degradation product of mammalian complement component C3)-based mRNA adjuvant, which evoked a protective immune response against SARS-CoV-2 at a dosage ten times lower. Of note, an increasing number of studies have revealed that adjuvant not only enhances the magnitude of immune response to vaccines, but guide the type of adaptive immune response.<sup><xref ref-type="bibr" rid="CR467">467</xref></sup> Zhu et al.<sup><xref ref-type="bibr" rid="CR468">468</xref></sup> fabricated mRNA LNPs and investigated the differential immune responses elicited by mRNA LNPs supplemented with the natural STING agonist 2'3&#8217;-cyclic GMP-AMP (cGAMP) and/or the mucosal adjuvant alpha-galactosylceramide (&#945;GC). The results indicated that mRNA LNPs containing cGAMP alone induced a stronger cellular immune response than mRNA LNPs containing both cGAMP and &#945;GC, which was consistent with higher levels of IgG and IgG2a antibody responses, as well as better protection against homologous viral challenge. The study also demonstrated that mRNA LNPs containing cGAMP could accumulate CD4<sup>+</sup> T cells in the lung, while mRNA LNPs containing &#945;GC could enlarge the iNKT cells in the spleen. Activated iNKT cells may exhibit potent cytotoxicity, indicating the paramount importance of the judicious selection and application of adjuvants. At the cellular level, it is well-established that Actinidia eriantha polysaccharide (AEPS) elicits a mixed CD4<sup>+</sup> Th1 and CD4<sup>+</sup> Th2 immune response, while Alum induces a strict Th2 response. Nevertheless, many intricate molecular mechanisms remain unclear. Du et al.<sup><xref ref-type="bibr" rid="CR469">469</xref></sup> conducted a comparative analysis of the innate immune responses elicited by the two adjuvants, and found that AEPS induced higher mRNA expression levels of C-X-C motif chemokine ligand (CCL) 2, CCL3, CCL4, CXCL10, IL-12&#946;, IL-23&#945; in immune effector process, and rapidly recruited neutrophils and monocytes. In comparison, Alum induced IL-7A, IL-17F, and IL-17RA, and recruited neutrophils and eosinophils.</p><p id="Par166">The delivery and storage challenges of mRNA can be resolved through optimization of the delivery vehicle.<sup><xref ref-type="bibr" rid="CR115">115</xref></sup> To date, a plethora of delivery systems for mRNA have been developed. Among them, LNPs has progressed in clinical practice most rapidly. LNPs not only possesses the capacity to encapsulate and transport mRNA, but also shields the mRNA from nuclease degradation. However, the use of LNPs still presents certain issues, such as the potential damage to cell membranes and organelles due to the cationic characteristics of the ionizable lipid. The development of biodegradable ionizable lipids appears to offer some solutions to this problem.<sup><xref ref-type="bibr" rid="CR102">102</xref>,<xref ref-type="bibr" rid="CR105">105</xref></sup> It is crucial to recognize that no ionizable lipid is universally optimal for all nucleic acid formats, and variations in nucleic acid modification, size, and structure can impact the effectiveness of LNPs delivery.<sup><xref ref-type="bibr" rid="CR470">470</xref></sup> On the other hand, the off-target accumulation of mRNA drugs may lead to suboptimal outcomes. In this case, various stimulus-responsive nanotechnologies have been developed to utilize specific internal stimulus within the cellular microenvironment, including the expression of specific enzymes, increased levels of ROS, hypoxic environments, and changes in the pH or temperature, as well as external stimulus such as light irradiation, magnetic fields, and ultrasound. These stimuli-responsive nanoplatforms have the potential to enhance tissue targeting, promote exosome escape of mRNA, improve the therapeutic effects of mRNA therapy, and reduce toxicity and side effects.<sup><xref ref-type="bibr" rid="CR471">471</xref></sup> The active targeting of mRNA drugs to desired biological sites through LNPs surface modification is also widely used. Several preclinical studies have already demonstrated the successful delivery of mRNA LNPs to target tissues and cells.<sup><xref ref-type="bibr" rid="CR472">472</xref>&#8211;<xref ref-type="bibr" rid="CR474">474</xref></sup> For instance, Kim et al.<sup><xref ref-type="bibr" rid="CR475">475</xref></sup> utilized LNPs modified with tumor-targeting peptides to encapsulate mRNA-encoding PETN. This PETN mRNA LNPs specifically induces ICD in mice 4T1 breast tumor, thereby eliciting effective antitumor immune responses. Tang et al.<sup><xref ref-type="bibr" rid="CR476">476</xref></sup> engineered LNPs with sialic acid for DCs targeting and efficient endosomal escape. Furthermore, it is anticipated that the next-generation LNPs with the ability to target drugs specifically to distinct intracellular organelles, such as mitochondria and the nucleus, will serve as an innovative paradigm.<sup><xref ref-type="bibr" rid="CR472">472</xref></sup> In addition to the optimization strategies mentioned above, the delivery system for mRNA can be optimized to enhance the precision of mRNA-based therapies for diseases by adjusting factors such as drug dissolution, diffusion rate, pharmacokinetics, toxicity, and half-life.<sup><xref ref-type="bibr" rid="CR477">477</xref></sup></p></sec><sec id="Sec28"><title>Potential of mRNA drugs to treat various diseases</title><p id="Par167">The mRNA vaccine has emerged as a forefront line in disease prevention and treatment.<sup><xref ref-type="bibr" rid="CR276">276</xref></sup> The rapid development and regulatory approval of mRNA vaccines against SARS-CoV-2 during the COVID-19 pandemic have demonstrated the advantages of mRNA technology,<sup><xref ref-type="bibr" rid="CR478">478</xref></sup> exerting a profound influence on its application in infectious diseases and cancer immunotherapy. The Phase III clinical trial of SARS-CoV-2 mRNA vaccine is currently the most clinically available. Additionally, a series of mRNA vaccines against other infectious diseases are under development. For example, the Phase I study (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04528719">NCT04528719</ext-link>) of mRNA-1345 encoding the prefusion stabilized F (preF) glycoprotein of RSV demonstrates favorable tolerability profiles in both young and elderly individuals, providing the foundation for further investigations where high-risk adults and solid organ transplant patients are enrolled (Phase III, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06067230">NCT06067230</ext-link>).<sup><xref ref-type="bibr" rid="CR479">479</xref></sup> Meanwhile, compared to mRNA-1345, the development of mRNA-1010 for seasonal influenza is progressing at a faster pace, which has successfully completed a Phase III trial with 22,510 adults aged over 50 years (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05566639">NCT05566639</ext-link>). mRNA-based immunotherapies have also been extensively researched for antibacterial and anti-parasite applications. Of note, aggressive fungal infections actually result in a higher annual mortality than malaria, yet there are very few mRNA-based treatments available for fungal infections. We aim to increase awareness of the potential of mRNA-based therapies for treating fungal diseases.<sup><xref ref-type="bibr" rid="CR480">480</xref></sup></p><p id="Par168">In the context of antitumor immunotherapy, increasing mRNA vaccines has entered the clinic. For example, mRNA-4157 encodes up to 34 patient-specific tumor neoantigens is used in combination with Pembrolizumab for the treatment of melanoma, which has entered Phase IIb clinical trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03897881">NCT03897881</ext-link>).<sup><xref ref-type="bibr" rid="CR481">481</xref></sup> Presently, the primary focus of research lies in the identification and design of mRNA sequences that target specific cancer antigens for the purpose of achieving personalized cancer mRNA vaccine therapy. Furthermore, while the majority of existing cancer mRNA vaccines are designed for therapeutic purposes rather than preventive measures, there is also significant potential for prophylactic cancer mRNA vaccines.<sup><xref ref-type="bibr" rid="CR181">181</xref></sup> Given the design flexibility and adaptability of mRNA, the development of personalized cancer mRNA vaccines to optimize antitumor effects based on diverse tumor types and individual patient variations represents a crucial avenue for future advancement.<sup><xref ref-type="bibr" rid="CR482">482</xref></sup></p><p id="Par169">It should be mentioned that mRNA-based immunotherapy not only has the potential to enhance immune responses against a wide range of infectious diseases and cancers, but also offers the possibility of modulating the immune response for the treatment of autoimmune conditions. mRNA therapeutics designed for autoimmune diseases can be tailored to encode disease-specific antigens or immunosuppressive cytokines. For instance, the mRNA-6231 encoding HSA-IL2m, intended for the treatment of autoimmune disorders, has entered Phase I clinical trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04916431">NCT04916431</ext-link>).<sup><xref ref-type="bibr" rid="CR221">221</xref></sup></p><p id="Par170">In contrast to immunotherapy where the incorporation of adjuvants is imperative, it is of vital importance for non-immunotherapy to mitigate the immunogenicity of mRNA drugs and to amplify the expression of encoded target proteins.<sup><xref ref-type="bibr" rid="CR483">483</xref></sup> mRNA-based therapeutics function to replenish deficient proteins or substitute abnormal proteins that exhibit diminished functionality/activity. For example, mRNA therapies for OTCD (ARCT-810, Phase II, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05526066">NCT05526066</ext-link>; MRT5201, Phase I/II, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03767270">NCT03767270</ext-link>), PA (mRNA-3927, Phase I/II, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04159103">NCT04159103</ext-link>), MMA (mRNA-3705, Phase I/II, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05295433">NCT05295433</ext-link>), and myocardial infarction (AZD8601, Phase IIa, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03370887">NCT03370887</ext-link>) have entered clinical trials (Table <xref rid="Tab2" ref-type="table">2</xref>).</p><p id="Par171">In this review, we summarize the preclinical and clinical progresses of mRNA drugs in both immunotherapy and non-immunotherapy, and highlight the importance of focusing on host-specific variations for maximized efficacy and safety. Although in the early stages of development, the therapeutic use of mRNA has demonstrated great potential in combating multiple diseases.<sup><xref ref-type="bibr" rid="CR484">484</xref></sup> The mRNA drugs described in this review primarily encompass traditional IVT mRNA. However, as mRNA technology constantly innovating and advancing, other forms of mRNA drugs, such as saRNA, trans-amplifying mRNA (taRNA), and circRNA, hold immense applicability. It is worth noting that successful clinical implementation of these next-generation mRNA drugs requires the involvement of suitable delivery vehicles and further modifications to the mRNA molecule itself for better tolerability and efficacy.<sup><xref ref-type="bibr" rid="CR485">485</xref></sup></p></sec></sec></body><back><fn-group><fn><p>These authors contributed equally: Yingying Shi, Meixing Shi</p></fn></fn-group><ack><title>Acknowledgements</title><p>This work was supported by the National Key R&amp;D Program of China (2023YFC340200), the National Natural Science Foundation of China (No. 82404520, 82273862), the China Postdoctoral Science Foundation (2024M752834), and the China National Postdoctoral Program for Innovative Talents (BX20230321).</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>Conceptualization: Yingying Shi. Literature collection: Yingying Shi and Meixing Shi. Resources: Yi Wang. Writing&#8212;original draft: Yingying Shi and Meixing Shi. Writing&#8212;review and editing: Yingying Shi and Meixing Shi. Visualization: Yingying Shi and Meixing Shi. Supervision: Yi Wang and Jian You. Funding acquisition: Jian You and Yingying Shi. All authors have read and approved the article.</p></notes><notes id="FPar20" notes-type="COI-statement"><title>Competing interests</title><p id="Par172">The authors declare no competing interests.</p></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Muslimov</surname><given-names>A</given-names></name><etal/></person-group><article-title>The dual role of the innate immune system in the effectiveness of mRNA therapeutics</article-title><source>Int. J. Mol. Sci.</source><year>2023</year><volume>24</volume><fpage>14820</fpage><pub-id pub-id-type="doi">10.3390/ijms241914820</pub-id><pub-id pub-id-type="pmid">37834268</pub-id><pub-id pub-id-type="pmcid">PMC10573212</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">Muslimov, A. et al. The dual role of the innate immune system in the effectiveness of mRNA therapeutics. <italic toggle="yes">Int. J. Mol. Sci.</italic><bold>24</bold>, 14820 (2023).<pub-id pub-id-type="pmid">37834268</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms241914820</pub-id><pub-id pub-id-type="pmcid">PMC10573212</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bonelli</surname><given-names>M</given-names></name><etal/></person-group><article-title>Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: a randomised controlled trial</article-title><source>Ann. Rheum. Dis.</source><year>2022</year><volume>81</volume><fpage>687</fpage><lpage>694</lpage><pub-id pub-id-type="doi">10.1136/annrheumdis-2021-221558</pub-id><pub-id pub-id-type="pmid">35027397</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Bonelli, M. et al. Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: a randomised controlled trial. <italic toggle="yes">Ann. Rheum. Dis.</italic><bold>81</bold>, 687&#8211;694 (2022).<pub-id pub-id-type="pmid">35027397</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/annrheumdis-2021-221558</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mrak</surname><given-names>D</given-names></name><etal/></person-group><article-title>Heterologous vector versus homologous mRNA COVID-19 booster vaccination in non-seroconverted immunosuppressed patients: a randomized controlled trial</article-title><source>Nat. Commun.</source><year>2022</year><volume>13</volume><fpage>5362</fpage><pub-id pub-id-type="doi">10.1038/s41467-022-33036-y</pub-id><pub-id pub-id-type="pmid">36097029</pub-id><pub-id pub-id-type="pmcid">PMC9467419</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Mrak, D. et al. Heterologous vector versus homologous mRNA COVID-19 booster vaccination in non-seroconverted immunosuppressed patients: a randomized controlled trial. <italic toggle="yes">Nat. Commun.</italic><bold>13</bold>, 5362 (2022).<pub-id pub-id-type="pmid">36097029</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-022-33036-y</pub-id><pub-id pub-id-type="pmcid">PMC9467419</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brenner</surname><given-names>S</given-names></name><name name-style="western"><surname>Jacob</surname><given-names>F</given-names></name><name name-style="western"><surname>Meselson</surname><given-names>M</given-names></name></person-group><article-title>An unstable intermediate carrying information from genes to ribosomes for protein synthesis</article-title><source>Nature</source><year>1961</year><volume>190</volume><fpage>576</fpage><lpage>581</lpage><pub-id pub-id-type="doi">10.1038/190576a0</pub-id><pub-id pub-id-type="pmid">20446365</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Brenner, S., Jacob, F. &amp; Meselson, M. An unstable intermediate carrying information from genes to ribosomes for protein synthesis. <italic toggle="yes">Nature</italic><bold>190</bold>, 576&#8211;581 (1961).<pub-id pub-id-type="pmid">20446365</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/190576a0</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wolff</surname><given-names>JA</given-names></name><etal/></person-group><article-title>Direct gene transfer into mouse muscle in vivo</article-title><source>Science</source><year>1990</year><volume>247</volume><fpage>1465</fpage><lpage>1468</lpage><pub-id pub-id-type="doi">10.1126/science.1690918</pub-id><pub-id pub-id-type="pmid">1690918</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Wolff, J. A. et al. Direct gene transfer into mouse muscle in vivo. <italic toggle="yes">Science</italic><bold>247</bold>, 1465&#8211;1468 (1990).<pub-id pub-id-type="pmid">1690918</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.1690918</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hou</surname><given-names>X</given-names></name><name name-style="western"><surname>Zaks</surname><given-names>T</given-names></name><name name-style="western"><surname>Langer</surname><given-names>R</given-names></name><name name-style="western"><surname>Dong</surname><given-names>Y</given-names></name></person-group><article-title>Lipid nanoparticles for mRNA delivery</article-title><source>Nat. Rev. Mater.</source><year>2021</year><volume>6</volume><fpage>1078</fpage><lpage>1094</lpage><pub-id pub-id-type="doi">10.1038/s41578-021-00358-0</pub-id><pub-id pub-id-type="pmid">34394960</pub-id><pub-id pub-id-type="pmcid">PMC8353930</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Hou, X., Zaks, T., Langer, R. &amp; Dong, Y. Lipid nanoparticles for mRNA delivery. <italic toggle="yes">Nat. Rev. Mater.</italic><bold>6</bold>, 1078&#8211;1094 (2021).<pub-id pub-id-type="pmid">34394960</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41578-021-00358-0</pub-id><pub-id pub-id-type="pmcid">PMC8353930</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><mixed-citation publication-type="other">Duke University. A safety and feasibility study of active immunotherapy in patients with metastatic prostate carcinoma using autologous dendritic cells pulsed with RNA encoding prostate specific antigen, PSA. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/study/NCT00004211">https://clinicaltrials.gov/study/NCT00004211</ext-link> (2013).</mixed-citation></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heiser</surname><given-names>A</given-names></name><etal/></person-group><article-title>Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors</article-title><source>J. Clin. Investig.</source><year>2002</year><volume>109</volume><fpage>409</fpage><lpage>417</lpage><pub-id pub-id-type="doi">10.1172/JCI0214364</pub-id><pub-id pub-id-type="pmid">11828001</pub-id><pub-id pub-id-type="pmcid">PMC150859</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Heiser, A. et al. Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. <italic toggle="yes">J. Clin. Investig.</italic><bold>109</bold>, 409&#8211;417 (2002).<pub-id pub-id-type="pmid">11828001</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1172/JCI14364</pub-id><pub-id pub-id-type="pmcid">PMC150859</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><mixed-citation publication-type="other">University Hospital Tuebingen. Induction of specific immune responses against melanoma-associated antigens in vivo by intradermal vaccination with stabilized tumor mRNA&#8212;a clinical Phase I/II trial. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/study/NCT00204607">https://clinicaltrials.gov/study/NCT00204607</ext-link> (2007).</mixed-citation></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weide</surname><given-names>B</given-names></name><etal/></person-group><article-title>Direct injection of protamine-protected mRNA: results of a phase 1/2 vaccination trial in metastatic melanoma patients</article-title><source>J. Immunother.</source><year>2009</year><volume>32</volume><fpage>498</fpage><lpage>507</lpage><pub-id pub-id-type="doi">10.1097/CJI.0b013e3181a00068</pub-id><pub-id pub-id-type="pmid">19609242</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Weide, B. et al. Direct injection of protamine-protected mRNA: results of a phase 1/2 vaccination trial in metastatic melanoma patients. <italic toggle="yes">J. Immunother.</italic><bold>32</bold>, 498&#8211;507 (2009).<pub-id pub-id-type="pmid">19609242</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/CJI.0b013e3181a00068</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Karik&#243;</surname><given-names>K</given-names></name><name name-style="western"><surname>Buckstein</surname><given-names>M</given-names></name><name name-style="western"><surname>Ni</surname><given-names>H</given-names></name><name name-style="western"><surname>Weissman</surname><given-names>D</given-names></name></person-group><article-title>Suppression of RNA recognition by toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA</article-title><source>Immunity</source><year>2005</year><volume>23</volume><fpage>165</fpage><lpage>175</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2005.06.008</pub-id><pub-id pub-id-type="pmid">16111635</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Karik&#243;, K., Buckstein, M., Ni, H. &amp; Weissman, D. Suppression of RNA recognition by toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. <italic toggle="yes">Immunity</italic><bold>23</bold>, 165&#8211;175 (2005).<pub-id pub-id-type="pmid">16111635</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.immuni.2005.06.008</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dolgin</surname><given-names>E</given-names></name></person-group><article-title>The tangled history of mRNA vaccines</article-title><source>Nature</source><year>2021</year><volume>597</volume><fpage>318</fpage><lpage>324</lpage><pub-id pub-id-type="doi">10.1038/d41586-021-02483-w</pub-id><pub-id pub-id-type="pmid">34522017</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Dolgin, E. The tangled history of mRNA vaccines. <italic toggle="yes">Nature</italic><bold>597</bold>, 318&#8211;324 (2021).<pub-id pub-id-type="pmid">34522017</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/d41586-021-02483-w</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alberer</surname><given-names>M</given-names></name><etal/></person-group><article-title>Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial</article-title><source>Lancet</source><year>2017</year><volume>390</volume><fpage>1511</fpage><lpage>1520</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(17)31665-3</pub-id><pub-id pub-id-type="pmid">28754494</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Alberer, M. et al. Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial. <italic toggle="yes">Lancet</italic><bold>390</bold>, 1511&#8211;1520 (2017).<pub-id pub-id-type="pmid">28754494</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(17)31665-3</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>C</given-names></name><etal/></person-group><article-title>Safety, Immunogenicity, and mechanism of a rotavirus mRNA-LNP vaccine in mice</article-title><source>Viruses</source><year>2024</year><volume>16</volume><fpage>211</fpage><pub-id pub-id-type="doi">10.3390/v16020211</pub-id><pub-id pub-id-type="pmid">38399987</pub-id><pub-id pub-id-type="pmcid">PMC10892174</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Lu, C. et al. Safety, Immunogenicity, and mechanism of a rotavirus mRNA-LNP vaccine in mice. <italic toggle="yes">Viruses</italic><bold>16</bold>, 211 (2024).<pub-id pub-id-type="pmid">38399987</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/v16020211</pub-id><pub-id pub-id-type="pmcid">PMC10892174</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>L</given-names></name><name name-style="western"><surname>Tang</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>M</given-names></name><name name-style="western"><surname>Liu</surname><given-names>C</given-names></name></person-group><article-title>Recent advances in the molecular design and delivery technology of mRNA for vaccination against infectious diseases</article-title><source>Front. Immunol.</source><year>2022</year><volume>13</volume><fpage>896958</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2022.896958</pub-id><pub-id pub-id-type="pmid">35928814</pub-id><pub-id pub-id-type="pmcid">PMC9345514</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Yang, L., Tang, L., Zhang, M. &amp; Liu, C. Recent advances in the molecular design and delivery technology of mRNA for vaccination against infectious diseases. <italic toggle="yes">Front. Immunol.</italic><bold>13</bold>, 896958 (2022).<pub-id pub-id-type="pmid">35928814</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2022.896958</pub-id><pub-id pub-id-type="pmcid">PMC9345514</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Han</surname><given-names>G</given-names></name><etal/></person-group><article-title>Advances in mRNA therapeutics for cancer immunotherapy: from modification to delivery</article-title><source>Adv. Drug Deliv. Rev.</source><year>2023</year><volume>199</volume><fpage>114973</fpage><pub-id pub-id-type="doi">10.1016/j.addr.2023.114973</pub-id><pub-id pub-id-type="pmid">37369262</pub-id><pub-id pub-id-type="pmcid">PMC10290897</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Han, G. et al. Advances in mRNA therapeutics for cancer immunotherapy: from modification to delivery. <italic toggle="yes">Adv. Drug Deliv. Rev.</italic><bold>199</bold>, 114973 (2023).<pub-id pub-id-type="pmid">37369262</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.addr.2023.114973</pub-id><pub-id pub-id-type="pmcid">PMC10290897</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boreikait&#279;</surname><given-names>V</given-names></name><name name-style="western"><surname>Passmore</surname><given-names>LA</given-names></name></person-group><article-title>3&#8242;-end processing of eukaryotic mRNA: machinery, regulation, and impact on gene expression</article-title><source>Annu. Rev. Biochem.</source><year>2023</year><volume>92</volume><fpage>199</fpage><lpage>225</lpage><pub-id pub-id-type="doi">10.1146/annurev-biochem-052521-012445</pub-id><pub-id pub-id-type="pmid">37001138</pub-id><pub-id pub-id-type="pmcid">PMC7614891</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Boreikait&#279;, V. &amp; Passmore, L. A. 3&#8242;-end processing of eukaryotic mRNA: machinery, regulation, and impact on gene expression. <italic toggle="yes">Annu. Rev. Biochem.</italic><bold>92</bold>, 199&#8211;225 (2023).<pub-id pub-id-type="pmid">37001138</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1146/annurev-biochem-052521-012445</pub-id><pub-id pub-id-type="pmcid">PMC7614891</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shen</surname><given-names>G</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J</given-names></name><name name-style="western"><surname>Yang</surname><given-names>H</given-names></name><name name-style="western"><surname>Xie</surname><given-names>N</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y</given-names></name></person-group><article-title>mRNA therapies: pioneering a new era in rare genetic disease treatment</article-title><source>J. Control Release</source><year>2024</year><volume>369</volume><fpage>696</fpage><lpage>721</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2024.03.056</pub-id><pub-id pub-id-type="pmid">38580137</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Shen, G., Liu, J., Yang, H., Xie, N. &amp; Yang, Y. mRNA therapies: pioneering a new era in rare genetic disease treatment. <italic toggle="yes">J. Control Release</italic><bold>369</bold>, 696&#8211;721 (2024).<pub-id pub-id-type="pmid">38580137</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jconrel.2024.03.056</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chaudhary</surname><given-names>N</given-names></name><name name-style="western"><surname>Weissman</surname><given-names>D</given-names></name><name name-style="western"><surname>Whitehead</surname><given-names>KA</given-names></name></person-group><article-title>mRNA vaccines for infectious diseases: principles, delivery and clinical translation</article-title><source>Nat. Rev. Drug Discov.</source><year>2021</year><volume>20</volume><fpage>817</fpage><lpage>838</lpage><pub-id pub-id-type="doi">10.1038/s41573-021-00283-5</pub-id><pub-id pub-id-type="pmid">34433919</pub-id><pub-id pub-id-type="pmcid">PMC8386155</pub-id></element-citation><mixed-citation id="mc-CR19" publication-type="journal">Chaudhary, N., Weissman, D. &amp; Whitehead, K. A. mRNA vaccines for infectious diseases: principles, delivery and clinical translation. <italic toggle="yes">Nat. Rev. Drug Discov.</italic><bold>20</bold>, 817&#8211;838 (2021).<pub-id pub-id-type="pmid">34433919</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41573-021-00283-5</pub-id><pub-id pub-id-type="pmcid">PMC8386155</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kwon</surname><given-names>S</given-names></name><name name-style="western"><surname>Kwon</surname><given-names>M</given-names></name><name name-style="western"><surname>Im</surname><given-names>S</given-names></name><name name-style="western"><surname>Lee</surname><given-names>K</given-names></name><name name-style="western"><surname>Lee</surname><given-names>H</given-names></name></person-group><article-title>mRNA vaccines: the most recent clinical applications of synthetic mRNA</article-title><source>Arch. Pharm. Res.</source><year>2022</year><volume>45</volume><fpage>245</fpage><lpage>262</lpage><pub-id pub-id-type="doi">10.1007/s12272-022-01381-7</pub-id><pub-id pub-id-type="pmid">35426547</pub-id><pub-id pub-id-type="pmcid">PMC9012156</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Kwon, S., Kwon, M., Im, S., Lee, K. &amp; Lee, H. mRNA vaccines: the most recent clinical applications of synthetic mRNA. <italic toggle="yes">Arch. Pharm. Res.</italic><bold>45</bold>, 245&#8211;262 (2022).<pub-id pub-id-type="pmid">35426547</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12272-022-01381-7</pub-id><pub-id pub-id-type="pmcid">PMC9012156</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bourke</surname><given-names>AM</given-names></name><name name-style="western"><surname>Schwarz</surname><given-names>A</given-names></name><name name-style="western"><surname>Schuman</surname><given-names>EM</given-names></name></person-group><article-title>De-centralizing the central dogma: mRNA translation in space and time</article-title><source>Mol. Cell</source><year>2023</year><volume>83</volume><fpage>452</fpage><lpage>468</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2022.12.030</pub-id><pub-id pub-id-type="pmid">36669490</pub-id></element-citation><mixed-citation id="mc-CR21" publication-type="journal">Bourke, A. M., Schwarz, A. &amp; Schuman, E. M. De-centralizing the central dogma: mRNA translation in space and time. <italic toggle="yes">Mol. Cell</italic><bold>83</bold>, 452&#8211;468 (2023).<pub-id pub-id-type="pmid">36669490</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.molcel.2022.12.030</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bai</surname><given-names>C</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Y</given-names></name></person-group><article-title>Novel vectors and administrations for mRNA delivery</article-title><source>Small</source><year>2023</year><volume>19</volume><fpage>2303713</fpage><pub-id pub-id-type="doi">10.1002/smll.202303713</pub-id><pub-id pub-id-type="pmid">37475520</pub-id></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Bai, C., Wang, C. &amp; Lu, Y. Novel vectors and administrations for mRNA delivery. <italic toggle="yes">Small</italic><bold>19</bold>, 2303713 (2023).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/smll.202303713</pub-id><pub-id pub-id-type="pmid">37475520</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Su</surname><given-names>L-J</given-names></name><etal/></person-group><article-title>Delivery of mRNA for cancer therapy: progress and prospects</article-title><source>Nano Today</source><year>2023</year><volume>53</volume><fpage>102013</fpage><pub-id pub-id-type="doi">10.1016/j.nantod.2023.102013</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Su, L.-J. et al. Delivery of mRNA for cancer therapy: progress and prospects. <italic toggle="yes">Nano Today</italic><bold>53</bold>, 102013 (2023).</mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ye</surname><given-names>Z</given-names></name><etal/></person-group><article-title>The mRNA vaccine revolution: COVID-19 has launched the future of vaccinology</article-title><source>ACS Nano</source><year>2023</year><volume>17</volume><fpage>15231</fpage><lpage>15253</lpage><pub-id pub-id-type="doi">10.1021/acsnano.2c12584</pub-id><pub-id pub-id-type="pmid">37535899</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">Ye, Z. et al. The mRNA vaccine revolution: COVID-19 has launched the future of vaccinology. <italic toggle="yes">ACS Nano</italic><bold>17</bold>, 15231&#8211;15253 (2023).<pub-id pub-id-type="pmid">37535899</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acsnano.2c12584</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pan</surname><given-names>S</given-names></name><name name-style="western"><surname>Fan</surname><given-names>R</given-names></name><name name-style="western"><surname>Han</surname><given-names>B</given-names></name><name name-style="western"><surname>Tong</surname><given-names>A</given-names></name><name name-style="western"><surname>Guo</surname><given-names>G</given-names></name></person-group><article-title>The potential of mRNA vaccines in cancer nanomedicine and immunotherapy</article-title><source>Trends Immunol.</source><year>2024</year><volume>45</volume><fpage>20</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1016/j.it.2023.11.003</pub-id><pub-id pub-id-type="pmid">38142147</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Pan, S., Fan, R., Han, B., Tong, A. &amp; Guo, G. The potential of mRNA vaccines in cancer nanomedicine and immunotherapy. <italic toggle="yes">Trends Immunol.</italic><bold>45</bold>, 20&#8211;31 (2024).<pub-id pub-id-type="pmid">38142147</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.it.2023.11.003</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Metkar</surname><given-names>M</given-names></name><name name-style="western"><surname>Pepin</surname><given-names>CS</given-names></name><name name-style="western"><surname>Moore</surname><given-names>MJ</given-names></name></person-group><article-title>Tailor made: the art of therapeutic mRNA design</article-title><source>Nat. Rev. Drug Discov.</source><year>2024</year><volume>23</volume><fpage>67</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1038/s41573-023-00827-x</pub-id><pub-id pub-id-type="pmid">38030688</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Metkar, M., Pepin, C. S. &amp; Moore, M. J. Tailor made: the art of therapeutic mRNA design. <italic toggle="yes">Nat. Rev. Drug Discov.</italic><bold>23</bold>, 67&#8211;83 (2024).<pub-id pub-id-type="pmid">38030688</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41573-023-00827-x</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kawamoto</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Takahashi</surname><given-names>Y</given-names></name><name name-style="western"><surname>Takakura</surname><given-names>Y</given-names></name></person-group><article-title>Development of nucleic acid medicines based on chemical technology</article-title><source>Adv. Drug Deliv. Rev.</source><year>2023</year><volume>199</volume><fpage>114872</fpage><pub-id pub-id-type="doi">10.1016/j.addr.2023.114872</pub-id><pub-id pub-id-type="pmid">37244354</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">Kawamoto, Y., Wu, Y., Takahashi, Y. &amp; Takakura, Y. Development of nucleic acid medicines based on chemical technology. <italic toggle="yes">Adv. Drug Deliv. Rev.</italic><bold>199</bold>, 114872 (2023).<pub-id pub-id-type="pmid">37244354</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.addr.2023.114872</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cao</surname><given-names>Q</given-names></name><name name-style="western"><surname>Fang</surname><given-names>H</given-names></name><name name-style="western"><surname>Tian</surname><given-names>H</given-names></name></person-group><article-title>mRNA vaccines contribute to innate and adaptive immunity to enhance immune response in vivo</article-title><source>Biomaterials</source><year>2024</year><volume>310</volume><fpage>122628</fpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2024.122628</pub-id><pub-id pub-id-type="pmid">38820767</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Cao, Q., Fang, H. &amp; Tian, H. mRNA vaccines contribute to innate and adaptive immunity to enhance immune response in vivo. <italic toggle="yes">Biomaterials</italic><bold>310</bold>, 122628 (2024).<pub-id pub-id-type="pmid">38820767</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biomaterials.2024.122628</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>H</given-names></name><name name-style="western"><surname>Li</surname><given-names>K</given-names></name><name name-style="western"><surname>Liu</surname><given-names>C</given-names></name><name name-style="western"><surname>Yi</surname><given-names>C</given-names></name></person-group><article-title>Regulation and functions of non-m6A mRNA modifications</article-title><source>Nat. Rev. Mol. Cell Biol.</source><year>2023</year><volume>24</volume><fpage>714</fpage><lpage>731</lpage><pub-id pub-id-type="doi">10.1038/s41580-023-00622-x</pub-id><pub-id pub-id-type="pmid">37369853</pub-id></element-citation><mixed-citation id="mc-CR29" publication-type="journal">Sun, H., Li, K., Liu, C. &amp; Yi, C. Regulation and functions of non-m6A mRNA modifications. <italic toggle="yes">Nat. Rev. Mol. Cell Biol.</italic><bold>24</bold>, 714&#8211;731 (2023).<pub-id pub-id-type="pmid">37369853</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41580-023-00622-x</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rodell</surname><given-names>R</given-names></name><name name-style="western"><surname>Robalin</surname><given-names>N</given-names></name><name name-style="western"><surname>Martinez</surname><given-names>NM</given-names></name></person-group><article-title>Why U matters: detection and functions of pseudouridine modifications in mRNAs</article-title><source>Trends Biochem. Sci.</source><year>2024</year><volume>49</volume><fpage>12</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1016/j.tibs.2023.10.008</pub-id><pub-id pub-id-type="pmid">38097411</pub-id><pub-id pub-id-type="pmcid">PMC10976346</pub-id></element-citation><mixed-citation id="mc-CR30" publication-type="journal">Rodell, R., Robalin, N. &amp; Martinez, N. M. Why U matters: detection and functions of pseudouridine modifications in mRNAs. <italic toggle="yes">Trends Biochem. Sci.</italic><bold>49</bold>, 12&#8211;27 (2024).<pub-id pub-id-type="pmid">38097411</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.tibs.2023.10.008</pub-id><pub-id pub-id-type="pmcid">PMC10976346</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>S</given-names></name><name name-style="western"><surname>Kuang</surname><given-names>M</given-names></name></person-group><article-title>RNA modification-mediated mRNA translation regulation in liver cancer: mechanisms and clinical perspectives</article-title><source>Nat. Rev. Gastroenterol. Hepatol.</source><year>2024</year><volume>21</volume><fpage>267</fpage><lpage>281</lpage><pub-id pub-id-type="doi">10.1038/s41575-023-00884-y</pub-id><pub-id pub-id-type="pmid">38243019</pub-id></element-citation><mixed-citation id="mc-CR31" publication-type="journal">Lin, S. &amp; Kuang, M. RNA modification-mediated mRNA translation regulation in liver cancer: mechanisms and clinical perspectives. <italic toggle="yes">Nat. Rev. Gastroenterol. Hepatol.</italic><bold>21</bold>, 267&#8211;281 (2024).<pub-id pub-id-type="pmid">38243019</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41575-023-00884-y</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Flamand</surname><given-names>MN</given-names></name><name name-style="western"><surname>Tegowski</surname><given-names>M</given-names></name><name name-style="western"><surname>Meyer</surname><given-names>KD</given-names></name></person-group><article-title>The proteins of mRNA modification: writers, readers, and erasers</article-title><source>Annu. Rev. Biochem.</source><year>2023</year><volume>92</volume><fpage>145</fpage><lpage>173</lpage><pub-id pub-id-type="doi">10.1146/annurev-biochem-052521-035330</pub-id><pub-id pub-id-type="pmid">37068770</pub-id><pub-id pub-id-type="pmcid">PMC10443600</pub-id></element-citation><mixed-citation id="mc-CR32" publication-type="journal">Flamand, M. N., Tegowski, M. &amp; Meyer, K. D. The proteins of mRNA modification: writers, readers, and erasers. <italic toggle="yes">Annu. Rev. Biochem.</italic><bold>92</bold>, 145&#8211;173 (2023).<pub-id pub-id-type="pmid">37068770</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1146/annurev-biochem-052521-035330</pub-id><pub-id pub-id-type="pmcid">PMC10443600</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qu</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Advanced nano-based strategies for mRNA tumor vaccine</article-title><source>Acta Pharm. Sin. B</source><year>2024</year><volume>14</volume><fpage>170</fpage><lpage>189</lpage><pub-id pub-id-type="doi">10.1016/j.apsb.2023.07.025</pub-id><pub-id pub-id-type="pmid">38239240</pub-id><pub-id pub-id-type="pmcid">PMC10792970</pub-id></element-citation><mixed-citation id="mc-CR33" publication-type="journal">Qu, Y. et al. Advanced nano-based strategies for mRNA tumor vaccine. <italic toggle="yes">Acta Pharm. Sin. B</italic><bold>14</bold>, 170&#8211;189 (2024).<pub-id pub-id-type="pmid">38239240</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.apsb.2023.07.025</pub-id><pub-id pub-id-type="pmcid">PMC10792970</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fan</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Encoding and display technologies for combinatorial libraries in drug discovery: the coming of age from biology to therapy</article-title><source>Acta Pharm. Sin. B</source><year>2024</year><volume>14</volume><fpage>3362</fpage><lpage>3384</lpage><pub-id pub-id-type="doi">10.1016/j.apsb.2024.04.006</pub-id><pub-id pub-id-type="pmid">39220863</pub-id><pub-id pub-id-type="pmcid">PMC11365444</pub-id></element-citation><mixed-citation id="mc-CR34" publication-type="journal">Fan, Y. et al. Encoding and display technologies for combinatorial libraries in drug discovery: the coming of age from biology to therapy. <italic toggle="yes">Acta Pharm. Sin. B</italic><bold>14</bold>, 3362&#8211;3384 (2024).<pub-id pub-id-type="pmid">39220863</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.apsb.2024.04.006</pub-id><pub-id pub-id-type="pmcid">PMC11365444</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>X</given-names></name><name name-style="western"><surname>Huang</surname><given-names>P</given-names></name><name name-style="western"><surname>Yang</surname><given-names>R</given-names></name><name name-style="western"><surname>Deng</surname><given-names>H</given-names></name></person-group><article-title>mRNA cancer vaccines: construction and boosting strategies</article-title><source>ACS Nano</source><year>2023</year><volume>17</volume><fpage>19550</fpage><lpage>19580</lpage><pub-id pub-id-type="doi">10.1021/acsnano.3c05635</pub-id><pub-id pub-id-type="pmid">37819640</pub-id></element-citation><mixed-citation id="mc-CR35" publication-type="journal">Liu, X., Huang, P., Yang, R. &amp; Deng, H. mRNA cancer vaccines: construction and boosting strategies. <italic toggle="yes">ACS Nano</italic><bold>17</bold>, 19550&#8211;19580 (2023).<pub-id pub-id-type="pmid">37819640</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acsnano.3c05635</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Son</surname><given-names>S</given-names></name><name name-style="western"><surname>Park</surname><given-names>M</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J</given-names></name><name name-style="western"><surname>Lee</surname><given-names>K</given-names></name></person-group><article-title>ACE mRNA (additional chimeric element incorporated IVT mRNA) for enhancing protein expression by modulating immunogenicity</article-title><source>Adv. Sci.</source><year>2024</year><volume>11</volume><fpage>2307541</fpage><pub-id pub-id-type="doi">10.1002/advs.202307541</pub-id><pub-id pub-id-type="pmcid">PMC11095206</pub-id><pub-id pub-id-type="pmid">38447169</pub-id></element-citation><mixed-citation id="mc-CR36" publication-type="journal">Son, S., Park, M., Kim, J. &amp; Lee, K. ACE mRNA (additional chimeric element incorporated IVT mRNA) for enhancing protein expression by modulating immunogenicity. <italic toggle="yes">Adv. Sci.</italic><bold>11</bold>, 2307541 (2024).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/advs.202307541</pub-id><pub-id pub-id-type="pmcid">PMC11095206</pub-id><pub-id pub-id-type="pmid">38447169</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>Y-K</given-names></name></person-group><article-title>RNA therapy: rich history, various applications and unlimited future prospects</article-title><source>Exp. Mol. Med.</source><year>2022</year><volume>54</volume><fpage>455</fpage><lpage>465</lpage><pub-id pub-id-type="doi">10.1038/s12276-022-00757-5</pub-id><pub-id pub-id-type="pmid">35440755</pub-id><pub-id pub-id-type="pmcid">PMC9016686</pub-id></element-citation><mixed-citation id="mc-CR37" publication-type="journal">Kim, Y.-K. RNA therapy: rich history, various applications and unlimited future prospects. <italic toggle="yes">Exp. Mol. Med.</italic><bold>54</bold>, 455&#8211;465 (2022).<pub-id pub-id-type="pmid">35440755</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s12276-022-00757-5</pub-id><pub-id pub-id-type="pmcid">PMC9016686</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>C</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>F</given-names></name></person-group><article-title>A comprehensive comparison of DNA and RNA vaccines</article-title><source>Adv. Drug Deliv. Rev.</source><year>2024</year><volume>210</volume><fpage>115340</fpage><pub-id pub-id-type="doi">10.1016/j.addr.2024.115340</pub-id><pub-id pub-id-type="pmid">38810703</pub-id><pub-id pub-id-type="pmcid">PMC11181159</pub-id></element-citation><mixed-citation id="mc-CR38" publication-type="journal">Wang, C. &amp; Yuan, F. A comprehensive comparison of DNA and RNA vaccines. <italic toggle="yes">Adv. Drug Deliv. Rev.</italic><bold>210</bold>, 115340 (2024).<pub-id pub-id-type="pmid">38810703</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.addr.2024.115340</pub-id><pub-id pub-id-type="pmcid">PMC11181159</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Minnaert</surname><given-names>A-K</given-names></name><etal/></person-group><article-title>Strategies for controlling the innate immune activity of conventional and self-amplifying mRNA therapeutics: getting the message across</article-title><source>Adv. Drug Deliv. Rev.</source><year>2021</year><volume>176</volume><fpage>113900</fpage><pub-id pub-id-type="doi">10.1016/j.addr.2021.113900</pub-id><pub-id pub-id-type="pmid">34324884</pub-id><pub-id pub-id-type="pmcid">PMC8325057</pub-id></element-citation><mixed-citation id="mc-CR39" publication-type="journal">Minnaert, A.-K. et al. Strategies for controlling the innate immune activity of conventional and self-amplifying mRNA therapeutics: getting the message across. <italic toggle="yes">Adv. Drug Deliv. Rev.</italic><bold>176</bold>, 113900 (2021).<pub-id pub-id-type="pmid">34324884</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.addr.2021.113900</pub-id><pub-id pub-id-type="pmcid">PMC8325057</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>C-X</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L-L</given-names></name></person-group><article-title>Circular RNAs: characterization, cellular roles, and applications</article-title><source>Cell</source><year>2022</year><volume>185</volume><fpage>2016</fpage><lpage>2034</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2022.04.021</pub-id><pub-id pub-id-type="pmid">35584701</pub-id></element-citation><mixed-citation id="mc-CR40" publication-type="journal">Liu, C.-X. &amp; Chen, L.-L. Circular RNAs: characterization, cellular roles, and applications. <italic toggle="yes">Cell</italic><bold>185</bold>, 2016&#8211;2034 (2022).<pub-id pub-id-type="pmid">35584701</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2022.04.021</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Silva-Pilipich</surname><given-names>N</given-names></name><name name-style="western"><surname>Beloki</surname><given-names>U</given-names></name><name name-style="western"><surname>Salaberry</surname><given-names>L</given-names></name><name name-style="western"><surname>Smerdou</surname><given-names>C</given-names></name></person-group><article-title>Self-amplifying RNA: a second revolution of mRNA vaccines against COVID-19</article-title><source>Vaccines</source><year>2024</year><volume>12</volume><fpage>318</fpage><pub-id pub-id-type="doi">10.3390/vaccines12030318</pub-id><pub-id pub-id-type="pmid">38543952</pub-id><pub-id pub-id-type="pmcid">PMC10974399</pub-id></element-citation><mixed-citation id="mc-CR41" publication-type="journal">Silva-Pilipich, N., Beloki, U., Salaberry, L. &amp; Smerdou, C. Self-amplifying RNA: a second revolution of mRNA vaccines against COVID-19. <italic toggle="yes">Vaccines</italic><bold>12</bold>, 318 (2024).<pub-id pub-id-type="pmid">38543952</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/vaccines12030318</pub-id><pub-id pub-id-type="pmcid">PMC10974399</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kr&#228;hling</surname><given-names>V</given-names></name><etal/></person-group><article-title>Self-amplifying RNA vaccine protects mice against lethal Ebola virus infection</article-title><source>Mol. Ther.</source><year>2023</year><volume>31</volume><fpage>374</fpage><lpage>386</lpage><pub-id pub-id-type="doi">10.1016/j.ymthe.2022.10.011</pub-id><pub-id pub-id-type="pmid">36303436</pub-id><pub-id pub-id-type="pmcid">PMC9931551</pub-id></element-citation><mixed-citation id="mc-CR42" publication-type="journal">Kr&#228;hling, V. et al. Self-amplifying RNA vaccine protects mice against lethal Ebola virus infection. <italic toggle="yes">Mol. Ther.</italic><bold>31</bold>, 374&#8211;386 (2023).<pub-id pub-id-type="pmid">36303436</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ymthe.2022.10.011</pub-id><pub-id pub-id-type="pmcid">PMC9931551</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><mixed-citation publication-type="other">McGee, J. E. et al. Complete substitution with modified nucleotides in self-amplifying RNA suppresses the interferon response and increases potency. <italic toggle="yes">Nat. Biotechnol</italic>. 10.1038/s41587-024-02306-z (2024).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41587-024-02306-z</pub-id><pub-id pub-id-type="pmcid">PMC11707045</pub-id><pub-id pub-id-type="pmid">38977924</pub-id></mixed-citation></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>J</given-names></name><name name-style="western"><surname>Eygeris</surname><given-names>Y</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>M</given-names></name><name name-style="western"><surname>Sahay</surname><given-names>G</given-names></name></person-group><article-title>Self-assembled mRNA vaccines</article-title><source>Adv. Drug Deliv. Rev.</source><year>2021</year><volume>170</volume><fpage>83</fpage><lpage>112</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2020.12.014</pub-id><pub-id pub-id-type="pmid">33400957</pub-id><pub-id pub-id-type="pmcid">PMC7837307</pub-id></element-citation><mixed-citation id="mc-CR44" publication-type="journal">Kim, J., Eygeris, Y., Gupta, M. &amp; Sahay, G. Self-assembled mRNA vaccines. <italic toggle="yes">Adv. Drug Deliv. Rev.</italic><bold>170</bold>, 83&#8211;112 (2021).<pub-id pub-id-type="pmid">33400957</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.addr.2020.12.014</pub-id><pub-id pub-id-type="pmcid">PMC7837307</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Comes</surname><given-names>JDG</given-names></name><name name-style="western"><surname>Pijlman</surname><given-names>GP</given-names></name><name name-style="western"><surname>Hick</surname><given-names>TAH</given-names></name></person-group><article-title>Rise of the RNA machines&#8212;self-amplification in mRNA vaccine design</article-title><source>Trends Biotechnol.</source><year>2023</year><volume>41</volume><fpage>1417</fpage><lpage>1429</lpage><pub-id pub-id-type="doi">10.1016/j.tibtech.2023.05.007</pub-id><pub-id pub-id-type="pmid">37328401</pub-id><pub-id pub-id-type="pmcid">PMC10266560</pub-id></element-citation><mixed-citation id="mc-CR45" publication-type="journal">Comes, J. D. G., Pijlman, G. P. &amp; Hick, T. A. H. Rise of the RNA machines&#8212;self-amplification in mRNA vaccine design. <italic toggle="yes">Trends Biotechnol.</italic><bold>41</bold>, 1417&#8211;1429 (2023).<pub-id pub-id-type="pmid">37328401</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.tibtech.2023.05.007</pub-id><pub-id pub-id-type="pmcid">PMC10266560</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Androsavich</surname><given-names>JR</given-names></name></person-group><article-title>Frameworks for transformational breakthroughs in RNA-based medicines</article-title><source>Nat. Rev. Drug Discov.</source><year>2024</year><volume>23</volume><fpage>421</fpage><lpage>444</lpage><pub-id pub-id-type="doi">10.1038/s41573-024-00943-2</pub-id><pub-id pub-id-type="pmid">38740953</pub-id></element-citation><mixed-citation id="mc-CR46" publication-type="journal">Androsavich, J. R. Frameworks for transformational breakthroughs in RNA-based medicines. <italic toggle="yes">Nat. Rev. Drug Discov.</italic><bold>23</bold>, 421&#8211;444 (2024).<pub-id pub-id-type="pmid">38740953</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41573-024-00943-2</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Blakney</surname><given-names>AK</given-names></name><name name-style="western"><surname>Ip</surname><given-names>S</given-names></name><name name-style="western"><surname>Geall</surname><given-names>AJ</given-names></name></person-group><article-title>An update on self-amplifying mRNA vaccine development</article-title><source>Vaccines</source><year>2021</year><volume>9</volume><fpage>97</fpage><pub-id pub-id-type="doi">10.3390/vaccines9020097</pub-id><pub-id pub-id-type="pmid">33525396</pub-id><pub-id pub-id-type="pmcid">PMC7911542</pub-id></element-citation><mixed-citation id="mc-CR47" publication-type="journal">Blakney, A. K., Ip, S. &amp; Geall, A. J. An update on self-amplifying mRNA vaccine development. <italic toggle="yes">Vaccines</italic><bold>9</bold>, 97 (2021).<pub-id pub-id-type="pmid">33525396</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/vaccines9020097</pub-id><pub-id pub-id-type="pmcid">PMC7911542</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dastgerdi</surname><given-names>NK</given-names></name><etal/></person-group><article-title>Charge neutralized poly(&#946;-amino ester) polyplex nanoparticles for delivery of self-amplifying RNA</article-title><source>Nanoscale Adv.</source><year>2024</year><volume>6</volume><fpage>1409</fpage><lpage>1422</lpage><pub-id pub-id-type="doi">10.1039/D3NA00794D</pub-id><pub-id pub-id-type="pmid">38419881</pub-id><pub-id pub-id-type="pmcid">PMC10898429</pub-id></element-citation><mixed-citation id="mc-CR48" publication-type="journal">Dastgerdi, N. K. et al. Charge neutralized poly(&#946;-amino ester) polyplex nanoparticles for delivery of self-amplifying RNA. <italic toggle="yes">Nanoscale Adv.</italic><bold>6</bold>, 1409&#8211;1422 (2024).<pub-id pub-id-type="pmid">38419881</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1039/d3na00794d</pub-id><pub-id pub-id-type="pmcid">PMC10898429</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>C</given-names></name><etal/></person-group><article-title>Amplifying mRNA vaccines: potential versatile magicians for oncotherapy</article-title><source>Front. Immunol.</source><year>2023</year><volume>14</volume><fpage>1261243</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2023.1261243</pub-id><pub-id pub-id-type="pmid">37936701</pub-id><pub-id pub-id-type="pmcid">PMC10626473</pub-id></element-citation><mixed-citation id="mc-CR49" publication-type="journal">Hu, C. et al. Amplifying mRNA vaccines: potential versatile magicians for oncotherapy. <italic toggle="yes">Front. Immunol.</italic><bold>14</bold>, 1261243 (2023).<pub-id pub-id-type="pmid">37936701</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2023.1261243</pub-id><pub-id pub-id-type="pmcid">PMC10626473</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR50"><label>50.</label><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Young</surname><given-names>TL</given-names></name><name name-style="western"><surname>Wang</surname><given-names>KC</given-names></name><name name-style="western"><surname>Varley</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Li</surname><given-names>B</given-names></name></person-group><article-title>Clinical delivery of circular RNA: lessons learned from RNA drug development</article-title><source>Adv. Drug Deliv. Rev.</source><year>2023</year><volume>197</volume><fpage>114826</fpage><pub-id pub-id-type="doi">10.1016/j.addr.2023.114826</pub-id><pub-id pub-id-type="pmid">37088404</pub-id></element-citation><mixed-citation id="mc-CR50" publication-type="journal">Young, T. L., Wang, K. C., Varley, A. J. &amp; Li, B. Clinical delivery of circular RNA: lessons learned from RNA drug development. <italic toggle="yes">Adv. Drug Deliv. Rev.</italic><bold>197</bold>, 114826 (2023).<pub-id pub-id-type="pmid">37088404</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.addr.2023.114826</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR51"><label>51.</label><citation-alternatives><element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hwang</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Kim</surname><given-names>YK</given-names></name></person-group><article-title>Molecular mechanisms of circular RNA translation</article-title><source>Exp. Mol. Med.</source><year>2024</year><volume>56</volume><fpage>1272</fpage><lpage>1280</lpage><pub-id pub-id-type="doi">10.1038/s12276-024-01220-3</pub-id><pub-id pub-id-type="pmid">38871818</pub-id><pub-id pub-id-type="pmcid">PMC11263353</pub-id></element-citation><mixed-citation id="mc-CR51" publication-type="journal">Hwang, H. J. &amp; Kim, Y. K. Molecular mechanisms of circular RNA translation. <italic toggle="yes">Exp. Mol. Med.</italic><bold>56</bold>, 1272&#8211;1280 (2024).<pub-id pub-id-type="pmid">38871818</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s12276-024-01220-3</pub-id><pub-id pub-id-type="pmcid">PMC11263353</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR52"><label>52.</label><citation-alternatives><element-citation id="ec-CR52" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Unti</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Jaffrey</surname><given-names>SR</given-names></name></person-group><article-title>Highly efficient cellular expression of circular mRNA enables prolonged protein expression</article-title><source>Cell Chem. Biol.</source><year>2024</year><volume>31</volume><fpage>163</fpage><lpage>176</lpage><pub-id pub-id-type="doi">10.1016/j.chembiol.2023.09.015</pub-id><pub-id pub-id-type="pmid">37883972</pub-id><pub-id pub-id-type="pmcid">PMC10841545</pub-id></element-citation><mixed-citation id="mc-CR52" publication-type="journal">Unti, M. J. &amp; Jaffrey, S. R. Highly efficient cellular expression of circular mRNA enables prolonged protein expression. <italic toggle="yes">Cell Chem. Biol.</italic><bold>31</bold>, 163&#8211;176 (2024).<pub-id pub-id-type="pmid">37883972</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.chembiol.2023.09.015</pub-id><pub-id pub-id-type="pmcid">PMC10841545</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR53"><label>53.</label><citation-alternatives><element-citation id="ec-CR53" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>F</given-names></name><name name-style="western"><surname>Li</surname><given-names>L</given-names></name><name name-style="western"><surname>Fan</surname><given-names>Z</given-names></name></person-group><article-title>circRNAs and their relationship with breast cancer: a review</article-title><source>World J. Surg. Oncol.</source><year>2022</year><volume>20</volume><fpage>373</fpage><pub-id pub-id-type="doi">10.1186/s12957-022-02842-5</pub-id><pub-id pub-id-type="pmid">36443878</pub-id><pub-id pub-id-type="pmcid">PMC9703749</pub-id></element-citation><mixed-citation id="mc-CR53" publication-type="journal">Zhang, F., Li, L. &amp; Fan, Z. circRNAs and their relationship with breast cancer: a review. <italic toggle="yes">World J. Surg. Oncol.</italic><bold>20</bold>, 373 (2022).<pub-id pub-id-type="pmid">36443878</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12957-022-02842-5</pub-id><pub-id pub-id-type="pmcid">PMC9703749</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR54"><label>54.</label><citation-alternatives><element-citation id="ec-CR54" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Niu</surname><given-names>D</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Lian</surname><given-names>J</given-names></name></person-group><article-title>Circular RNA vaccine in disease prevention and treatment</article-title><source>Signal Transduct. Target. Ther.</source><year>2023</year><volume>8</volume><fpage>341</fpage><pub-id pub-id-type="doi">10.1038/s41392-023-01561-x</pub-id><pub-id pub-id-type="pmid">37691066</pub-id><pub-id pub-id-type="pmcid">PMC10493228</pub-id></element-citation><mixed-citation id="mc-CR54" publication-type="journal">Niu, D., Wu, Y. &amp; Lian, J. Circular RNA vaccine in disease prevention and treatment. <italic toggle="yes">Signal Transduct. Target. Ther.</italic><bold>8</bold>, 341 (2023).<pub-id pub-id-type="pmid">37691066</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41392-023-01561-x</pub-id><pub-id pub-id-type="pmcid">PMC10493228</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR55"><label>55.</label><citation-alternatives><element-citation id="ec-CR55" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J</given-names></name></person-group><article-title>Circular mRNAs: More stable RNAs lead to more persistent protein expression</article-title><source>Mol. Ther. Nucleic Acids</source><year>2022</year><volume>30</volume><fpage>357</fpage><lpage>358</lpage><pub-id pub-id-type="doi">10.1016/j.omtn.2022.10.014</pub-id><pub-id pub-id-type="pmid">36381583</pub-id><pub-id pub-id-type="pmcid">PMC9647421</pub-id></element-citation><mixed-citation id="mc-CR55" publication-type="journal">Zhang, J. &amp; Chen, J. Circular mRNAs: More stable RNAs lead to more persistent protein expression. <italic toggle="yes">Mol. Ther. Nucleic Acids</italic><bold>30</bold>, 357&#8211;358 (2022).<pub-id pub-id-type="pmid">36381583</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.omtn.2022.10.014</pub-id><pub-id pub-id-type="pmcid">PMC9647421</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR56"><label>56.</label><citation-alternatives><element-citation id="ec-CR56" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>T</given-names></name><etal/></person-group><article-title>Components, formulations, deliveries, and combinations of tumor vaccines</article-title><source>ACS Nano</source><year>2024</year><volume>18</volume><fpage>18801</fpage><lpage>18833</lpage><pub-id pub-id-type="doi">10.1021/acsnano.4c05065</pub-id><pub-id pub-id-type="pmid">38979917</pub-id></element-citation><mixed-citation id="mc-CR56" publication-type="journal">Liu, T. et al. Components, formulations, deliveries, and combinations of tumor vaccines. <italic toggle="yes">ACS Nano</italic><bold>18</bold>, 18801&#8211;18833 (2024).<pub-id pub-id-type="pmid">38979917</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acsnano.4c05065</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR57"><label>57.</label><citation-alternatives><element-citation id="ec-CR57" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shui</surname><given-names>M</given-names></name><etal/></person-group><article-title>Engineering polyphenol-based carriers for nucleic acid delivery</article-title><source>Theranostics</source><year>2023</year><volume>13</volume><fpage>3204</fpage><lpage>3223</lpage><pub-id pub-id-type="doi">10.7150/thno.81604</pub-id><pub-id pub-id-type="pmid">37351161</pub-id><pub-id pub-id-type="pmcid">PMC10283064</pub-id></element-citation><mixed-citation id="mc-CR57" publication-type="journal">Shui, M. et al. Engineering polyphenol-based carriers for nucleic acid delivery. <italic toggle="yes">Theranostics</italic><bold>13</bold>, 3204&#8211;3223 (2023).<pub-id pub-id-type="pmid">37351161</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7150/thno.81604</pub-id><pub-id pub-id-type="pmcid">PMC10283064</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR58"><label>58.</label><citation-alternatives><element-citation id="ec-CR58" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Puri</surname><given-names>S</given-names></name><etal/></person-group><article-title>Evolution of nanomedicine formulations for targeted delivery and controlled release</article-title><source>Adv. Drug Deliv. Rev.</source><year>2023</year><volume>200</volume><fpage>114962</fpage><pub-id pub-id-type="doi">10.1016/j.addr.2023.114962</pub-id><pub-id pub-id-type="pmid">37321376</pub-id></element-citation><mixed-citation id="mc-CR58" publication-type="journal">Puri, S. et al. Evolution of nanomedicine formulations for targeted delivery and controlled release. <italic toggle="yes">Adv. Drug Deliv. Rev.</italic><bold>200</bold>, 114962 (2023).<pub-id pub-id-type="pmid">37321376</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.addr.2023.114962</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR59"><label>59.</label><citation-alternatives><element-citation id="ec-CR59" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>B</given-names></name><etal/></person-group><article-title>Engineering nanoparticle toolkits for mRNA delivery</article-title><source>Adv. Drug Deliv. Rev.</source><year>2023</year><volume>200</volume><fpage>115042</fpage><pub-id pub-id-type="doi">10.1016/j.addr.2023.115042</pub-id><pub-id pub-id-type="pmid">37536506</pub-id></element-citation><mixed-citation id="mc-CR59" publication-type="journal">Sun, B. et al. Engineering nanoparticle toolkits for mRNA delivery. <italic toggle="yes">Adv. Drug Deliv. Rev.</italic><bold>200</bold>, 115042 (2023).<pub-id pub-id-type="pmid">37536506</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.addr.2023.115042</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR60"><label>60.</label><citation-alternatives><element-citation id="ec-CR60" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huayamares</surname><given-names>SG</given-names></name><name name-style="western"><surname>Loughrey</surname><given-names>D</given-names></name><name name-style="western"><surname>Kim</surname><given-names>H</given-names></name><name name-style="western"><surname>Dahlman</surname><given-names>JE</given-names></name><name name-style="western"><surname>Sorscher</surname><given-names>EJ</given-names></name></person-group><article-title>Nucleic acid-based drugs for patients with solid tumours</article-title><source>Nat. Rev. Clin. Oncol.</source><year>2024</year><volume>21</volume><fpage>407</fpage><lpage>427</lpage><pub-id pub-id-type="doi">10.1038/s41571-024-00883-1</pub-id><pub-id pub-id-type="pmid">38589512</pub-id></element-citation><mixed-citation id="mc-CR60" publication-type="journal">Huayamares, S. G., Loughrey, D., Kim, H., Dahlman, J. E. &amp; Sorscher, E. J. Nucleic acid-based drugs for patients with solid tumours. <italic toggle="yes">Nat. Rev. Clin. Oncol.</italic><bold>21</bold>, 407&#8211;427 (2024).<pub-id pub-id-type="pmid">38589512</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41571-024-00883-1</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR61"><label>61.</label><citation-alternatives><element-citation id="ec-CR61" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saiding</surname><given-names>Q</given-names></name><etal/></person-group><article-title>Nano-bio interactions in mRNA nanomedicine: challenges and opportunities for targeted mRNA delivery</article-title><source>Adv. Drug Deliv. Rev.</source><year>2023</year><volume>203</volume><fpage>115116</fpage><pub-id pub-id-type="doi">10.1016/j.addr.2023.115116</pub-id><pub-id pub-id-type="pmid">37871748</pub-id></element-citation><mixed-citation id="mc-CR61" publication-type="journal">Saiding, Q. et al. Nano-bio interactions in mRNA nanomedicine: challenges and opportunities for targeted mRNA delivery. <italic toggle="yes">Adv. Drug Deliv. Rev.</italic><bold>203</bold>, 115116 (2023).<pub-id pub-id-type="pmid">37871748</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.addr.2023.115116</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR62"><label>62.</label><citation-alternatives><element-citation id="ec-CR62" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Malla</surname><given-names>R</given-names></name><name name-style="western"><surname>Srilatha</surname><given-names>M</given-names></name><name name-style="western"><surname>Farran</surname><given-names>B</given-names></name><name name-style="western"><surname>Nagaraju</surname><given-names>GP</given-names></name></person-group><article-title>mRNA vaccines and their delivery strategies: a journey from infectious diseases to cancer</article-title><source>Mol. Ther.</source><year>2024</year><volume>32</volume><fpage>13</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1016/j.ymthe.2023.10.024</pub-id><pub-id pub-id-type="pmid">37919901</pub-id><pub-id pub-id-type="pmcid">PMC10787123</pub-id></element-citation><mixed-citation id="mc-CR62" publication-type="journal">Malla, R., Srilatha, M., Farran, B. &amp; Nagaraju, G. P. mRNA vaccines and their delivery strategies: a journey from infectious diseases to cancer. <italic toggle="yes">Mol. Ther.</italic><bold>32</bold>, 13&#8211;31 (2024).<pub-id pub-id-type="pmid">37919901</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ymthe.2023.10.024</pub-id><pub-id pub-id-type="pmcid">PMC10787123</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR63"><label>63.</label><citation-alternatives><element-citation id="ec-CR63" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de los Reyes</surname><given-names>E</given-names></name><etal/></person-group><article-title>Single-dose AAV9-CLN6 gene transfer slows the decline in motor and language function in variant late infantile neuronal ceroid lipofuscinosis 6: interim results from phase 1/2 trial</article-title><source>Mol. Genet. Metab.</source><year>2021</year><volume>132</volume><fpage>S32</fpage><lpage>S33</lpage><pub-id pub-id-type="doi">10.1016/j.ymgme.2020.12.061</pub-id></element-citation><mixed-citation id="mc-CR63" publication-type="journal">de los Reyes, E. et al. Single-dose AAV9-CLN6 gene transfer slows the decline in motor and language function in variant late infantile neuronal ceroid lipofuscinosis 6: interim results from phase 1/2 trial. <italic toggle="yes">Mol. Genet. Metab.</italic><bold>132</bold>, S32&#8211;S33 (2021).</mixed-citation></citation-alternatives></ref><ref id="CR64"><label>64.</label><citation-alternatives><element-citation id="ec-CR64" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gu</surname><given-names>J</given-names></name><etal/></person-group><article-title>Building a better silver bullet: current status and perspectives of non&#8208;viral vectors for mRNA vaccines</article-title><source>Adv. Healthc. Mater.</source><year>2024</year><volume>13</volume><fpage>2302409</fpage><pub-id pub-id-type="doi">10.1002/adhm.202302409</pub-id><pub-id pub-id-type="pmid">37964681</pub-id></element-citation><mixed-citation id="mc-CR64" publication-type="journal">Gu, J. et al. Building a better silver bullet: current status and perspectives of non&#8208;viral vectors for mRNA vaccines. <italic toggle="yes">Adv. Healthc. Mater.</italic><bold>13</bold>, 2302409 (2024).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/adhm.202302409</pub-id><pub-id pub-id-type="pmid">37964681</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR65"><label>65.</label><citation-alternatives><element-citation id="ec-CR65" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Masarwy</surname><given-names>R</given-names></name><name name-style="western"><surname>Stotsky-Oterin</surname><given-names>L</given-names></name><name name-style="western"><surname>Elisha</surname><given-names>A</given-names></name><name name-style="western"><surname>Hazan-Halevy</surname><given-names>I</given-names></name><name name-style="western"><surname>Peer</surname><given-names>D</given-names></name></person-group><article-title>Delivery of nucleic acid based genome editing platforms via lipid nanoparticles: clinical applications</article-title><source>Adv. Drug Deliv. Rev.</source><year>2024</year><volume>211</volume><fpage>115359</fpage><pub-id pub-id-type="doi">10.1016/j.addr.2024.115359</pub-id><pub-id pub-id-type="pmid">38857763</pub-id></element-citation><mixed-citation id="mc-CR65" publication-type="journal">Masarwy, R., Stotsky-Oterin, L., Elisha, A., Hazan-Halevy, I. &amp; Peer, D. Delivery of nucleic acid based genome editing platforms via lipid nanoparticles: clinical applications. <italic toggle="yes">Adv. Drug Deliv. Rev.</italic><bold>211</bold>, 115359 (2024).<pub-id pub-id-type="pmid">38857763</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.addr.2024.115359</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR66"><label>66.</label><citation-alternatives><element-citation id="ec-CR66" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Du</surname><given-names>G</given-names></name><name name-style="western"><surname>Sun</surname><given-names>X</given-names></name></person-group><article-title>Emerging advances in delivery systems for mRNA cancer vaccines</article-title><source>J. Control Release</source><year>2024</year><volume>370</volume><fpage>287</fpage><lpage>301</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2024.04.039</pub-id><pub-id pub-id-type="pmid">38679162</pub-id></element-citation><mixed-citation id="mc-CR66" publication-type="journal">Jiang, Z., Xu, Y., Du, G. &amp; Sun, X. Emerging advances in delivery systems for mRNA cancer vaccines. <italic toggle="yes">J. Control Release</italic><bold>370</bold>, 287&#8211;301 (2024).<pub-id pub-id-type="pmid">38679162</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jconrel.2024.04.039</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR67"><label>67.</label><citation-alternatives><element-citation id="ec-CR67" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kong</surname><given-names>B</given-names></name><name name-style="western"><surname>Kim</surname><given-names>Y</given-names></name><name name-style="western"><surname>Kim</surname><given-names>EH</given-names></name><name name-style="western"><surname>Suk</surname><given-names>JS</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y</given-names></name></person-group><article-title>mRNA: a promising platform for cancer immunotherapy</article-title><source>Adv. Drug Deliv. Rev.</source><year>2023</year><volume>199</volume><fpage>114993</fpage><pub-id pub-id-type="doi">10.1016/j.addr.2023.114993</pub-id><pub-id pub-id-type="pmid">37414361</pub-id><pub-id pub-id-type="pmcid">PMC11797636</pub-id></element-citation><mixed-citation id="mc-CR67" publication-type="journal">Kong, B., Kim, Y., Kim, E. H., Suk, J. S. &amp; Yang, Y. mRNA: a promising platform for cancer immunotherapy. <italic toggle="yes">Adv. Drug Deliv. Rev.</italic><bold>199</bold>, 114993 (2023).<pub-id pub-id-type="pmid">37414361</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.addr.2023.114993</pub-id><pub-id pub-id-type="pmcid">PMC11797636</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR68"><label>68.</label><citation-alternatives><element-citation id="ec-CR68" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhong</surname><given-names>Y</given-names></name><name name-style="western"><surname>Du</surname><given-names>S</given-names></name><name name-style="western"><surname>Dong</surname><given-names>Y</given-names></name></person-group><article-title>mRNA delivery in cancer immunotherapy</article-title><source>Acta Pharm. Sin. B</source><year>2023</year><volume>13</volume><fpage>1348</fpage><lpage>1357</lpage><pub-id pub-id-type="doi">10.1016/j.apsb.2023.03.001</pub-id><pub-id pub-id-type="pmid">37139419</pub-id><pub-id pub-id-type="pmcid">PMC10150179</pub-id></element-citation><mixed-citation id="mc-CR68" publication-type="journal">Zhong, Y., Du, S. &amp; Dong, Y. mRNA delivery in cancer immunotherapy. <italic toggle="yes">Acta Pharm. Sin. B</italic><bold>13</bold>, 1348&#8211;1357 (2023).<pub-id pub-id-type="pmid">37139419</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.apsb.2023.03.001</pub-id><pub-id pub-id-type="pmcid">PMC10150179</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR69"><label>69.</label><citation-alternatives><element-citation id="ec-CR69" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>W</given-names></name><name name-style="western"><surname>Mixich</surname><given-names>L</given-names></name><name name-style="western"><surname>Boonstra</surname><given-names>E</given-names></name><name name-style="western"><surname>Cabral</surname><given-names>H</given-names></name></person-group><article-title>Polymer-based mRNA delivery strategies for advanced therapies</article-title><source>Adv. Healthc. Mater.</source><year>2023</year><volume>12</volume><fpage>2202688</fpage><pub-id pub-id-type="doi">10.1002/adhm.202202688</pub-id><pub-id pub-id-type="pmid">36785927</pub-id><pub-id pub-id-type="pmcid">PMC11469255</pub-id></element-citation><mixed-citation id="mc-CR69" publication-type="journal">Yang, W., Mixich, L., Boonstra, E. &amp; Cabral, H. Polymer-based mRNA delivery strategies for advanced therapies. <italic toggle="yes">Adv. Healthc. Mater.</italic><bold>12</bold>, 2202688 (2023).<pub-id pub-id-type="pmid">36785927</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/adhm.202202688</pub-id><pub-id pub-id-type="pmcid">PMC11469255</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR70"><label>70.</label><citation-alternatives><element-citation id="ec-CR70" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Percec</surname><given-names>V</given-names></name><name name-style="western"><surname>Sahoo</surname><given-names>D</given-names></name></person-group><article-title>From Frank&#8211;Kasper, quasicrystals, and biological membrane mimics to reprogramming in vivo the living factory to target the delivery of mRNA with one-component amphiphilic Janus dendrimers</article-title><source>Biomacromolecules</source><year>2024</year><volume>25</volume><fpage>1353</fpage><lpage>1370</lpage><pub-id pub-id-type="doi">10.1021/acs.biomac.3c01390</pub-id><pub-id pub-id-type="pmid">38232372</pub-id></element-citation><mixed-citation id="mc-CR70" publication-type="journal">Percec, V. &amp; Sahoo, D. From Frank&#8211;Kasper, quasicrystals, and biological membrane mimics to reprogramming in vivo the living factory to target the delivery of mRNA with one-component amphiphilic Janus dendrimers. <italic toggle="yes">Biomacromolecules</italic><bold>25</bold>, 1353&#8211;1370 (2024).<pub-id pub-id-type="pmid">38232372</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.biomac.3c01390</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR71"><label>71.</label><citation-alternatives><element-citation id="ec-CR71" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhai</surname><given-names>J</given-names></name><name name-style="western"><surname>Fong</surname><given-names>C</given-names></name><name name-style="western"><surname>Tran</surname><given-names>N</given-names></name><name name-style="western"><surname>Drummond</surname><given-names>CJ</given-names></name></person-group><article-title>Non-lamellar lyotropic liquid crystalline lipid nanoparticles for the next generation of nanomedicine</article-title><source>ACS Nano</source><year>2019</year><volume>13</volume><fpage>6178</fpage><lpage>6206</lpage><pub-id pub-id-type="doi">10.1021/acsnano.8b07961</pub-id><pub-id pub-id-type="pmid">31082192</pub-id></element-citation><mixed-citation id="mc-CR71" publication-type="journal">Zhai, J., Fong, C., Tran, N. &amp; Drummond, C. J. Non-lamellar lyotropic liquid crystalline lipid nanoparticles for the next generation of nanomedicine. <italic toggle="yes">ACS Nano</italic><bold>13</bold>, 6178&#8211;6206 (2019).<pub-id pub-id-type="pmid">31082192</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acsnano.8b07961</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR72"><label>72.</label><citation-alternatives><element-citation id="ec-CR72" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iscaro</surname><given-names>J</given-names></name><etal/></person-group><article-title>Lyotropic liquid crystalline phase nanostructure and cholesterol enhance lipid nanoparticle mediated mRNA transfection in macrophages</article-title><source>Adv. Funct. Mater.</source><year>2024</year><pub-id pub-id-type="doi">10.1002/adfm.202405286</pub-id></element-citation><mixed-citation id="mc-CR72" publication-type="journal">Iscaro, J. et al. Lyotropic liquid crystalline phase nanostructure and cholesterol enhance lipid nanoparticle mediated mRNA transfection in macrophages. <italic toggle="yes">Adv. Funct. Mater.</italic>10.1002/adfm.202405286 (2024).</mixed-citation></citation-alternatives></ref><ref id="CR73"><label>73.</label><citation-alternatives><element-citation id="ec-CR73" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Borrajo</surname><given-names>ML</given-names></name><etal/></person-group><article-title>Ionizable nanoemulsions for RNA delivery into the central nervous system &#8211; importance of diffusivity</article-title><source>J. Control Release</source><year>2024</year><volume>372</volume><fpage>295</fpage><lpage>303</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2024.06.051</pub-id><pub-id pub-id-type="pmid">38909703</pub-id></element-citation><mixed-citation id="mc-CR73" publication-type="journal">Borrajo, M. L. et al. Ionizable nanoemulsions for RNA delivery into the central nervous system &#8211; importance of diffusivity. <italic toggle="yes">J. Control Release</italic><bold>372</bold>, 295&#8211;303 (2024).<pub-id pub-id-type="pmid">38909703</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jconrel.2024.06.051</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR74"><label>74.</label><citation-alternatives><element-citation id="ec-CR74" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>T</given-names></name><etal/></person-group><article-title>Lipid nanoparticle-based mRNA vaccines in cancers: current advances and future prospects</article-title><source>Front. Immunol.</source><year>2022</year><volume>13</volume><fpage>922301</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2022.922301</pub-id><pub-id pub-id-type="pmid">36090974</pub-id><pub-id pub-id-type="pmcid">PMC9458914</pub-id></element-citation><mixed-citation id="mc-CR74" publication-type="journal">Huang, T. et al. Lipid nanoparticle-based mRNA vaccines in cancers: current advances and future prospects. <italic toggle="yes">Front. Immunol.</italic><bold>13</bold>, 922301 (2022).<pub-id pub-id-type="pmid">36090974</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2022.922301</pub-id><pub-id pub-id-type="pmcid">PMC9458914</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR75"><label>75.</label><citation-alternatives><element-citation id="ec-CR75" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><name name-style="western"><surname>Fang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Luo</surname><given-names>Z</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Y</given-names></name></person-group><article-title>Emerging mRNA technology for liver disease therapy</article-title><source>ACS Nano</source><year>2024</year><volume>18</volume><fpage>17378</fpage><lpage>17406</lpage><pub-id pub-id-type="doi">10.1021/acsnano.4c02987</pub-id><pub-id pub-id-type="pmid">38916747</pub-id></element-citation><mixed-citation id="mc-CR75" publication-type="journal">Wang, J., Fang, Y., Luo, Z., Wang, J. &amp; Zhao, Y. Emerging mRNA technology for liver disease therapy. <italic toggle="yes">ACS Nano</italic><bold>18</bold>, 17378&#8211;17406 (2024).<pub-id pub-id-type="pmid">38916747</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acsnano.4c02987</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR76"><label>76.</label><citation-alternatives><element-citation id="ec-CR76" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>DeJulius</surname><given-names>CR</given-names></name><etal/></person-group><article-title>Engineering approaches for RNA-based and cell-based osteoarthritis therapies</article-title><source>Nat. Rev. Rheumatol.</source><year>2024</year><volume>20</volume><fpage>81</fpage><lpage>100</lpage><pub-id pub-id-type="doi">10.1038/s41584-023-01067-4</pub-id><pub-id pub-id-type="pmid">38253889</pub-id><pub-id pub-id-type="pmcid">PMC11129836</pub-id></element-citation><mixed-citation id="mc-CR76" publication-type="journal">DeJulius, C. R. et al. Engineering approaches for RNA-based and cell-based osteoarthritis therapies. <italic toggle="yes">Nat. Rev. Rheumatol.</italic><bold>20</bold>, 81&#8211;100 (2024).<pub-id pub-id-type="pmid">38253889</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41584-023-01067-4</pub-id><pub-id pub-id-type="pmcid">PMC11129836</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR77"><label>77.</label><citation-alternatives><element-citation id="ec-CR77" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ji</surname><given-names>P</given-names></name><etal/></person-group><article-title>Modular hydrogel vaccine for programmable and coordinate elicitation of cancer immunotherapy</article-title><source>Adv. Sci.</source><year>2023</year><volume>10</volume><fpage>2301789</fpage><pub-id pub-id-type="doi">10.1002/advs.202301789</pub-id><pub-id pub-id-type="pmcid">PMC10401092</pub-id><pub-id pub-id-type="pmid">37222047</pub-id></element-citation><mixed-citation id="mc-CR77" publication-type="journal">Ji, P. et al. Modular hydrogel vaccine for programmable and coordinate elicitation of cancer immunotherapy. <italic toggle="yes">Adv. Sci.</italic><bold>10</bold>, 2301789 (2023).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/advs.202301789</pub-id><pub-id pub-id-type="pmcid">PMC10401092</pub-id><pub-id pub-id-type="pmid">37222047</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR78"><label>78.</label><citation-alternatives><element-citation id="ec-CR78" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Neshat</surname><given-names>SY</given-names></name><etal/></person-group><article-title>Polymeric nanoparticle gel for intracellular mRNA delivery and immunological reprogramming of tumors</article-title><source>Biomaterials</source><year>2023</year><volume>300</volume><fpage>122185</fpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2023.122185</pub-id><pub-id pub-id-type="pmid">37290232</pub-id><pub-id pub-id-type="pmcid">PMC10330908</pub-id></element-citation><mixed-citation id="mc-CR78" publication-type="journal">Neshat, S. Y. et al. Polymeric nanoparticle gel for intracellular mRNA delivery and immunological reprogramming of tumors. <italic toggle="yes">Biomaterials</italic><bold>300</bold>, 122185 (2023).<pub-id pub-id-type="pmid">37290232</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biomaterials.2023.122185</pub-id><pub-id pub-id-type="pmcid">PMC10330908</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR79"><label>79.</label><citation-alternatives><element-citation id="ec-CR79" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>P</given-names></name><name name-style="western"><surname>Deng</surname><given-names>H</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X</given-names></name></person-group><article-title>Cellular trafficking of nanotechnology&#8208;mediated mRNA delivery</article-title><source>Adv. Mater.</source><year>2024</year><volume>36</volume><fpage>2307822</fpage><pub-id pub-id-type="doi">10.1002/adma.202307822</pub-id><pub-id pub-id-type="pmid">37929780</pub-id></element-citation><mixed-citation id="mc-CR79" publication-type="journal">Huang, P., Deng, H., Wang, C., Zhou, Y. &amp; Chen, X. Cellular trafficking of nanotechnology&#8208;mediated mRNA delivery. <italic toggle="yes">Adv. Mater.</italic><bold>36</bold>, 2307822 (2024).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/adma.202307822</pub-id><pub-id pub-id-type="pmid">37929780</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR80"><label>80.</label><citation-alternatives><element-citation id="ec-CR80" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jeong</surname><given-names>M</given-names></name><name name-style="western"><surname>Lee</surname><given-names>Y</given-names></name><name name-style="western"><surname>Park</surname><given-names>J</given-names></name><name name-style="western"><surname>Jung</surname><given-names>H</given-names></name><name name-style="western"><surname>Lee</surname><given-names>H</given-names></name></person-group><article-title>Lipid nanoparticles (LNPs) for in vivo RNA delivery and their breakthrough technology for future applications</article-title><source>Adv. Drug Deliv. Rev.</source><year>2023</year><volume>200</volume><fpage>114990</fpage><pub-id pub-id-type="doi">10.1016/j.addr.2023.114990</pub-id><pub-id pub-id-type="pmid">37423563</pub-id></element-citation><mixed-citation id="mc-CR80" publication-type="journal">Jeong, M., Lee, Y., Park, J., Jung, H. &amp; Lee, H. Lipid nanoparticles (LNPs) for in vivo RNA delivery and their breakthrough technology for future applications. <italic toggle="yes">Adv. Drug Deliv. Rev.</italic><bold>200</bold>, 114990 (2023).<pub-id pub-id-type="pmid">37423563</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.addr.2023.114990</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR81"><label>81.</label><citation-alternatives><element-citation id="ec-CR81" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Neary</surname><given-names>MT</given-names></name><etal/></person-group><article-title>Nebulised delivery of RNA formulations to the lungs: From aerosol to cytosol</article-title><source>J. Control Release</source><year>2024</year><volume>366</volume><fpage>812</fpage><lpage>833</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2023.12.012</pub-id><pub-id pub-id-type="pmid">38101753</pub-id></element-citation><mixed-citation id="mc-CR81" publication-type="journal">Neary, M. T. et al. Nebulised delivery of RNA formulations to the lungs: From aerosol to cytosol. <italic toggle="yes">J. Control Release</italic><bold>366</bold>, 812&#8211;833 (2024).<pub-id pub-id-type="pmid">38101753</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jconrel.2023.12.012</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR82"><label>82.</label><citation-alternatives><element-citation id="ec-CR82" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Exosomes decorated with a recombinant SARS-CoV-2 receptor-binding domain as an inhalable COVID-19 vaccine</article-title><source>Nat. Biomed. Eng.</source><year>2022</year><volume>6</volume><fpage>791</fpage><lpage>805</lpage><pub-id pub-id-type="doi">10.1038/s41551-022-00902-5</pub-id><pub-id pub-id-type="pmid">35788687</pub-id><pub-id pub-id-type="pmcid">PMC10782831</pub-id></element-citation><mixed-citation id="mc-CR82" publication-type="journal">Wang, Z. et al. Exosomes decorated with a recombinant SARS-CoV-2 receptor-binding domain as an inhalable COVID-19 vaccine. <italic toggle="yes">Nat. Biomed. Eng.</italic><bold>6</bold>, 791&#8211;805 (2022).<pub-id pub-id-type="pmid">35788687</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41551-022-00902-5</pub-id><pub-id pub-id-type="pmcid">PMC10782831</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR83"><label>83.</label><citation-alternatives><element-citation id="ec-CR83" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>M</given-names></name><name name-style="western"><surname>Hu</surname><given-names>S</given-names></name><name name-style="western"><surname>Yan</surname><given-names>N</given-names></name><name name-style="western"><surname>Popowski</surname><given-names>KD</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>K</given-names></name></person-group><article-title>Inhalable extracellular vesicle delivery of IL-12 mRNA to treat lung cancer and promote systemic immunity</article-title><source>Nat. Nanotechnol.</source><year>2024</year><volume>19</volume><fpage>565</fpage><lpage>575</lpage><pub-id pub-id-type="doi">10.1038/s41565-023-01580-3</pub-id><pub-id pub-id-type="pmid">38212521</pub-id></element-citation><mixed-citation id="mc-CR83" publication-type="journal">Liu, M., Hu, S., Yan, N., Popowski, K. D. &amp; Cheng, K. Inhalable extracellular vesicle delivery of IL-12 mRNA to treat lung cancer and promote systemic immunity. <italic toggle="yes">Nat. Nanotechnol.</italic><bold>19</bold>, 565&#8211;575 (2024).<pub-id pub-id-type="pmid">38212521</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41565-023-01580-3</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR84"><label>84.</label><citation-alternatives><element-citation id="ec-CR84" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cotto</surname><given-names>HAM</given-names></name><etal/></person-group><article-title>Cationic-motif-modified exosomes for mRNA delivery to retinal photoreceptors</article-title><source>J. Mater. Chem. B</source><year>2024</year><volume>12</volume><fpage>7384</fpage><lpage>7400</lpage><pub-id pub-id-type="doi">10.1039/D4TB00849A</pub-id><pub-id pub-id-type="pmid">38946491</pub-id><pub-id pub-id-type="pmcid">PMC11323772</pub-id></element-citation><mixed-citation id="mc-CR84" publication-type="journal">Cotto, H. A. M. et al. Cationic-motif-modified exosomes for mRNA delivery to retinal photoreceptors. <italic toggle="yes">J. Mater. Chem. B</italic><bold>12</bold>, 7384&#8211;7400 (2024).<pub-id pub-id-type="pmid">38946491</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1039/d4tb00849a</pub-id><pub-id pub-id-type="pmcid">PMC11323772</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR85"><label>85.</label><citation-alternatives><element-citation id="ec-CR85" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Esih</surname><given-names>H</given-names></name><etal/></person-group><article-title>Mucoadhesive film for oral delivery of vaccines for protection of the respiratory tract</article-title><source>J. Control Release</source><year>2024</year><volume>371</volume><fpage>179</fpage><lpage>192</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2024.05.041</pub-id><pub-id pub-id-type="pmid">38795814</pub-id></element-citation><mixed-citation id="mc-CR85" publication-type="journal">Esih, H. et al. Mucoadhesive film for oral delivery of vaccines for protection of the respiratory tract. <italic toggle="yes">J. Control Release</italic><bold>371</bold>, 179&#8211;192 (2024).<pub-id pub-id-type="pmid">38795814</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jconrel.2024.05.041</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR86"><label>86.</label><citation-alternatives><element-citation id="ec-CR86" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luo</surname><given-names>P-K</given-names></name><etal/></person-group><article-title>pH-responsive &#946;-glucans-complexed mRNA in LNPs as an oral vaccine for enhancing cancer immunotherapy</article-title><source>Adv. Mater.</source><year>2024</year><volume>36</volume><fpage>2404830</fpage><pub-id pub-id-type="doi">10.1002/adma.202404830</pub-id><pub-id pub-id-type="pmid">38895941</pub-id></element-citation><mixed-citation id="mc-CR86" publication-type="journal">Luo, P.-K. et al. pH-responsive &#946;-glucans-complexed mRNA in LNPs as an oral vaccine for enhancing cancer immunotherapy. <italic toggle="yes">Adv. Mater.</italic><bold>36</bold>, 2404830 (2024).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/adma.202404830</pub-id><pub-id pub-id-type="pmid">38895941</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR87"><label>87.</label><citation-alternatives><element-citation id="ec-CR87" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>K</given-names></name><etal/></person-group><article-title>Delivery of mRNA vaccines and anti-PDL1 siRNA through non-invasive transcutaneous route effectively inhibits tumor growth</article-title><source>Compos. Part B Eng.</source><year>2022</year><volume>233</volume><fpage>109648</fpage><pub-id pub-id-type="doi">10.1016/j.compositesb.2022.109648</pub-id></element-citation><mixed-citation id="mc-CR87" publication-type="journal">Wang, K. et al. Delivery of mRNA vaccines and anti-PDL1 siRNA through non-invasive transcutaneous route effectively inhibits tumor growth. <italic toggle="yes">Compos. Part B Eng.</italic><bold>233</bold>, 109648 (2022).</mixed-citation></citation-alternatives></ref><ref id="CR88"><label>88.</label><citation-alternatives><element-citation id="ec-CR88" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gao</surname><given-names>K</given-names></name><etal/></person-group><article-title>In utero delivery of mRNA to the heart, diaphragm and muscle with lipid nanoparticles</article-title><source>Bioact. Mater.</source><year>2023</year><volume>25</volume><fpage>387</fpage><lpage>398</lpage><pub-id pub-id-type="pmid">36844366</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bioactmat.2023.02.011</pub-id><pub-id pub-id-type="pmcid">PMC9950423</pub-id></element-citation><mixed-citation id="mc-CR88" publication-type="journal">Gao, K. et al. In utero delivery of mRNA to the heart, diaphragm and muscle with lipid nanoparticles. <italic toggle="yes">Bioact. Mater.</italic><bold>25</bold>, 387&#8211;398 (2023).<pub-id pub-id-type="pmid">36844366</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bioactmat.2023.02.011</pub-id><pub-id pub-id-type="pmcid">PMC9950423</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR89"><label>89.</label><citation-alternatives><element-citation id="ec-CR89" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Suzuki</surname><given-names>Y</given-names></name><name name-style="western"><surname>Katsurada</surname><given-names>Y</given-names></name><name name-style="western"><surname>Hyodo</surname><given-names>K</given-names></name></person-group><article-title>Differences and similarities of the intravenously administered lipid nanoparticles in three clinical trials: potential linkage between lipid nanoparticles and extracellular vesicles</article-title><source>Mol. Pharm.</source><year>2023</year><volume>20</volume><fpage>4883</fpage><lpage>4892</lpage><pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.3c00547</pub-id><pub-id pub-id-type="pmid">37717247</pub-id></element-citation><mixed-citation id="mc-CR89" publication-type="journal">Suzuki, Y., Katsurada, Y. &amp; Hyodo, K. Differences and similarities of the intravenously administered lipid nanoparticles in three clinical trials: potential linkage between lipid nanoparticles and extracellular vesicles. <italic toggle="yes">Mol. Pharm.</italic><bold>20</bold>, 4883&#8211;4892 (2023).<pub-id pub-id-type="pmid">37717247</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.molpharmaceut.3c00547</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR90"><label>90.</label><citation-alternatives><element-citation id="ec-CR90" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zimmermann</surname><given-names>CM</given-names></name><etal/></person-group><article-title>Spray drying siRNA-lipid nanoparticles for dry powder pulmonary delivery</article-title><source>J. Control Release</source><year>2022</year><volume>351</volume><fpage>137</fpage><lpage>150</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2022.09.021</pub-id><pub-id pub-id-type="pmid">36126785</pub-id><pub-id pub-id-type="pmcid">PMC7613708</pub-id></element-citation><mixed-citation id="mc-CR90" publication-type="journal">Zimmermann, C. M. et al. Spray drying siRNA-lipid nanoparticles for dry powder pulmonary delivery. <italic toggle="yes">J. Control Release</italic><bold>351</bold>, 137&#8211;150 (2022).<pub-id pub-id-type="pmid">36126785</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jconrel.2022.09.021</pub-id><pub-id pub-id-type="pmcid">PMC7613708</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR91"><label>91.</label><citation-alternatives><element-citation id="ec-CR91" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zai</surname><given-names>W</given-names></name><etal/></person-group><article-title>Optimized RNA interference therapeutics combined with interleukin-2 mRNA for treating hepatitis B virus infection</article-title><source>Signal Transduct. Target. Ther.</source><year>2024</year><volume>9</volume><fpage>150</fpage><pub-id pub-id-type="doi">10.1038/s41392-024-01871-8</pub-id><pub-id pub-id-type="pmid">38902241</pub-id><pub-id pub-id-type="pmcid">PMC11189933</pub-id></element-citation><mixed-citation id="mc-CR91" publication-type="journal">Zai, W. et al. Optimized RNA interference therapeutics combined with interleukin-2 mRNA for treating hepatitis B virus infection. <italic toggle="yes">Signal Transduct. Target. Ther.</italic><bold>9</bold>, 150 (2024).<pub-id pub-id-type="pmid">38902241</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41392-024-01871-8</pub-id><pub-id pub-id-type="pmcid">PMC11189933</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR92"><label>92.</label><citation-alternatives><element-citation id="ec-CR92" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Albertsen</surname><given-names>CH</given-names></name><etal/></person-group><article-title>The role of lipid components in lipid nanoparticles for vaccines and gene therapy</article-title><source>Adv. Drug Deliv. Rev.</source><year>2022</year><volume>188</volume><fpage>114416</fpage><pub-id pub-id-type="doi">10.1016/j.addr.2022.114416</pub-id><pub-id pub-id-type="pmid">35787388</pub-id><pub-id pub-id-type="pmcid">PMC9250827</pub-id></element-citation><mixed-citation id="mc-CR92" publication-type="journal">Albertsen, C. H. et al. The role of lipid components in lipid nanoparticles for vaccines and gene therapy. <italic toggle="yes">Adv. Drug Deliv. Rev.</italic><bold>188</bold>, 114416 (2022).<pub-id pub-id-type="pmid">35787388</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.addr.2022.114416</pub-id><pub-id pub-id-type="pmcid">PMC9250827</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR93"><label>93.</label><citation-alternatives><element-citation id="ec-CR93" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Han</surname><given-names>X</given-names></name><etal/></person-group><article-title>An ionizable lipid toolbox for RNA delivery</article-title><source>Nat. Commun.</source><year>2021</year><volume>12</volume><fpage>7233</fpage><pub-id pub-id-type="doi">10.1038/s41467-021-27493-0</pub-id><pub-id pub-id-type="pmid">34903741</pub-id><pub-id pub-id-type="pmcid">PMC8668901</pub-id></element-citation><mixed-citation id="mc-CR93" publication-type="journal">Han, X. et al. An ionizable lipid toolbox for RNA delivery. <italic toggle="yes">Nat. Commun.</italic><bold>12</bold>, 7233 (2021).<pub-id pub-id-type="pmid">34903741</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-021-27493-0</pub-id><pub-id pub-id-type="pmcid">PMC8668901</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR94"><label>94.</label><citation-alternatives><element-citation id="ec-CR94" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Han</surname><given-names>J</given-names></name><etal/></person-group><article-title>Lipid nanoparticle-based mRNA delivery systems for cancer immunotherapy</article-title><source>Nano Converg.</source><year>2023</year><volume>10</volume><fpage>36</fpage><pub-id pub-id-type="doi">10.1186/s40580-023-00385-3</pub-id><pub-id pub-id-type="pmid">37550567</pub-id><pub-id pub-id-type="pmcid">PMC10406775</pub-id></element-citation><mixed-citation id="mc-CR94" publication-type="journal">Han, J. et al. Lipid nanoparticle-based mRNA delivery systems for cancer immunotherapy. <italic toggle="yes">Nano Converg.</italic><bold>10</bold>, 36 (2023).<pub-id pub-id-type="pmid">37550567</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s40580-023-00385-3</pub-id><pub-id pub-id-type="pmcid">PMC10406775</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR95"><label>95.</label><citation-alternatives><element-citation id="ec-CR95" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kulkarni</surname><given-names>JA</given-names></name><name name-style="western"><surname>Witzigmann</surname><given-names>D</given-names></name><name name-style="western"><surname>Leung</surname><given-names>J</given-names></name><name name-style="western"><surname>Tam</surname><given-names>YYC</given-names></name><name name-style="western"><surname>Cullis</surname><given-names>PR</given-names></name></person-group><article-title>On the role of helper lipids in lipid nanoparticle formulations of siRNA</article-title><source>Nanoscale</source><year>2019</year><volume>11</volume><fpage>21733</fpage><lpage>21739</lpage><pub-id pub-id-type="doi">10.1039/C9NR09347H</pub-id><pub-id pub-id-type="pmid">31713568</pub-id></element-citation><mixed-citation id="mc-CR95" publication-type="journal">Kulkarni, J. A., Witzigmann, D., Leung, J., Tam, Y. Y. C. &amp; Cullis, P. R. On the role of helper lipids in lipid nanoparticle formulations of siRNA. <italic toggle="yes">Nanoscale</italic><bold>11</bold>, 21733&#8211;21739 (2019).<pub-id pub-id-type="pmid">31713568</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1039/c9nr09347h</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR96"><label>96.</label><citation-alternatives><element-citation id="ec-CR96" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>C&#225;rdenas</surname><given-names>M</given-names></name><name name-style="western"><surname>Campbell</surname><given-names>RA</given-names></name><name name-style="western"><surname>Arteta</surname><given-names>MY</given-names></name><name name-style="western"><surname>Lawrence</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Sebastiani</surname><given-names>F</given-names></name></person-group><article-title>Review of structural design guiding the development of lipid nanoparticles for nucleic acid delivery</article-title><source>Curr. Opin. Colloid Interface Sci.</source><year>2023</year><volume>66</volume><fpage>101705</fpage><pub-id pub-id-type="doi">10.1016/j.cocis.2023.101705</pub-id></element-citation><mixed-citation id="mc-CR96" publication-type="journal">C&#225;rdenas, M., Campbell, R. A., Arteta, M. Y., Lawrence, M. J. &amp; Sebastiani, F. Review of structural design guiding the development of lipid nanoparticles for nucleic acid delivery. <italic toggle="yes">Curr. Opin. Colloid Interface Sci.</italic><bold>66</bold>, 101705 (2023).</mixed-citation></citation-alternatives></ref><ref id="CR97"><label>97.</label><citation-alternatives><element-citation id="ec-CR97" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Su</surname><given-names>K</given-names></name><etal/></person-group><article-title>Reformulating lipid nanoparticles for organ-targeted mRNA accumulation and translation</article-title><source>Nat. Commun.</source><year>2024</year><volume>15</volume><fpage>5659</fpage><pub-id pub-id-type="doi">10.1038/s41467-024-50093-7</pub-id><pub-id pub-id-type="pmid">38969646</pub-id><pub-id pub-id-type="pmcid">PMC11226454</pub-id></element-citation><mixed-citation id="mc-CR97" publication-type="journal">Su, K. et al. Reformulating lipid nanoparticles for organ-targeted mRNA accumulation and translation. <italic toggle="yes">Nat. Commun.</italic><bold>15</bold>, 5659 (2024).<pub-id pub-id-type="pmid">38969646</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-024-50093-7</pub-id><pub-id pub-id-type="pmcid">PMC11226454</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR98"><label>98.</label><citation-alternatives><element-citation id="ec-CR98" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gyanani</surname><given-names>V</given-names></name><name name-style="western"><surname>Goswami</surname><given-names>R</given-names></name></person-group><article-title>Key design features of lipid nanoparticles and electrostatic charge-based lipid nanoparticle targeting</article-title><source>Pharmaceutics</source><year>2023</year><volume>15</volume><fpage>1184</fpage><pub-id pub-id-type="doi">10.3390/pharmaceutics15041184</pub-id><pub-id pub-id-type="pmid">37111668</pub-id><pub-id pub-id-type="pmcid">PMC10144967</pub-id></element-citation><mixed-citation id="mc-CR98" publication-type="journal">Gyanani, V. &amp; Goswami, R. Key design features of lipid nanoparticles and electrostatic charge-based lipid nanoparticle targeting. <italic toggle="yes">Pharmaceutics</italic><bold>15</bold>, 1184 (2023).<pub-id pub-id-type="pmid">37111668</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/pharmaceutics15041184</pub-id><pub-id pub-id-type="pmcid">PMC10144967</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR99"><label>99.</label><mixed-citation publication-type="other">Han, X. et al. Fast and facile synthesis of amidine-incorporated degradable lipids for versatile mRNA delivery in vivo. <italic toggle="yes">Nat. Chem</italic>. 10.1038/s41557-024-01557-2 (2024).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41557-024-01557-2</pub-id><pub-id pub-id-type="pmcid">PMC11446653</pub-id><pub-id pub-id-type="pmid">38982196</pub-id></mixed-citation></ref><ref id="CR100"><label>100.</label><citation-alternatives><element-citation id="ec-CR100" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carrasco</surname><given-names>MJ</given-names></name><etal/></person-group><article-title>Ionization and structural properties of mRNA lipid nanoparticles influence expression in intramuscular and intravascular administration</article-title><source>Commun. Biol.</source><year>2021</year><volume>4</volume><fpage>956</fpage><pub-id pub-id-type="doi">10.1038/s42003-021-02441-2</pub-id><pub-id pub-id-type="pmid">34381159</pub-id><pub-id pub-id-type="pmcid">PMC8358000</pub-id></element-citation><mixed-citation id="mc-CR100" publication-type="journal">Carrasco, M. J. et al. Ionization and structural properties of mRNA lipid nanoparticles influence expression in intramuscular and intravascular administration. <italic toggle="yes">Commun. Biol.</italic><bold>4</bold>, 956 (2021).<pub-id pub-id-type="pmid">34381159</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s42003-021-02441-2</pub-id><pub-id pub-id-type="pmcid">PMC8358000</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR101"><label>101.</label><citation-alternatives><element-citation id="ec-CR101" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Uchida</surname><given-names>S</given-names></name><name name-style="western"><surname>Lau</surname><given-names>CYJ</given-names></name><name name-style="western"><surname>Oba</surname><given-names>M</given-names></name><name name-style="western"><surname>Miyata</surname><given-names>K</given-names></name></person-group><article-title>Polyplex designs for improving the stability and safety of RNA therapeutics</article-title><source>Adv. Drug Deliv. Rev.</source><year>2023</year><volume>199</volume><fpage>114972</fpage><pub-id pub-id-type="doi">10.1016/j.addr.2023.114972</pub-id><pub-id pub-id-type="pmid">37364611</pub-id></element-citation><mixed-citation id="mc-CR101" publication-type="journal">Uchida, S., Lau, C. Y. J., Oba, M. &amp; Miyata, K. Polyplex designs for improving the stability and safety of RNA therapeutics. <italic toggle="yes">Adv. Drug Deliv. Rev.</italic><bold>199</bold>, 114972 (2023).<pub-id pub-id-type="pmid">37364611</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.addr.2023.114972</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR102"><label>102.</label><citation-alternatives><element-citation id="ec-CR102" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>J&#246;rgensen</surname><given-names>AM</given-names></name><name name-style="western"><surname>Wibel</surname><given-names>R</given-names></name><name name-style="western"><surname>Bernkop-Schn&#252;rch</surname><given-names>A</given-names></name></person-group><article-title>Biodegradable cationic and ionizable cationic lipids: a roadmap for safer pharmaceutical excipients</article-title><source>Small</source><year>2023</year><volume>19</volume><fpage>2206968</fpage><pub-id pub-id-type="doi">10.1002/smll.202206968</pub-id><pub-id pub-id-type="pmid">36610004</pub-id></element-citation><mixed-citation id="mc-CR102" publication-type="journal">J&#246;rgensen, A. M., Wibel, R. &amp; Bernkop-Schn&#252;rch, A. Biodegradable cationic and ionizable cationic lipids: a roadmap for safer pharmaceutical excipients. <italic toggle="yes">Small</italic><bold>19</bold>, 2206968 (2023).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/smll.202206968</pub-id><pub-id pub-id-type="pmid">36610004</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR103"><label>103.</label><citation-alternatives><element-citation id="ec-CR103" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ripoll</surname><given-names>M</given-names></name><etal/></person-group><article-title>An imidazole modified lipid confers enhanced mRNA-LNP stability and strong immunization properties in mice and non-human primates</article-title><source>Biomaterials</source><year>2022</year><volume>286</volume><fpage>121570</fpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2022.121570</pub-id><pub-id pub-id-type="pmid">35576809</pub-id><pub-id pub-id-type="pmcid">PMC9078044</pub-id></element-citation><mixed-citation id="mc-CR103" publication-type="journal">Ripoll, M. et al. An imidazole modified lipid confers enhanced mRNA-LNP stability and strong immunization properties in mice and non-human primates. <italic toggle="yes">Biomaterials</italic><bold>286</bold>, 121570 (2022).<pub-id pub-id-type="pmid">35576809</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biomaterials.2022.121570</pub-id><pub-id pub-id-type="pmcid">PMC9078044</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR104"><label>104.</label><citation-alternatives><element-citation id="ec-CR104" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Yu</surname><given-names>F</given-names></name><name name-style="western"><surname>Hsu</surname><given-names>JC</given-names></name><name name-style="western"><surname>Shi</surname><given-names>J</given-names></name><name name-style="western"><surname>Cai</surname><given-names>W</given-names></name></person-group><article-title>Soybean oil-derived lipids for efficient mRNA delivery</article-title><source>Adv. Mater.</source><year>2024</year><volume>36</volume><fpage>2302901</fpage><pub-id pub-id-type="doi">10.1002/adma.202302901</pub-id><pub-id pub-id-type="pmcid">PMC10996393</pub-id><pub-id pub-id-type="pmid">38113460</pub-id></element-citation><mixed-citation id="mc-CR104" publication-type="journal">Tang, Z., Yu, F., Hsu, J. C., Shi, J. &amp; Cai, W. Soybean oil-derived lipids for efficient mRNA delivery. <italic toggle="yes">Adv. Mater.</italic><bold>36</bold>, 2302901 (2024).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/adma.202302901</pub-id><pub-id pub-id-type="pmcid">PMC10996393</pub-id><pub-id pub-id-type="pmid">38113460</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR105"><label>105.</label><citation-alternatives><element-citation id="ec-CR105" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yuan</surname><given-names>Z</given-names></name><name name-style="western"><surname>Yan</surname><given-names>R</given-names></name><name name-style="western"><surname>Fu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Wu</surname><given-names>T</given-names></name><name name-style="western"><surname>Ren</surname><given-names>C</given-names></name></person-group><article-title>Impact of physicochemical properties on biological effects of lipid nanoparticles: are they completely safe</article-title><source>Sci. Total Environ.</source><year>2024</year><volume>927</volume><fpage>172240</fpage><pub-id pub-id-type="doi">10.1016/j.scitotenv.2024.172240</pub-id><pub-id pub-id-type="pmid">38582114</pub-id></element-citation><mixed-citation id="mc-CR105" publication-type="journal">Yuan, Z., Yan, R., Fu, Z., Wu, T. &amp; Ren, C. Impact of physicochemical properties on biological effects of lipid nanoparticles: are they completely safe. <italic toggle="yes">Sci. Total Environ.</italic><bold>927</bold>, 172240 (2024).<pub-id pub-id-type="pmid">38582114</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.scitotenv.2024.172240</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR106"><label>106.</label><citation-alternatives><element-citation id="ec-CR106" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Papi</surname><given-names>M</given-names></name><name name-style="western"><surname>Pozzi</surname><given-names>D</given-names></name><name name-style="western"><surname>Palmieri</surname><given-names>V</given-names></name><name name-style="western"><surname>Caracciolo</surname><given-names>G</given-names></name></person-group><article-title>Principles for optimization and validation of mRNA lipid nanoparticle vaccines against COVID-19 using 3D bioprinting</article-title><source>Nano Today</source><year>2022</year><volume>43</volume><fpage>101403</fpage><pub-id pub-id-type="doi">10.1016/j.nantod.2022.101403</pub-id><pub-id pub-id-type="pmid">35079274</pub-id><pub-id pub-id-type="pmcid">PMC8776405</pub-id></element-citation><mixed-citation id="mc-CR106" publication-type="journal">Papi, M., Pozzi, D., Palmieri, V. &amp; Caracciolo, G. Principles for optimization and validation of mRNA lipid nanoparticle vaccines against COVID-19 using 3D bioprinting. <italic toggle="yes">Nano Today</italic><bold>43</bold>, 101403 (2022).<pub-id pub-id-type="pmid">35079274</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.nantod.2022.101403</pub-id><pub-id pub-id-type="pmcid">PMC8776405</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR107"><label>107.</label><citation-alternatives><element-citation id="ec-CR107" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>J</given-names></name><etal/></person-group><article-title>Screening libraries to discover molecular design principles for the targeted delivery of mRNA with one-component ionizable amphiphilic Janus dendrimers derived from plant phenolic acids</article-title><source>Pharmaceutics</source><year>2023</year><volume>15</volume><fpage>1572</fpage><pub-id pub-id-type="doi">10.3390/pharmaceutics15061572</pub-id><pub-id pub-id-type="pmid">37376020</pub-id><pub-id pub-id-type="pmcid">PMC10303357</pub-id></element-citation><mixed-citation id="mc-CR107" publication-type="journal">Lu, J. et al. Screening libraries to discover molecular design principles for the targeted delivery of mRNA with one-component ionizable amphiphilic Janus dendrimers derived from plant phenolic acids. <italic toggle="yes">Pharmaceutics</italic><bold>15</bold>, 1572 (2023).<pub-id pub-id-type="pmid">37376020</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/pharmaceutics15061572</pub-id><pub-id pub-id-type="pmcid">PMC10303357</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR108"><label>108.</label><citation-alternatives><element-citation id="ec-CR108" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Seo</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Recent progress of lipid nanoparticles-based lipophilic drug delivery: focus on surface modifications</article-title><source>Pharmaceutics</source><year>2023</year><volume>15</volume><fpage>772</fpage><pub-id pub-id-type="doi">10.3390/pharmaceutics15030772</pub-id><pub-id pub-id-type="pmid">36986633</pub-id><pub-id pub-id-type="pmcid">PMC10058399</pub-id></element-citation><mixed-citation id="mc-CR108" publication-type="journal">Seo, Y. et al. Recent progress of lipid nanoparticles-based lipophilic drug delivery: focus on surface modifications. <italic toggle="yes">Pharmaceutics</italic><bold>15</bold>, 772 (2023).<pub-id pub-id-type="pmid">36986633</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/pharmaceutics15030772</pub-id><pub-id pub-id-type="pmcid">PMC10058399</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR109"><label>109.</label><citation-alternatives><element-citation id="ec-CR109" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>W</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Y</given-names></name></person-group><article-title>Lipid nanocarrier&#8208;based mRNA therapy: challenges and promise for clinical transformation</article-title><source>Small</source><year>2024</year><volume>20</volume><fpage>2310531</fpage><pub-id pub-id-type="doi">10.1002/smll.202310531</pub-id><pub-id pub-id-type="pmid">38287729</pub-id></element-citation><mixed-citation id="mc-CR109" publication-type="journal">Li, W., Wang, C., Zhang, Y. &amp; Lu, Y. Lipid nanocarrier&#8208;based mRNA therapy: challenges and promise for clinical transformation. <italic toggle="yes">Small</italic><bold>20</bold>, 2310531 (2024).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/smll.202310531</pub-id><pub-id pub-id-type="pmid">38287729</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR110"><label>110.</label><citation-alternatives><element-citation id="ec-CR110" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>Z</given-names></name><name name-style="western"><surname>Zou</surname><given-names>Z</given-names></name><name name-style="western"><surname>Pu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Wu</surname><given-names>M</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name></person-group><article-title>Application of microfluidic technologies on COVID-19 diagnosis and drug discovery</article-title><source>Acta Pharm. Sin. B</source><year>2023</year><volume>13</volume><fpage>2877</fpage><lpage>2896</lpage><pub-id pub-id-type="doi">10.1016/j.apsb.2023.02.014</pub-id><pub-id pub-id-type="pmid">36855672</pub-id><pub-id pub-id-type="pmcid">PMC9951611</pub-id></element-citation><mixed-citation id="mc-CR110" publication-type="journal">Lin, Z., Zou, Z., Pu, Z., Wu, M. &amp; Zhang, Y. Application of microfluidic technologies on COVID-19 diagnosis and drug discovery. <italic toggle="yes">Acta Pharm. Sin. B</italic><bold>13</bold>, 2877&#8211;2896 (2023).<pub-id pub-id-type="pmid">36855672</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.apsb.2023.02.014</pub-id><pub-id pub-id-type="pmcid">PMC9951611</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR111"><label>111.</label><citation-alternatives><element-citation id="ec-CR111" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>H</given-names></name><etal/></person-group><article-title>Microfluidics for nano-drug delivery systems: from fundamentals to industrialization</article-title><source>Acta Pharm. Sin. B</source><year>2023</year><volume>13</volume><fpage>3277</fpage><lpage>3299</lpage><pub-id pub-id-type="doi">10.1016/j.apsb.2023.01.018</pub-id><pub-id pub-id-type="pmid">37655333</pub-id><pub-id pub-id-type="pmcid">PMC10466004</pub-id></element-citation><mixed-citation id="mc-CR111" publication-type="journal">Zhang, H. et al. Microfluidics for nano-drug delivery systems: from fundamentals to industrialization. <italic toggle="yes">Acta Pharm. Sin. B</italic><bold>13</bold>, 3277&#8211;3299 (2023).<pub-id pub-id-type="pmid">37655333</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.apsb.2023.01.018</pub-id><pub-id pub-id-type="pmcid">PMC10466004</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR112"><label>112.</label><citation-alternatives><element-citation id="ec-CR112" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fan</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Automated high-throughput preparation and characterization of oligonucleotide-loaded lipid nanoparticles</article-title><source>Int. J. Pharm.</source><year>2021</year><volume>599</volume><fpage>120392</fpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2021.120392</pub-id><pub-id pub-id-type="pmid">33639228</pub-id></element-citation><mixed-citation id="mc-CR112" publication-type="journal">Fan, Y. et al. Automated high-throughput preparation and characterization of oligonucleotide-loaded lipid nanoparticles. <italic toggle="yes">Int. J. Pharm.</italic><bold>599</bold>, 120392 (2021).<pub-id pub-id-type="pmid">33639228</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijpharm.2021.120392</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR113"><label>113.</label><citation-alternatives><element-citation id="ec-CR113" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>H</given-names></name><etal/></person-group><article-title>Combined helical-blade-strengthened co-flow focusing and high-throughput screening for the synthesis of highly homogeneous nanoliposomes</article-title><source>Nano Today</source><year>2024</year><volume>56</volume><fpage>102301</fpage><pub-id pub-id-type="doi">10.1016/j.nantod.2024.102301</pub-id></element-citation><mixed-citation id="mc-CR113" publication-type="journal">Wang, H. et al. Combined helical-blade-strengthened co-flow focusing and high-throughput screening for the synthesis of highly homogeneous nanoliposomes. <italic toggle="yes">Nano Today</italic><bold>56</bold>, 102301 (2024).</mixed-citation></citation-alternatives></ref><ref id="CR114"><label>114.</label><citation-alternatives><element-citation id="ec-CR114" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chehelgerdi</surname><given-names>M</given-names></name><name name-style="western"><surname>Chehelgerdi</surname><given-names>M</given-names></name></person-group><article-title>The use of RNA-based treatments in the field of cancer immunotherapy</article-title><source>Mol. Cancer</source><year>2023</year><volume>22</volume><fpage>106</fpage><pub-id pub-id-type="doi">10.1186/s12943-023-01807-w</pub-id><pub-id pub-id-type="pmid">37420174</pub-id><pub-id pub-id-type="pmcid">PMC10401791</pub-id></element-citation><mixed-citation id="mc-CR114" publication-type="journal">Chehelgerdi, M. &amp; Chehelgerdi, M. The use of RNA-based treatments in the field of cancer immunotherapy. <italic toggle="yes">Mol. Cancer</italic><bold>22</bold>, 106 (2023).<pub-id pub-id-type="pmid">37420174</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12943-023-01807-w</pub-id><pub-id pub-id-type="pmcid">PMC10401791</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR115"><label>115.</label><citation-alternatives><element-citation id="ec-CR115" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Han</surname><given-names>X</given-names></name><etal/></person-group><article-title>Adjuvant lipidoid-substituted lipid nanoparticles augment the immunogenicity of SARS-CoV-2 mRNA vaccines</article-title><source>Nat. Nanotechnol.</source><year>2023</year><volume>18</volume><fpage>1105</fpage><lpage>1114</lpage><pub-id pub-id-type="doi">10.1038/s41565-023-01404-4</pub-id><pub-id pub-id-type="pmid">37365276</pub-id></element-citation><mixed-citation id="mc-CR115" publication-type="journal">Han, X. et al. Adjuvant lipidoid-substituted lipid nanoparticles augment the immunogenicity of SARS-CoV-2 mRNA vaccines. <italic toggle="yes">Nat. Nanotechnol.</italic><bold>18</bold>, 1105&#8211;1114 (2023).<pub-id pub-id-type="pmid">37365276</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41565-023-01404-4</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR116"><label>116.</label><citation-alternatives><element-citation id="ec-CR116" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gote</surname><given-names>V</given-names></name><etal/></person-group><article-title>A comprehensive review of mRNA vaccines</article-title><source>Int. J. Mol. Sci.</source><year>2023</year><volume>24</volume><fpage>2700</fpage><pub-id pub-id-type="doi">10.3390/ijms24032700</pub-id><pub-id pub-id-type="pmid">36769023</pub-id><pub-id pub-id-type="pmcid">PMC9917162</pub-id></element-citation><mixed-citation id="mc-CR116" publication-type="journal">Gote, V. et al. A comprehensive review of mRNA vaccines. <italic toggle="yes">Int. J. Mol. Sci.</italic><bold>24</bold>, 2700 (2023).<pub-id pub-id-type="pmid">36769023</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms24032700</pub-id><pub-id pub-id-type="pmcid">PMC9917162</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR117"><label>117.</label><citation-alternatives><element-citation id="ec-CR117" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>W</given-names></name><etal/></person-group><article-title>Nanoformulations targeting immune cells for cancer therapy: mRNA therapeutics</article-title><source>Bioact. Mater.</source><year>2023</year><volume>23</volume><fpage>438</fpage><lpage>470</lpage><pub-id pub-id-type="pmid">36471724</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bioactmat.2022.11.014</pub-id><pub-id pub-id-type="pmcid">PMC9712057</pub-id></element-citation><mixed-citation id="mc-CR117" publication-type="journal">Yang, W. et al. Nanoformulations targeting immune cells for cancer therapy: mRNA therapeutics. <italic toggle="yes">Bioact. Mater.</italic><bold>23</bold>, 438&#8211;470 (2023).<pub-id pub-id-type="pmid">36471724</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bioactmat.2022.11.014</pub-id><pub-id pub-id-type="pmcid">PMC9712057</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR118"><label>118.</label><citation-alternatives><element-citation id="ec-CR118" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Picciotto</surname><given-names>S</given-names></name><etal/></person-group><article-title>Selective activation and expansion of regulatory T cells using lipid encapsulated mRNA encoding a long-acting IL-2 mutein</article-title><source>Nat. Commun.</source><year>2022</year><volume>13</volume><fpage>3866</fpage><pub-id pub-id-type="doi">10.1038/s41467-022-31130-9</pub-id><pub-id pub-id-type="pmid">35790728</pub-id><pub-id pub-id-type="pmcid">PMC9256694</pub-id></element-citation><mixed-citation id="mc-CR118" publication-type="journal">de Picciotto, S. et al. Selective activation and expansion of regulatory T cells using lipid encapsulated mRNA encoding a long-acting IL-2 mutein. <italic toggle="yes">Nat. Commun.</italic><bold>13</bold>, 3866 (2022).<pub-id pub-id-type="pmid">35790728</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-022-31130-9</pub-id><pub-id pub-id-type="pmcid">PMC9256694</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR119"><label>119.</label><citation-alternatives><element-citation id="ec-CR119" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>L</given-names></name><etal/></person-group><article-title>New therapeutic strategies based on IL-2 to modulate Treg cells for autoimmune diseases</article-title><source>Int. Immunopharmacol.</source><year>2019</year><volume>72</volume><fpage>322</fpage><lpage>329</lpage><pub-id pub-id-type="doi">10.1016/j.intimp.2019.03.064</pub-id><pub-id pub-id-type="pmid">31005777</pub-id></element-citation><mixed-citation id="mc-CR119" publication-type="journal">Xu, L. et al. New therapeutic strategies based on IL-2 to modulate Treg cells for autoimmune diseases. <italic toggle="yes">Int. Immunopharmacol.</italic><bold>72</bold>, 322&#8211;329 (2019).<pub-id pub-id-type="pmid">31005777</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.intimp.2019.03.064</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR120"><label>120.</label><citation-alternatives><element-citation id="ec-CR120" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mackensen</surname><given-names>A</given-names></name><etal/></person-group><article-title>958 BNT211: a phase I/II trial to evaluate safety and efficacy of CLDN6 CAR-T cells and vaccine-mediated in vivo expansion in patients with CLDN6-positive advanced solid tumors</article-title><source>J. Immunother. Cancer</source><year>2021</year><volume>9</volume><fpage>A1008</fpage></element-citation><mixed-citation id="mc-CR120" publication-type="journal">Mackensen, A. et al. 958 BNT211: a phase I/II trial to evaluate safety and efficacy of CLDN6 CAR-T cells and vaccine-mediated in vivo expansion in patients with CLDN6-positive advanced solid tumors. <italic toggle="yes">J. Immunother. Cancer</italic><bold>9</bold>, A1008 (2021).</mixed-citation></citation-alternatives></ref><ref id="CR121"><label>121.</label><citation-alternatives><element-citation id="ec-CR121" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Granit</surname><given-names>V</given-names></name><etal/></person-group><article-title>Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b/2a study</article-title><source>Lancet Neurol.</source><year>2023</year><volume>22</volume><fpage>578</fpage><lpage>590</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(23)00194-1</pub-id><pub-id pub-id-type="pmid">37353278</pub-id><pub-id pub-id-type="pmcid">PMC10416207</pub-id></element-citation><mixed-citation id="mc-CR121" publication-type="journal">Granit, V. et al. Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b/2a study. <italic toggle="yes">Lancet Neurol.</italic><bold>22</bold>, 578&#8211;590 (2023).<pub-id pub-id-type="pmid">37353278</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1474-4422(23)00194-1</pub-id><pub-id pub-id-type="pmcid">PMC10416207</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR122"><label>122.</label><citation-alternatives><element-citation id="ec-CR122" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hussain</surname><given-names>A</given-names></name><etal/></person-group><article-title>mRNA vaccines for COVID-19 and diverse diseases</article-title><source>J. Control Release</source><year>2022</year><volume>345</volume><fpage>314</fpage><lpage>333</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2022.03.032</pub-id><pub-id pub-id-type="pmid">35331783</pub-id><pub-id pub-id-type="pmcid">PMC8935967</pub-id></element-citation><mixed-citation id="mc-CR122" publication-type="journal">Hussain, A. et al. mRNA vaccines for COVID-19 and diverse diseases. <italic toggle="yes">J. Control Release</italic><bold>345</bold>, 314&#8211;333 (2022).<pub-id pub-id-type="pmid">35331783</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jconrel.2022.03.032</pub-id><pub-id pub-id-type="pmcid">PMC8935967</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR123"><label>123.</label><citation-alternatives><element-citation id="ec-CR123" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lamb</surname><given-names>YN</given-names></name></person-group><article-title>BNT162b2 mRNA COVID-19 vaccine: first approval</article-title><source>Drugs</source><year>2021</year><volume>81</volume><fpage>495</fpage><lpage>501</lpage><pub-id pub-id-type="doi">10.1007/s40265-021-01480-7</pub-id><pub-id pub-id-type="pmid">33683637</pub-id><pub-id pub-id-type="pmcid">PMC7938284</pub-id></element-citation><mixed-citation id="mc-CR123" publication-type="journal">Lamb, Y. N. BNT162b2 mRNA COVID-19 vaccine: first approval. <italic toggle="yes">Drugs</italic><bold>81</bold>, 495&#8211;501 (2021).<pub-id pub-id-type="pmid">33683637</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40265-021-01480-7</pub-id><pub-id pub-id-type="pmcid">PMC7938284</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR124"><label>124.</label><citation-alternatives><element-citation id="ec-CR124" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>X</given-names></name><etal/></person-group><article-title>The landscape of mRNA nanomedicine</article-title><source>Nat. Med.</source><year>2022</year><volume>28</volume><fpage>2273</fpage><lpage>2287</lpage><pub-id pub-id-type="doi">10.1038/s41591-022-02061-1</pub-id><pub-id pub-id-type="pmid">36357682</pub-id></element-citation><mixed-citation id="mc-CR124" publication-type="journal">Huang, X. et al. The landscape of mRNA nanomedicine. <italic toggle="yes">Nat. Med.</italic><bold>28</bold>, 2273&#8211;2287 (2022).<pub-id pub-id-type="pmid">36357682</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-022-02061-1</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR125"><label>125.</label><mixed-citation publication-type="other">World Health Organization. COVID-19 vaccine tracker and landscape. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines">https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines</ext-link> (2023).</mixed-citation></ref><ref id="CR126"><label>126.</label><citation-alternatives><element-citation id="ec-CR126" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><etal/></person-group><article-title>A nanoparticle vaccine displaying varicella-zoster virus gE antigen induces a superior cellular immune response than a licensed vaccine in mice and non-human primates</article-title><source>Front. Immunol.</source><year>2024</year><volume>15</volume><fpage>1419634</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2024.1419634</pub-id><pub-id pub-id-type="pmid">39081325</pub-id><pub-id pub-id-type="pmcid">PMC11286566</pub-id></element-citation><mixed-citation id="mc-CR126" publication-type="journal">Li, Y. et al. A nanoparticle vaccine displaying varicella-zoster virus gE antigen induces a superior cellular immune response than a licensed vaccine in mice and non-human primates. <italic toggle="yes">Front. Immunol.</italic><bold>15</bold>, 1419634 (2024).<pub-id pub-id-type="pmid">39081325</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2024.1419634</pub-id><pub-id pub-id-type="pmcid">PMC11286566</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR127"><label>127.</label><citation-alternatives><element-citation id="ec-CR127" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>S</given-names></name><etal/></person-group><article-title>Identification and characterization of Varicella Zoster Virus circular RNA in lytic infection</article-title><source>Nat. Commun.</source><year>2024</year><volume>15</volume><fpage>4932</fpage><pub-id pub-id-type="doi">10.1038/s41467-024-49112-4</pub-id><pub-id pub-id-type="pmid">38858365</pub-id><pub-id pub-id-type="pmcid">PMC11164961</pub-id></element-citation><mixed-citation id="mc-CR127" publication-type="journal">Yang, S. et al. Identification and characterization of Varicella Zoster Virus circular RNA in lytic infection. <italic toggle="yes">Nat. Commun.</italic><bold>15</bold>, 4932 (2024).<pub-id pub-id-type="pmid">38858365</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-024-49112-4</pub-id><pub-id pub-id-type="pmcid">PMC11164961</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR128"><label>128.</label><citation-alternatives><element-citation id="ec-CR128" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>L</given-names></name><etal/></person-group><article-title>Herpes zoster mRNA vaccine induces superior vaccine immunity over licensed vaccine in mice and rhesus macaques</article-title><source>Emerg. Microbes Infect.</source><year>2024</year><volume>13</volume><fpage>2309985</fpage><pub-id pub-id-type="doi">10.1080/22221751.2024.2309985</pub-id><pub-id pub-id-type="pmid">38258878</pub-id><pub-id pub-id-type="pmcid">PMC10860463</pub-id></element-citation><mixed-citation id="mc-CR128" publication-type="journal">Huang, L. et al. Herpes zoster mRNA vaccine induces superior vaccine immunity over licensed vaccine in mice and rhesus macaques. <italic toggle="yes">Emerg. Microbes Infect.</italic><bold>13</bold>, 2309985 (2024).<pub-id pub-id-type="pmid">38258878</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/22221751.2024.2309985</pub-id><pub-id pub-id-type="pmcid">PMC10860463</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR129"><label>129.</label><citation-alternatives><element-citation id="ec-CR129" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Meissner</surname><given-names>HC</given-names></name></person-group><article-title>Disarming the respiratory syncytial virus</article-title><source>New Engl. J. Med.</source><year>2020</year><volume>383</volume><fpage>487</fpage><lpage>488</lpage><pub-id pub-id-type="doi">10.1056/NEJMe2021648</pub-id><pub-id pub-id-type="pmid">32726536</pub-id></element-citation><mixed-citation id="mc-CR129" publication-type="journal">Meissner, H. C. Disarming the respiratory syncytial virus. <italic toggle="yes">New Engl. J. Med.</italic><bold>383</bold>, 487&#8211;488 (2020).<pub-id pub-id-type="pmid">32726536</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMe2021648</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR130"><label>130.</label><citation-alternatives><element-citation id="ec-CR130" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nam</surname><given-names>HH</given-names></name><name name-style="western"><surname>Ison</surname><given-names>MG</given-names></name></person-group><article-title>respiratory syncytial virus</article-title><source>Semin. Respir. Crit. Care Med.</source><year>2021</year><volume>42</volume><fpage>788</fpage><lpage>799</lpage><pub-id pub-id-type="doi">10.1055/s-0041-1736182</pub-id><pub-id pub-id-type="pmid">34918321</pub-id></element-citation><mixed-citation id="mc-CR130" publication-type="journal">Nam, H. H. &amp; Ison, M. G. respiratory syncytial virus. <italic toggle="yes">Semin. Respir. Crit. Care Med.</italic><bold>42</bold>, 788&#8211;799 (2021).<pub-id pub-id-type="pmid">34918321</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1055/s-0041-1736182</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR131"><label>131.</label><mixed-citation publication-type="other">Shaw, C. A. et al. Safety, tolerability, and immunogenicity of an mRNA-based respiratory syncytial virus vaccine in healthy young adults in a phase 1 clinical trial. <italic toggle="yes">J. Infect. Dis</italic>. 10.1093/infdis/jiae035 (2024).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/infdis/jiae035</pub-id><pub-id pub-id-type="pmcid">PMC11420805</pub-id><pub-id pub-id-type="pmid">38298125</pub-id></mixed-citation></ref><ref id="CR132"><label>132.</label><citation-alternatives><element-citation id="ec-CR132" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qiu</surname><given-names>X</given-names></name><etal/></person-group><article-title>Development of mRNA vaccines against respiratory syncytial virus (RSV)</article-title><source>Cytokine Growth Factor Rev.</source><year>2022</year><volume>68</volume><fpage>37</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1016/j.cytogfr.2022.10.001</pub-id><pub-id pub-id-type="pmid">36280532</pub-id></element-citation><mixed-citation id="mc-CR132" publication-type="journal">Qiu, X. et al. Development of mRNA vaccines against respiratory syncytial virus (RSV). <italic toggle="yes">Cytokine Growth Factor Rev.</italic><bold>68</bold>, 37&#8211;53 (2022).<pub-id pub-id-type="pmid">36280532</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cytogfr.2022.10.001</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR133"><label>133.</label><citation-alternatives><element-citation id="ec-CR133" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hutchinson</surname><given-names>EC</given-names></name></person-group><article-title>Influenza virus</article-title><source>Trends Microbiol.</source><year>2018</year><volume>26</volume><fpage>809</fpage><lpage>810</lpage><pub-id pub-id-type="doi">10.1016/j.tim.2018.05.013</pub-id><pub-id pub-id-type="pmid">29909041</pub-id></element-citation><mixed-citation id="mc-CR133" publication-type="journal">Hutchinson, E. C. Influenza virus. <italic toggle="yes">Trends Microbiol.</italic><bold>26</bold>, 809&#8211;810 (2018).<pub-id pub-id-type="pmid">29909041</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.tim.2018.05.013</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR134"><label>134.</label><citation-alternatives><element-citation id="ec-CR134" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>IT</given-names></name><etal/></person-group><article-title>Safety and immunogenicity of a phase 1/2 randomized clinical trial of a quadrivalent, mRNA-based seasonal influenza vaccine (mRNA-1010) in healthy adults: interim analysis</article-title><source>Nat. Commun.</source><year>2023</year><volume>14</volume><fpage>3631</fpage><pub-id pub-id-type="doi">10.1038/s41467-023-39376-7</pub-id><pub-id pub-id-type="pmid">37336877</pub-id><pub-id pub-id-type="pmcid">PMC10279702</pub-id></element-citation><mixed-citation id="mc-CR134" publication-type="journal">Lee, I. T. et al. Safety and immunogenicity of a phase 1/2 randomized clinical trial of a quadrivalent, mRNA-based seasonal influenza vaccine (mRNA-1010) in healthy adults: interim analysis. <italic toggle="yes">Nat. Commun.</italic><bold>14</bold>, 3631 (2023).<pub-id pub-id-type="pmid">37336877</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-023-39376-7</pub-id><pub-id pub-id-type="pmcid">PMC10279702</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR135"><label>135.</label><mixed-citation publication-type="other">ModernaTX, Inc. A phase 3, randomized, observer-blind, active-controlled study to evaluate the safety and efficacy of mRNA-1010 candidate seasonal influenza vaccine in adults 50 years and older. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/study/NCT05566639">https://clinicaltrials.gov/study/NCT05566639</ext-link> (2024).</mixed-citation></ref><ref id="CR136"><label>136.</label><mixed-citation publication-type="other">ModernaTX, Inc. A phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/study/NCT05827978">https://clinicaltrials.gov/study/NCT05827978</ext-link> (2024).</mixed-citation></ref><ref id="CR137"><label>137.</label><citation-alternatives><element-citation id="ec-CR137" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>K</given-names></name><etal/></person-group><article-title>Characterization of humoral and cellular immunologic responses to an mRNA-based human cytomegalovirus vaccine from a phase 1 trial of healthy adults</article-title><source>J. Virol.</source><year>2024</year><volume>98</volume><fpage>e01603</fpage><lpage>e01623</lpage><pub-id pub-id-type="doi">10.1128/jvi.01603-23</pub-id><pub-id pub-id-type="pmid">38526054</pub-id><pub-id pub-id-type="pmcid">PMC11019844</pub-id></element-citation><mixed-citation id="mc-CR137" publication-type="journal">Wu, K. et al. Characterization of humoral and cellular immunologic responses to an mRNA-based human cytomegalovirus vaccine from a phase 1 trial of healthy adults. <italic toggle="yes">J. Virol.</italic><bold>98</bold>, e01603&#8211;e01623 (2024).<pub-id pub-id-type="pmid">38526054</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/jvi.01603-23</pub-id><pub-id pub-id-type="pmcid">PMC11019844</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR138"><label>138.</label><mixed-citation publication-type="other">Fierro, C. et al. Safety and immunogenicity of a messenger RNA-based cytomegalovirus vaccine in healthy adults: results from a phase 1, randomized, clinical trial. <italic toggle="yes">J. Infect. Dis</italic>. 10.1093/infdis/jiae114 (2024).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/infdis/jiae114</pub-id><pub-id pub-id-type="pmcid">PMC11420795</pub-id><pub-id pub-id-type="pmid">38478705</pub-id></mixed-citation></ref><ref id="CR139"><label>139.</label><mixed-citation publication-type="other">Hu, X. et al. Human cytomegalovirus mRNA-1647 vaccine candidate elicits potent and broad neutralization and higher antibody-dependent cellular cytotoxicity responses than the gb/mf59 vaccine. <italic toggle="yes">J. Infect. Dis</italic>. 10.1093/infdis/jiad593 (2024).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/infdis/jiad593</pub-id><pub-id pub-id-type="pmcid">PMC11326847</pub-id><pub-id pub-id-type="pmid">38324766</pub-id></mixed-citation></ref><ref id="CR140"><label>140.</label><mixed-citation publication-type="other">ModernaTX, Inc. A phase 3, randomized, observer-blind, placebo-controlled study to evaluate the efficacy, safety, and immunogenicity of mRNA-1647 cytomegalovirus (CMV) vaccine in healthy participants 16 to 40 years of age. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/study/NCT05085366">https://clinicaltrials.gov/study/NCT05085366</ext-link> (2023).</mixed-citation></ref><ref id="CR141"><label>141.</label><citation-alternatives><element-citation id="ec-CR141" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sivars</surname><given-names>L</given-names></name><etal/></person-group><article-title>Cell-free human papillomavirus DNA is a sensitive biomarker for prognosis and for early detection of relapse in locally advanced cervical cancer</article-title><source>Clin. Cancer Res.</source><year>2024</year><volume>30</volume><fpage>2764</fpage><lpage>2771</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-23-3941</pub-id><pub-id pub-id-type="pmid">38669077</pub-id></element-citation><mixed-citation id="mc-CR141" publication-type="journal">Sivars, L. et al. Cell-free human papillomavirus DNA is a sensitive biomarker for prognosis and for early detection of relapse in locally advanced cervical cancer. <italic toggle="yes">Clin. Cancer Res.</italic><bold>30</bold>, 2764&#8211;2771 (2024).<pub-id pub-id-type="pmid">38669077</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1078-0432.CCR-23-3941</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR142"><label>142.</label><citation-alternatives><element-citation id="ec-CR142" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Malag&#243;n</surname><given-names>T</given-names></name><name name-style="western"><surname>Franco</surname><given-names>EL</given-names></name><name name-style="western"><surname>Tejada</surname><given-names>R</given-names></name><name name-style="western"><surname>Vaccarella</surname><given-names>S</given-names></name></person-group><article-title>Epidemiology of HPV-associated cancers past, present and future: towards prevention and elimination</article-title><source>Nat. Rev. Clin. Oncol.</source><year>2024</year><volume>21</volume><fpage>522</fpage><lpage>538</lpage><pub-id pub-id-type="doi">10.1038/s41571-024-00904-z</pub-id><pub-id pub-id-type="pmid">38760499</pub-id></element-citation><mixed-citation id="mc-CR142" publication-type="journal">Malag&#243;n, T., Franco, E. L., Tejada, R. &amp; Vaccarella, S. Epidemiology of HPV-associated cancers past, present and future: towards prevention and elimination. <italic toggle="yes">Nat. Rev. Clin. Oncol.</italic><bold>21</bold>, 522&#8211;538 (2024).<pub-id pub-id-type="pmid">38760499</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41571-024-00904-z</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR143"><label>143.</label><citation-alternatives><element-citation id="ec-CR143" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>S</given-names></name><etal/></person-group><article-title>mRNA-HPV vaccine encoding E6 and E7 improves therapeutic potential for HPV-mediated cancers via subcutaneous immunization</article-title><source>J. Med. Virol.</source><year>2023</year><volume>95</volume><fpage>e29309</fpage><pub-id pub-id-type="doi">10.1002/jmv.29309</pub-id><pub-id pub-id-type="pmid">38100632</pub-id></element-citation><mixed-citation id="mc-CR143" publication-type="journal">Lee, S. et al. mRNA-HPV vaccine encoding E6 and E7 improves therapeutic potential for HPV-mediated cancers via subcutaneous immunization. <italic toggle="yes">J. Med. Virol.</italic><bold>95</bold>, e29309 (2023).<pub-id pub-id-type="pmid">38100632</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jmv.29309</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR144"><label>144.</label><citation-alternatives><element-citation id="ec-CR144" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xiang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>LMP2-mRNA lipid nanoparticle sensitizes EBV-related tumors to anti-PD-1 therapy by reversing T cell exhaustion</article-title><source>J. Nanobiotechnol.</source><year>2023</year><volume>21</volume><fpage>324</fpage><pub-id pub-id-type="doi">10.1186/s12951-023-02069-w</pub-id><pub-id pub-id-type="pmcid">PMC10486025</pub-id><pub-id pub-id-type="pmid">37679769</pub-id></element-citation><mixed-citation id="mc-CR144" publication-type="journal">Xiang, Y. et al. LMP2-mRNA lipid nanoparticle sensitizes EBV-related tumors to anti-PD-1 therapy by reversing T cell exhaustion. <italic toggle="yes">J. Nanobiotechnol.</italic><bold>21</bold>, 324 (2023).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12951-023-02069-w</pub-id><pub-id pub-id-type="pmcid">PMC10486025</pub-id><pub-id pub-id-type="pmid">37679769</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR145"><label>145.</label><citation-alternatives><element-citation id="ec-CR145" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>G-X</given-names></name><etal/></person-group><article-title>mRNA&#8208;based vaccines targeting the T-cell epitope-rich domain of Epstein Barr virus latent proteins elicit robust anti-tumor immunity in mice</article-title><source>Adv. Sci.</source><year>2023</year><volume>10</volume><fpage>2302116</fpage><pub-id pub-id-type="doi">10.1002/advs.202302116</pub-id><pub-id pub-id-type="pmcid">PMC10724410</pub-id><pub-id pub-id-type="pmid">37890462</pub-id></element-citation><mixed-citation id="mc-CR145" publication-type="journal">Zhao, G.-X. et al. mRNA&#8208;based vaccines targeting the T-cell epitope-rich domain of Epstein Barr virus latent proteins elicit robust anti-tumor immunity in mice. <italic toggle="yes">Adv. Sci.</italic><bold>10</bold>, 2302116 (2023).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/advs.202302116</pub-id><pub-id pub-id-type="pmcid">PMC10724410</pub-id><pub-id pub-id-type="pmid">37890462</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR146"><label>146.</label><citation-alternatives><element-citation id="ec-CR146" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Armbruster</surname><given-names>N</given-names></name><name name-style="western"><surname>Jasny</surname><given-names>E</given-names></name><name name-style="western"><surname>Petsch</surname><given-names>B</given-names></name></person-group><article-title>Advances in RNA vaccines for preventive indications: a case study of a vaccine against rabies</article-title><source>Vaccines</source><year>2019</year><volume>7</volume><fpage>132</fpage><pub-id pub-id-type="doi">10.3390/vaccines7040132</pub-id><pub-id pub-id-type="pmid">31569785</pub-id><pub-id pub-id-type="pmcid">PMC6963972</pub-id></element-citation><mixed-citation id="mc-CR146" publication-type="journal">Armbruster, N., Jasny, E. &amp; Petsch, B. Advances in RNA vaccines for preventive indications: a case study of a vaccine against rabies. <italic toggle="yes">Vaccines</italic><bold>7</bold>, 132 (2019).<pub-id pub-id-type="pmid">31569785</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/vaccines7040132</pub-id><pub-id pub-id-type="pmcid">PMC6963972</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR147"><label>147.</label><citation-alternatives><element-citation id="ec-CR147" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aleem</surname><given-names>MT</given-names></name><name name-style="western"><surname>Munir</surname><given-names>F</given-names></name><name name-style="western"><surname>Shakoor</surname><given-names>A</given-names></name><name name-style="western"><surname>Gao</surname><given-names>F</given-names></name></person-group><article-title>mRNA vaccines against infectious diseases and future direction</article-title><source>Int. Immunopharmacol.</source><year>2024</year><volume>135</volume><fpage>112320</fpage><pub-id pub-id-type="doi">10.1016/j.intimp.2024.112320</pub-id><pub-id pub-id-type="pmid">38788451</pub-id></element-citation><mixed-citation id="mc-CR147" publication-type="journal">Aleem, M. T., Munir, F., Shakoor, A. &amp; Gao, F. mRNA vaccines against infectious diseases and future direction. <italic toggle="yes">Int. Immunopharmacol.</italic><bold>135</bold>, 112320 (2024).<pub-id pub-id-type="pmid">38788451</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.intimp.2024.112320</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR148"><label>148.</label><citation-alternatives><element-citation id="ec-CR148" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>M</given-names></name><etal/></person-group><article-title>An mRNA vaccine against rabies provides strong and durable protection in mice</article-title><source>Front. Immunol.</source><year>2023</year><volume>14</volume><fpage>1288879</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2023.1288879</pub-id><pub-id pub-id-type="pmid">37954577</pub-id><pub-id pub-id-type="pmcid">PMC10639119</pub-id></element-citation><mixed-citation id="mc-CR148" publication-type="journal">Li, M. et al. An mRNA vaccine against rabies provides strong and durable protection in mice. <italic toggle="yes">Front. Immunol.</italic><bold>14</bold>, 1288879 (2023).<pub-id pub-id-type="pmid">37954577</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2023.1288879</pub-id><pub-id pub-id-type="pmcid">PMC10639119</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR149"><label>149.</label><citation-alternatives><element-citation id="ec-CR149" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Long</surname><given-names>J</given-names></name><etal/></person-group><article-title>A rabies mRNA vaccine provides a rapid and long-term immune response in mice</article-title><source>Nano Today</source><year>2023</year><volume>53</volume><fpage>102038</fpage><pub-id pub-id-type="doi">10.1016/j.nantod.2023.102038</pub-id></element-citation><mixed-citation id="mc-CR149" publication-type="journal">Long, J. et al. A rabies mRNA vaccine provides a rapid and long-term immune response in mice. <italic toggle="yes">Nano Today</italic><bold>53</bold>, 102038 (2023).</mixed-citation></citation-alternatives></ref><ref id="CR150"><label>150.</label><citation-alternatives><element-citation id="ec-CR150" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hellgren</surname><given-names>F</given-names></name><etal/></person-group><article-title>Unmodified rabies mRNA vaccine elicits high cross-neutralizing antibody titers and diverse B cell memory responses</article-title><source>Nat. Commun.</source><year>2023</year><volume>14</volume><fpage>3713</fpage><pub-id pub-id-type="doi">10.1038/s41467-023-39421-5</pub-id><pub-id pub-id-type="pmid">37349310</pub-id><pub-id pub-id-type="pmcid">PMC10287699</pub-id></element-citation><mixed-citation id="mc-CR150" publication-type="journal">Hellgren, F. et al. Unmodified rabies mRNA vaccine elicits high cross-neutralizing antibody titers and diverse B cell memory responses. <italic toggle="yes">Nat. Commun.</italic><bold>14</bold>, 3713 (2023).<pub-id pub-id-type="pmid">37349310</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-023-39421-5</pub-id><pub-id pub-id-type="pmcid">PMC10287699</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR151"><label>151.</label><citation-alternatives><element-citation id="ec-CR151" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wan</surname><given-names>J</given-names></name><etal/></person-group><article-title>A single immunization with core&#8211;shell structured lipopolyplex mRNA vaccine against rabies induces potent humoral immunity in mice and dogs</article-title><source>Emerg. Microbes Infect.</source><year>2023</year><volume>12</volume><fpage>2270081</fpage><pub-id pub-id-type="doi">10.1080/22221751.2023.2270081</pub-id><pub-id pub-id-type="pmid">37819147</pub-id><pub-id pub-id-type="pmcid">PMC10768744</pub-id></element-citation><mixed-citation id="mc-CR151" publication-type="journal">Wan, J. et al. A single immunization with core&#8211;shell structured lipopolyplex mRNA vaccine against rabies induces potent humoral immunity in mice and dogs. <italic toggle="yes">Emerg. Microbes Infect.</italic><bold>12</bold>, 2270081 (2023).<pub-id pub-id-type="pmid">37819147</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/22221751.2023.2270081</pub-id><pub-id pub-id-type="pmcid">PMC10768744</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR152"><label>152.</label><citation-alternatives><element-citation id="ec-CR152" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cao</surname><given-names>H</given-names></name><etal/></person-group><article-title>A rabies mRNA vaccine with H270P mutation in its glycoprotein induces strong cellular and humoral immunity</article-title><source>Vaccine</source><year>2024</year><volume>42</volume><fpage>1116</fpage><lpage>1121</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2024.01.057</pub-id><pub-id pub-id-type="pmid">38262810</pub-id></element-citation><mixed-citation id="mc-CR152" publication-type="journal">Cao, H. et al. A rabies mRNA vaccine with H270P mutation in its glycoprotein induces strong cellular and humoral immunity. <italic toggle="yes">Vaccine</italic><bold>42</bold>, 1116&#8211;1121 (2024).<pub-id pub-id-type="pmid">38262810</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2024.01.057</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR153"><label>153.</label><citation-alternatives><element-citation id="ec-CR153" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>G&#243;mez</surname><given-names>CE</given-names></name><etal/></person-group><article-title>Enhancement of the HIV-1-specific immune response induced by an mRNA vaccine through boosting with a poxvirus MVA vector expressing the same antigen</article-title><source>Vaccines</source><year>2021</year><volume>9</volume><fpage>959</fpage><pub-id pub-id-type="doi">10.3390/vaccines9090959</pub-id><pub-id pub-id-type="pmid">34579196</pub-id><pub-id pub-id-type="pmcid">PMC8473054</pub-id></element-citation><mixed-citation id="mc-CR153" publication-type="journal">G&#243;mez, C. E. et al. Enhancement of the HIV-1-specific immune response induced by an mRNA vaccine through boosting with a poxvirus MVA vector expressing the same antigen. <italic toggle="yes">Vaccines</italic><bold>9</bold>, 959 (2021).<pub-id pub-id-type="pmid">34579196</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/vaccines9090959</pub-id><pub-id pub-id-type="pmcid">PMC8473054</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR154"><label>154.</label><citation-alternatives><element-citation id="ec-CR154" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Haynes</surname><given-names>BF</given-names></name><name name-style="western"><surname>Cain</surname><given-names>DW</given-names></name></person-group><article-title>HIV mRNA vaccines&#8212;progress and future paths</article-title><source>Vaccines</source><year>2021</year><volume>9</volume><fpage>134</fpage><pub-id pub-id-type="doi">10.3390/vaccines9020134</pub-id><pub-id pub-id-type="pmid">33562203</pub-id><pub-id pub-id-type="pmcid">PMC7915550</pub-id></element-citation><mixed-citation id="mc-CR154" publication-type="journal">Mu, Z., Haynes, B. F. &amp; Cain, D. W. HIV mRNA vaccines&#8212;progress and future paths. <italic toggle="yes">Vaccines</italic><bold>9</bold>, 134 (2021).<pub-id pub-id-type="pmid">33562203</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/vaccines9020134</pub-id><pub-id pub-id-type="pmcid">PMC7915550</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR155"><label>155.</label><citation-alternatives><element-citation id="ec-CR155" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Usero</surname><given-names>L</given-names></name><etal/></person-group><article-title>The combination of an mRNA immunogen, a TLR7 agonist and a PD1 blocking agent enhances in-vitro HIV T-cell immune responses</article-title><source>Vaccines</source><year>2023</year><volume>11</volume><fpage>286</fpage><pub-id pub-id-type="doi">10.3390/vaccines11020286</pub-id><pub-id pub-id-type="pmid">36851164</pub-id><pub-id pub-id-type="pmcid">PMC9961394</pub-id></element-citation><mixed-citation id="mc-CR155" publication-type="journal">Usero, L. et al. The combination of an mRNA immunogen, a TLR7 agonist and a PD1 blocking agent enhances in-vitro HIV T-cell immune responses. <italic toggle="yes">Vaccines</italic><bold>11</bold>, 286 (2023).<pub-id pub-id-type="pmid">36851164</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/vaccines11020286</pub-id><pub-id pub-id-type="pmcid">PMC9961394</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR156"><label>156.</label><citation-alternatives><element-citation id="ec-CR156" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leggat</surname><given-names>DJ</given-names></name><etal/></person-group><article-title>Vaccination induces HIV broadly neutralizing antibody precursors in humans</article-title><source>Science</source><year>2022</year><volume>378</volume><fpage>eadd6502</fpage><pub-id pub-id-type="doi">10.1126/science.add6502</pub-id><pub-id pub-id-type="pmid">36454825</pub-id><pub-id pub-id-type="pmcid">PMC11103259</pub-id></element-citation><mixed-citation id="mc-CR156" publication-type="journal">Leggat, D. J. et al. Vaccination induces HIV broadly neutralizing antibody precursors in humans. <italic toggle="yes">Science</italic><bold>378</bold>, eadd6502 (2022).<pub-id pub-id-type="pmid">36454825</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.add6502</pub-id><pub-id pub-id-type="pmcid">PMC11103259</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR157"><label>157.</label><citation-alternatives><element-citation id="ec-CR157" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tarr&#233;s-Freixas</surname><given-names>F</given-names></name><name name-style="western"><surname>Clotet</surname><given-names>B</given-names></name><name name-style="western"><surname>Carrillo</surname><given-names>J</given-names></name><name name-style="western"><surname>Blanco</surname><given-names>J</given-names></name></person-group><article-title>Nucleic acid vaccines encoding proteins and virus-like particles for HIV prevention</article-title><source>Vaccines</source><year>2024</year><volume>12</volume><fpage>298</fpage><pub-id pub-id-type="doi">10.3390/vaccines12030298</pub-id><pub-id pub-id-type="pmid">38543932</pub-id><pub-id pub-id-type="pmcid">PMC10975260</pub-id></element-citation><mixed-citation id="mc-CR157" publication-type="journal">Tarr&#233;s-Freixas, F., Clotet, B., Carrillo, J. &amp; Blanco, J. Nucleic acid vaccines encoding proteins and virus-like particles for HIV prevention. <italic toggle="yes">Vaccines</italic><bold>12</bold>, 298 (2024).<pub-id pub-id-type="pmid">38543932</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/vaccines12030298</pub-id><pub-id pub-id-type="pmcid">PMC10975260</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR158"><label>158.</label><citation-alternatives><element-citation id="ec-CR158" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>P</given-names></name><etal/></person-group><article-title>A multiclade env&#8211;gag VLP mRNA vaccine elicits tier-2 HIV-1-neutralizing antibodies and reduces the risk of heterologous SHIV infection in macaques</article-title><source>Nat. Med.</source><year>2021</year><volume>27</volume><fpage>2234</fpage><lpage>2245</lpage><pub-id pub-id-type="doi">10.1038/s41591-021-01574-5</pub-id><pub-id pub-id-type="pmid">34887575</pub-id></element-citation><mixed-citation id="mc-CR158" publication-type="journal">Zhang, P. et al. A multiclade env&#8211;gag VLP mRNA vaccine elicits tier-2 HIV-1-neutralizing antibodies and reduces the risk of heterologous SHIV infection in macaques. <italic toggle="yes">Nat. Med.</italic><bold>27</bold>, 2234&#8211;2245 (2021).<pub-id pub-id-type="pmid">34887575</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-021-01574-5</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR159"><label>159.</label><citation-alternatives><element-citation id="ec-CR159" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mandal</surname><given-names>S</given-names></name><etal/></person-group><article-title>A long-term stable cold-chain-friendly HIV mRNA vaccine encoding multi-epitope viral protease cleavage site immunogens inducing immunogen-specific protective T cell immunity</article-title><source>Emerg. Microbes Infect.</source><year>2024</year><volume>13</volume><fpage>2377606</fpage><pub-id pub-id-type="doi">10.1080/22221751.2024.2377606</pub-id><pub-id pub-id-type="pmid">38979723</pub-id><pub-id pub-id-type="pmcid">PMC11259082</pub-id></element-citation><mixed-citation id="mc-CR159" publication-type="journal">Mandal, S. et al. A long-term stable cold-chain-friendly HIV mRNA vaccine encoding multi-epitope viral protease cleavage site immunogens inducing immunogen-specific protective T cell immunity. <italic toggle="yes">Emerg. Microbes Infect.</italic><bold>13</bold>, 2377606 (2024).<pub-id pub-id-type="pmid">38979723</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/22221751.2024.2377606</pub-id><pub-id pub-id-type="pmcid">PMC11259082</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR160"><label>160.</label><citation-alternatives><element-citation id="ec-CR160" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Esteban</surname><given-names>I</given-names></name><etal/></person-group><article-title>In the Era of mRNA vaccines, is there any hope for HIV functional cure?</article-title><source>Viruses</source><year>2021</year><volume>13</volume><fpage>501</fpage><pub-id pub-id-type="doi">10.3390/v13030501</pub-id><pub-id pub-id-type="pmid">33803790</pub-id><pub-id pub-id-type="pmcid">PMC8003302</pub-id></element-citation><mixed-citation id="mc-CR160" publication-type="journal">Esteban, I. et al. In the Era of mRNA vaccines, is there any hope for HIV functional cure? <italic toggle="yes">Viruses</italic><bold>13</bold>, 501 (2021).<pub-id pub-id-type="pmid">33803790</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/v13030501</pub-id><pub-id pub-id-type="pmcid">PMC8003302</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR161"><label>161.</label><citation-alternatives><element-citation id="ec-CR161" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Morris</surname><given-names>L</given-names></name></person-group><article-title>mRNA vaccines offer hope for HIV</article-title><source>Nat. Med.</source><year>2021</year><volume>27</volume><fpage>2082</fpage><lpage>2084</lpage><pub-id pub-id-type="doi">10.1038/s41591-021-01602-4</pub-id><pub-id pub-id-type="pmid">34887576</pub-id></element-citation><mixed-citation id="mc-CR161" publication-type="journal">Morris, L. mRNA vaccines offer hope for HIV. <italic toggle="yes">Nat. Med.</italic><bold>27</bold>, 2082&#8211;2084 (2021).<pub-id pub-id-type="pmid">34887576</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-021-01602-4</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR162"><label>162.</label><citation-alternatives><element-citation id="ec-CR162" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>F</given-names></name><name name-style="western"><surname>Qin</surname><given-names>M</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H</given-names></name><name name-style="western"><surname>Sun</surname><given-names>X</given-names></name></person-group><article-title>Nanovaccines to combat virus-related diseases</article-title><source>Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol.</source><year>2023</year><volume>15</volume><fpage>e1857</fpage><pub-id pub-id-type="doi">10.1002/wnan.1857</pub-id><pub-id pub-id-type="pmid">36184873</pub-id></element-citation><mixed-citation id="mc-CR162" publication-type="journal">Wu, F., Qin, M., Wang, H. &amp; Sun, X. Nanovaccines to combat virus-related diseases. <italic toggle="yes">Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol.</italic><bold>15</bold>, e1857 (2023).<pub-id pub-id-type="pmid">36184873</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/wnan.1857</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR163"><label>163.</label><citation-alternatives><element-citation id="ec-CR163" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Crunkhorn</surname><given-names>S</given-names></name></person-group><article-title>Monkeypox mRNA vaccine protects mice and macaques</article-title><source>Nat. Rev. Drug Discov.</source><year>2024</year><volume>23</volume><fpage>251</fpage><pub-id pub-id-type="doi">10.1038/d41573-024-00038-y</pub-id><pub-id pub-id-type="pmid">38467772</pub-id></element-citation><mixed-citation id="mc-CR163" publication-type="journal">Crunkhorn, S. Monkeypox mRNA vaccine protects mice and macaques. <italic toggle="yes">Nat. Rev. Drug Discov.</italic><bold>23</bold>, 251 (2024).<pub-id pub-id-type="pmid">38467772</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/d41573-024-00038-y</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR164"><label>164.</label><citation-alternatives><element-citation id="ec-CR164" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shah</surname><given-names>M</given-names></name><etal/></person-group><article-title>Deciphering the immunogenicity of monkeypox proteins for designing the potential mRNA vaccine</article-title><source>ACS Omega</source><year>2023</year><volume>8</volume><fpage>43341</fpage><lpage>43355</lpage><pub-id pub-id-type="doi">10.1021/acsomega.3c07866</pub-id><pub-id pub-id-type="pmid">38024731</pub-id><pub-id pub-id-type="pmcid">PMC10652822</pub-id></element-citation><mixed-citation id="mc-CR164" publication-type="journal">Shah, M. et al. Deciphering the immunogenicity of monkeypox proteins for designing the potential mRNA vaccine. <italic toggle="yes">ACS Omega</italic><bold>8</bold>, 43341&#8211;43355 (2023).<pub-id pub-id-type="pmid">38024731</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acsomega.3c07866</pub-id><pub-id pub-id-type="pmcid">PMC10652822</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR165"><label>165.</label><citation-alternatives><element-citation id="ec-CR165" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Monkeypox virus quadrivalent mRNA vaccine induces immune response and protects against vaccinia virus</article-title><source>Signal Transduct. Target. Ther.</source><year>2023</year><volume>8</volume><fpage>172</fpage><pub-id pub-id-type="doi">10.1038/s41392-023-01432-5</pub-id><pub-id pub-id-type="pmid">37117161</pub-id><pub-id pub-id-type="pmcid">PMC10144886</pub-id></element-citation><mixed-citation id="mc-CR165" publication-type="journal">Sang, Y. et al. Monkeypox virus quadrivalent mRNA vaccine induces immune response and protects against vaccinia virus. <italic toggle="yes">Signal Transduct. Target. Ther.</italic><bold>8</bold>, 172 (2023).<pub-id pub-id-type="pmid">37117161</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41392-023-01432-5</pub-id><pub-id pub-id-type="pmcid">PMC10144886</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR166"><label>166.</label><citation-alternatives><element-citation id="ec-CR166" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hou</surname><given-names>F</given-names></name><etal/></person-group><article-title>mRNA vaccines encoding fusion proteins of monkeypox virus antigens protect mice from vaccinia virus challenge</article-title><source>Nat. Commun.</source><year>2023</year><volume>14</volume><fpage>5925</fpage><pub-id pub-id-type="doi">10.1038/s41467-023-41628-5</pub-id><pub-id pub-id-type="pmid">37739969</pub-id><pub-id pub-id-type="pmcid">PMC10516993</pub-id></element-citation><mixed-citation id="mc-CR166" publication-type="journal">Hou, F. et al. mRNA vaccines encoding fusion proteins of monkeypox virus antigens protect mice from vaccinia virus challenge. <italic toggle="yes">Nat. Commun.</italic><bold>14</bold>, 5925 (2023).<pub-id pub-id-type="pmid">37739969</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-023-41628-5</pub-id><pub-id pub-id-type="pmcid">PMC10516993</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR167"><label>167.</label><citation-alternatives><element-citation id="ec-CR167" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zuiani</surname><given-names>A</given-names></name><etal/></person-group><article-title>A multivalent mRNA monkeypox virus vaccine (BNT166) protects mice and macaques from orthopoxvirus disease</article-title><source>Cell</source><year>2024</year><volume>187</volume><fpage>1363</fpage><lpage>1373</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2024.01.017</pub-id><pub-id pub-id-type="pmid">38366591</pub-id></element-citation><mixed-citation id="mc-CR167" publication-type="journal">Zuiani, A. et al. A multivalent mRNA monkeypox virus vaccine (BNT166) protects mice and macaques from orthopoxvirus disease. <italic toggle="yes">Cell</italic><bold>187</bold>, 1363&#8211;1373 (2024).<pub-id pub-id-type="pmid">38366591</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2024.01.017</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR168"><label>168.</label><citation-alternatives><element-citation id="ec-CR168" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tian</surname><given-names>Y</given-names></name><etal/></person-group><article-title>An MPXV mRNA-LNP vaccine candidate elicits protective immune responses against monkeypox virus</article-title><source>Chin. Chem. Lett.</source><year>2024</year><volume>35</volume><fpage>109270</fpage><pub-id pub-id-type="doi">10.1016/j.cclet.2023.109270</pub-id></element-citation><mixed-citation id="mc-CR168" publication-type="journal">Tian, Y. et al. An MPXV mRNA-LNP vaccine candidate elicits protective immune responses against monkeypox virus. <italic toggle="yes">Chin. Chem. Lett.</italic><bold>35</bold>, 109270 (2024).</mixed-citation></citation-alternatives></ref><ref id="CR169"><label>169.</label><citation-alternatives><element-citation id="ec-CR169" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Su</surname><given-names>C</given-names></name><etal/></person-group><article-title>A quadrivalent mRNA immunization elicits potent immune responses against multiple orthopoxviral antigens and neutralization of monkeypox virus in rodent models</article-title><source>Vaccines</source><year>2024</year><volume>12</volume><fpage>385</fpage><pub-id pub-id-type="doi">10.3390/vaccines12040385</pub-id><pub-id pub-id-type="pmid">38675767</pub-id><pub-id pub-id-type="pmcid">PMC11053415</pub-id></element-citation><mixed-citation id="mc-CR169" publication-type="journal">Su, C. et al. A quadrivalent mRNA immunization elicits potent immune responses against multiple orthopoxviral antigens and neutralization of monkeypox virus in rodent models. <italic toggle="yes">Vaccines</italic><bold>12</bold>, 385 (2024).<pub-id pub-id-type="pmid">38675767</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/vaccines12040385</pub-id><pub-id pub-id-type="pmcid">PMC11053415</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR170"><label>170.</label><citation-alternatives><element-citation id="ec-CR170" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tadic</surname><given-names>S</given-names></name><name name-style="western"><surname>Mart&#237;nez</surname><given-names>A</given-names></name></person-group><article-title>Nucleic acid cancer vaccines targeting tumor related angiogenesis. Could mRNA vaccines constitute a game changer?</article-title><source>Front. Immunol.</source><year>2024</year><volume>15</volume><fpage>1433185</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2024.1433185</pub-id><pub-id pub-id-type="pmid">39081320</pub-id><pub-id pub-id-type="pmcid">PMC11286457</pub-id></element-citation><mixed-citation id="mc-CR170" publication-type="journal">Tadic, S. &amp; Mart&#237;nez, A. Nucleic acid cancer vaccines targeting tumor related angiogenesis. Could mRNA vaccines constitute a game changer? <italic toggle="yes">Front. Immunol.</italic><bold>15</bold>, 1433185 (2024).<pub-id pub-id-type="pmid">39081320</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2024.1433185</pub-id><pub-id pub-id-type="pmcid">PMC11286457</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR171"><label>171.</label><citation-alternatives><element-citation id="ec-CR171" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Conry</surname><given-names>RM</given-names></name><etal/></person-group><article-title>Characterization of a messenger RNA polynucleotide vaccine vector</article-title><source>Cancer Res</source><year>1995</year><volume>55</volume><fpage>1397</fpage><lpage>1400</lpage><pub-id pub-id-type="pmid">7882341</pub-id></element-citation><mixed-citation id="mc-CR171" publication-type="journal">Conry, R. M. et al. Characterization of a messenger RNA polynucleotide vaccine vector. <italic toggle="yes">Cancer Res</italic><bold>55</bold>, 1397&#8211;1400 (1995).<pub-id pub-id-type="pmid">7882341</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR172"><label>172.</label><citation-alternatives><element-citation id="ec-CR172" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sobhani</surname><given-names>N</given-names></name><etal/></person-group><article-title>Therapeutic cancer vaccines: from biological mechanisms and engineering to ongoing clinical trials</article-title><source>Cancer Treat. Rev.</source><year>2022</year><volume>109</volume><fpage>102429</fpage><pub-id pub-id-type="doi">10.1016/j.ctrv.2022.102429</pub-id><pub-id pub-id-type="pmid">35759856</pub-id><pub-id pub-id-type="pmcid">PMC9217071</pub-id></element-citation><mixed-citation id="mc-CR172" publication-type="journal">Sobhani, N. et al. Therapeutic cancer vaccines: from biological mechanisms and engineering to ongoing clinical trials. <italic toggle="yes">Cancer Treat. Rev.</italic><bold>109</bold>, 102429 (2022).<pub-id pub-id-type="pmid">35759856</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ctrv.2022.102429</pub-id><pub-id pub-id-type="pmcid">PMC9217071</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR173"><label>173.</label><citation-alternatives><element-citation id="ec-CR173" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yuan</surname><given-names>Y</given-names></name><name name-style="western"><surname>Gao</surname><given-names>F</given-names></name><name name-style="western"><surname>Chang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Q</given-names></name><name name-style="western"><surname>He</surname><given-names>X</given-names></name></person-group><article-title>Advances of mRNA vaccine in tumor: a maze of opportunities and challenges</article-title><source>Biomark. Res.</source><year>2023</year><volume>11</volume><fpage>6</fpage><pub-id pub-id-type="doi">10.1186/s40364-023-00449-w</pub-id><pub-id pub-id-type="pmid">36650562</pub-id><pub-id pub-id-type="pmcid">PMC9845107</pub-id></element-citation><mixed-citation id="mc-CR173" publication-type="journal">Yuan, Y., Gao, F., Chang, Y., Zhao, Q. &amp; He, X. Advances of mRNA vaccine in tumor: a maze of opportunities and challenges. <italic toggle="yes">Biomark. Res.</italic><bold>11</bold>, 6 (2023).<pub-id pub-id-type="pmid">36650562</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s40364-023-00449-w</pub-id><pub-id pub-id-type="pmcid">PMC9845107</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR174"><label>174.</label><citation-alternatives><element-citation id="ec-CR174" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Loquai</surname><given-names>C</given-names></name><etal/></person-group><article-title>549 An RNA-lipoplex (RNA-LPX) vaccine demonstrates strong immunogenicity and promising clinical activity in a phase I trial in cutaneous melanoma patients with no evidence of disease at trial inclusion</article-title><source>J. Immunother. Cancer</source><year>2021</year><volume>9</volume><fpage>A579</fpage></element-citation><mixed-citation id="mc-CR174" publication-type="journal">Loquai, C. et al. 549 An RNA-lipoplex (RNA-LPX) vaccine demonstrates strong immunogenicity and promising clinical activity in a phase I trial in cutaneous melanoma patients with no evidence of disease at trial inclusion. <italic toggle="yes">J. Immunother. Cancer</italic><bold>9</bold>, A579 (2021).</mixed-citation></citation-alternatives></ref><ref id="CR175"><label>175.</label><citation-alternatives><element-citation id="ec-CR175" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sahin</surname><given-names>U</given-names></name><etal/></person-group><article-title>An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma</article-title><source>Nature</source><year>2020</year><volume>585</volume><fpage>107</fpage><lpage>112</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2537-9</pub-id><pub-id pub-id-type="pmid">32728218</pub-id></element-citation><mixed-citation id="mc-CR175" publication-type="journal">Sahin, U. et al. An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma. <italic toggle="yes">Nature</italic><bold>585</bold>, 107&#8211;112 (2020).<pub-id pub-id-type="pmid">32728218</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-020-2537-9</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR176"><label>176.</label><citation-alternatives><element-citation id="ec-CR176" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yao</surname><given-names>R</given-names></name><name name-style="western"><surname>Xie</surname><given-names>C</given-names></name><name name-style="western"><surname>Xia</surname><given-names>X</given-names></name></person-group><article-title>Recent progress in mRNA cancer vaccines</article-title><source>Hum. Vaccin Immunother.</source><year>2024</year><volume>20</volume><fpage>2307187</fpage><pub-id pub-id-type="doi">10.1080/21645515.2024.2307187</pub-id><pub-id pub-id-type="pmid">38282471</pub-id><pub-id pub-id-type="pmcid">PMC10826636</pub-id></element-citation><mixed-citation id="mc-CR176" publication-type="journal">Yao, R., Xie, C. &amp; Xia, X. Recent progress in mRNA cancer vaccines. <italic toggle="yes">Hum. Vaccin Immunother.</italic><bold>20</bold>, 2307187 (2024).<pub-id pub-id-type="pmid">38282471</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/21645515.2024.2307187</pub-id><pub-id pub-id-type="pmcid">PMC10826636</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR177"><label>177.</label><citation-alternatives><element-citation id="ec-CR177" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nierengarten</surname><given-names>MB</given-names></name></person-group><article-title>Messenger RNA vaccine advances provide treatment possibilities for cancer</article-title><source>Cancer</source><year>2022</year><volume>128</volume><fpage>213</fpage><lpage>214</lpage><pub-id pub-id-type="doi">10.1002/cncr.34068</pub-id><pub-id pub-id-type="pmid">34990010</pub-id></element-citation><mixed-citation id="mc-CR177" publication-type="journal">Nierengarten, M. B. Messenger RNA vaccine advances provide treatment possibilities for cancer. <italic toggle="yes">Cancer</italic><bold>128</bold>, 213&#8211;214 (2022).<pub-id pub-id-type="pmid">34990010</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cncr.34068</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR178"><label>178.</label><citation-alternatives><element-citation id="ec-CR178" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sayour</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Boczkowski</surname><given-names>D</given-names></name><name name-style="western"><surname>Mitchell</surname><given-names>DA</given-names></name><name name-style="western"><surname>Nair</surname><given-names>SK</given-names></name></person-group><article-title>Cancer mRNA vaccines: clinical advances and future opportunities</article-title><source>Nat. Rev. Clin. Oncol.</source><year>2024</year><volume>21</volume><fpage>489</fpage><lpage>500</lpage><pub-id pub-id-type="doi">10.1038/s41571-024-00902-1</pub-id><pub-id pub-id-type="pmid">38760500</pub-id></element-citation><mixed-citation id="mc-CR178" publication-type="journal">Sayour, E. J., Boczkowski, D., Mitchell, D. A. &amp; Nair, S. K. Cancer mRNA vaccines: clinical advances and future opportunities. <italic toggle="yes">Nat. Rev. Clin. Oncol.</italic><bold>21</bold>, 489&#8211;500 (2024).<pub-id pub-id-type="pmid">38760500</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41571-024-00902-1</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR179"><label>179.</label><citation-alternatives><element-citation id="ec-CR179" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Trivedi</surname><given-names>V</given-names></name><etal/></person-group><article-title>mRNA-based precision targeting of neoantigens and tumor-associated antigens in malignant brain tumors</article-title><source>Genome Med.</source><year>2024</year><volume>16</volume><fpage>17</fpage><pub-id pub-id-type="doi">10.1186/s13073-024-01281-z</pub-id><pub-id pub-id-type="pmid">38268001</pub-id><pub-id pub-id-type="pmcid">PMC10809449</pub-id></element-citation><mixed-citation id="mc-CR179" publication-type="journal">Trivedi, V. et al. mRNA-based precision targeting of neoantigens and tumor-associated antigens in malignant brain tumors. <italic toggle="yes">Genome Med.</italic><bold>16</bold>, 17 (2024).<pub-id pub-id-type="pmid">38268001</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13073-024-01281-z</pub-id><pub-id pub-id-type="pmcid">PMC10809449</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR180"><label>180.</label><citation-alternatives><element-citation id="ec-CR180" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ben-Akiva</surname><given-names>E</given-names></name><etal/></person-group><article-title>Biodegradable lipophilic polymeric mRNA nanoparticles for ligand-free targeting of splenic dendritic cells for cancer vaccination</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2023</year><volume>120</volume><fpage>e2301606120</fpage><pub-id pub-id-type="doi">10.1073/pnas.2301606120</pub-id><pub-id pub-id-type="pmid">37339211</pub-id><pub-id pub-id-type="pmcid">PMC10293809</pub-id></element-citation><mixed-citation id="mc-CR180" publication-type="journal">Ben-Akiva, E. et al. Biodegradable lipophilic polymeric mRNA nanoparticles for ligand-free targeting of splenic dendritic cells for cancer vaccination. <italic toggle="yes">Proc. Natl. Acad. Sci. USA</italic><bold>120</bold>, e2301606120 (2023).<pub-id pub-id-type="pmid">37339211</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.2301606120</pub-id><pub-id pub-id-type="pmcid">PMC10293809</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR181"><label>181.</label><citation-alternatives><element-citation id="ec-CR181" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yan</surname><given-names>Q</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>Z</given-names></name><name name-style="western"><surname>Fan</surname><given-names>C</given-names></name><name name-style="western"><surname>Xiong</surname><given-names>W</given-names></name></person-group><article-title>Advances and prospects of mRNA vaccines in cancer immunotherapy</article-title><source>Biochim. Biophys. Acta Rev. Cancer</source><year>2024</year><volume>1879</volume><fpage>189068</fpage><pub-id pub-id-type="doi">10.1016/j.bbcan.2023.189068</pub-id><pub-id pub-id-type="pmid">38171406</pub-id></element-citation><mixed-citation id="mc-CR181" publication-type="journal">Liu, Y., Yan, Q., Zeng, Z., Fan, C. &amp; Xiong, W. Advances and prospects of mRNA vaccines in cancer immunotherapy. <italic toggle="yes">Biochim. Biophys. Acta Rev. Cancer</italic><bold>1879</bold>, 189068 (2024).<pub-id pub-id-type="pmid">38171406</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbcan.2023.189068</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR182"><label>182.</label><citation-alternatives><element-citation id="ec-CR182" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tian</surname><given-names>Y</given-names></name><name name-style="western"><surname>Hu</surname><given-names>D</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yang</surname><given-names>L</given-names></name></person-group><article-title>Development of therapeutic vaccines for the treatment of diseases</article-title><source>Mol. Biomed.</source><year>2022</year><volume>3</volume><fpage>40</fpage><pub-id pub-id-type="doi">10.1186/s43556-022-00098-9</pub-id><pub-id pub-id-type="pmid">36477638</pub-id><pub-id pub-id-type="pmcid">PMC9729511</pub-id></element-citation><mixed-citation id="mc-CR182" publication-type="journal">Tian, Y., Hu, D., Li, Y. &amp; Yang, L. Development of therapeutic vaccines for the treatment of diseases. <italic toggle="yes">Mol. Biomed.</italic><bold>3</bold>, 40 (2022).<pub-id pub-id-type="pmid">36477638</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s43556-022-00098-9</pub-id><pub-id pub-id-type="pmcid">PMC9729511</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR183"><label>183.</label><citation-alternatives><element-citation id="ec-CR183" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>F</given-names></name><etal/></person-group><article-title>Advancing personalized medicine in brain cancer: exploring the role of mRNA vaccines</article-title><source>J. Transl. Med.</source><year>2023</year><volume>21</volume><fpage>830</fpage><pub-id pub-id-type="doi">10.1186/s12967-023-04724-0</pub-id><pub-id pub-id-type="pmid">37978542</pub-id><pub-id pub-id-type="pmcid">PMC10656921</pub-id></element-citation><mixed-citation id="mc-CR183" publication-type="journal">Lin, F. et al. Advancing personalized medicine in brain cancer: exploring the role of mRNA vaccines. <italic toggle="yes">J. Transl. Med.</italic><bold>21</bold>, 830 (2023).<pub-id pub-id-type="pmid">37978542</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12967-023-04724-0</pub-id><pub-id pub-id-type="pmcid">PMC10656921</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR184"><label>184.</label><mixed-citation publication-type="other">Search for: mRNA, Phase: 3, 4 | List Results | ClinicalTrials.gov. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/search?intr=mRNA&amp;aggFilters=phase:3%204">https://clinicaltrials.gov/search?intr=mRNA&amp;aggFilters=phase:3%204</ext-link> (2024).</mixed-citation></ref><ref id="CR185"><label>185.</label><citation-alternatives><element-citation id="ec-CR185" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bergstrom</surname><given-names>C</given-names></name><name name-style="western"><surname>Fischer</surname><given-names>NO</given-names></name><name name-style="western"><surname>Kubicek-Sutherland</surname><given-names>JZ</given-names></name><name name-style="western"><surname>Stromberg</surname><given-names>ZR</given-names></name></person-group><article-title>mRNA vaccine platforms to prevent bacterial infections</article-title><source>Trends Mol. Med.</source><year>2024</year><volume>30</volume><fpage>524</fpage><lpage>526</lpage><pub-id pub-id-type="doi">10.1016/j.molmed.2024.02.013</pub-id><pub-id pub-id-type="pmid">38485647</pub-id></element-citation><mixed-citation id="mc-CR185" publication-type="journal">Bergstrom, C., Fischer, N. O., Kubicek-Sutherland, J. Z. &amp; Stromberg, Z. R. mRNA vaccine platforms to prevent bacterial infections. <italic toggle="yes">Trends Mol. Med.</italic><bold>30</bold>, 524&#8211;526 (2024).<pub-id pub-id-type="pmid">38485647</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.molmed.2024.02.013</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR186"><label>186.</label><citation-alternatives><element-citation id="ec-CR186" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maruggi</surname><given-names>G</given-names></name><etal/></person-group><article-title>Immunogenicity and protective efficacy induced by self-amplifying mRNA vaccines encoding bacterial antigens</article-title><source>Vaccine</source><year>2017</year><volume>35</volume><fpage>361</fpage><lpage>368</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2016.11.040</pub-id><pub-id pub-id-type="pmid">27939014</pub-id></element-citation><mixed-citation id="mc-CR186" publication-type="journal">Maruggi, G. et al. Immunogenicity and protective efficacy induced by self-amplifying mRNA vaccines encoding bacterial antigens. <italic toggle="yes">Vaccine</italic><bold>35</bold>, 361&#8211;368 (2017).<pub-id pub-id-type="pmid">27939014</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2016.11.040</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR187"><label>187.</label><citation-alternatives><element-citation id="ec-CR187" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pine</surname><given-names>M</given-names></name><etal/></person-group><article-title>Development of an mRNA-lipid nanoparticle vaccine against Lyme disease</article-title><source>Mol. Ther.</source><year>2023</year><volume>31</volume><fpage>2702</fpage><lpage>2714</lpage><pub-id pub-id-type="doi">10.1016/j.ymthe.2023.07.022</pub-id><pub-id pub-id-type="pmid">37533256</pub-id><pub-id pub-id-type="pmcid">PMC10492027</pub-id></element-citation><mixed-citation id="mc-CR187" publication-type="journal">Pine, M. et al. Development of an mRNA-lipid nanoparticle vaccine against Lyme disease. <italic toggle="yes">Mol. Ther.</italic><bold>31</bold>, 2702&#8211;2714 (2023).<pub-id pub-id-type="pmid">37533256</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ymthe.2023.07.022</pub-id><pub-id pub-id-type="pmcid">PMC10492027</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR188"><label>188.</label><mixed-citation publication-type="other">ModernaTX, Inc. A phase 1/2, randomized, observer-blind, placebo-controlled, dose-ranging study to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and Monovalent mRNA-1982 (SR1) in parallel against Lyme disease in healthy participants 18 through 70 years of age. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/study/NCT05975099">https://clinicaltrials.gov/study/NCT05975099</ext-link> (2023).</mixed-citation></ref><ref id="CR189"><label>189.</label><citation-alternatives><element-citation id="ec-CR189" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Matarazzo</surname><given-names>L</given-names></name><name name-style="western"><surname>Bettencourt</surname><given-names>PJG</given-names></name></person-group><article-title>mRNA vaccines: a new opportunity for malaria, tuberculosis and HIV</article-title><source>Front. Immunol.</source><year>2023</year><volume>14</volume><fpage>1172691</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2023.1172691</pub-id><pub-id pub-id-type="pmid">37168860</pub-id><pub-id pub-id-type="pmcid">PMC10166207</pub-id></element-citation><mixed-citation id="mc-CR189" publication-type="journal">Matarazzo, L. &amp; Bettencourt, P. J. G. mRNA vaccines: a new opportunity for malaria, tuberculosis and HIV. <italic toggle="yes">Front. Immunol.</italic><bold>14</bold>, 1172691 (2023).<pub-id pub-id-type="pmid">37168860</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2023.1172691</pub-id><pub-id pub-id-type="pmcid">PMC10166207</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR190"><label>190.</label><citation-alternatives><element-citation id="ec-CR190" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>F</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>D</given-names></name></person-group><article-title>Recent advance in the development of tuberculosis vaccines in clinical trials and virus-like particle-based vaccine candidates</article-title><source>Front. Immunol.</source><year>2023</year><volume>14</volume><fpage>1238649</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2023.1238649</pub-id><pub-id pub-id-type="pmid">38022657</pub-id><pub-id pub-id-type="pmcid">PMC10652786</pub-id></element-citation><mixed-citation id="mc-CR190" publication-type="journal">Zhou, F. &amp; Zhang, D. Recent advance in the development of tuberculosis vaccines in clinical trials and virus-like particle-based vaccine candidates. <italic toggle="yes">Front. Immunol.</italic><bold>14</bold>, 1238649 (2023).<pub-id pub-id-type="pmid">38022657</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2023.1238649</pub-id><pub-id pub-id-type="pmcid">PMC10652786</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR191"><label>191.</label><citation-alternatives><element-citation id="ec-CR191" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fan</surname><given-names>X-Y</given-names></name><name name-style="western"><surname>Lowrie</surname><given-names>DB</given-names></name></person-group><article-title>Where are the RNA vaccines for TB?</article-title><source>Emerg. Microbes Infect.</source><year>2021</year><volume>10</volume><fpage>1217</fpage><lpage>1218</lpage><pub-id pub-id-type="doi">10.1080/22221751.2021.1935328</pub-id><pub-id pub-id-type="pmid">34036874</pub-id><pub-id pub-id-type="pmcid">PMC8216257</pub-id></element-citation><mixed-citation id="mc-CR191" publication-type="journal">Fan, X.-Y. &amp; Lowrie, D. B. Where are the RNA vaccines for TB? <italic toggle="yes">Emerg. Microbes Infect.</italic><bold>10</bold>, 1217&#8211;1218 (2021).<pub-id pub-id-type="pmid">34036874</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/22221751.2021.1935328</pub-id><pub-id pub-id-type="pmcid">PMC8216257</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR192"><label>192.</label><citation-alternatives><element-citation id="ec-CR192" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Larsen</surname><given-names>SE</given-names></name><etal/></person-group><article-title>An RNA-based vaccine platform for use against mycobacterium tuberculosis</article-title><source>Vaccines</source><year>2023</year><volume>11</volume><fpage>130</fpage><pub-id pub-id-type="doi">10.3390/vaccines11010130</pub-id><pub-id pub-id-type="pmid">36679975</pub-id><pub-id pub-id-type="pmcid">PMC9862644</pub-id></element-citation><mixed-citation id="mc-CR192" publication-type="journal">Larsen, S. E. et al. An RNA-based vaccine platform for use against mycobacterium tuberculosis. <italic toggle="yes">Vaccines</italic><bold>11</bold>, 130 (2023).<pub-id pub-id-type="pmid">36679975</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/vaccines11010130</pub-id><pub-id pub-id-type="pmcid">PMC9862644</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR193"><label>193.</label><citation-alternatives><element-citation id="ec-CR193" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>S</given-names></name><name name-style="western"><surname>Yang</surname><given-names>K</given-names></name><name name-style="western"><surname>Li</surname><given-names>R</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name></person-group><article-title>mRNA vaccine era&#8212;mechanisms, drug platform and clinical prospection</article-title><source>Int. J. Mol. Sci.</source><year>2020</year><volume>21</volume><fpage>6582</fpage><pub-id pub-id-type="doi">10.3390/ijms21186582</pub-id><pub-id pub-id-type="pmid">32916818</pub-id><pub-id pub-id-type="pmcid">PMC7554980</pub-id></element-citation><mixed-citation id="mc-CR193" publication-type="journal">Xu, S., Yang, K., Li, R. &amp; Zhang, L. mRNA vaccine era&#8212;mechanisms, drug platform and clinical prospection. <italic toggle="yes">Int. J. Mol. Sci.</italic><bold>21</bold>, 6582 (2020).<pub-id pub-id-type="pmid">32916818</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms21186582</pub-id><pub-id pub-id-type="pmcid">PMC7554980</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR194"><label>194.</label><citation-alternatives><element-citation id="ec-CR194" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Meulewaeter</surname><given-names>S</given-names></name><etal/></person-group><article-title>Alpha-galactosylceramide improves the potency of mRNA LNP vaccines against cancer and intracellular bacteria</article-title><source>J. Control Release</source><year>2024</year><volume>370</volume><fpage>379</fpage><lpage>391</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2024.04.052</pub-id><pub-id pub-id-type="pmid">38697317</pub-id></element-citation><mixed-citation id="mc-CR194" publication-type="journal">Meulewaeter, S. et al. Alpha-galactosylceramide improves the potency of mRNA LNP vaccines against cancer and intracellular bacteria. <italic toggle="yes">J. Control Release</italic><bold>370</bold>, 379&#8211;391 (2024).<pub-id pub-id-type="pmid">38697317</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jconrel.2024.04.052</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR195"><label>195.</label><citation-alternatives><element-citation id="ec-CR195" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Singh</surname><given-names>B</given-names></name><etal/></person-group><article-title>Host-directed therapies for parasitic diseases</article-title><source>Future Med. Chem.</source><year>2019</year><volume>11</volume><fpage>1999</fpage><lpage>2018</lpage><pub-id pub-id-type="doi">10.4155/fmc-2018-0439</pub-id><pub-id pub-id-type="pmid">31390889</pub-id></element-citation><mixed-citation id="mc-CR195" publication-type="journal">Singh, B. et al. Host-directed therapies for parasitic diseases. <italic toggle="yes">Future Med. Chem.</italic><bold>11</bold>, 1999&#8211;2018 (2019).<pub-id pub-id-type="pmid">31390889</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4155/fmc-2018-0439</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR196"><label>196.</label><citation-alternatives><element-citation id="ec-CR196" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>AlGabbani</surname><given-names>Q</given-names></name></person-group><article-title>Nanotechnology: a promising strategy for the control of parasitic infections</article-title><source>Exp. Parasitol.</source><year>2023</year><volume>250</volume><fpage>108548</fpage><pub-id pub-id-type="doi">10.1016/j.exppara.2023.108548</pub-id><pub-id pub-id-type="pmid">37196702</pub-id></element-citation><mixed-citation id="mc-CR196" publication-type="journal">AlGabbani, Q. Nanotechnology: a promising strategy for the control of parasitic infections. <italic toggle="yes">Exp. Parasitol.</italic><bold>250</bold>, 108548 (2023).<pub-id pub-id-type="pmid">37196702</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.exppara.2023.108548</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR197"><label>197.</label><citation-alternatives><element-citation id="ec-CR197" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>You</surname><given-names>H</given-names></name><etal/></person-group><article-title>The mRNA vaccine technology era and the future control of parasitic infections</article-title><source>Clin. Microbiol. Rev.</source><year>2023</year><volume>36</volume><fpage>e00241</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1128/cmr.00241-21</pub-id><pub-id pub-id-type="pmid">36625671</pub-id><pub-id pub-id-type="pmcid">PMC10035331</pub-id></element-citation><mixed-citation id="mc-CR197" publication-type="journal">You, H. et al. The mRNA vaccine technology era and the future control of parasitic infections. <italic toggle="yes">Clin. Microbiol. Rev.</italic><bold>36</bold>, e00241&#8211;21 (2023).<pub-id pub-id-type="pmid">36625671</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/cmr.00241-21</pub-id><pub-id pub-id-type="pmcid">PMC10035331</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR198"><label>198.</label><citation-alternatives><element-citation id="ec-CR198" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chuang</surname><given-names>Y-M</given-names></name><etal/></person-group><article-title>A mosquito AgTRIO mRNA vaccine contributes to immunity against malaria</article-title><source>NPJ Vaccines</source><year>2023</year><volume>8</volume><fpage>88</fpage><pub-id pub-id-type="doi">10.1038/s41541-023-00679-x</pub-id><pub-id pub-id-type="pmid">37286568</pub-id><pub-id pub-id-type="pmcid">PMC10244833</pub-id></element-citation><mixed-citation id="mc-CR198" publication-type="journal">Chuang, Y.-M. et al. A mosquito AgTRIO mRNA vaccine contributes to immunity against malaria. <italic toggle="yes">NPJ Vaccines</italic><bold>8</bold>, 88 (2023).<pub-id pub-id-type="pmid">37286568</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41541-023-00679-x</pub-id><pub-id pub-id-type="pmcid">PMC10244833</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR199"><label>199.</label><citation-alternatives><element-citation id="ec-CR199" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hassert</surname><given-names>M</given-names></name><name name-style="western"><surname>Harty</surname><given-names>JT</given-names></name></person-group><article-title>Alt-RNAtive vaccines elicit anti-malarial TRM cells</article-title><source>Nat. Immunol.</source><year>2023</year><volume>24</volume><fpage>1397</fpage><lpage>1398</lpage><pub-id pub-id-type="doi">10.1038/s41590-023-01594-y</pub-id><pub-id pub-id-type="pmid">37580607</pub-id></element-citation><mixed-citation id="mc-CR199" publication-type="journal">Hassert, M. &amp; Harty, J. T. Alt-RNAtive vaccines elicit anti-malarial TRM cells. <italic toggle="yes">Nat. Immunol.</italic><bold>24</bold>, 1397&#8211;1398 (2023).<pub-id pub-id-type="pmid">37580607</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41590-023-01594-y</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR200"><label>200.</label><citation-alternatives><element-citation id="ec-CR200" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Waghela</surname><given-names>IN</given-names></name><etal/></person-group><article-title>Exploring in vitro expression and immune potency in mice using mRNA encoding the <italic toggle="yes">Plasmodium falciparum</italic> malaria antigen</article-title><source>CelTOS. Front. Immunol.</source><year>2022</year><volume>13</volume><fpage>1026052</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2022.1026052</pub-id><pub-id pub-id-type="pmid">36591298</pub-id><pub-id pub-id-type="pmcid">PMC9798330</pub-id></element-citation><mixed-citation id="mc-CR200" publication-type="journal">Waghela, I. N. et al. Exploring in vitro expression and immune potency in mice using mRNA encoding the <italic toggle="yes">Plasmodium falciparum</italic> malaria antigen. <italic toggle="yes">CelTOS. Front. Immunol.</italic><bold>13</bold>, 1026052 (2022).<pub-id pub-id-type="pmid">36591298</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2022.1026052</pub-id><pub-id pub-id-type="pmcid">PMC9798330</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR201"><label>201.</label><citation-alternatives><element-citation id="ec-CR201" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tsoumani</surname><given-names>ME</given-names></name><name name-style="western"><surname>Voyiatzaki</surname><given-names>C</given-names></name><name name-style="western"><surname>Efstathiou</surname><given-names>A</given-names></name></person-group><article-title>Malaria vaccines: from the past towards the mRNA vaccine era</article-title><source>Vaccines</source><year>2023</year><volume>11</volume><fpage>1452</fpage><pub-id pub-id-type="doi">10.3390/vaccines11091452</pub-id><pub-id pub-id-type="pmid">37766129</pub-id><pub-id pub-id-type="pmcid">PMC10536368</pub-id></element-citation><mixed-citation id="mc-CR201" publication-type="journal">Tsoumani, M. E., Voyiatzaki, C. &amp; Efstathiou, A. Malaria vaccines: from the past towards the mRNA vaccine era. <italic toggle="yes">Vaccines</italic><bold>11</bold>, 1452 (2023).<pub-id pub-id-type="pmid">37766129</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/vaccines11091452</pub-id><pub-id pub-id-type="pmcid">PMC10536368</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR202"><label>202.</label><citation-alternatives><element-citation id="ec-CR202" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kunkeaw</surname><given-names>N</given-names></name><etal/></person-group><article-title>A Pvs25 mRNA vaccine induces complete and durable transmission-blocking immunity to Plasmodium vivax</article-title><source>NPJ Vaccines</source><year>2023</year><volume>8</volume><fpage>187</fpage><pub-id pub-id-type="doi">10.1038/s41541-023-00786-9</pub-id><pub-id pub-id-type="pmid">38092803</pub-id><pub-id pub-id-type="pmcid">PMC10719277</pub-id></element-citation><mixed-citation id="mc-CR202" publication-type="journal">Kunkeaw, N. et al. A Pvs25 mRNA vaccine induces complete and durable transmission-blocking immunity to Plasmodium vivax. <italic toggle="yes">NPJ Vaccines</italic><bold>8</bold>, 187 (2023).<pub-id pub-id-type="pmid">38092803</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41541-023-00786-9</pub-id><pub-id pub-id-type="pmcid">PMC10719277</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR203"><label>203.</label><citation-alternatives><element-citation id="ec-CR203" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Makoni</surname><given-names>M</given-names></name></person-group><article-title>mRNA vaccine against malaria effective in preclinical model</article-title><source>Lancet Microbe</source><year>2023</year><volume>4</volume><fpage>e970</fpage><pub-id pub-id-type="doi">10.1016/S2666-5247(23)00332-4</pub-id><pub-id pub-id-type="pmid">37865114</pub-id></element-citation><mixed-citation id="mc-CR203" publication-type="journal">Makoni, M. mRNA vaccine against malaria effective in preclinical model. <italic toggle="yes">Lancet Microbe</italic><bold>4</bold>, e970 (2023).<pub-id pub-id-type="pmid">37865114</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2666-5247(23)00332-4</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR204"><label>204.</label><citation-alternatives><element-citation id="ec-CR204" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ganley</surname><given-names>M</given-names></name><etal/></person-group><article-title>mRNA vaccine against malaria tailored for liver-resident memory T cells</article-title><source>Nat. Immunol.</source><year>2023</year><volume>24</volume><fpage>1487</fpage><lpage>1498</lpage><pub-id pub-id-type="doi">10.1038/s41590-023-01562-6</pub-id><pub-id pub-id-type="pmid">37474653</pub-id></element-citation><mixed-citation id="mc-CR204" publication-type="journal">Ganley, M. et al. mRNA vaccine against malaria tailored for liver-resident memory T cells. <italic toggle="yes">Nat. Immunol.</italic><bold>24</bold>, 1487&#8211;1498 (2023).<pub-id pub-id-type="pmid">37474653</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41590-023-01562-6</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR205"><label>205.</label><citation-alternatives><element-citation id="ec-CR205" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scaria</surname><given-names>PV</given-names></name><etal/></person-group><article-title>mRNA vaccines expressing malaria transmission-blocking antigens Pfs25 and Pfs230D1 induce a functional immune response</article-title><source>NPJ Vaccines</source><year>2024</year><volume>9</volume><fpage>9</fpage><pub-id pub-id-type="doi">10.1038/s41541-023-00783-y</pub-id><pub-id pub-id-type="pmid">38184666</pub-id><pub-id pub-id-type="pmcid">PMC10771442</pub-id></element-citation><mixed-citation id="mc-CR205" publication-type="journal">Scaria, P. V. et al. mRNA vaccines expressing malaria transmission-blocking antigens Pfs25 and Pfs230D1 induce a functional immune response. <italic toggle="yes">NPJ Vaccines</italic><bold>9</bold>, 9 (2024).<pub-id pub-id-type="pmid">38184666</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41541-023-00783-y</pub-id><pub-id pub-id-type="pmcid">PMC10771442</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR206"><label>206.</label><citation-alternatives><element-citation id="ec-CR206" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Versteeg</surname><given-names>L</given-names></name><name name-style="western"><surname>Almutairi</surname><given-names>MM</given-names></name><name name-style="western"><surname>Hotez</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Pollet</surname><given-names>J</given-names></name></person-group><article-title>Enlisting the mRNA vaccine platform to combat parasitic infections</article-title><source>Vaccines</source><year>2019</year><volume>7</volume><fpage>122</fpage><pub-id pub-id-type="doi">10.3390/vaccines7040122</pub-id><pub-id pub-id-type="pmid">31547081</pub-id><pub-id pub-id-type="pmcid">PMC6963228</pub-id></element-citation><mixed-citation id="mc-CR206" publication-type="journal">Versteeg, L., Almutairi, M. M., Hotez, P. J. &amp; Pollet, J. Enlisting the mRNA vaccine platform to combat parasitic infections. <italic toggle="yes">Vaccines</italic><bold>7</bold>, 122 (2019).<pub-id pub-id-type="pmid">31547081</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/vaccines7040122</pub-id><pub-id pub-id-type="pmcid">PMC6963228</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR207"><label>207.</label><citation-alternatives><element-citation id="ec-CR207" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Niazi</surname><given-names>SK</given-names></name></person-group><article-title>Anti-idiotypic mRNA vaccine to treat autoimmune disorders</article-title><source>Vaccines</source><year>2024</year><volume>12</volume><fpage>9</fpage><pub-id pub-id-type="doi">10.3390/vaccines12010009</pub-id><pub-id pub-id-type="pmcid">PMC10819008</pub-id><pub-id pub-id-type="pmid">38276668</pub-id></element-citation><mixed-citation id="mc-CR207" publication-type="journal">Niazi, S. K. Anti-idiotypic mRNA vaccine to treat autoimmune disorders. <italic toggle="yes">Vaccines</italic><bold>12</bold>, 9 (2024).<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/vaccines12010009</pub-id><pub-id pub-id-type="pmcid">PMC10819008</pub-id><pub-id pub-id-type="pmid">38276668</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR208"><label>208.</label><citation-alternatives><element-citation id="ec-CR208" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cao</surname><given-names>W</given-names></name><name name-style="western"><surname>Xia</surname><given-names>T</given-names></name></person-group><article-title>mRNA lipid nanoparticles induce immune tolerance to treat human diseases</article-title><source>Med. Rev.</source><year>2023</year><volume>3</volume><fpage>180</fpage><lpage>183</lpage><pub-id pub-id-type="doi">10.1515/mr-2023-0008</pub-id><pub-id pub-id-type="pmcid">PMC10471105</pub-id><pub-id pub-id-type="pmid">37724087</pub-id></element-citation><mixed-citation id="mc-CR208" publication-type="journal">Cao, W. &amp; Xia, T. mRNA lipid nanoparticles induce immune tolerance to treat human diseases. <italic toggle="yes">Med. Rev.</italic><bold>3</bold>, 180&#8211;183 (2023).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1515/mr-2023-0008</pub-id><pub-id pub-id-type="pmcid">PMC10471105</pub-id><pub-id pub-id-type="pmid">37724087</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR209"><label>209.</label><citation-alternatives><element-citation id="ec-CR209" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pisetsky</surname><given-names>DS</given-names></name></person-group><article-title>Pathogenesis of autoimmune disease</article-title><source>Nat. Rev. Nephrol.</source><year>2023</year><volume>19</volume><fpage>509</fpage><lpage>524</lpage><pub-id pub-id-type="doi">10.1038/s41581-023-00720-1</pub-id><pub-id pub-id-type="pmid">37165096</pub-id><pub-id pub-id-type="pmcid">PMC10171171</pub-id></element-citation><mixed-citation id="mc-CR209" publication-type="journal">Pisetsky, D. S. Pathogenesis of autoimmune disease. <italic toggle="yes">Nat. Rev. Nephrol.</italic><bold>19</bold>, 509&#8211;524 (2023).<pub-id pub-id-type="pmid">37165096</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41581-023-00720-1</pub-id><pub-id pub-id-type="pmcid">PMC10171171</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR210"><label>210.</label><citation-alternatives><element-citation id="ec-CR210" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Krienke</surname><given-names>C</given-names></name><etal/></person-group><article-title>A noninflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis</article-title><source>Science</source><year>2021</year><volume>371</volume><fpage>145</fpage><lpage>153</lpage><pub-id pub-id-type="doi">10.1126/science.aay3638</pub-id><pub-id pub-id-type="pmid">33414215</pub-id></element-citation><mixed-citation id="mc-CR210" publication-type="journal">Krienke, C. et al. A noninflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis. <italic toggle="yes">Science</italic><bold>371</bold>, 145&#8211;153 (2021).<pub-id pub-id-type="pmid">33414215</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.aay3638</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR211"><label>211.</label><citation-alternatives><element-citation id="ec-CR211" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Herold</surname><given-names>KC</given-names></name><etal/></person-group><article-title>The immunology of type 1 diabetes</article-title><source>Nat. Rev. Immunol.</source><year>2024</year><volume>24</volume><fpage>435</fpage><lpage>451</lpage><pub-id pub-id-type="doi">10.1038/s41577-023-00985-4</pub-id><pub-id pub-id-type="pmid">38308004</pub-id><pub-id pub-id-type="pmcid">PMC7616056</pub-id></element-citation><mixed-citation id="mc-CR211" publication-type="journal">Herold, K. C. et al. The immunology of type 1 diabetes. <italic toggle="yes">Nat. Rev. Immunol.</italic><bold>24</bold>, 435&#8211;451 (2024).<pub-id pub-id-type="pmid">38308004</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41577-023-00985-4</pub-id><pub-id pub-id-type="pmcid">PMC7616056</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR212"><label>212.</label><citation-alternatives><element-citation id="ec-CR212" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Parayath</surname><given-names>NN</given-names></name><etal/></person-group><article-title>Genetic in situ engineering of myeloid regulatory cells controls inflammation in autoimmunity</article-title><source>J. Control Release</source><year>2021</year><volume>339</volume><fpage>553</fpage><lpage>561</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2021.08.040</pub-id><pub-id pub-id-type="pmid">34437913</pub-id><pub-id pub-id-type="pmcid">PMC8599636</pub-id></element-citation><mixed-citation id="mc-CR212" publication-type="journal">Parayath, N. N. et al. Genetic in situ engineering of myeloid regulatory cells controls inflammation in autoimmunity. <italic toggle="yes">J. Control Release</italic><bold>339</bold>, 553&#8211;561 (2021).<pub-id pub-id-type="pmid">34437913</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jconrel.2021.08.040</pub-id><pub-id pub-id-type="pmcid">PMC8599636</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR213"><label>213.</label><citation-alternatives><element-citation id="ec-CR213" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>A</given-names></name><name name-style="western"><surname>Xie</surname><given-names>F</given-names></name><name name-style="western"><surname>Abed</surname><given-names>OA</given-names></name><name name-style="western"><surname>Moon</surname><given-names>JJ</given-names></name></person-group><article-title>Vaccines for immune tolerance against autoimmune disease</article-title><source>Adv. Drug Deliv. Rev.</source><year>2023</year><volume>203</volume><fpage>115140</fpage><pub-id pub-id-type="doi">10.1016/j.addr.2023.115140</pub-id><pub-id pub-id-type="pmid">37980949</pub-id><pub-id pub-id-type="pmcid">PMC10757742</pub-id></element-citation><mixed-citation id="mc-CR213" publication-type="journal">Kim, A., Xie, F., Abed, O. A. &amp; Moon, J. J. Vaccines for immune tolerance against autoimmune disease. <italic toggle="yes">Adv. Drug Deliv. Rev.</italic><bold>203</bold>, 115140 (2023).<pub-id pub-id-type="pmid">37980949</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.addr.2023.115140</pub-id><pub-id pub-id-type="pmcid">PMC10757742</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR214"><label>214.</label><citation-alternatives><element-citation id="ec-CR214" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lodde</surname><given-names>V</given-names></name><name name-style="western"><surname>Floris</surname><given-names>M</given-names></name><name name-style="western"><surname>Zoroddu</surname><given-names>E</given-names></name><name name-style="western"><surname>Zarbo</surname><given-names>IR</given-names></name><name name-style="western"><surname>Idda</surname><given-names>ML</given-names></name></person-group><article-title>RNA-binding proteins in autoimmunity: from genetics to molecular biology</article-title><source>Wiley Interdiscip. Rev. RNA</source><year>2023</year><volume>14</volume><fpage>e1772</fpage><pub-id pub-id-type="doi">10.1002/wrna.1772</pub-id><pub-id pub-id-type="pmid">36658783</pub-id></element-citation><mixed-citation id="mc-CR214" publication-type="journal">Lodde, V., Floris, M., Zoroddu, E., Zarbo, I. R. &amp; Idda, M. L. RNA-binding proteins in autoimmunity: from genetics to molecular biology. <italic toggle="yes">Wiley Interdiscip. Rev. RNA</italic><bold>14</bold>, e1772 (2023).<pub-id pub-id-type="pmid">36658783</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/wrna.1772</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR215"><label>215.</label><citation-alternatives><element-citation id="ec-CR215" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Flemming</surname><given-names>A</given-names></name></person-group><article-title>mRNA vaccine shows promise in autoimmunity</article-title><source>Nat. Rev. Immunol.</source><year>2021</year><volume>21</volume><fpage>72</fpage><pub-id pub-id-type="doi">10.1038/s41577-021-00504-3</pub-id><pub-id pub-id-type="pmid">33437044</pub-id><pub-id pub-id-type="pmcid">PMC7802056</pub-id></element-citation><mixed-citation id="mc-CR215" publication-type="journal">Flemming, A. mRNA vaccine shows promise in autoimmunity. <italic toggle="yes">Nat. Rev. Immunol.</italic><bold>21</bold>, 72 (2021).<pub-id pub-id-type="pmid">33437044</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41577-021-00504-3</pub-id><pub-id pub-id-type="pmcid">PMC7802056</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR216"><label>216.</label><citation-alternatives><element-citation id="ec-CR216" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wardell</surname><given-names>CM</given-names></name><name name-style="western"><surname>Levings</surname><given-names>MK</given-names></name></person-group><article-title>mRNA vaccines take on immune tolerance</article-title><source>Nat. Biotechnol.</source><year>2021</year><volume>39</volume><fpage>419</fpage><lpage>421</lpage><pub-id pub-id-type="doi">10.1038/s41587-021-00880-0</pub-id><pub-id pub-id-type="pmid">33785909</pub-id></element-citation><mixed-citation id="mc-CR216" publication-type="journal">Wardell, C. M. &amp; Levings, M. K. mRNA vaccines take on immune tolerance. <italic toggle="yes">Nat. Biotechnol.</italic><bold>39</bold>, 419&#8211;421 (2021).<pub-id pub-id-type="pmid">33785909</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41587-021-00880-0</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR217"><label>217.</label><citation-alternatives><element-citation id="ec-CR217" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Furlan</surname><given-names>R</given-names></name></person-group><article-title>A tolerizing mRNA vaccine against autoimmunity?</article-title><source>Mol. Ther.</source><year>2021</year><volume>29</volume><fpage>896</fpage><lpage>897</lpage><pub-id pub-id-type="doi">10.1016/j.ymthe.2021.02.003</pub-id><pub-id pub-id-type="pmid">33571462</pub-id><pub-id pub-id-type="pmcid">PMC7875549</pub-id></element-citation><mixed-citation id="mc-CR217" publication-type="journal">Furlan, R. A tolerizing mRNA vaccine against autoimmunity? <italic toggle="yes">Mol. Ther.</italic><bold>29</bold>, 896&#8211;897 (2021).<pub-id pub-id-type="pmid">33571462</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ymthe.2021.02.003</pub-id><pub-id pub-id-type="pmcid">PMC7875549</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR218"><label>218.</label><citation-alternatives><element-citation id="ec-CR218" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Villanueva</surname><given-names>MT</given-names></name></person-group><article-title>Suppressing autoimmunity with mRNA vaccines</article-title><source>Nat. Rev. Drug Discov.</source><year>2021</year><volume>20</volume><fpage>99</fpage><pub-id pub-id-type="doi">10.1038/d41573-021-00014-w</pub-id><pub-id pub-id-type="pmid">33446883</pub-id></element-citation><mixed-citation id="mc-CR218" publication-type="journal">Villanueva, M. T. Suppressing autoimmunity with mRNA vaccines. <italic toggle="yes">Nat. Rev. Drug Discov.</italic><bold>20</bold>, 99 (2021).<pub-id pub-id-type="pmid">33446883</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/d41573-021-00014-w</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR219"><label>219.</label><citation-alternatives><element-citation id="ec-CR219" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Krishnamurthy</surname><given-names>B</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>HE</given-names></name></person-group><article-title>METTL3 restrains autoimmunity in &#946;-cells</article-title><source>Nat. Cell Biol.</source><year>2024</year><volume>26</volume><fpage>321</fpage><lpage>322</lpage><pub-id pub-id-type="doi">10.1038/s41556-024-01352-8</pub-id><pub-id pub-id-type="pmid">38409326</pub-id></element-citation><mixed-citation id="mc-CR219" publication-type="journal">Krishnamurthy, B. &amp; Thomas, H. E. METTL3 restrains autoimmunity in &#946;-cells. <italic toggle="yes">Nat. Cell Biol.</italic><bold>26</bold>, 321&#8211;322 (2024).<pub-id pub-id-type="pmid">38409326</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41556-024-01352-8</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR220"><label>220.</label><citation-alternatives><element-citation id="ec-CR220" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Foster</surname><given-names>TP</given-names></name><name name-style="western"><surname>Haller</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Schatz</surname><given-names>D</given-names></name><name name-style="western"><surname>Wasserfall</surname><given-names>C</given-names></name><name name-style="western"><surname>Sayour</surname><given-names>E</given-names></name></person-group><article-title>743-P: delayed diabetes with proinsulin mRNA vaccines in NOD mice</article-title><source>Diabetes</source><year>2023</year><volume>72</volume><fpage>743</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.2337/db23-743-P</pub-id></element-citation><mixed-citation id="mc-CR220" publication-type="journal">Foster, T. P., Haller, M. J., Schatz, D., Wasserfall, C. &amp; Sayour, E. 743-P: delayed diabetes with proinsulin mRNA vaccines in NOD mice. <italic toggle="yes">Diabetes</italic><bold>72</bold>, 743&#8211;74 (2023).</mixed-citation></citation-alternatives></ref><ref id="CR221"><label>221.</label><citation-alternatives><element-citation id="ec-CR221" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Deyhimfar</surname><given-names>R</given-names></name><etal/></person-group><article-title>The clinical impact of mRNA therapeutics in the treatment of cancers, infections, genetic disorders, and autoimmune diseases</article-title><source>Heliyon</source><year>2024</year><volume>10</volume><fpage>e26971</fpage><pub-id pub-id-type="doi">10.1016/j.heliyon.2024.e26971</pub-id><pub-id pub-id-type="pmid">38486748</pub-id><pub-id pub-id-type="pmcid">PMC10937594</pub-id></element-citation><mixed-citation id="mc-CR221" publication-type="journal">Deyhimfar, R. et al. The clinical impact of mRNA therapeutics in the treatment of cancers, infections, genetic disorders, and autoimmune diseases. <italic toggle="yes">Heliyon</italic><bold>10</bold>, e26971 (2024).<pub-id pub-id-type="pmid">38486748</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.heliyon.2024.e26971</pub-id><pub-id pub-id-type="pmcid">PMC10937594</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR222"><label>222.</label><citation-alternatives><element-citation id="ec-CR222" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shi</surname><given-names>J</given-names></name><etal/></person-group><article-title>Delivery of mRNA for regulating functions of immune cells</article-title><source>J. Control Release</source><year>2022</year><volume>345</volume><fpage>494</fpage><lpage>511</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2022.03.033</pub-id><pub-id pub-id-type="pmid">35337940</pub-id><pub-id pub-id-type="pmcid">PMC8942439</pub-id></element-citation><mixed-citation id="mc-CR222" publication-type="journal">Shi, J. et al. Delivery of mRNA for regulating functions of immune cells. <italic toggle="yes">J. Control Release</italic><bold>345</bold>, 494&#8211;511 (2022).<pub-id pub-id-type="pmid">35337940</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jconrel.2022.03.033</pub-id><pub-id pub-id-type="pmcid">PMC8942439</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR223"><label>223.</label><citation-alternatives><element-citation id="ec-CR223" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sharma</surname><given-names>P</given-names></name><name name-style="western"><surname>Joshi</surname><given-names>RV</given-names></name><name name-style="western"><surname>Pritchard</surname><given-names>R</given-names></name><name name-style="western"><surname>Xu</surname><given-names>K</given-names></name><name name-style="western"><surname>Eicher</surname><given-names>MA</given-names></name></person-group><article-title>Therapeutic antibodies in medicine</article-title><source>Molecules</source><year>2023</year><volume>28</volume><fpage>6438</fpage><pub-id pub-id-type="doi">10.3390/molecules28186438</pub-id><pub-id pub-id-type="pmid">37764213</pub-id><pub-id pub-id-type="pmcid">PMC10535987</pub-id></element-citation><mixed-citation id="mc-CR223" publication-type="journal">Sharma, P., Joshi, R. V., Pritchard, R., Xu, K. &amp; Eicher, M. A. Therapeutic antibodies in medicine. <italic toggle="yes">Molecules</italic><bold>28</bold>, 6438 (2023).<pub-id pub-id-type="pmid">37764213</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/molecules28186438</pub-id><pub-id pub-id-type="pmcid">PMC10535987</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR224"><label>224.</label><citation-alternatives><element-citation id="ec-CR224" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Deal</surname><given-names>CE</given-names></name><name name-style="western"><surname>Carfi</surname><given-names>A</given-names></name><name name-style="western"><surname>Plante</surname><given-names>OJ</given-names></name></person-group><article-title>Advancements in mRNA encoded antibodies for passive immunotherapy</article-title><source>Vaccines</source><year>2021</year><volume>9</volume><fpage>108</fpage><pub-id pub-id-type="doi">10.3390/vaccines9020108</pub-id><pub-id pub-id-type="pmid">33572679</pub-id><pub-id pub-id-type="pmcid">PMC7910832</pub-id></element-citation><mixed-citation id="mc-CR224" publication-type="journal">Deal, C. E., Carfi, A. &amp; Plante, O. J. Advancements in mRNA encoded antibodies for passive immunotherapy. <italic toggle="yes">Vaccines</italic><bold>9</bold>, 108 (2021).<pub-id pub-id-type="pmid">33572679</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/vaccines9020108</pub-id><pub-id pub-id-type="pmcid">PMC7910832</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR225"><label>225.</label><citation-alternatives><element-citation id="ec-CR225" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>An</surname><given-names>Z</given-names></name></person-group><article-title>Magic Bullets&#8221; at the center stage of immune therapy: a special issue on therapeutic antibodies</article-title><source>Protein Cell</source><year>2018</year><volume>9</volume><fpage>1</fpage><lpage>2</lpage><pub-id pub-id-type="doi">10.1007/s13238-017-0488-1</pub-id><pub-id pub-id-type="pmid">29139027</pub-id><pub-id pub-id-type="pmcid">PMC5777979</pub-id></element-citation><mixed-citation id="mc-CR225" publication-type="journal">An, Z. Magic Bullets&#8221; at the center stage of immune therapy: a special issue on therapeutic antibodies. <italic toggle="yes">Protein Cell</italic><bold>9</bold>, 1&#8211;2 (2018).<pub-id pub-id-type="pmid">29139027</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s13238-017-0488-1</pub-id><pub-id pub-id-type="pmcid">PMC5777979</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR226"><label>226.</label><citation-alternatives><element-citation id="ec-CR226" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hafeez</surname><given-names>U</given-names></name><name name-style="western"><surname>Gan</surname><given-names>HK</given-names></name><name name-style="western"><surname>Scott</surname><given-names>AM</given-names></name></person-group><article-title>Monoclonal antibodies as immunomodulatory therapy against cancer and autoimmune diseases</article-title><source>Curr. Opin. Pharmacol.</source><year>2018</year><volume>41</volume><fpage>114</fpage><lpage>121</lpage><pub-id pub-id-type="doi">10.1016/j.coph.2018.05.010</pub-id><pub-id pub-id-type="pmid">29883853</pub-id></element-citation><mixed-citation id="mc-CR226" publication-type="journal">Hafeez, U., Gan, H. K. &amp; Scott, A. M. Monoclonal antibodies as immunomodulatory therapy against cancer and autoimmune diseases. <italic toggle="yes">Curr. Opin. Pharmacol.</italic><bold>41</bold>, 114&#8211;121 (2018).<pub-id pub-id-type="pmid">29883853</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.coph.2018.05.010</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR227"><label>227.</label><citation-alternatives><element-citation id="ec-CR227" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Van Hoecke</surname><given-names>L</given-names></name><name name-style="western"><surname>Roose</surname><given-names>K</given-names></name></person-group><article-title>How mRNA therapeutics are entering the monoclonal antibody field</article-title><source>J. Transl. Med.</source><year>2019</year><volume>17</volume><fpage>54</fpage><pub-id pub-id-type="doi">10.1186/s12967-019-1804-8</pub-id><pub-id pub-id-type="pmid">30795778</pub-id><pub-id pub-id-type="pmcid">PMC6387507</pub-id></element-citation><mixed-citation id="mc-CR227" publication-type="journal">Van Hoecke, L. &amp; Roose, K. How mRNA therapeutics are entering the monoclonal antibody field. <italic toggle="yes">J. Transl. Med.</italic><bold>17</bold>, 54 (2019).<pub-id pub-id-type="pmid">30795778</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12967-019-1804-8</pub-id><pub-id pub-id-type="pmcid">PMC6387507</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR228"><label>228.</label><citation-alternatives><element-citation id="ec-CR228" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Deal</surname><given-names>CE</given-names></name><etal/></person-group><article-title>An mRNA-based platform for the delivery of pathogen-specific IgA into mucosal secretions</article-title><source>Cell Rep. Med.</source><year>2023</year><volume>4</volume><fpage>101253</fpage><pub-id pub-id-type="doi">10.1016/j.xcrm.2023.101253</pub-id><pub-id pub-id-type="pmid">37918405</pub-id><pub-id pub-id-type="pmcid">PMC10694625</pub-id></element-citation><mixed-citation id="mc-CR228" publication-type="journal">Deal, C. E. et al. An mRNA-based platform for the delivery of pathogen-specific IgA into mucosal secretions. <italic toggle="yes">Cell Rep. Med.</italic><bold>4</bold>, 101253 (2023).<pub-id pub-id-type="pmid">37918405</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.xcrm.2023.101253</pub-id><pub-id pub-id-type="pmcid">PMC10694625</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR229"><label>229.</label><citation-alternatives><element-citation id="ec-CR229" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Le</surname><given-names>ND</given-names></name><etal/></person-group><article-title>Antiangiogenic therapeutic mRNA delivery using lung-selective polymeric nanomedicine for lung cancer treatment</article-title><source>ACS Nano</source><year>2024</year><volume>18</volume><fpage>8392</fpage><lpage>8410</lpage><pub-id pub-id-type="doi">10.1021/acsnano.3c13039</pub-id><pub-id pub-id-type="pmid">38450656</pub-id></element-citation><mixed-citation id="mc-CR229" publication-type="journal">Le, N. D. et al. Antiangiogenic therapeutic mRNA delivery using lung-selective polymeric nanomedicine for lung cancer treatment. <italic toggle="yes">ACS Nano</italic><bold>18</bold>, 8392&#8211;8410 (2024).<pub-id pub-id-type="pmid">38450656</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acsnano.3c13039</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR230"><label>230.</label><citation-alternatives><element-citation id="ec-CR230" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chi</surname><given-names>H</given-names></name><etal/></person-group><article-title>Rapid development of double-hit mRNA antibody cocktail against orthopoxviruses</article-title><source>Signal Transduct. Target. Ther.</source><year>2024</year><volume>9</volume><fpage>69</fpage><pub-id pub-id-type="doi">10.1038/s41392-024-01766-8</pub-id><pub-id pub-id-type="pmid">38531869</pub-id><pub-id pub-id-type="pmcid">PMC10966106</pub-id></element-citation><mixed-citation id="mc-CR230" publication-type="journal">Chi, H. et al. Rapid development of double-hit mRNA antibody cocktail against orthopoxviruses. <italic toggle="yes">Signal Transduct. Target. Ther.</italic><bold>9</bold>, 69 (2024).<pub-id pub-id-type="pmid">38531869</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41392-024-01766-8</pub-id><pub-id pub-id-type="pmcid">PMC10966106</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR231"><label>231.</label><citation-alternatives><element-citation id="ec-CR231" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>Q</given-names></name><etal/></person-group><article-title>Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends</article-title><source>Signal Transduct. Target. Ther.</source><year>2023</year><volume>8</volume><fpage>320</fpage><pub-id pub-id-type="doi">10.1038/s41392-023-01522-4</pub-id><pub-id pub-id-type="pmid">37635168</pub-id><pub-id pub-id-type="pmcid">PMC10460796</pub-id></element-citation><mixed-citation id="mc-CR231" publication-type="journal">Sun, Q. et al. Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends. <italic toggle="yes">Signal Transduct. Target. Ther.</italic><bold>8</bold>, 320 (2023).<pub-id pub-id-type="pmid">37635168</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41392-023-01522-4</pub-id><pub-id pub-id-type="pmcid">PMC10460796</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR232"><label>232.</label><citation-alternatives><element-citation id="ec-CR232" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>W</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Pan</surname><given-names>W</given-names></name><name name-style="western"><surname>Xu</surname><given-names>M</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L</given-names></name></person-group><article-title>Strategies for developing PD-1 inhibitors and future directions</article-title><source>Biochem. Pharmacol.</source><year>2022</year><volume>202</volume><fpage>115113</fpage><pub-id pub-id-type="doi">10.1016/j.bcp.2022.115113</pub-id><pub-id pub-id-type="pmid">35640711</pub-id></element-citation><mixed-citation id="mc-CR232" publication-type="journal">Chen, W., Huang, Y., Pan, W., Xu, M. &amp; Chen, L. Strategies for developing PD-1 inhibitors and future directions. <italic toggle="yes">Biochem. Pharmacol.</italic><bold>202</bold>, 115113 (2022).<pub-id pub-id-type="pmid">35640711</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bcp.2022.115113</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR233"><label>233.</label><citation-alternatives><element-citation id="ec-CR233" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Gan</surname><given-names>L</given-names></name><name name-style="western"><surname>Ke</surname><given-names>D</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Q</given-names></name><name name-style="western"><surname>Fu</surname><given-names>Y</given-names></name></person-group><article-title>Mechanisms and research advances in mRNA antibody drug-mediated passive immunotherapy</article-title><source>J. Transl. Med.</source><year>2023</year><volume>21</volume><fpage>693</fpage><pub-id pub-id-type="doi">10.1186/s12967-023-04553-1</pub-id><pub-id pub-id-type="pmid">37794448</pub-id><pub-id pub-id-type="pmcid">PMC10552228</pub-id></element-citation><mixed-citation id="mc-CR233" publication-type="journal">Zhao, Y., Gan, L., Ke, D., Chen, Q. &amp; Fu, Y. Mechanisms and research advances in mRNA antibody drug-mediated passive immunotherapy. <italic toggle="yes">J. Transl. Med.</italic><bold>21</bold>, 693 (2023).<pub-id pub-id-type="pmid">37794448</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12967-023-04553-1</pub-id><pub-id pub-id-type="pmcid">PMC10552228</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR234"><label>234.</label><citation-alternatives><element-citation id="ec-CR234" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hamilton</surname><given-names>AG</given-names></name><etal/></person-group><article-title>Ionizable lipid nanoparticles with integrated immune checkpoint inhibition for mRNA CAR T cell engineering</article-title><source>Adv. Healthc. Mater.</source><year>2023</year><volume>12</volume><fpage>2301515</fpage><pub-id pub-id-type="doi">10.1002/adhm.202301515</pub-id><pub-id pub-id-type="pmid">37602495</pub-id></element-citation><mixed-citation id="mc-CR234" publication-type="journal">Hamilton, A. G. et al. Ionizable lipid nanoparticles with integrated immune checkpoint inhibition for mRNA CAR T cell engineering. <italic toggle="yes">Adv. Healthc. Mater.</italic><bold>12</bold>, 2301515 (2023).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/adhm.202301515</pub-id><pub-id pub-id-type="pmid">37602495</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR235"><label>235.</label><citation-alternatives><element-citation id="ec-CR235" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Van Hoecke</surname><given-names>L</given-names></name><etal/></person-group><article-title>mRNA in cancer immunotherapy: beyond a source of antigen</article-title><source>Mol. Cancer</source><year>2021</year><volume>20</volume><fpage>48</fpage><pub-id pub-id-type="doi">10.1186/s12943-021-01329-3</pub-id><pub-id pub-id-type="pmid">33658037</pub-id><pub-id pub-id-type="pmcid">PMC7926200</pub-id></element-citation><mixed-citation id="mc-CR235" publication-type="journal">Van Hoecke, L. et al. mRNA in cancer immunotherapy: beyond a source of antigen. <italic toggle="yes">Mol. Cancer</italic><bold>20</bold>, 48 (2021).<pub-id pub-id-type="pmid">33658037</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12943-021-01329-3</pub-id><pub-id pub-id-type="pmcid">PMC7926200</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR236"><label>236.</label><citation-alternatives><element-citation id="ec-CR236" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pruitt</surname><given-names>SK</given-names></name><etal/></person-group><article-title>Enhancement of anti&#8208;tumor immunity through local modulation of CTLA&#8208;4 and GITR by dendritic cells</article-title><source>Eur. J. Immunol.</source><year>2011</year><volume>41</volume><fpage>3553</fpage><lpage>3563</lpage><pub-id pub-id-type="doi">10.1002/eji.201141383</pub-id><pub-id pub-id-type="pmid">22028176</pub-id><pub-id pub-id-type="pmcid">PMC3594439</pub-id></element-citation><mixed-citation id="mc-CR236" publication-type="journal">Pruitt, S. K. et al. Enhancement of anti&#8208;tumor immunity through local modulation of CTLA&#8208;4 and GITR by dendritic cells. <italic toggle="yes">Eur. J. Immunol.</italic><bold>41</bold>, 3553&#8211;3563 (2011).<pub-id pub-id-type="pmid">22028176</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/eji.201141383</pub-id><pub-id pub-id-type="pmcid">PMC3594439</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR237"><label>237.</label><citation-alternatives><element-citation id="ec-CR237" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zeng</surname><given-names>J</given-names></name><etal/></person-group><article-title>Antitumor activity of Z15-0-2, a bispecific nanobody targeting PD-1 and CTLA-4</article-title><source>Oncogene</source><year>2024</year><volume>43</volume><fpage>2244</fpage><lpage>2252</lpage><pub-id pub-id-type="doi">10.1038/s41388-024-03066-5</pub-id><pub-id pub-id-type="pmid">38806619</pub-id><pub-id pub-id-type="pmcid">PMC11245388</pub-id></element-citation><mixed-citation id="mc-CR237" publication-type="journal">Zeng, J. et al. Antitumor activity of Z15-0-2, a bispecific nanobody targeting PD-1 and CTLA-4. <italic toggle="yes">Oncogene</italic><bold>43</bold>, 2244&#8211;2252 (2024).<pub-id pub-id-type="pmid">38806619</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41388-024-03066-5</pub-id><pub-id pub-id-type="pmcid">PMC11245388</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR238"><label>238.</label><citation-alternatives><element-citation id="ec-CR238" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chung</surname><given-names>E</given-names></name><etal/></person-group><article-title>Abstract 1368: novel mRNA encoding anti-PD-L1 monoclonal antibodies for cancer immunotherapy</article-title><source>Cancer Res.</source><year>2024</year><volume>84</volume><fpage>1368</fpage><pub-id pub-id-type="doi">10.1158/1538-7445.AM2024-1368</pub-id></element-citation><mixed-citation id="mc-CR238" publication-type="journal">Chung, E. et al. Abstract 1368: novel mRNA encoding anti-PD-L1 monoclonal antibodies for cancer immunotherapy. <italic toggle="yes">Cancer Res.</italic><bold>84</bold>, 1368 (2024).</mixed-citation></citation-alternatives></ref><ref id="CR239"><label>239.</label><mixed-citation publication-type="other">ModernaTX, Inc. Moderna builds on clinical validation of systemic delivery with two additional development candidates in new autoimmune therapeutic area. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://investors.modernatx.com/news/news-details/2020/Moderna-Builds-on-Clinical-Validation-of-Systemic-Delivery-with-Two-Additional-Development-Candidates-in-New-Autoimmune-Therapeutic-Area/default.aspx">https://investors.modernatx.com/news/news-details/2020/Moderna-Builds-on-Clinical-Validation-of-Systemic-Delivery-with-Two-Additional-Development-Candidates-in-New-Autoimmune-Therapeutic-Area/default.aspx</ext-link> (2020).</mixed-citation></ref><ref id="CR240"><label>240.</label><citation-alternatives><element-citation id="ec-CR240" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Salles</surname><given-names>G</given-names></name><etal/></person-group><article-title>Rituximab in B-cell hematologic malignancies: a review of 20 years of clinical experience</article-title><source>Adv. Ther.</source><year>2017</year><volume>34</volume><fpage>2232</fpage><lpage>2273</lpage><pub-id pub-id-type="doi">10.1007/s12325-017-0612-x</pub-id><pub-id pub-id-type="pmid">28983798</pub-id><pub-id pub-id-type="pmcid">PMC5656728</pub-id></element-citation><mixed-citation id="mc-CR240" publication-type="journal">Salles, G. et al. Rituximab in B-cell hematologic malignancies: a review of 20 years of clinical experience. <italic toggle="yes">Adv. Ther.</italic><bold>34</bold>, 2232&#8211;2273 (2017).<pub-id pub-id-type="pmid">28983798</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12325-017-0612-x</pub-id><pub-id pub-id-type="pmcid">PMC5656728</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR241"><label>241.</label><citation-alternatives><element-citation id="ec-CR241" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thran</surname><given-names>M</given-names></name><etal/></person-group><article-title>mRNA mediates passive vaccination against infectious agents, toxins, and tumors</article-title><source>EMBO Mol. Med.</source><year>2017</year><volume>9</volume><fpage>1434</fpage><lpage>1447</lpage><pub-id pub-id-type="doi">10.15252/emmm.201707678</pub-id><pub-id pub-id-type="pmid">28794134</pub-id><pub-id pub-id-type="pmcid">PMC5623855</pub-id></element-citation><mixed-citation id="mc-CR241" publication-type="journal">Thran, M. et al. mRNA mediates passive vaccination against infectious agents, toxins, and tumors. <italic toggle="yes">EMBO Mol. Med.</italic><bold>9</bold>, 1434&#8211;1447 (2017).<pub-id pub-id-type="pmid">28794134</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.15252/emmm.201707678</pub-id><pub-id pub-id-type="pmcid">PMC5623855</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR242"><label>242.</label><citation-alternatives><element-citation id="ec-CR242" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>L</given-names></name><etal/></person-group><article-title>Intravenous delivery of RNA encoding anti-PD-1 human monoclonal antibody for treating intestinal cancer</article-title><source>J. Cancer</source><year>2022</year><volume>13</volume><fpage>579</fpage><lpage>588</lpage><pub-id pub-id-type="doi">10.7150/jca.63991</pub-id><pub-id pub-id-type="pmid">35069904</pub-id><pub-id pub-id-type="pmcid">PMC8771528</pub-id></element-citation><mixed-citation id="mc-CR242" publication-type="journal">Wu, L. et al. Intravenous delivery of RNA encoding anti-PD-1 human monoclonal antibody for treating intestinal cancer. <italic toggle="yes">J. Cancer</italic><bold>13</bold>, 579&#8211;588 (2022).<pub-id pub-id-type="pmid">35069904</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7150/jca.63991</pub-id><pub-id pub-id-type="pmcid">PMC8771528</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR243"><label>243.</label><citation-alternatives><element-citation id="ec-CR243" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miao</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Huang</surname><given-names>L</given-names></name></person-group><article-title>mRNA vaccine for cancer immunotherapy</article-title><source>Mol. Cancer</source><year>2021</year><volume>20</volume><fpage>41</fpage><pub-id pub-id-type="doi">10.1186/s12943-021-01335-5</pub-id><pub-id pub-id-type="pmid">33632261</pub-id><pub-id pub-id-type="pmcid">PMC7905014</pub-id></element-citation><mixed-citation id="mc-CR243" publication-type="journal">Miao, L., Zhang, Y. &amp; Huang, L. mRNA vaccine for cancer immunotherapy. <italic toggle="yes">Mol. Cancer</italic><bold>20</bold>, 41 (2021).<pub-id pub-id-type="pmid">33632261</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12943-021-01335-5</pub-id><pub-id pub-id-type="pmcid">PMC7905014</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR244"><label>244.</label><citation-alternatives><element-citation id="ec-CR244" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ramesh</surname><given-names>P</given-names></name><name name-style="western"><surname>Shivde</surname><given-names>R</given-names></name><name name-style="western"><surname>Jaishankar</surname><given-names>D</given-names></name><name name-style="western"><surname>Saleiro</surname><given-names>D</given-names></name><name name-style="western"><surname>Le Poole</surname><given-names>IC</given-names></name></person-group><article-title>A palette of cytokines to measure anti-tumor efficacy of T cell-based therapeutics</article-title><source>Cancers</source><year>2021</year><volume>13</volume><fpage>821</fpage><pub-id pub-id-type="doi">10.3390/cancers13040821</pub-id><pub-id pub-id-type="pmid">33669271</pub-id><pub-id pub-id-type="pmcid">PMC7920025</pub-id></element-citation><mixed-citation id="mc-CR244" publication-type="journal">Ramesh, P., Shivde, R., Jaishankar, D., Saleiro, D. &amp; Le Poole, I. C. A palette of cytokines to measure anti-tumor efficacy of T cell-based therapeutics. <italic toggle="yes">Cancers</italic><bold>13</bold>, 821 (2021).<pub-id pub-id-type="pmid">33669271</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cancers13040821</pub-id><pub-id pub-id-type="pmcid">PMC7920025</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR245"><label>245.</label><citation-alternatives><element-citation id="ec-CR245" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bentebibel</surname><given-names>S-E</given-names></name><name name-style="western"><surname>Diab</surname><given-names>A</given-names></name></person-group><article-title>Cytokines in the treatment of melanoma</article-title><source>Curr. Oncol. Rep.</source><year>2021</year><volume>23</volume><fpage>83</fpage><pub-id pub-id-type="doi">10.1007/s11912-021-01064-4</pub-id><pub-id pub-id-type="pmid">34003395</pub-id></element-citation><mixed-citation id="mc-CR245" publication-type="journal">Bentebibel, S.-E. &amp; Diab, A. Cytokines in the treatment of melanoma. <italic toggle="yes">Curr. Oncol. Rep.</italic><bold>23</bold>, 83 (2021).<pub-id pub-id-type="pmid">34003395</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11912-021-01064-4</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR246"><label>246.</label><citation-alternatives><element-citation id="ec-CR246" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cho</surname><given-names>J</given-names></name><name name-style="western"><surname>Ritz</surname><given-names>J</given-names></name><name name-style="western"><surname>Zylberberg</surname><given-names>C</given-names></name></person-group><article-title>Comparing the functionality of proleukin&#174; and Akron interleukin-2 through an analysis of key T cell subsets</article-title><source>Cytotherapy</source><year>2020</year><volume>22</volume><fpage>S121</fpage><lpage>S122</lpage><pub-id pub-id-type="doi">10.1016/j.jcyt.2020.03.228</pub-id></element-citation><mixed-citation id="mc-CR246" publication-type="journal">Cho, J., Ritz, J. &amp; Zylberberg, C. Comparing the functionality of proleukin&#174; and Akron interleukin-2 through an analysis of key T cell subsets. <italic toggle="yes">Cytotherapy</italic><bold>22</bold>, S121&#8211;S122 (2020).</mixed-citation></citation-alternatives></ref><ref id="CR247"><label>247.</label><citation-alternatives><element-citation id="ec-CR247" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>H</given-names></name><etal/></person-group><article-title>Viral vectors expressing interleukin 2 for cancer immunotherapy</article-title><source>Hum. Gene Ther.</source><year>2023</year><volume>34</volume><fpage>878</fpage><lpage>895</lpage><pub-id pub-id-type="doi">10.1089/hum.2023.099</pub-id><pub-id pub-id-type="pmid">37578106</pub-id><pub-id pub-id-type="pmcid">PMC10623065</pub-id></element-citation><mixed-citation id="mc-CR247" publication-type="journal">Wang, H. et al. Viral vectors expressing interleukin 2 for cancer immunotherapy. <italic toggle="yes">Hum. Gene Ther.</italic><bold>34</bold>, 878&#8211;895 (2023).<pub-id pub-id-type="pmid">37578106</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1089/hum.2023.099</pub-id><pub-id pub-id-type="pmcid">PMC10623065</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR248"><label>248.</label><citation-alternatives><element-citation id="ec-CR248" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ko</surname><given-names>B</given-names></name><name name-style="western"><surname>Takebe</surname><given-names>N</given-names></name><name name-style="western"><surname>Andrews</surname><given-names>O</given-names></name><name name-style="western"><surname>Makena</surname><given-names>MR</given-names></name><name name-style="western"><surname>Chen</surname><given-names>AP</given-names></name></person-group><article-title>Rethinking oncologic treatment strategies with interleukin-2</article-title><source>Cells</source><year>2023</year><volume>12</volume><fpage>1316</fpage><pub-id pub-id-type="doi">10.3390/cells12091316</pub-id><pub-id pub-id-type="pmid">37174716</pub-id><pub-id pub-id-type="pmcid">PMC10177415</pub-id></element-citation><mixed-citation id="mc-CR248" publication-type="journal">Ko, B., Takebe, N., Andrews, O., Makena, M. R. &amp; Chen, A. P. Rethinking oncologic treatment strategies with interleukin-2. <italic toggle="yes">Cells</italic><bold>12</bold>, 1316 (2023).<pub-id pub-id-type="pmid">37174716</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cells12091316</pub-id><pub-id pub-id-type="pmcid">PMC10177415</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR249"><label>249.</label><citation-alternatives><element-citation id="ec-CR249" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shin</surname><given-names>H</given-names></name><name name-style="western"><surname>Kang</surname><given-names>S</given-names></name><name name-style="western"><surname>Won</surname><given-names>C</given-names></name><name name-style="western"><surname>Min</surname><given-names>D-H</given-names></name></person-group><article-title>Enhanced local delivery of engineered IL-2 mRNA by porous silica nanoparticles to promote effective antitumor immunity</article-title><source>ACS Nano</source><year>2023</year><volume>17</volume><fpage>17554</fpage><lpage>17567</lpage><pub-id pub-id-type="doi">10.1021/acsnano.3c06733</pub-id><pub-id pub-id-type="pmid">37643221</pub-id></element-citation><mixed-citation id="mc-CR249" publication-type="journal">Shin, H., Kang, S., Won, C. &amp; Min, D.-H. Enhanced local delivery of engineered IL-2 mRNA by porous silica nanoparticles to promote effective antitumor immunity. <italic toggle="yes">ACS Nano</italic><bold>17</bold>, 17554&#8211;17567 (2023).<pub-id pub-id-type="pmid">37643221</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acsnano.3c06733</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR250"><label>250.</label><citation-alternatives><element-citation id="ec-CR250" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Tumor-activated IL-2 mRNA delivered by lipid nanoparticles for cancer immunotherapy</article-title><source>J. Control Release</source><year>2024</year><volume>368</volume><fpage>663</fpage><lpage>675</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2024.03.016</pub-id><pub-id pub-id-type="pmid">38492862</pub-id></element-citation><mixed-citation id="mc-CR250" publication-type="journal">Jiang, Y. et al. Tumor-activated IL-2 mRNA delivered by lipid nanoparticles for cancer immunotherapy. <italic toggle="yes">J. Control Release</italic><bold>368</bold>, 663&#8211;675 (2024).<pub-id pub-id-type="pmid">38492862</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jconrel.2024.03.016</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR251"><label>251.</label><citation-alternatives><element-citation id="ec-CR251" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Beck</surname><given-names>JD</given-names></name><etal/></person-group><article-title>Long-lasting mRNA-encoded interleukin-2 restores CD8+ T cell neoantigen immunity in MHC class I-deficient cancers</article-title><source>Cancer Cell</source><year>2024</year><volume>42</volume><fpage>568</fpage><lpage>582</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2024.02.013</pub-id><pub-id pub-id-type="pmid">38490213</pub-id></element-citation><mixed-citation id="mc-CR251" publication-type="journal">Beck, J. D. et al. Long-lasting mRNA-encoded interleukin-2 restores CD8+ T cell neoantigen immunity in MHC class I-deficient cancers. <italic toggle="yes">Cancer Cell</italic><bold>42</bold>, 568&#8211;582 (2024).<pub-id pub-id-type="pmid">38490213</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ccell.2024.02.013</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR252"><label>252.</label><citation-alternatives><element-citation id="ec-CR252" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Van Acker</surname><given-names>HH</given-names></name><etal/></person-group><article-title>The role of the common gamma-chain family cytokines in &#947;<italic toggle="yes">&#948;</italic> T cell-based anti-cancer immunotherapy</article-title><source>Cytokine Growth Factor Rev.</source><year>2018</year><volume>41</volume><fpage>54</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1016/j.cytogfr.2018.05.002</pub-id><pub-id pub-id-type="pmid">29773448</pub-id></element-citation><mixed-citation id="mc-CR252" publication-type="journal">Van Acker, H. H. et al. The role of the common gamma-chain family cytokines in &#947;<italic toggle="yes">&#948;</italic> T cell-based anti-cancer immunotherapy. <italic toggle="yes">Cytokine Growth Factor Rev.</italic><bold>41</bold>, 54&#8211;64 (2018).<pub-id pub-id-type="pmid">29773448</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cytogfr.2018.05.002</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR253"><label>253.</label><citation-alternatives><element-citation id="ec-CR253" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shen</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Lipid nanoparticle-mediated delivery of IL-21-encoding mRNA induces viral clearance in mouse models of hepatitis B virus persistence</article-title><source>J. Med. Virol.</source><year>2023</year><volume>95</volume><fpage>e29062</fpage><pub-id pub-id-type="doi">10.1002/jmv.29062</pub-id><pub-id pub-id-type="pmid">37665238</pub-id></element-citation><mixed-citation id="mc-CR253" publication-type="journal">Shen, Z. et al. Lipid nanoparticle-mediated delivery of IL-21-encoding mRNA induces viral clearance in mouse models of hepatitis B virus persistence. <italic toggle="yes">J. Med. Virol.</italic><bold>95</bold>, e29062 (2023).<pub-id pub-id-type="pmid">37665238</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jmv.29062</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR254"><label>254.</label><citation-alternatives><element-citation id="ec-CR254" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lei</surname><given-names>S</given-names></name><etal/></person-group><article-title>Efficient colorectal cancer gene therapy with IL-15 mRNA nanoformulation</article-title><source>Mol. Pharm.</source><year>2020</year><volume>17</volume><fpage>3378</fpage><lpage>3391</lpage><pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.0c00451</pub-id><pub-id pub-id-type="pmid">32787272</pub-id></element-citation><mixed-citation id="mc-CR254" publication-type="journal">Lei, S. et al. Efficient colorectal cancer gene therapy with IL-15 mRNA nanoformulation. <italic toggle="yes">Mol. Pharm.</italic><bold>17</bold>, 3378&#8211;3391 (2020).<pub-id pub-id-type="pmid">32787272</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.molpharmaceut.0c00451</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR255"><label>255.</label><mixed-citation publication-type="other">Yu, J. et al. Targeted LNPs deliver mRNA encoding IL-15 superagonists to balance efficacy and toxicity in cancer therapy. Preprint at <italic toggle="yes">biorxiv</italic>10.1101/2024.01.11.575299 (2024).</mixed-citation></ref><ref id="CR256"><label>256.</label><citation-alternatives><element-citation id="ec-CR256" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><etal/></person-group><article-title>A combination of PD-L1-targeted IL-15 mRNA nanotherapy and ultrasound-targeted microbubble destruction for tumor immunotherapy</article-title><source>J. Control Release</source><year>2024</year><volume>367</volume><fpage>45</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2024.01.039</pub-id><pub-id pub-id-type="pmid">38246204</pub-id></element-citation><mixed-citation id="mc-CR256" publication-type="journal">Wang, X. et al. A combination of PD-L1-targeted IL-15 mRNA nanotherapy and ultrasound-targeted microbubble destruction for tumor immunotherapy. <italic toggle="yes">J. Control Release</italic><bold>367</bold>, 45&#8211;60 (2024).<pub-id pub-id-type="pmid">38246204</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jconrel.2024.01.039</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR257"><label>257.</label><citation-alternatives><element-citation id="ec-CR257" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gavigan</surname><given-names>J-A</given-names></name><etal/></person-group><article-title>Abstract 1711: induction of anti-tumor immunity by intratumoral delivery of mRNA encoding cytokines and TNFRSF agonists</article-title><source>Cancer Res.</source><year>2021</year><volume>81</volume><fpage>1711</fpage><pub-id pub-id-type="doi">10.1158/1538-7445.AM2021-1711</pub-id></element-citation><mixed-citation id="mc-CR257" publication-type="journal">Gavigan, J.-A. et al. Abstract 1711: induction of anti-tumor immunity by intratumoral delivery of mRNA encoding cytokines and TNFRSF agonists. <italic toggle="yes">Cancer Res.</italic><bold>81</bold>, 1711 (2021).</mixed-citation></citation-alternatives></ref><ref id="CR258"><label>258.</label><mixed-citation publication-type="other">Liu, H. et al. Oxaliplatin lipidated prodrug synergistically enhances the anti-colorectal cancer effect of IL12 mRNA. <italic toggle="yes">Drug Deliv. Transl. Res</italic>. 10.1007/s13346-024-01540-x (2024).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s13346-024-01540-x</pub-id><pub-id pub-id-type="pmid">38457025</pub-id></mixed-citation></ref><ref id="CR259"><label>259.</label><citation-alternatives><element-citation id="ec-CR259" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hewitt</surname><given-names>SL</given-names></name><etal/></person-group><article-title>Intratumoral IL12 mRNA therapy promotes Th1 transformation of the tumor microenvironment</article-title><source>Clin. Cancer Res.</source><year>2020</year><volume>26</volume><fpage>6284</fpage><lpage>6298</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-20-0472</pub-id><pub-id pub-id-type="pmid">32817076</pub-id></element-citation><mixed-citation id="mc-CR259" publication-type="journal">Hewitt, S. L. et al. Intratumoral IL12 mRNA therapy promotes Th1 transformation of the tumor microenvironment. <italic toggle="yes">Clin. Cancer Res.</italic><bold>26</bold>, 6284&#8211;6298 (2020).<pub-id pub-id-type="pmid">32817076</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1078-0432.CCR-20-0472</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR260"><label>260.</label><citation-alternatives><element-citation id="ec-CR260" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Di Trani</surname><given-names>CA</given-names></name><etal/></person-group><article-title>Intratumoral injection of IL-12-encoding mRNA targeted to CSF1R and PD-L1 exerts potent anti-tumor effects without substantial systemic exposure</article-title><source>Mol. Ther. Nucleic Acids</source><year>2023</year><volume>33</volume><fpage>599</fpage><lpage>616</lpage><pub-id pub-id-type="doi">10.1016/j.omtn.2023.07.020</pub-id><pub-id pub-id-type="pmid">37637207</pub-id><pub-id pub-id-type="pmcid">PMC10450355</pub-id></element-citation><mixed-citation id="mc-CR260" publication-type="journal">Di Trani, C. A. et al. Intratumoral injection of IL-12-encoding mRNA targeted to CSF1R and PD-L1 exerts potent anti-tumor effects without substantial systemic exposure. <italic toggle="yes">Mol. Ther. Nucleic Acids</italic><bold>33</bold>, 599&#8211;616 (2023).<pub-id pub-id-type="pmid">37637207</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.omtn.2023.07.020</pub-id><pub-id pub-id-type="pmcid">PMC10450355</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR261"><label>261.</label><citation-alternatives><element-citation id="ec-CR261" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>J-Q</given-names></name><etal/></person-group><article-title>Intratumoral delivery of IL-12 and IL-27 mRNA using lipid nanoparticles for cancer immunotherapy</article-title><source>J. Control Release</source><year>2022</year><volume>345</volume><fpage>306</fpage><lpage>313</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2022.03.021</pub-id><pub-id pub-id-type="pmid">35301053</pub-id><pub-id pub-id-type="pmcid">PMC9133152</pub-id></element-citation><mixed-citation id="mc-CR261" publication-type="journal">Liu, J.-Q. et al. Intratumoral delivery of IL-12 and IL-27 mRNA using lipid nanoparticles for cancer immunotherapy. <italic toggle="yes">J. Control Release</italic><bold>345</bold>, 306&#8211;313 (2022).<pub-id pub-id-type="pmid">35301053</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jconrel.2022.03.021</pub-id><pub-id pub-id-type="pmcid">PMC9133152</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR262"><label>262.</label><citation-alternatives><element-citation id="ec-CR262" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kumar</surname><given-names>A</given-names></name><name name-style="western"><surname>Taghi Khani</surname><given-names>A</given-names></name><name name-style="western"><surname>Sanchez Ortiz</surname><given-names>A</given-names></name><name name-style="western"><surname>Swaminathan</surname><given-names>S</given-names></name></person-group><article-title>GM-CSF: a double-edged sword in cancer immunotherapy</article-title><source>Front. Immunol.</source><year>2022</year><volume>13</volume><fpage>901277</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2022.901277</pub-id><pub-id pub-id-type="pmid">35865534</pub-id><pub-id pub-id-type="pmcid">PMC9294178</pub-id></element-citation><mixed-citation id="mc-CR262" publication-type="journal">Kumar, A., Taghi Khani, A., Sanchez Ortiz, A. &amp; Swaminathan, S. GM-CSF: a double-edged sword in cancer immunotherapy. <italic toggle="yes">Front. Immunol.</italic><bold>13</bold>, 901277 (2022).<pub-id pub-id-type="pmid">35865534</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2022.901277</pub-id><pub-id pub-id-type="pmcid">PMC9294178</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR263"><label>263.</label><citation-alternatives><element-citation id="ec-CR263" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bechter</surname><given-names>O</given-names></name><etal/></person-group><article-title>391 A first-in-human study of intratumoral SAR441000, an mRNA mixture encoding IL-12sc, interferon alpha2b, GM-CSF and IL-15sushi as monotherapy and in combination with cemiplimab in advanced solid tumors</article-title><source>J. Immunother. Cancer</source><year>2020</year><volume>8</volume><fpage>A237</fpage><lpage>A238</lpage></element-citation><mixed-citation id="mc-CR263" publication-type="journal">Bechter, O. et al. 391 A first-in-human study of intratumoral SAR441000, an mRNA mixture encoding IL-12sc, interferon alpha2b, GM-CSF and IL-15sushi as monotherapy and in combination with cemiplimab in advanced solid tumors. <italic toggle="yes">J. Immunother. Cancer</italic><bold>8</bold>, A237&#8211;A238 (2020).</mixed-citation></citation-alternatives></ref><ref id="CR264"><label>264.</label><citation-alternatives><element-citation id="ec-CR264" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yeapuri</surname><given-names>P</given-names></name><etal/></person-group><article-title>Development of an extended half-life GM-CSF fusion protein for Parkinson&#8217;s disease</article-title><source>J. Control Release</source><year>2022</year><volume>348</volume><fpage>951</fpage><lpage>965</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2022.06.024</pub-id><pub-id pub-id-type="pmid">35738463</pub-id><pub-id pub-id-type="pmcid">PMC10350880</pub-id></element-citation><mixed-citation id="mc-CR264" publication-type="journal">Yeapuri, P. et al. Development of an extended half-life GM-CSF fusion protein for Parkinson&#8217;s disease. <italic toggle="yes">J. Control Release</italic><bold>348</bold>, 951&#8211;965 (2022).<pub-id pub-id-type="pmid">35738463</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jconrel.2022.06.024</pub-id><pub-id pub-id-type="pmcid">PMC10350880</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR265"><label>265.</label><citation-alternatives><element-citation id="ec-CR265" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eggenhuizen</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Ng</surname><given-names>BH</given-names></name><name name-style="western"><surname>Ooi</surname><given-names>JD</given-names></name></person-group><article-title>Treg enhancing therapies to treat autoimmune diseases</article-title><source>Int. J. Mol. Sci.</source><year>2020</year><volume>21</volume><fpage>7015</fpage><pub-id pub-id-type="doi">10.3390/ijms21197015</pub-id><pub-id pub-id-type="pmid">32977677</pub-id><pub-id pub-id-type="pmcid">PMC7582931</pub-id></element-citation><mixed-citation id="mc-CR265" publication-type="journal">Eggenhuizen, P. J., Ng, B. H. &amp; Ooi, J. D. Treg enhancing therapies to treat autoimmune diseases. <italic toggle="yes">Int. J. Mol. Sci.</italic><bold>21</bold>, 7015 (2020).<pub-id pub-id-type="pmid">32977677</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms21197015</pub-id><pub-id pub-id-type="pmcid">PMC7582931</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR266"><label>266.</label><citation-alternatives><element-citation id="ec-CR266" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Beheshti</surname><given-names>SA</given-names></name><name name-style="western"><surname>Shamsasenjan</surname><given-names>K</given-names></name><name name-style="western"><surname>Ahmadi</surname><given-names>M</given-names></name><name name-style="western"><surname>Abbasi</surname><given-names>B</given-names></name></person-group><article-title>CAR Treg: a new approach in the treatment of autoimmune diseases</article-title><source>Int. Immunopharmacol.</source><year>2022</year><volume>102</volume><fpage>108409</fpage><pub-id pub-id-type="doi">10.1016/j.intimp.2021.108409</pub-id><pub-id pub-id-type="pmid">34863655</pub-id></element-citation><mixed-citation id="mc-CR266" publication-type="journal">Beheshti, S. A., Shamsasenjan, K., Ahmadi, M. &amp; Abbasi, B. CAR Treg: a new approach in the treatment of autoimmune diseases. <italic toggle="yes">Int. Immunopharmacol.</italic><bold>102</bold>, 108409 (2022).<pub-id pub-id-type="pmid">34863655</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.intimp.2021.108409</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR267"><label>267.</label><citation-alternatives><element-citation id="ec-CR267" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mikami</surname><given-names>N</given-names></name><name name-style="western"><surname>Kawakami</surname><given-names>R</given-names></name><name name-style="western"><surname>Sakaguchi</surname><given-names>S</given-names></name></person-group><article-title>New Treg cell-based therapies of autoimmune diseases: towards antigen-specific immune suppression</article-title><source>Curr. Opin. Immunol.</source><year>2020</year><volume>67</volume><fpage>36</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1016/j.coi.2020.07.004</pub-id><pub-id pub-id-type="pmid">32827951</pub-id></element-citation><mixed-citation id="mc-CR267" publication-type="journal">Mikami, N., Kawakami, R. &amp; Sakaguchi, S. New Treg cell-based therapies of autoimmune diseases: towards antigen-specific immune suppression. <italic toggle="yes">Curr. Opin. Immunol.</italic><bold>67</bold>, 36&#8211;41 (2020).<pub-id pub-id-type="pmid">32827951</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.coi.2020.07.004</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR268"><label>268.</label><citation-alternatives><element-citation id="ec-CR268" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goswami</surname><given-names>TK</given-names></name><etal/></person-group><article-title>Regulatory T cells (Tregs) and their therapeutic potential against autoimmune disorders&#8212;advances and challenges</article-title><source>Hum. Vaccin Immunother.</source><year>2022</year><volume>18</volume><fpage>2035117</fpage><pub-id pub-id-type="doi">10.1080/21645515.2022.2035117</pub-id><pub-id pub-id-type="pmid">35240914</pub-id><pub-id pub-id-type="pmcid">PMC9009914</pub-id></element-citation><mixed-citation id="mc-CR268" publication-type="journal">Goswami, T. K. et al. Regulatory T cells (Tregs) and their therapeutic potential against autoimmune disorders&#8212;advances and challenges. <italic toggle="yes">Hum. Vaccin Immunother.</italic><bold>18</bold>, 2035117 (2022).<pub-id pub-id-type="pmid">35240914</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/21645515.2022.2035117</pub-id><pub-id pub-id-type="pmcid">PMC9009914</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR269"><label>269.</label><citation-alternatives><element-citation id="ec-CR269" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dong</surname><given-names>C</given-names></name><name name-style="western"><surname>Fu</surname><given-names>T</given-names></name><name name-style="western"><surname>Ji</surname><given-names>J</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z</given-names></name><name name-style="western"><surname>Gu</surname><given-names>Z</given-names></name></person-group><article-title>The role of interleukin-4 in rheumatic diseases</article-title><source>Clin. Exp. Pharmacol. Physiol.</source><year>2018</year><volume>45</volume><fpage>747</fpage><lpage>754</lpage><pub-id pub-id-type="doi">10.1111/1440-1681.12946</pub-id><pub-id pub-id-type="pmid">29655253</pub-id></element-citation><mixed-citation id="mc-CR269" publication-type="journal">Dong, C., Fu, T., Ji, J., Li, Z. &amp; Gu, Z. The role of interleukin-4 in rheumatic diseases. <italic toggle="yes">Clin. Exp. Pharmacol. Physiol.</italic><bold>45</bold>, 747&#8211;754 (2018).<pub-id pub-id-type="pmid">29655253</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/1440-1681.12946</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR270"><label>270.</label><citation-alternatives><element-citation id="ec-CR270" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Creusot</surname><given-names>RJ</given-names></name><etal/></person-group><article-title>A short pulse of IL-4 delivered by DCs electroporated with modified mRNA can both prevent and treat autoimmune diabetes in NOD mice</article-title><source>Mol. Ther.</source><year>2010</year><volume>18</volume><fpage>2112</fpage><lpage>2120</lpage><pub-id pub-id-type="doi">10.1038/mt.2010.146</pub-id><pub-id pub-id-type="pmid">20628358</pub-id><pub-id pub-id-type="pmcid">PMC2997578</pub-id></element-citation><mixed-citation id="mc-CR270" publication-type="journal">Creusot, R. J. et al. A short pulse of IL-4 delivered by DCs electroporated with modified mRNA can both prevent and treat autoimmune diabetes in NOD mice. <italic toggle="yes">Mol. Ther.</italic><bold>18</bold>, 2112&#8211;2120 (2010).<pub-id pub-id-type="pmid">20628358</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/mt.2010.146</pub-id><pub-id pub-id-type="pmcid">PMC2997578</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR271"><label>271.</label><citation-alternatives><element-citation id="ec-CR271" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ozgur</surname><given-names>BA</given-names></name><etal/></person-group><article-title>255-LB: the role of Th1, Th2, Th17, and Treg cells in various clinical phases of type 1 diabetes</article-title><source>Diabetes</source><year>2019</year><volume>68</volume><fpage>255</fpage><lpage>2</lpage><pub-id pub-id-type="doi">10.2337/db19-255-LB</pub-id></element-citation><mixed-citation id="mc-CR271" publication-type="journal">Ozgur, B. A. et al. 255-LB: the role of Th1, Th2, Th17, and Treg cells in various clinical phases of type 1 diabetes. <italic toggle="yes">Diabetes</italic><bold>68</bold>, 255&#8211;2 (2019).</mixed-citation></citation-alternatives></ref><ref id="CR272"><label>272.</label><citation-alternatives><element-citation id="ec-CR272" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vaseghi</surname><given-names>H</given-names></name><name name-style="western"><surname>Jadali</surname><given-names>Z</given-names></name></person-group><article-title>Th1/Th2 cytokines in type 1 diabetes: relation to duration of disease and gender</article-title><source>Indian J. Endocrinol. Metab.</source><year>2016</year><volume>20</volume><fpage>312</fpage><lpage>316</lpage><pub-id pub-id-type="doi">10.4103/2230-8210.180002</pub-id><pub-id pub-id-type="pmid">27186546</pub-id><pub-id pub-id-type="pmcid">PMC4855957</pub-id></element-citation><mixed-citation id="mc-CR272" publication-type="journal">Vaseghi, H. &amp; Jadali, Z. Th1/Th2 cytokines in type 1 diabetes: relation to duration of disease and gender. <italic toggle="yes">Indian J. Endocrinol. Metab.</italic><bold>20</bold>, 312&#8211;316 (2016).<pub-id pub-id-type="pmid">27186546</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4103/2230-8210.180002</pub-id><pub-id pub-id-type="pmcid">PMC4855957</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR273"><label>273.</label><citation-alternatives><element-citation id="ec-CR273" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Avi&#241;a</surname><given-names>AE</given-names></name><etal/></person-group><article-title>IL-10 modified mRNA monotherapy prolongs survival after composite facial allografting through the induction of mixed chimerism</article-title><source>Mol. Ther. Nucleic Acids</source><year>2023</year><volume>31</volume><fpage>610</fpage><lpage>627</lpage><pub-id pub-id-type="doi">10.1016/j.omtn.2023.02.016</pub-id><pub-id pub-id-type="pmid">36910717</pub-id><pub-id pub-id-type="pmcid">PMC9996371</pub-id></element-citation><mixed-citation id="mc-CR273" publication-type="journal">Avi&#241;a, A. E. et al. IL-10 modified mRNA monotherapy prolongs survival after composite facial allografting through the induction of mixed chimerism. <italic toggle="yes">Mol. Ther. Nucleic Acids</italic><bold>31</bold>, 610&#8211;627 (2023).<pub-id pub-id-type="pmid">36910717</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.omtn.2023.02.016</pub-id><pub-id pub-id-type="pmcid">PMC9996371</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR274"><label>274.</label><citation-alternatives><element-citation id="ec-CR274" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>Z</given-names></name><etal/></person-group><article-title>A polyphenol-assisted IL-10 mRNA delivery system for ulcerative colitis</article-title><source>Acta Pharm. Sin. B</source><year>2022</year><volume>12</volume><fpage>3367</fpage><lpage>3382</lpage><pub-id pub-id-type="doi">10.1016/j.apsb.2022.03.025</pub-id><pub-id pub-id-type="pmid">35967288</pub-id><pub-id pub-id-type="pmcid">PMC9366313</pub-id></element-citation><mixed-citation id="mc-CR274" publication-type="journal">Chen, Z. et al. A polyphenol-assisted IL-10 mRNA delivery system for ulcerative colitis. <italic toggle="yes">Acta Pharm. Sin. B</italic><bold>12</bold>, 3367&#8211;3382 (2022).<pub-id pub-id-type="pmid">35967288</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.apsb.2022.03.025</pub-id><pub-id pub-id-type="pmcid">PMC9366313</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR275"><label>275.</label><citation-alternatives><element-citation id="ec-CR275" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bu</surname><given-names>T</given-names></name><etal/></person-group><article-title>Exosome-mediated delivery of inflammation-responsive IL-10 mRNA for controlled atherosclerosis treatment</article-title><source>Theranostics</source><year>2021</year><volume>11</volume><fpage>9988</fpage><lpage>10000</lpage><pub-id pub-id-type="doi">10.7150/thno.64229</pub-id><pub-id pub-id-type="pmid">34815799</pub-id><pub-id pub-id-type="pmcid">PMC8581418</pub-id></element-citation><mixed-citation id="mc-CR275" publication-type="journal">Bu, T. et al. Exosome-mediated delivery of inflammation-responsive IL-10 mRNA for controlled atherosclerosis treatment. <italic toggle="yes">Theranostics</italic><bold>11</bold>, 9988&#8211;10000 (2021).<pub-id pub-id-type="pmid">34815799</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7150/thno.64229</pub-id><pub-id pub-id-type="pmcid">PMC8581418</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR276"><label>276.</label><citation-alternatives><element-citation id="ec-CR276" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>G</given-names></name><name name-style="western"><surname>Tang</surname><given-names>T</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Huang</surname><given-names>X</given-names></name><name name-style="western"><surname>Liang</surname><given-names>T</given-names></name></person-group><article-title>mRNA vaccines in disease prevention and treatment</article-title><source>Signal Transduct. Target. Ther.</source><year>2023</year><volume>8</volume><fpage>365</fpage><pub-id pub-id-type="doi">10.1038/s41392-023-01579-1</pub-id><pub-id pub-id-type="pmid">37726283</pub-id><pub-id pub-id-type="pmcid">PMC10509165</pub-id></element-citation><mixed-citation id="mc-CR276" publication-type="journal">Zhang, G., Tang, T., Chen, Y., Huang, X. &amp; Liang, T. mRNA vaccines in disease prevention and treatment. <italic toggle="yes">Signal Transduct. Target. Ther.</italic><bold>8</bold>, 365 (2023).<pub-id pub-id-type="pmid">37726283</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41392-023-01579-1</pub-id><pub-id pub-id-type="pmcid">PMC10509165</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR277"><label>277.</label><citation-alternatives><element-citation id="ec-CR277" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arance Fernandez</surname><given-names>AM</given-names></name><etal/></person-group><article-title>A phase I study (E011-MEL) of a TriMix-based mRNA immunotherapy (ECI-006) in resected melanoma patients: Analysis of safety and immunogenicity</article-title><source>J. Clin. Oncol.</source><year>2019</year><volume>37</volume><fpage>2641</fpage><pub-id pub-id-type="doi">10.1200/JCO.2019.37.15_suppl.2641</pub-id></element-citation><mixed-citation id="mc-CR277" publication-type="journal">Arance Fernandez, A. M. et al. A phase I study (E011-MEL) of a TriMix-based mRNA immunotherapy (ECI-006) in resected melanoma patients: Analysis of safety and immunogenicity. <italic toggle="yes">J. Clin. Oncol.</italic><bold>37</bold>, 2641 (2019).</mixed-citation></citation-alternatives></ref><ref id="CR278"><label>278.</label><citation-alternatives><element-citation id="ec-CR278" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>T</given-names></name><name name-style="western"><surname>Huang</surname><given-names>C</given-names></name><name name-style="western"><surname>Yao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Du</surname><given-names>Z</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z</given-names></name></person-group><article-title>Suicide gene delivery system mediated by ultrasound-targeted microbubble destruction: a promising strategy for cancer therapy</article-title><source>Hum. Gene Ther.</source><year>2022</year><volume>33</volume><fpage>1246</fpage><lpage>1259</lpage><pub-id pub-id-type="doi">10.1089/hum.2022.152</pub-id><pub-id pub-id-type="pmid">36215248</pub-id></element-citation><mixed-citation id="mc-CR278" publication-type="journal">Wu, T., Huang, C., Yao, Y., Du, Z. &amp; Liu, Z. Suicide gene delivery system mediated by ultrasound-targeted microbubble destruction: a promising strategy for cancer therapy. <italic toggle="yes">Hum. Gene Ther.</italic><bold>33</bold>, 1246&#8211;1259 (2022).<pub-id pub-id-type="pmid">36215248</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1089/hum.2022.152</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR279"><label>279.</label><citation-alternatives><element-citation id="ec-CR279" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nguyen</surname><given-names>QM</given-names></name><name name-style="western"><surname>Dupr&#233;</surname><given-names>P-F</given-names></name><name name-style="western"><surname>Haute</surname><given-names>T</given-names></name><name name-style="western"><surname>Montier</surname><given-names>T</given-names></name><name name-style="western"><surname>d&#8217;Arbonneau</surname><given-names>F</given-names></name></person-group><article-title>Suicide gene strategies applied in ovarian cancer studies</article-title><source>Cancer Gene Ther.</source><year>2023</year><volume>30</volume><fpage>812</fpage><lpage>821</lpage><pub-id pub-id-type="doi">10.1038/s41417-023-00590-6</pub-id><pub-id pub-id-type="pmid">36717737</pub-id></element-citation><mixed-citation id="mc-CR279" publication-type="journal">Nguyen, Q. M., Dupr&#233;, P.-F., Haute, T., Montier, T. &amp; d&#8217;Arbonneau, F. Suicide gene strategies applied in ovarian cancer studies. <italic toggle="yes">Cancer Gene Ther.</italic><bold>30</bold>, 812&#8211;821 (2023).<pub-id pub-id-type="pmid">36717737</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41417-023-00590-6</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR280"><label>280.</label><citation-alternatives><element-citation id="ec-CR280" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Song</surname><given-names>N</given-names></name><etal/></person-group><article-title>Suicide gene delivery by morphology-adaptable enantiomeric peptide assemblies for combined ovarian cancer therapy</article-title><source>Acta Biomater.</source><year>2024</year><volume>175</volume><fpage>250</fpage><lpage>261</lpage><pub-id pub-id-type="doi">10.1016/j.actbio.2023.12.020</pub-id><pub-id pub-id-type="pmid">38122884</pub-id></element-citation><mixed-citation id="mc-CR280" publication-type="journal">Song, N. et al. Suicide gene delivery by morphology-adaptable enantiomeric peptide assemblies for combined ovarian cancer therapy. <italic toggle="yes">Acta Biomater.</italic><bold>175</bold>, 250&#8211;261 (2024).<pub-id pub-id-type="pmid">38122884</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.actbio.2023.12.020</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR281"><label>281.</label><citation-alternatives><element-citation id="ec-CR281" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Falcon</surname><given-names>C</given-names></name><etal/></person-group><article-title>Combinatorial suicide gene strategies for the safety of cell therapies</article-title><source>Front. Immunol.</source><year>2022</year><volume>13</volume><fpage>975233</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2022.975233</pub-id><pub-id pub-id-type="pmid">36189285</pub-id><pub-id pub-id-type="pmcid">PMC9515659</pub-id></element-citation><mixed-citation id="mc-CR281" publication-type="journal">Falcon, C. et al. Combinatorial suicide gene strategies for the safety of cell therapies. <italic toggle="yes">Front. Immunol.</italic><bold>13</bold>, 975233 (2022).<pub-id pub-id-type="pmid">36189285</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2022.975233</pub-id><pub-id pub-id-type="pmcid">PMC9515659</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR282"><label>282.</label><citation-alternatives><element-citation id="ec-CR282" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saeb</surname><given-names>S</given-names></name><etal/></person-group><article-title>Suicide gene therapy in cancer and HIV-1 infection: an alternative to conventional treatments</article-title><source>Biochem. Pharmacol.</source><year>2022</year><volume>197</volume><fpage>114893</fpage><pub-id pub-id-type="doi">10.1016/j.bcp.2021.114893</pub-id><pub-id pub-id-type="pmid">34968484</pub-id></element-citation><mixed-citation id="mc-CR282" publication-type="journal">Saeb, S. et al. Suicide gene therapy in cancer and HIV-1 infection: an alternative to conventional treatments. <italic toggle="yes">Biochem. Pharmacol.</italic><bold>197</bold>, 114893 (2022).<pub-id pub-id-type="pmid">34968484</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bcp.2021.114893</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR283"><label>283.</label><citation-alternatives><element-citation id="ec-CR283" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mizrak</surname><given-names>A</given-names></name><etal/></person-group><article-title>Genetically engineered microvesicles carrying suicide mRNA/protein inhibit schwannoma tumor growth</article-title><source>Mol. Ther.</source><year>2013</year><volume>21</volume><fpage>101</fpage><lpage>108</lpage><pub-id pub-id-type="doi">10.1038/mt.2012.161</pub-id><pub-id pub-id-type="pmid">22910294</pub-id><pub-id pub-id-type="pmcid">PMC3538300</pub-id></element-citation><mixed-citation id="mc-CR283" publication-type="journal">Mizrak, A. et al. Genetically engineered microvesicles carrying suicide mRNA/protein inhibit schwannoma tumor growth. <italic toggle="yes">Mol. Ther.</italic><bold>21</bold>, 101&#8211;108 (2013).<pub-id pub-id-type="pmid">22910294</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/mt.2012.161</pub-id><pub-id pub-id-type="pmcid">PMC3538300</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR284"><label>284.</label><citation-alternatives><element-citation id="ec-CR284" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mohammadi</surname><given-names>S</given-names></name><name name-style="western"><surname>Akbari&#8208;Birgani</surname><given-names>S</given-names></name><name name-style="western"><surname>Nikfarjam</surname><given-names>N</given-names></name><name name-style="western"><surname>Rasekhian</surname><given-names>M</given-names></name></person-group><article-title>Polyethyleneimine-decorated graphene oxide quantum dot as a carrier for suicide gene delivery to the breast cancer three-dimensional model</article-title><source>J. Drug Deliv. Sci. Technol.</source><year>2023</year><volume>88</volume><fpage>104849</fpage><pub-id pub-id-type="doi">10.1016/j.jddst.2023.104849</pub-id></element-citation><mixed-citation id="mc-CR284" publication-type="journal">Mohammadi, S., Akbari&#8208;Birgani, S., Nikfarjam, N. &amp; Rasekhian, M. Polyethyleneimine-decorated graphene oxide quantum dot as a carrier for suicide gene delivery to the breast cancer three-dimensional model. <italic toggle="yes">J. Drug Deliv. Sci. Technol.</italic><bold>88</bold>, 104849 (2023).</mixed-citation></citation-alternatives></ref><ref id="CR285"><label>285.</label><citation-alternatives><element-citation id="ec-CR285" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nakashima</surname><given-names>I</given-names></name><etal/></person-group><article-title>Non-viral inducible caspase 9 mRNA delivery using lipid nanoparticles against breast cancer: an in vitro study</article-title><source>Biochem. Biophys. Res. Commun.</source><year>2022</year><volume>635</volume><fpage>144</fpage><lpage>153</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2022.09.105</pub-id><pub-id pub-id-type="pmid">36274364</pub-id></element-citation><mixed-citation id="mc-CR285" publication-type="journal">Nakashima, I. et al. Non-viral inducible caspase 9 mRNA delivery using lipid nanoparticles against breast cancer: an in vitro study. <italic toggle="yes">Biochem. Biophys. Res. Commun.</italic><bold>635</bold>, 144&#8211;153 (2022).<pub-id pub-id-type="pmid">36274364</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbrc.2022.09.105</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR286"><label>286.</label><citation-alternatives><element-citation id="ec-CR286" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saito</surname><given-names>S</given-names></name><etal/></person-group><article-title>Tumor-tropic liposome-mediated therapeutic delivery of mRNA for T cell malignancies</article-title><source>Blood</source><year>2020</year><volume>136</volume><fpage>21</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1182/blood-2020-139020</pub-id></element-citation><mixed-citation id="mc-CR286" publication-type="journal">Saito, S. et al. Tumor-tropic liposome-mediated therapeutic delivery of mRNA for T cell malignancies. <italic toggle="yes">Blood</italic><bold>136</bold>, 21&#8211;22 (2020).</mixed-citation></citation-alternatives></ref><ref id="CR287"><label>287.</label><citation-alternatives><element-citation id="ec-CR287" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>L</given-names></name><name name-style="western"><surname>Liu</surname><given-names>S</given-names></name><name name-style="western"><surname>Tao</surname><given-names>Y</given-names></name></person-group><article-title>Regulating tumor suppressor genes: post-translational modifications</article-title><source>Signal Transduct. Target. Ther.</source><year>2020</year><volume>5</volume><fpage>90</fpage><pub-id pub-id-type="doi">10.1038/s41392-020-0196-9</pub-id><pub-id pub-id-type="pmid">32532965</pub-id><pub-id pub-id-type="pmcid">PMC7293209</pub-id></element-citation><mixed-citation id="mc-CR287" publication-type="journal">Chen, L., Liu, S. &amp; Tao, Y. Regulating tumor suppressor genes: post-translational modifications. <italic toggle="yes">Signal Transduct. Target. Ther.</italic><bold>5</bold>, 90 (2020).<pub-id pub-id-type="pmid">32532965</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41392-020-0196-9</pub-id><pub-id pub-id-type="pmcid">PMC7293209</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR288"><label>288.</label><citation-alternatives><element-citation id="ec-CR288" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peuget</surname><given-names>S</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>X</given-names></name><name name-style="western"><surname>Selivanova</surname><given-names>G</given-names></name></person-group><article-title>Translating p53-based therapies for cancer into the clinic</article-title><source>Nat. Rev. Cancer</source><year>2024</year><volume>24</volume><fpage>192</fpage><lpage>215</lpage><pub-id pub-id-type="doi">10.1038/s41568-023-00658-3</pub-id><pub-id pub-id-type="pmid">38287107</pub-id></element-citation><mixed-citation id="mc-CR288" publication-type="journal">Peuget, S., Zhou, X. &amp; Selivanova, G. Translating p53-based therapies for cancer into the clinic. <italic toggle="yes">Nat. Rev. Cancer</italic><bold>24</bold>, 192&#8211;215 (2024).<pub-id pub-id-type="pmid">38287107</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41568-023-00658-3</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR289"><label>289.</label><citation-alternatives><element-citation id="ec-CR289" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>C</given-names></name><etal/></person-group><article-title>Chemotherapy drugs derived nanoparticles encapsulating mRNA encoding tumor suppressor proteins to treat triple-negative breast cancer</article-title><source>Nano Res.</source><year>2019</year><volume>12</volume><fpage>855</fpage><lpage>861</lpage><pub-id pub-id-type="doi">10.1007/s12274-019-2308-9</pub-id><pub-id pub-id-type="pmid">31737223</pub-id><pub-id pub-id-type="pmcid">PMC6858063</pub-id></element-citation><mixed-citation id="mc-CR289" publication-type="journal">Zhang, C. et al. Chemotherapy drugs derived nanoparticles encapsulating mRNA encoding tumor suppressor proteins to treat triple-negative breast cancer. <italic toggle="yes">Nano Res.</italic><bold>12</bold>, 855&#8211;861 (2019).<pub-id pub-id-type="pmid">31737223</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12274-019-2308-9</pub-id><pub-id pub-id-type="pmcid">PMC6858063</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR290"><label>290.</label><citation-alternatives><element-citation id="ec-CR290" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>H</given-names></name><etal/></person-group><article-title>ROS-responsive nanoparticle delivery of mRNA and photosensitizer for combinatorial cancer therapy</article-title><source>Nano Lett.</source><year>2023</year><volume>23</volume><fpage>3661</fpage><lpage>3668</lpage><pub-id pub-id-type="doi">10.1021/acs.nanolett.2c03784</pub-id><pub-id pub-id-type="pmid">37093620</pub-id></element-citation><mixed-citation id="mc-CR290" publication-type="journal">Zhou, H. et al. ROS-responsive nanoparticle delivery of mRNA and photosensitizer for combinatorial cancer therapy. <italic toggle="yes">Nano Lett.</italic><bold>23</bold>, 3661&#8211;3668 (2023).<pub-id pub-id-type="pmid">37093620</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.nanolett.2c03784</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR291"><label>291.</label><citation-alternatives><element-citation id="ec-CR291" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cao</surname><given-names>C</given-names></name><etal/></person-group><article-title>Enhancement of protein translation by CRISPR/dCasRx coupled with SINEB2 repeat of noncoding RNAs</article-title><source>Nucleic Acids Res.</source><year>2023</year><volume>51</volume><fpage>e33</fpage><pub-id pub-id-type="doi">10.1093/nar/gkad010</pub-id><pub-id pub-id-type="pmid">36715335</pub-id><pub-id pub-id-type="pmcid">PMC10085674</pub-id></element-citation><mixed-citation id="mc-CR291" publication-type="journal">Cao, C. et al. Enhancement of protein translation by CRISPR/dCasRx coupled with SINEB2 repeat of noncoding RNAs. <italic toggle="yes">Nucleic Acids Res.</italic><bold>51</bold>, e33 (2023).<pub-id pub-id-type="pmid">36715335</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/nar/gkad010</pub-id><pub-id pub-id-type="pmcid">PMC10085674</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR292"><label>292.</label><citation-alternatives><element-citation id="ec-CR292" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Non-invasive PTEN mRNA brain delivery effectively mitigates growth of orthotopic glioblastoma</article-title><source>Nano Today</source><year>2023</year><volume>49</volume><fpage>101790</fpage><pub-id pub-id-type="doi">10.1016/j.nantod.2023.101790</pub-id></element-citation><mixed-citation id="mc-CR292" publication-type="journal">Liu, Y. et al. Non-invasive PTEN mRNA brain delivery effectively mitigates growth of orthotopic glioblastoma. <italic toggle="yes">Nano Today</italic><bold>49</bold>, 101790 (2023).</mixed-citation></citation-alternatives></ref><ref id="CR293"><label>293.</label><citation-alternatives><element-citation id="ec-CR293" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ma</surname><given-names>P</given-names></name><etal/></person-group><article-title>Local and systemic delivery of the bims gene nano-complex for efficient oral squamous cell carcinoma therapy</article-title><source>Int. J. Nanomed.</source><year>2022</year><volume>17</volume><fpage>2925</fpage><lpage>2941</lpage><pub-id pub-id-type="doi">10.2147/IJN.S357702</pub-id><pub-id pub-id-type="pmcid">PMC9270013</pub-id><pub-id pub-id-type="pmid">35814613</pub-id></element-citation><mixed-citation id="mc-CR293" publication-type="journal">Ma, P. et al. Local and systemic delivery of the bims gene nano-complex for efficient oral squamous cell carcinoma therapy. <italic toggle="yes">Int. J. Nanomed.</italic><bold>17</bold>, 2925&#8211;2941 (2022).<pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/IJN.S357702</pub-id><pub-id pub-id-type="pmcid">PMC9270013</pub-id><pub-id pub-id-type="pmid">35814613</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR294"><label>294.</label><citation-alternatives><element-citation id="ec-CR294" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gao</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Functionalized DMP-039 hybrid nanoparticle as a novel mRNA vector for efficient cancer suicide gene therapy</article-title><source>Int. J. Nanomed.</source><year>2021</year><volume>16</volume><fpage>5211</fpage><lpage>5232</lpage><pub-id pub-id-type="doi">10.2147/IJN.S319092</pub-id><pub-id pub-id-type="pmcid">PMC8335320</pub-id><pub-id pub-id-type="pmid">34366664</pub-id></element-citation><mixed-citation id="mc-CR294" publication-type="journal">Gao, Y. et al. Functionalized DMP-039 hybrid nanoparticle as a novel mRNA vector for efficient cancer suicide gene therapy. <italic toggle="yes">Int. J. Nanomed.</italic><bold>16</bold>, 5211&#8211;5232 (2021).<pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/IJN.S319092</pub-id><pub-id pub-id-type="pmcid">PMC8335320</pub-id><pub-id pub-id-type="pmid">34366664</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR295"><label>295.</label><citation-alternatives><element-citation id="ec-CR295" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Okumura</surname><given-names>K</given-names></name><etal/></person-group><article-title>Bax mRNA therapy using cationic liposomes for human malignant melanoma</article-title><source>J. Gene Med.</source><year>2008</year><volume>10</volume><fpage>910</fpage><lpage>917</lpage><pub-id pub-id-type="doi">10.1002/jgm.1214</pub-id><pub-id pub-id-type="pmid">18563851</pub-id></element-citation><mixed-citation id="mc-CR295" publication-type="journal">Okumura, K. et al. Bax mRNA therapy using cationic liposomes for human malignant melanoma. <italic toggle="yes">J. Gene Med.</italic><bold>10</bold>, 910&#8211;917 (2008).<pub-id pub-id-type="pmid">18563851</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jgm.1214</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR296"><label>296.</label><citation-alternatives><element-citation id="ec-CR296" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gu</surname><given-names>T</given-names></name><etal/></person-group><article-title>Intratumoural delivery of TRAIL mRNA induces colon cancer cell apoptosis</article-title><source>Biomed. Pharmacother.</source><year>2024</year><volume>174</volume><fpage>116603</fpage><pub-id pub-id-type="doi">10.1016/j.biopha.2024.116603</pub-id><pub-id pub-id-type="pmid">38636395</pub-id></element-citation><mixed-citation id="mc-CR296" publication-type="journal">Gu, T. et al. Intratumoural delivery of TRAIL mRNA induces colon cancer cell apoptosis. <italic toggle="yes">Biomed. Pharmacother.</italic><bold>174</bold>, 116603 (2024).<pub-id pub-id-type="pmid">38636395</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biopha.2024.116603</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR297"><label>297.</label><citation-alternatives><element-citation id="ec-CR297" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>da Silva</surname><given-names>WN</given-names></name><etal/></person-group><article-title>Ionizable lipid nanoparticle-mediated TRAIL mRNA delivery in the tumor microenvironment to inhibit colon cancer progression</article-title><source>Int. J. Nanomed.</source><year>2024</year><volume>19</volume><fpage>2655</fpage><lpage>2673</lpage><pub-id pub-id-type="doi">10.2147/IJN.S452896</pub-id><pub-id pub-id-type="pmcid">PMC10946446</pub-id><pub-id pub-id-type="pmid">38500680</pub-id></element-citation><mixed-citation id="mc-CR297" publication-type="journal">da Silva, W. N. et al. Ionizable lipid nanoparticle-mediated TRAIL mRNA delivery in the tumor microenvironment to inhibit colon cancer progression. <italic toggle="yes">Int. J. Nanomed.</italic><bold>19</bold>, 2655&#8211;2673 (2024).<pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/IJN.S452896</pub-id><pub-id pub-id-type="pmcid">PMC10946446</pub-id><pub-id pub-id-type="pmid">38500680</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR298"><label>298.</label><citation-alternatives><element-citation id="ec-CR298" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van der Eb</surname><given-names>MM</given-names></name><etal/></person-group><article-title>Gene therapy with Apoptin induces regression of xenografted human hepatomas</article-title><source>Cancer Gene Ther.</source><year>2002</year><volume>9</volume><fpage>53</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1038/sj.cgt.7700397</pub-id><pub-id pub-id-type="pmid">11924525</pub-id></element-citation><mixed-citation id="mc-CR298" publication-type="journal">van der Eb, M. M. et al. Gene therapy with Apoptin induces regression of xenografted human hepatomas. <italic toggle="yes">Cancer Gene Ther.</italic><bold>9</bold>, 53&#8211;61 (2002).<pub-id pub-id-type="pmid">11924525</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/sj.cgt.7700397</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR299"><label>299.</label><citation-alternatives><element-citation id="ec-CR299" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Self-assembled small messenger RNA nanospheres for efficient therapeutic apoptin expression and synergistic gene-chemotherapy of breast cancer</article-title><source>J. Colloid Interface Sci.</source><year>2021</year><volume>603</volume><fpage>191</fpage><lpage>198</lpage><pub-id pub-id-type="doi">10.1016/j.jcis.2021.06.061</pub-id><pub-id pub-id-type="pmid">34192626</pub-id></element-citation><mixed-citation id="mc-CR299" publication-type="journal">Tang, Y. et al. Self-assembled small messenger RNA nanospheres for efficient therapeutic apoptin expression and synergistic gene-chemotherapy of breast cancer. <italic toggle="yes">J. Colloid Interface Sci.</italic><bold>603</bold>, 191&#8211;198 (2021).<pub-id pub-id-type="pmid">34192626</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jcis.2021.06.061</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR300"><label>300.</label><citation-alternatives><element-citation id="ec-CR300" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Castro</surname><given-names>J</given-names></name><name name-style="western"><surname>Ribo</surname><given-names>M</given-names></name><name name-style="western"><surname>Benito</surname><given-names>A</given-names></name><name name-style="western"><surname>Vilanova</surname><given-names>M</given-names></name></person-group><article-title>Apoptin, A versatile protein with selective antitumor activity</article-title><source>Curr. Med. Chem.</source><year>2018</year><volume>25</volume><fpage>3540</fpage><lpage>3559</lpage><pub-id pub-id-type="doi">10.2174/0929867325666180309112023</pub-id><pub-id pub-id-type="pmid">29521208</pub-id></element-citation><mixed-citation id="mc-CR300" publication-type="journal">Castro, J., Ribo, M., Benito, A. &amp; Vilanova, M. Apoptin, A versatile protein with selective antitumor activity. <italic toggle="yes">Curr. Med. Chem.</italic><bold>25</bold>, 3540&#8211;3559 (2018).<pub-id pub-id-type="pmid">29521208</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/0929867325666180309112023</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR301"><label>301.</label><citation-alternatives><element-citation id="ec-CR301" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bae</surname><given-names>Y</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J</given-names></name><name name-style="western"><surname>Kho</surname><given-names>C</given-names></name><name name-style="western"><surname>Choi</surname><given-names>JS</given-names></name><name name-style="western"><surname>Han</surname><given-names>J</given-names></name></person-group><article-title>Apoptin gene delivery by a PAMAM dendrimer modified with a nuclear localization signal peptide as a gene carrier for brain cancer therapy</article-title><source>Korean J. Physiol. Pharmacol.</source><year>2021</year><volume>25</volume><fpage>467</fpage><lpage>478</lpage><pub-id pub-id-type="doi">10.4196/kjpp.2021.25.5.467</pub-id><pub-id pub-id-type="pmid">34448464</pub-id><pub-id pub-id-type="pmcid">PMC8405440</pub-id></element-citation><mixed-citation id="mc-CR301" publication-type="journal">Bae, Y., Lee, J., Kho, C., Choi, J. S. &amp; Han, J. Apoptin gene delivery by a PAMAM dendrimer modified with a nuclear localization signal peptide as a gene carrier for brain cancer therapy. <italic toggle="yes">Korean J. Physiol. Pharmacol.</italic><bold>25</bold>, 467&#8211;478 (2021).<pub-id pub-id-type="pmid">34448464</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4196/kjpp.2021.25.5.467</pub-id><pub-id pub-id-type="pmcid">PMC8405440</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR302"><label>302.</label><citation-alternatives><element-citation id="ec-CR302" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qu</surname><given-names>Y-M</given-names></name><etal/></person-group><article-title>Huntingtin-associated protein 1 is a potential tumor suppressor for gastric cancer</article-title><source>Mol. Biol. Rep.</source><year>2023</year><volume>50</volume><fpage>1517</fpage><lpage>1531</lpage><pub-id pub-id-type="doi">10.1007/s11033-022-08090-w</pub-id><pub-id pub-id-type="pmid">36509909</pub-id></element-citation><mixed-citation id="mc-CR302" publication-type="journal">Qu, Y.-M. et al. Huntingtin-associated protein 1 is a potential tumor suppressor for gastric cancer. <italic toggle="yes">Mol. Biol. Rep.</italic><bold>50</bold>, 1517&#8211;1531 (2023).<pub-id pub-id-type="pmid">36509909</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11033-022-08090-w</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR303"><label>303.</label><citation-alternatives><element-citation id="ec-CR303" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zheng</surname><given-names>Z</given-names></name><name name-style="western"><surname>Song</surname><given-names>Y</given-names></name></person-group><article-title>Synaptopodin-2: a potential tumor suppressor</article-title><source>Cancer Cell Int.</source><year>2023</year><volume>23</volume><fpage>158</fpage><pub-id pub-id-type="doi">10.1186/s12935-023-03013-6</pub-id><pub-id pub-id-type="pmid">37544991</pub-id><pub-id pub-id-type="pmcid">PMC10405370</pub-id></element-citation><mixed-citation id="mc-CR303" publication-type="journal">Zheng, Z. &amp; Song, Y. Synaptopodin-2: a potential tumor suppressor. <italic toggle="yes">Cancer Cell Int.</italic><bold>23</bold>, 158 (2023).<pub-id pub-id-type="pmid">37544991</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12935-023-03013-6</pub-id><pub-id pub-id-type="pmcid">PMC10405370</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR304"><label>304.</label><citation-alternatives><element-citation id="ec-CR304" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Polito</surname><given-names>L</given-names></name><name name-style="western"><surname>Djemil</surname><given-names>A</given-names></name><name name-style="western"><surname>Bortolotti</surname><given-names>M</given-names></name></person-group><article-title>Plant toxin-based immunotoxins for cancer therapy: a short overview</article-title><source>Biomedicines</source><year>2016</year><volume>4</volume><fpage>12</fpage><pub-id pub-id-type="doi">10.3390/biomedicines4020012</pub-id><pub-id pub-id-type="pmid">28536379</pub-id><pub-id pub-id-type="pmcid">PMC5344252</pub-id></element-citation><mixed-citation id="mc-CR304" publication-type="journal">Polito, L., Djemil, A. &amp; Bortolotti, M. Plant toxin-based immunotoxins for cancer therapy: a short overview. <italic toggle="yes">Biomedicines</italic><bold>4</bold>, 12 (2016).<pub-id pub-id-type="pmid">28536379</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/biomedicines4020012</pub-id><pub-id pub-id-type="pmcid">PMC5344252</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR305"><label>305.</label><citation-alternatives><element-citation id="ec-CR305" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kreitman</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Pastan</surname><given-names>I</given-names></name></person-group><article-title>Immunotoxins: from design to clinical application</article-title><source>Biomolecules</source><year>2021</year><volume>11</volume><fpage>1696</fpage><pub-id pub-id-type="doi">10.3390/biom11111696</pub-id><pub-id pub-id-type="pmid">34827694</pub-id><pub-id pub-id-type="pmcid">PMC8615697</pub-id></element-citation><mixed-citation id="mc-CR305" publication-type="journal">Kreitman, R. J. &amp; Pastan, I. Immunotoxins: from design to clinical application. <italic toggle="yes">Biomolecules</italic><bold>11</bold>, 1696 (2021).<pub-id pub-id-type="pmid">34827694</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/biom11111696</pub-id><pub-id pub-id-type="pmcid">PMC8615697</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR306"><label>306.</label><citation-alternatives><element-citation id="ec-CR306" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Akbari</surname><given-names>B</given-names></name><etal/></person-group><article-title>Immunotoxins in cancer therapy: review and update</article-title><source>Int. Rev. Immunol.</source><year>2017</year><volume>36</volume><fpage>207</fpage><lpage>219</lpage><pub-id pub-id-type="doi">10.1080/08830185.2017.1284211</pub-id><pub-id pub-id-type="pmid">28282218</pub-id></element-citation><mixed-citation id="mc-CR306" publication-type="journal">Akbari, B. et al. Immunotoxins in cancer therapy: review and update. <italic toggle="yes">Int. Rev. Immunol.</italic><bold>36</bold>, 207&#8211;219 (2017).<pub-id pub-id-type="pmid">28282218</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/08830185.2017.1284211</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR307"><label>307.</label><citation-alternatives><element-citation id="ec-CR307" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dashtiahangar</surname><given-names>M</given-names></name><etal/></person-group><article-title>Anti-cancer immunotoxins, challenges, and approaches</article-title><source>Curr. Pharm. Des.</source><year>2021</year><volume>27</volume><fpage>932</fpage><lpage>941</lpage><pub-id pub-id-type="doi">10.2174/1381612826666201006155346</pub-id><pub-id pub-id-type="pmid">33023437</pub-id></element-citation><mixed-citation id="mc-CR307" publication-type="journal">Dashtiahangar, M. et al. Anti-cancer immunotoxins, challenges, and approaches. <italic toggle="yes">Curr. Pharm. Des.</italic><bold>27</bold>, 932&#8211;941 (2021).<pub-id pub-id-type="pmid">33023437</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/1381612826666201006155346</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR308"><label>308.</label><citation-alternatives><element-citation id="ec-CR308" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>R</given-names></name><etal/></person-group><article-title>Fusion of an albumin-binding domain extends the half-life of immunotoxins</article-title><source>Int. J. Pharm.</source><year>2016</year><volume>511</volume><fpage>538</fpage><lpage>549</lpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2016.07.046</pub-id><pub-id pub-id-type="pmid">27457423</pub-id></element-citation><mixed-citation id="mc-CR308" publication-type="journal">Guo, R. et al. Fusion of an albumin-binding domain extends the half-life of immunotoxins. <italic toggle="yes">Int. J. Pharm.</italic><bold>511</bold>, 538&#8211;549 (2016).<pub-id pub-id-type="pmid">27457423</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijpharm.2016.07.046</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR309"><label>309.</label><citation-alternatives><element-citation id="ec-CR309" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>St&#246;cker</surname><given-names>M</given-names></name><etal/></person-group><article-title>Secretion of functional anti-CD30-angiogenin immunotoxins into the supernatant of transfected 293T-cells</article-title><source>Protein Expr. Purif.</source><year>2003</year><volume>28</volume><fpage>211</fpage><lpage>219</lpage><pub-id pub-id-type="doi">10.1016/S1046-5928(02)00709-X</pub-id><pub-id pub-id-type="pmid">12699683</pub-id></element-citation><mixed-citation id="mc-CR309" publication-type="journal">St&#246;cker, M. et al. Secretion of functional anti-CD30-angiogenin immunotoxins into the supernatant of transfected 293T-cells. <italic toggle="yes">Protein Expr. Purif.</italic><bold>28</bold>, 211&#8211;219 (2003).<pub-id pub-id-type="pmid">12699683</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s1046-5928(02)00709-x</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR310"><label>310.</label><citation-alternatives><element-citation id="ec-CR310" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Granot-Matok</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Lipid nanoparticles-loaded with toxin mRNA represents a new strategy for the treatment of solid tumors</article-title><source>Theranostics</source><year>2023</year><volume>13</volume><fpage>3497</fpage><lpage>3508</lpage><pub-id pub-id-type="doi">10.7150/thno.82228</pub-id><pub-id pub-id-type="pmid">37441597</pub-id><pub-id pub-id-type="pmcid">PMC10334842</pub-id></element-citation><mixed-citation id="mc-CR310" publication-type="journal">Granot-Matok, Y. et al. Lipid nanoparticles-loaded with toxin mRNA represents a new strategy for the treatment of solid tumors. <italic toggle="yes">Theranostics</italic><bold>13</bold>, 3497&#8211;3508 (2023).<pub-id pub-id-type="pmid">37441597</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7150/thno.82228</pub-id><pub-id pub-id-type="pmcid">PMC10334842</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR311"><label>311.</label><citation-alternatives><element-citation id="ec-CR311" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eggers</surname><given-names>R</given-names></name><name name-style="western"><surname>Philippi</surname><given-names>A</given-names></name><name name-style="western"><surname>Altmeyer</surname><given-names>MO</given-names></name><name name-style="western"><surname>Breinig</surname><given-names>F</given-names></name><name name-style="western"><surname>Schmitt</surname><given-names>MJ</given-names></name></person-group><article-title>Primary T cells for mRNA-mediated immunotoxin delivery</article-title><source>Gene Ther.</source><year>2018</year><volume>25</volume><fpage>47</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1038/gt.2017.87</pub-id><pub-id pub-id-type="pmid">28937681</pub-id></element-citation><mixed-citation id="mc-CR311" publication-type="journal">Eggers, R., Philippi, A., Altmeyer, M. O., Breinig, F. &amp; Schmitt, M. J. Primary T cells for mRNA-mediated immunotoxin delivery. <italic toggle="yes">Gene Ther.</italic><bold>25</bold>, 47&#8211;53 (2018).<pub-id pub-id-type="pmid">28937681</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/gt.2017.87</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR312"><label>312.</label><citation-alternatives><element-citation id="ec-CR312" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hirschberger</surname><given-names>K</given-names></name><etal/></person-group><article-title>Exploring cytotoxic mRNAs as a novel class of anti-cancer biotherapeutics</article-title><source>Mol. Ther. Methods Clin. Dev.</source><year>2018</year><volume>8</volume><fpage>141</fpage><lpage>151</lpage><pub-id pub-id-type="doi">10.1016/j.omtm.2017.12.006</pub-id><pub-id pub-id-type="pmid">29687033</pub-id><pub-id pub-id-type="pmcid">PMC5908148</pub-id></element-citation><mixed-citation id="mc-CR312" publication-type="journal">Hirschberger, K. et al. Exploring cytotoxic mRNAs as a novel class of anti-cancer biotherapeutics. <italic toggle="yes">Mol. Ther. Methods Clin. Dev.</italic><bold>8</bold>, 141&#8211;151 (2018).<pub-id pub-id-type="pmid">29687033</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.omtm.2017.12.006</pub-id><pub-id pub-id-type="pmcid">PMC5908148</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR313"><label>313.</label><citation-alternatives><element-citation id="ec-CR313" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Spiess</surname><given-names>K</given-names></name><name name-style="western"><surname>Jakobsen</surname><given-names>MH</given-names></name><name name-style="western"><surname>Kledal</surname><given-names>TN</given-names></name><name name-style="western"><surname>Rosenkilde</surname><given-names>MM</given-names></name></person-group><article-title>The future of antiviral immunotoxins</article-title><source>J. Leukoc. Biol.</source><year>2016</year><volume>99</volume><fpage>911</fpage><lpage>925</lpage><pub-id pub-id-type="doi">10.1189/jlb.2MR1015-468R</pub-id><pub-id pub-id-type="pmid">26729815</pub-id></element-citation><mixed-citation id="mc-CR313" publication-type="journal">Spiess, K., Jakobsen, M. H., Kledal, T. N. &amp; Rosenkilde, M. M. The future of antiviral immunotoxins. <italic toggle="yes">J. Leukoc. Biol.</italic><bold>99</bold>, 911&#8211;925 (2016).<pub-id pub-id-type="pmid">26729815</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1189/jlb.2MR1015-468R</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR314"><label>314.</label><citation-alternatives><element-citation id="ec-CR314" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><etal/></person-group><article-title>The potential and promise for clinical application of adoptive T cell therapy in cancer</article-title><source>J. Transl. Med.</source><year>2024</year><volume>22</volume><fpage>413</fpage><pub-id pub-id-type="doi">10.1186/s12967-024-05206-7</pub-id><pub-id pub-id-type="pmid">38693513</pub-id><pub-id pub-id-type="pmcid">PMC11064426</pub-id></element-citation><mixed-citation id="mc-CR314" publication-type="journal">Li, Y. et al. The potential and promise for clinical application of adoptive T cell therapy in cancer. <italic toggle="yes">J. Transl. Med.</italic><bold>22</bold>, 413 (2024).<pub-id pub-id-type="pmid">38693513</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12967-024-05206-7</pub-id><pub-id pub-id-type="pmcid">PMC11064426</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR315"><label>315.</label><citation-alternatives><element-citation id="ec-CR315" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chehrazi-Raffle</surname><given-names>A</given-names></name><name name-style="western"><surname>Budde</surname><given-names>LE</given-names></name><name name-style="western"><surname>Pal</surname><given-names>SK</given-names></name></person-group><article-title>Boosting CAR T cells with anti-tumor mRNA vaccines</article-title><source>Nat. Med.</source><year>2023</year><volume>29</volume><fpage>2711</fpage><lpage>2712</lpage><pub-id pub-id-type="doi">10.1038/s41591-023-02623-x</pub-id><pub-id pub-id-type="pmid">37932550</pub-id></element-citation><mixed-citation id="mc-CR315" publication-type="journal">Chehrazi-Raffle, A., Budde, L. E. &amp; Pal, S. K. Boosting CAR T cells with anti-tumor mRNA vaccines. <italic toggle="yes">Nat. Med.</italic><bold>29</bold>, 2711&#8211;2712 (2023).<pub-id pub-id-type="pmid">37932550</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-023-02623-x</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR316"><label>316.</label><citation-alternatives><element-citation id="ec-CR316" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mackensen</surname><given-names>A</given-names></name><etal/></person-group><article-title>CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial</article-title><source>Nat. Med.</source><year>2023</year><volume>29</volume><fpage>2844</fpage><lpage>2853</lpage><pub-id pub-id-type="doi">10.1038/s41591-023-02612-0</pub-id><pub-id pub-id-type="pmid">37872225</pub-id><pub-id pub-id-type="pmcid">PMC10667102</pub-id></element-citation><mixed-citation id="mc-CR316" publication-type="journal">Mackensen, A. et al. CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial. <italic toggle="yes">Nat. Med.</italic><bold>29</bold>, 2844&#8211;2853 (2023).<pub-id pub-id-type="pmid">37872225</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-023-02612-0</pub-id><pub-id pub-id-type="pmcid">PMC10667102</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR317"><label>317.</label><citation-alternatives><element-citation id="ec-CR317" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tomb&#225;cz</surname><given-names>I</given-names></name><etal/></person-group><article-title>Highly efficient CD4+ T cell targeting and genetic recombination using engineered CD4+ cell-homing mRNA-LNPs</article-title><source>Mol. Ther.</source><year>2021</year><volume>29</volume><fpage>3293</fpage><lpage>3304</lpage><pub-id pub-id-type="doi">10.1016/j.ymthe.2021.06.004</pub-id><pub-id pub-id-type="pmid">34091054</pub-id><pub-id pub-id-type="pmcid">PMC8571164</pub-id></element-citation><mixed-citation id="mc-CR317" publication-type="journal">Tomb&#225;cz, I. et al. Highly efficient CD4+ T cell targeting and genetic recombination using engineered CD4+ cell-homing mRNA-LNPs. <italic toggle="yes">Mol. Ther.</italic><bold>29</bold>, 3293&#8211;3304 (2021).<pub-id pub-id-type="pmid">34091054</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ymthe.2021.06.004</pub-id><pub-id pub-id-type="pmcid">PMC8571164</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR318"><label>318.</label><citation-alternatives><element-citation id="ec-CR318" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>J</given-names></name><etal/></person-group><article-title>Lipid nanoparticles produce chimeric antigen receptor T cells with interleukin-6 knockdown in vivo</article-title><source>J. Control Release</source><year>2022</year><volume>350</volume><fpage>298</fpage><lpage>307</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2022.08.033</pub-id><pub-id pub-id-type="pmid">36002054</pub-id></element-citation><mixed-citation id="mc-CR318" publication-type="journal">Zhou, J. et al. Lipid nanoparticles produce chimeric antigen receptor T cells with interleukin-6 knockdown in vivo. <italic toggle="yes">J. Control Release</italic><bold>350</bold>, 298&#8211;307 (2022).<pub-id pub-id-type="pmid">36002054</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jconrel.2022.08.033</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR319"><label>319.</label><citation-alternatives><element-citation id="ec-CR319" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rurik</surname><given-names>JG</given-names></name><etal/></person-group><article-title>CAR T cells produced in vivo to treat cardiac injury</article-title><source>Science</source><year>2022</year><volume>375</volume><fpage>91</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.1126/science.abm0594</pub-id><pub-id pub-id-type="pmid">34990237</pub-id><pub-id pub-id-type="pmcid">PMC9983611</pub-id></element-citation><mixed-citation id="mc-CR319" publication-type="journal">Rurik, J. G. et al. CAR T cells produced in vivo to treat cardiac injury. <italic toggle="yes">Science</italic><bold>375</bold>, 91&#8211;96 (2022).<pub-id pub-id-type="pmid">34990237</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.abm0594</pub-id><pub-id pub-id-type="pmcid">PMC9983611</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR320"><label>320.</label><citation-alternatives><element-citation id="ec-CR320" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liuzzo</surname><given-names>G</given-names></name><name name-style="western"><surname>Patrono</surname><given-names>C</given-names></name></person-group><article-title>In vivo generated chimeric antigen receptor T cells reduce fibrosis and restore cardiac function in experimental heart failure</article-title><source>Eur. Heart J.</source><year>2022</year><volume>43</volume><fpage>1531</fpage><lpage>1532</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehac090</pub-id><pub-id pub-id-type="pmid">35187570</pub-id></element-citation><mixed-citation id="mc-CR320" publication-type="journal">Liuzzo, G. &amp; Patrono, C. In vivo generated chimeric antigen receptor T cells reduce fibrosis and restore cardiac function in experimental heart failure. <italic toggle="yes">Eur. Heart J.</italic><bold>43</bold>, 1531&#8211;1532 (2022).<pub-id pub-id-type="pmid">35187570</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/eurheartj/ehac090</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR321"><label>321.</label><citation-alternatives><element-citation id="ec-CR321" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Blache</surname><given-names>U</given-names></name><name name-style="western"><surname>Tretbar</surname><given-names>S</given-names></name><name name-style="western"><surname>Koehl</surname><given-names>U</given-names></name><name name-style="western"><surname>Mougiakakos</surname><given-names>D</given-names></name><name name-style="western"><surname>Fricke</surname><given-names>S</given-names></name></person-group><article-title>CAR T cells for treating autoimmune diseases</article-title><source>RMD Open</source><year>2023</year><volume>9</volume><fpage>e002907</fpage><pub-id pub-id-type="doi">10.1136/rmdopen-2022-002907</pub-id><pub-id pub-id-type="pmid">37996128</pub-id><pub-id pub-id-type="pmcid">PMC10668249</pub-id></element-citation><mixed-citation id="mc-CR321" publication-type="journal">Blache, U., Tretbar, S., Koehl, U., Mougiakakos, D. &amp; Fricke, S. CAR T cells for treating autoimmune diseases. <italic toggle="yes">RMD Open</italic><bold>9</bold>, e002907 (2023).<pub-id pub-id-type="pmid">37996128</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/rmdopen-2022-002907</pub-id><pub-id pub-id-type="pmcid">PMC10668249</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR322"><label>322.</label><mixed-citation publication-type="other">Cartesian Therapeutics. Descartes-08 for patients with systemic lupus erythematosus. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/study/NCT06038474">https://clinicaltrials.gov/study/NCT06038474</ext-link> (2024).</mixed-citation></ref><ref id="CR323"><label>323.</label><citation-alternatives><element-citation id="ec-CR323" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thatte</surname><given-names>AS</given-names></name><etal/></person-group><article-title>mRNA lipid nanoparticles for ex vivo engineering of immunosuppressive T cells for autoimmunity therapies</article-title><source>Nano Lett.</source><year>2023</year><volume>23</volume><fpage>10179</fpage><lpage>10188</lpage><pub-id pub-id-type="doi">10.1021/acs.nanolett.3c02573</pub-id><pub-id pub-id-type="pmid">37906000</pub-id></element-citation><mixed-citation id="mc-CR323" publication-type="journal">Thatte, A. S. et al. mRNA lipid nanoparticles for ex vivo engineering of immunosuppressive T cells for autoimmunity therapies. <italic toggle="yes">Nano Lett.</italic><bold>23</bold>, 10179&#8211;10188 (2023).<pub-id pub-id-type="pmid">37906000</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.nanolett.3c02573</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR324"><label>324.</label><citation-alternatives><element-citation id="ec-CR324" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>F</given-names></name><etal/></person-group><article-title>Messenger RNA electroporated hepatitis B virus (HBV) antigen-specific T cell receptor (TCR) redirected T cell therapy is well-tolerated in patients with recurrent HBV-related hepatocellular carcinoma post-liver transplantation: results from a phase I trial</article-title><source>Hepatol. Int.</source><year>2023</year><volume>17</volume><fpage>850</fpage><lpage>859</lpage><pub-id pub-id-type="doi">10.1007/s12072-023-10524-x</pub-id><pub-id pub-id-type="pmid">37067675</pub-id></element-citation><mixed-citation id="mc-CR324" publication-type="journal">Yang, F. et al. Messenger RNA electroporated hepatitis B virus (HBV) antigen-specific T cell receptor (TCR) redirected T cell therapy is well-tolerated in patients with recurrent HBV-related hepatocellular carcinoma post-liver transplantation: results from a phase I trial. <italic toggle="yes">Hepatol. Int.</italic><bold>17</bold>, 850&#8211;859 (2023).<pub-id pub-id-type="pmid">37067675</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12072-023-10524-x</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR325"><label>325.</label><citation-alternatives><element-citation id="ec-CR325" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maggadottir</surname><given-names>SM</given-names></name><etal/></person-group><article-title>Transient TCR-based T cell therapy in a patient with advanced treatment-resistant MSI-high colorectal cancer</article-title><source>Mol. Ther.</source><year>2024</year><volume>32</volume><fpage>2021</fpage><lpage>2029</lpage><pub-id pub-id-type="doi">10.1016/j.ymthe.2024.04.009</pub-id><pub-id pub-id-type="pmid">38582964</pub-id><pub-id pub-id-type="pmcid">PMC11184326</pub-id></element-citation><mixed-citation id="mc-CR325" publication-type="journal">Maggadottir, S. M. et al. Transient TCR-based T cell therapy in a patient with advanced treatment-resistant MSI-high colorectal cancer. <italic toggle="yes">Mol. Ther.</italic><bold>32</bold>, 2021&#8211;2029 (2024).<pub-id pub-id-type="pmid">38582964</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ymthe.2024.04.009</pub-id><pub-id pub-id-type="pmcid">PMC11184326</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR326"><label>326.</label><citation-alternatives><element-citation id="ec-CR326" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ling</surname><given-names>K</given-names></name><etal/></person-group><article-title>Genome editing mRNA nanotherapies inhibit cervical cancer progression and regulate the immunosuppressive microenvironment for adoptive T-cell therapy</article-title><source>J. Control Release</source><year>2023</year><volume>360</volume><fpage>496</fpage><lpage>513</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2023.07.007</pub-id><pub-id pub-id-type="pmid">37423524</pub-id></element-citation><mixed-citation id="mc-CR326" publication-type="journal">Ling, K. et al. Genome editing mRNA nanotherapies inhibit cervical cancer progression and regulate the immunosuppressive microenvironment for adoptive T-cell therapy. <italic toggle="yes">J. Control Release</italic><bold>360</bold>, 496&#8211;513 (2023).<pub-id pub-id-type="pmid">37423524</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jconrel.2023.07.007</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR327"><label>327.</label><citation-alternatives><element-citation id="ec-CR327" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name><etal/></person-group><article-title>CAR-macrophage: a new immunotherapy candidate against solid tumors</article-title><source>Biomed. Pharmacother.</source><year>2021</year><volume>139</volume><fpage>111605</fpage><pub-id pub-id-type="doi">10.1016/j.biopha.2021.111605</pub-id><pub-id pub-id-type="pmid">33901872</pub-id></element-citation><mixed-citation id="mc-CR327" publication-type="journal">Chen, Y. et al. CAR-macrophage: a new immunotherapy candidate against solid tumors. <italic toggle="yes">Biomed. Pharmacother.</italic><bold>139</bold>, 111605 (2021).<pub-id pub-id-type="pmid">33901872</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biopha.2021.111605</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR328"><label>328.</label><citation-alternatives><element-citation id="ec-CR328" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reiss</surname><given-names>K</given-names></name><etal/></person-group><article-title>951 A phase 1 first in human study of adenovirally transduced anti-HER2 CAR macrophages in subjects with HER2 overexpressing solid tumors: preliminary safety, pharmacokinetics, and TME reprogramming data</article-title><source>J. Immunother. Cancer</source><year>2021</year><volume>9</volume><fpage>A1000</fpage></element-citation><mixed-citation id="mc-CR328" publication-type="journal">Reiss, K. et al. 951 A phase 1 first in human study of adenovirally transduced anti-HER2 CAR macrophages in subjects with HER2 overexpressing solid tumors: preliminary safety, pharmacokinetics, and TME reprogramming data. <italic toggle="yes">J. Immunother. Cancer</italic><bold>9</bold>, A1000 (2021).</mixed-citation></citation-alternatives></ref><ref id="CR329"><label>329.</label><citation-alternatives><element-citation id="ec-CR329" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kasimsetty</surname><given-names>S</given-names></name><name name-style="western"><surname>Gatla</surname><given-names>H</given-names></name><name name-style="western"><surname>Chinnasamy</surname><given-names>D</given-names></name></person-group><article-title>108 MCY-M11, a CAR-PBMC cell product transiently expressing a mesothelin targeted mRNA CAR, exhibits desirable functional and immune phenotype attributed to sustained antitumor immunity in vitro</article-title><source>J. Immunother. Cancer</source><year>2020</year><volume>8</volume><fpage>A67</fpage><lpage>A68</lpage></element-citation><mixed-citation id="mc-CR329" publication-type="journal">Kasimsetty, S., Gatla, H. &amp; Chinnasamy, D. 108 MCY-M11, a CAR-PBMC cell product transiently expressing a mesothelin targeted mRNA CAR, exhibits desirable functional and immune phenotype attributed to sustained antitumor immunity in vitro. <italic toggle="yes">J. Immunother. Cancer</italic><bold>8</bold>, A67&#8211;A68 (2020).</mixed-citation></citation-alternatives></ref><ref id="CR330"><label>330.</label><citation-alternatives><element-citation id="ec-CR330" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tang</surname><given-names>C</given-names></name><etal/></person-group><article-title>mRNA-laden lipid-nanoparticle-enabled in situ CAR-macrophage engineering for the eradication of multidrug-resistant bacteria in a sepsis mouse model</article-title><source>ACS Nano</source><year>2024</year><volume>18</volume><fpage>2261</fpage><lpage>2278</lpage><pub-id pub-id-type="doi">10.1021/acsnano.3c10109</pub-id><pub-id pub-id-type="pmid">38207332</pub-id></element-citation><mixed-citation id="mc-CR330" publication-type="journal">Tang, C. et al. mRNA-laden lipid-nanoparticle-enabled in situ CAR-macrophage engineering for the eradication of multidrug-resistant bacteria in a sepsis mouse model. <italic toggle="yes">ACS Nano</italic><bold>18</bold>, 2261&#8211;2278 (2024).<pub-id pub-id-type="pmid">38207332</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acsnano.3c10109</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR331"><label>331.</label><citation-alternatives><element-citation id="ec-CR331" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Close the cancer&#8211;immunity cycle by integrating lipid nanoparticle&#8211;mRNA formulations and dendritic cell therapy</article-title><source>Nat. Nanotechnol.</source><year>2023</year><volume>18</volume><fpage>1364</fpage><lpage>1374</lpage><pub-id pub-id-type="doi">10.1038/s41565-023-01453-9</pub-id><pub-id pub-id-type="pmid">37500773</pub-id><pub-id pub-id-type="pmcid">PMC11282451</pub-id></element-citation><mixed-citation id="mc-CR331" publication-type="journal">Zhang, Y. et al. Close the cancer&#8211;immunity cycle by integrating lipid nanoparticle&#8211;mRNA formulations and dendritic cell therapy. <italic toggle="yes">Nat. Nanotechnol.</italic><bold>18</bold>, 1364&#8211;1374 (2023).<pub-id pub-id-type="pmid">37500773</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41565-023-01453-9</pub-id><pub-id pub-id-type="pmcid">PMC11282451</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR332"><label>332.</label><mixed-citation publication-type="other">Dueland, S. Phase I/II trial of vaccine therapy with mRNA- transfected dendritic cells in patients with advanced malignant melanoma. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/study/NCT01278940">https://clinicaltrials.gov/study/NCT01278940</ext-link> (2016).</mixed-citation></ref><ref id="CR333"><label>333.</label><citation-alternatives><element-citation id="ec-CR333" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kyte</surname><given-names>JA</given-names></name><etal/></person-group><article-title>Phase I/II trial of melanoma therapy with dendritic cells transfected with autologous tumor-mRNA</article-title><source>Cancer Gene Ther.</source><year>2006</year><volume>13</volume><fpage>905</fpage><lpage>918</lpage><pub-id pub-id-type="doi">10.1038/sj.cgt.7700961</pub-id><pub-id pub-id-type="pmid">16710345</pub-id></element-citation><mixed-citation id="mc-CR333" publication-type="journal">Kyte, J. A. et al. Phase I/II trial of melanoma therapy with dendritic cells transfected with autologous tumor-mRNA. <italic toggle="yes">Cancer Gene Ther.</italic><bold>13</bold>, 905&#8211;918 (2006).<pub-id pub-id-type="pmid">16710345</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/sj.cgt.7700961</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR334"><label>334.</label><citation-alternatives><element-citation id="ec-CR334" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anguille</surname><given-names>S</given-names></name><etal/></person-group><article-title>Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemia</article-title><source>Blood</source><year>2017</year><volume>130</volume><fpage>1713</fpage><lpage>1721</lpage><pub-id pub-id-type="doi">10.1182/blood-2017-04-780155</pub-id><pub-id pub-id-type="pmid">28830889</pub-id><pub-id pub-id-type="pmcid">PMC5649080</pub-id></element-citation><mixed-citation id="mc-CR334" publication-type="journal">Anguille, S. et al. Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemia. <italic toggle="yes">Blood</italic><bold>130</bold>, 1713&#8211;1721 (2017).<pub-id pub-id-type="pmid">28830889</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1182/blood-2017-04-780155</pub-id><pub-id pub-id-type="pmcid">PMC5649080</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR335"><label>335.</label><citation-alternatives><element-citation id="ec-CR335" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qin</surname><given-names>S</given-names></name><etal/></person-group><article-title>mRNA-based therapeutics: powerful and versatile tools to combat diseases</article-title><source>Signal Transduct. Target. Ther.</source><year>2022</year><volume>7</volume><fpage>166</fpage><pub-id pub-id-type="doi">10.1038/s41392-022-01007-w</pub-id><pub-id pub-id-type="pmid">35597779</pub-id><pub-id pub-id-type="pmcid">PMC9123296</pub-id></element-citation><mixed-citation id="mc-CR335" publication-type="journal">Qin, S. et al. mRNA-based therapeutics: powerful and versatile tools to combat diseases. <italic toggle="yes">Signal Transduct. Target. Ther.</italic><bold>7</bold>, 166 (2022).<pub-id pub-id-type="pmid">35597779</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41392-022-01007-w</pub-id><pub-id pub-id-type="pmcid">PMC9123296</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR336"><label>336.</label><citation-alternatives><element-citation id="ec-CR336" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sahin</surname><given-names>U</given-names></name><name name-style="western"><surname>Karik&#243;</surname><given-names>K</given-names></name><name name-style="western"><surname>T&#252;reci</surname><given-names>&#214;</given-names></name></person-group><article-title>mRNA-based therapeutics&#8212;developing a new class of drugs</article-title><source>Nat. Rev. Drug Discov.</source><year>2014</year><volume>13</volume><fpage>759</fpage><lpage>780</lpage><pub-id pub-id-type="doi">10.1038/nrd4278</pub-id><pub-id pub-id-type="pmid">25233993</pub-id></element-citation><mixed-citation id="mc-CR336" publication-type="journal">Sahin, U., Karik&#243;, K. &amp; T&#252;reci, &#214;. mRNA-based therapeutics&#8212;developing a new class of drugs. <italic toggle="yes">Nat. Rev. Drug Discov.</italic><bold>13</bold>, 759&#8211;780 (2014).<pub-id pub-id-type="pmid">25233993</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrd4278</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR337"><label>337.</label><citation-alternatives><element-citation id="ec-CR337" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vlatkovic</surname><given-names>I</given-names></name></person-group><article-title>Non-immunotherapy application of LNP-mRNA: maximizing efficacy and safety</article-title><source>Biomedicines</source><year>2021</year><volume>9</volume><fpage>530</fpage><pub-id pub-id-type="doi">10.3390/biomedicines9050530</pub-id><pub-id pub-id-type="pmid">34068715</pub-id><pub-id pub-id-type="pmcid">PMC8151051</pub-id></element-citation><mixed-citation id="mc-CR337" publication-type="journal">Vlatkovic, I. Non-immunotherapy application of LNP-mRNA: maximizing efficacy and safety. <italic toggle="yes">Biomedicines</italic><bold>9</bold>, 530 (2021).<pub-id pub-id-type="pmid">34068715</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/biomedicines9050530</pub-id><pub-id pub-id-type="pmcid">PMC8151051</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR338"><label>338.</label><citation-alternatives><element-citation id="ec-CR338" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rohner</surname><given-names>E</given-names></name><name name-style="western"><surname>Yang</surname><given-names>R</given-names></name><name name-style="western"><surname>Foo</surname><given-names>KS</given-names></name><name name-style="western"><surname>Goedel</surname><given-names>A</given-names></name><name name-style="western"><surname>Chien</surname><given-names>KR</given-names></name></person-group><article-title>Unlocking the promise of mRNA therapeutics</article-title><source>Nat. Biotechnol.</source><year>2022</year><volume>40</volume><fpage>1586</fpage><lpage>1600</lpage><pub-id pub-id-type="doi">10.1038/s41587-022-01491-z</pub-id><pub-id pub-id-type="pmid">36329321</pub-id></element-citation><mixed-citation id="mc-CR338" publication-type="journal">Rohner, E., Yang, R., Foo, K. S., Goedel, A. &amp; Chien, K. R. Unlocking the promise of mRNA therapeutics. <italic toggle="yes">Nat. Biotechnol.</italic><bold>40</bold>, 1586&#8211;1600 (2022).<pub-id pub-id-type="pmid">36329321</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41587-022-01491-z</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR339"><label>339.</label><citation-alternatives><element-citation id="ec-CR339" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lonez</surname><given-names>C</given-names></name><etal/></person-group><article-title>Critical residues involved in Toll-like receptor 4 activation by cationic lipid nanocarriers are not located at the lipopolysaccharide-binding interface</article-title><source>Cell. Mol. Life Sci.</source><year>2015</year><volume>72</volume><fpage>3971</fpage><lpage>3982</lpage><pub-id pub-id-type="doi">10.1007/s00018-015-1915-1</pub-id><pub-id pub-id-type="pmid">25956320</pub-id><pub-id pub-id-type="pmcid">PMC4575701</pub-id></element-citation><mixed-citation id="mc-CR339" publication-type="journal">Lonez, C. et al. Critical residues involved in Toll-like receptor 4 activation by cationic lipid nanocarriers are not located at the lipopolysaccharide-binding interface. <italic toggle="yes">Cell. Mol. Life Sci.</italic><bold>72</bold>, 3971&#8211;3982 (2015).<pub-id pub-id-type="pmid">25956320</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00018-015-1915-1</pub-id><pub-id pub-id-type="pmcid">PMC4575701</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR340"><label>340.</label><citation-alternatives><element-citation id="ec-CR340" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Romerio</surname><given-names>A</given-names></name><name name-style="western"><surname>Peri</surname><given-names>F</given-names></name></person-group><article-title>Increasing the chemical variety of small-molecule-based TLR4 modulators: an overview</article-title><source>Front. Immunol.</source><year>2020</year><volume>11</volume><fpage>1210</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2020.01210</pub-id><pub-id pub-id-type="pmid">32765484</pub-id><pub-id pub-id-type="pmcid">PMC7381287</pub-id></element-citation><mixed-citation id="mc-CR340" publication-type="journal">Romerio, A. &amp; Peri, F. Increasing the chemical variety of small-molecule-based TLR4 modulators: an overview. <italic toggle="yes">Front. Immunol.</italic><bold>11</bold>, 1210 (2020).<pub-id pub-id-type="pmid">32765484</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2020.01210</pub-id><pub-id pub-id-type="pmcid">PMC7381287</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR341"><label>341.</label><citation-alternatives><element-citation id="ec-CR341" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kedmi</surname><given-names>R</given-names></name><name name-style="western"><surname>Ben-Arie</surname><given-names>N</given-names></name><name name-style="western"><surname>Peer</surname><given-names>D</given-names></name></person-group><article-title>The systemic toxicity of positively charged lipid nanoparticles and the role of Toll-like receptor 4 in immune activation</article-title><source>Biomaterials</source><year>2010</year><volume>31</volume><fpage>6867</fpage><lpage>6875</lpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2010.05.027</pub-id><pub-id pub-id-type="pmid">20541799</pub-id></element-citation><mixed-citation id="mc-CR341" publication-type="journal">Kedmi, R., Ben-Arie, N. &amp; Peer, D. The systemic toxicity of positively charged lipid nanoparticles and the role of Toll-like receptor 4 in immune activation. <italic toggle="yes">Biomaterials</italic><bold>31</bold>, 6867&#8211;6875 (2010).<pub-id pub-id-type="pmid">20541799</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biomaterials.2010.05.027</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR342"><label>342.</label><citation-alternatives><element-citation id="ec-CR342" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lonez</surname><given-names>C</given-names></name><etal/></person-group><article-title>Cationic lipid nanocarriers activate Toll-like receptor 2 and NLRP3 inflammasome pathways</article-title><source>Nanomed. Nanotechnol. Biol. Med.</source><year>2014</year><volume>10</volume><fpage>775</fpage><lpage>782</lpage><pub-id pub-id-type="doi">10.1016/j.nano.2013.12.003</pub-id><pub-id pub-id-type="pmid">24361386</pub-id></element-citation><mixed-citation id="mc-CR342" publication-type="journal">Lonez, C. et al. Cationic lipid nanocarriers activate Toll-like receptor 2 and NLRP3 inflammasome pathways. <italic toggle="yes">Nanomed. Nanotechnol. Biol. Med.</italic><bold>10</bold>, 775&#8211;782 (2014).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.nano.2013.12.003</pub-id><pub-id pub-id-type="pmid">24361386</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR343"><label>343.</label><citation-alternatives><element-citation id="ec-CR343" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qin</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ou</surname><given-names>L</given-names></name><name name-style="western"><surname>Zha</surname><given-names>L</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>L</given-names></name></person-group><article-title>Delivery of nucleic acids using nanomaterials</article-title><source>Mol. Biomed.</source><year>2023</year><volume>4</volume><fpage>48</fpage><pub-id pub-id-type="doi">10.1186/s43556-023-00160-0</pub-id><pub-id pub-id-type="pmid">38092998</pub-id><pub-id pub-id-type="pmcid">PMC10719232</pub-id></element-citation><mixed-citation id="mc-CR343" publication-type="journal">Qin, Y., Ou, L., Zha, L., Zeng, Y. &amp; Li, L. Delivery of nucleic acids using nanomaterials. <italic toggle="yes">Mol. Biomed.</italic><bold>4</bold>, 48 (2023).<pub-id pub-id-type="pmid">38092998</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s43556-023-00160-0</pub-id><pub-id pub-id-type="pmcid">PMC10719232</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR344"><label>344.</label><citation-alternatives><element-citation id="ec-CR344" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ohto</surname><given-names>T</given-names></name><etal/></person-group><article-title>Inhibition of the inflammatory pathway enhances both the in vitro and in vivo transfection activity of exogenous in vitro-transcribed mRNAs delivered by lipid nanoparticles</article-title><source>Biol. Pharm. Bull.</source><year>2019</year><volume>42</volume><fpage>299</fpage><lpage>302</lpage><pub-id pub-id-type="doi">10.1248/bpb.b18-00783</pub-id><pub-id pub-id-type="pmid">30713260</pub-id></element-citation><mixed-citation id="mc-CR344" publication-type="journal">Ohto, T. et al. Inhibition of the inflammatory pathway enhances both the in vitro and in vivo transfection activity of exogenous in vitro-transcribed mRNAs delivered by lipid nanoparticles. <italic toggle="yes">Biol. Pharm. Bull.</italic><bold>42</bold>, 299&#8211;302 (2019).<pub-id pub-id-type="pmid">30713260</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1248/bpb.b18-00783</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR345"><label>345.</label><citation-alternatives><element-citation id="ec-CR345" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vavilis</surname><given-names>T</given-names></name><etal/></person-group><article-title>mRNA in the context of protein replacement therapy</article-title><source>Pharmaceutics</source><year>2023</year><volume>15</volume><fpage>166</fpage><pub-id pub-id-type="doi">10.3390/pharmaceutics15010166</pub-id><pub-id pub-id-type="pmid">36678793</pub-id><pub-id pub-id-type="pmcid">PMC9866414</pub-id></element-citation><mixed-citation id="mc-CR345" publication-type="journal">Vavilis, T. et al. mRNA in the context of protein replacement therapy. <italic toggle="yes">Pharmaceutics</italic><bold>15</bold>, 166 (2023).<pub-id pub-id-type="pmid">36678793</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/pharmaceutics15010166</pub-id><pub-id pub-id-type="pmcid">PMC9866414</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR346"><label>346.</label><citation-alternatives><element-citation id="ec-CR346" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schwarze</surname><given-names>SR</given-names></name><name name-style="western"><surname>Ho</surname><given-names>A</given-names></name><name name-style="western"><surname>Vocero-Akbani</surname><given-names>A</given-names></name><name name-style="western"><surname>Dowdy</surname><given-names>SF</given-names></name></person-group><article-title>In vivo protein transduction: delivery of a biologically active protein into the mouse</article-title><source>Science</source><year>1999</year><volume>285</volume><fpage>1569</fpage><lpage>1572</lpage><pub-id pub-id-type="doi">10.1126/science.285.5433.1569</pub-id><pub-id pub-id-type="pmid">10477521</pub-id></element-citation><mixed-citation id="mc-CR346" publication-type="journal">Schwarze, S. R., Ho, A., Vocero-Akbani, A. &amp; Dowdy, S. F. In vivo protein transduction: delivery of a biologically active protein into the mouse. <italic toggle="yes">Science</italic><bold>285</bold>, 1569&#8211;1572 (1999).<pub-id pub-id-type="pmid">10477521</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.285.5433.1569</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR347"><label>347.</label><citation-alternatives><element-citation id="ec-CR347" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>C-Y</given-names></name><etal/></person-group><article-title>Treatment of hemophilia A using factor VIII messenger RNA lipid nanoparticles</article-title><source>Mol. Ther. Nucleic Acids</source><year>2020</year><volume>20</volume><fpage>534</fpage><lpage>544</lpage><pub-id pub-id-type="doi">10.1016/j.omtn.2020.03.015</pub-id><pub-id pub-id-type="pmid">32330871</pub-id><pub-id pub-id-type="pmcid">PMC7178004</pub-id></element-citation><mixed-citation id="mc-CR347" publication-type="journal">Chen, C.-Y. et al. Treatment of hemophilia A using factor VIII messenger RNA lipid nanoparticles. <italic toggle="yes">Mol. Ther. Nucleic Acids</italic><bold>20</bold>, 534&#8211;544 (2020).<pub-id pub-id-type="pmid">32330871</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.omtn.2020.03.015</pub-id><pub-id pub-id-type="pmcid">PMC7178004</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR348"><label>348.</label><mixed-citation publication-type="other">Commissioner, O. of the. FDA approves first gene therapy for adults with severe hemophilia A. <italic toggle="yes">FDA</italic><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapy-adults-severe-hemophilia">https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapy-adults-severe-hemophilia</ext-link> (2023).</mixed-citation></ref><ref id="CR349"><label>349.</label><citation-alternatives><element-citation id="ec-CR349" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Prieve</surname><given-names>MG</given-names></name><etal/></person-group><article-title>Targeted mRNA therapy for ornithine transcarbamylase deficiency</article-title><source>Mol. Ther.</source><year>2018</year><volume>26</volume><fpage>801</fpage><lpage>813</lpage><pub-id pub-id-type="doi">10.1016/j.ymthe.2017.12.024</pub-id><pub-id pub-id-type="pmid">29433939</pub-id><pub-id pub-id-type="pmcid">PMC5910669</pub-id></element-citation><mixed-citation id="mc-CR349" publication-type="journal">Prieve, M. G. et al. Targeted mRNA therapy for ornithine transcarbamylase deficiency. <italic toggle="yes">Mol. Ther.</italic><bold>26</bold>, 801&#8211;813 (2018).<pub-id pub-id-type="pmid">29433939</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ymthe.2017.12.024</pub-id><pub-id pub-id-type="pmcid">PMC5910669</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR350"><label>350.</label><mixed-citation publication-type="other">Arcturus Therapeutics, Inc. Phase 2, randomized, double-blind, placebo-controlled, nested single and multiple ascending dose study to evaluate the safety, tolerability and pharmacokinetics of ARCT-810 in adolescent and adult participants with ornithine transcarbamylase deficiency. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/study/NCT05526066">https://clinicaltrials.gov/study/NCT05526066</ext-link> (2023).</mixed-citation></ref><ref id="CR351"><label>351.</label><citation-alternatives><element-citation id="ec-CR351" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>DeRosa</surname><given-names>F</given-names></name><etal/></person-group><article-title>Improved efficacy in a fabry disease model using a systemic mRNA liver depot system as compared to enzyme replacement therapy</article-title><source>Mol. Ther.</source><year>2019</year><volume>27</volume><fpage>878</fpage><lpage>889</lpage><pub-id pub-id-type="doi">10.1016/j.ymthe.2019.03.001</pub-id><pub-id pub-id-type="pmid">30879951</pub-id><pub-id pub-id-type="pmcid">PMC6453518</pub-id></element-citation><mixed-citation id="mc-CR351" publication-type="journal">DeRosa, F. et al. Improved efficacy in a fabry disease model using a systemic mRNA liver depot system as compared to enzyme replacement therapy. <italic toggle="yes">Mol. Ther.</italic><bold>27</bold>, 878&#8211;889 (2019).<pub-id pub-id-type="pmid">30879951</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ymthe.2019.03.001</pub-id><pub-id pub-id-type="pmcid">PMC6453518</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR352"><label>352.</label><citation-alternatives><element-citation id="ec-CR352" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rodr&#237;guez-Castej&#243;n</surname><given-names>J</given-names></name><name name-style="western"><surname>Beraza-Millor</surname><given-names>M</given-names></name><name name-style="western"><surname>Solin&#237;s</surname><given-names>M&#193;</given-names></name><name name-style="western"><surname>Rodr&#237;guez-Gasc&#243;n</surname><given-names>A</given-names></name><name name-style="western"><surname>del Pozo-Rodr&#237;guez</surname><given-names>A</given-names></name></person-group><article-title>Targeting strategies with lipid vectors for nucleic acid supplementation therapy in Fabry disease: a systematic review</article-title><source>Drug Deliv. Transl. Res.</source><year>2024</year><volume>14</volume><fpage>2615</fpage><lpage>2628</lpage><pub-id pub-id-type="doi">10.1007/s13346-024-01583-0</pub-id><pub-id pub-id-type="pmid">38587758</pub-id><pub-id pub-id-type="pmcid">PMC11383842</pub-id></element-citation><mixed-citation id="mc-CR352" publication-type="journal">Rodr&#237;guez-Castej&#243;n, J., Beraza-Millor, M., Solin&#237;s, M. &#193;., Rodr&#237;guez-Gasc&#243;n, A. &amp; del Pozo-Rodr&#237;guez, A. Targeting strategies with lipid vectors for nucleic acid supplementation therapy in Fabry disease: a systematic review. <italic toggle="yes">Drug Deliv. Transl. Res.</italic><bold>14</bold>, 2615&#8211;2628 (2024).<pub-id pub-id-type="pmid">38587758</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s13346-024-01583-0</pub-id><pub-id pub-id-type="pmcid">PMC11383842</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR353"><label>353.</label><citation-alternatives><element-citation id="ec-CR353" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>X</given-names></name><etal/></person-group><article-title>Systemic mRNA therapy for the treatment of fabry disease: preclinical studies in wild-type mice, fabry mouse model, and wild-type non-human primates</article-title><source>Am. J. Hum. Genet.</source><year>2019</year><volume>104</volume><fpage>625</fpage><lpage>637</lpage><pub-id pub-id-type="doi">10.1016/j.ajhg.2019.02.003</pub-id><pub-id pub-id-type="pmid">30879639</pub-id><pub-id pub-id-type="pmcid">PMC6451694</pub-id></element-citation><mixed-citation id="mc-CR353" publication-type="journal">Zhu, X. et al. Systemic mRNA therapy for the treatment of fabry disease: preclinical studies in wild-type mice, fabry mouse model, and wild-type non-human primates. <italic toggle="yes">Am. J. Hum. Genet.</italic><bold>104</bold>, 625&#8211;637 (2019).<pub-id pub-id-type="pmid">30879639</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ajhg.2019.02.003</pub-id><pub-id pub-id-type="pmcid">PMC6451694</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR354"><label>354.</label><citation-alternatives><element-citation id="ec-CR354" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Koeberl</surname><given-names>D</given-names></name><etal/></person-group><article-title>Interim analyses of a first-in-human phase 1/2 mRNA trial for propionic acidaemia</article-title><source>Nature</source><year>2024</year><volume>628</volume><fpage>872</fpage><lpage>877</lpage><pub-id pub-id-type="doi">10.1038/s41586-024-07266-7</pub-id><pub-id pub-id-type="pmid">38570682</pub-id><pub-id pub-id-type="pmcid">PMC11156579</pub-id></element-citation><mixed-citation id="mc-CR354" publication-type="journal">Koeberl, D. et al. Interim analyses of a first-in-human phase 1/2 mRNA trial for propionic acidaemia. <italic toggle="yes">Nature</italic><bold>628</bold>, 872&#8211;877 (2024).<pub-id pub-id-type="pmid">38570682</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-024-07266-7</pub-id><pub-id pub-id-type="pmcid">PMC11156579</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR355"><label>355.</label><citation-alternatives><element-citation id="ec-CR355" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Behyar</surname><given-names>MB</given-names></name><name name-style="western"><surname>Mirzaie</surname><given-names>A</given-names></name><name name-style="western"><surname>Hasanzadeh</surname><given-names>M</given-names></name><name name-style="western"><surname>Shadjou</surname><given-names>N</given-names></name></person-group><article-title>Advancements in biosensing of hormones: recent progress and future trends</article-title><source>Trends Anal. Chem.</source><year>2024</year><volume>173</volume><fpage>117600</fpage><pub-id pub-id-type="doi">10.1016/j.trac.2024.117600</pub-id></element-citation><mixed-citation id="mc-CR355" publication-type="journal">Behyar, M. B., Mirzaie, A., Hasanzadeh, M. &amp; Shadjou, N. Advancements in biosensing of hormones: recent progress and future trends. <italic toggle="yes">Trends Anal. Chem.</italic><bold>173</bold>, 117600 (2024).</mixed-citation></citation-alternatives></ref><ref id="CR356"><label>356.</label><citation-alternatives><element-citation id="ec-CR356" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kielb</surname><given-names>J</given-names></name><etal/></person-group><article-title>Transformation or replacement&#8212;effects of hormone therapy on cardiovascular risk</article-title><source>Pharmacol. Ther.</source><year>2024</year><volume>254</volume><fpage>108592</fpage><pub-id pub-id-type="doi">10.1016/j.pharmthera.2024.108592</pub-id><pub-id pub-id-type="pmid">38286163</pub-id></element-citation><mixed-citation id="mc-CR356" publication-type="journal">Kielb, J. et al. Transformation or replacement&#8212;effects of hormone therapy on cardiovascular risk. <italic toggle="yes">Pharmacol. Ther.</italic><bold>254</bold>, 108592 (2024).<pub-id pub-id-type="pmid">38286163</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.pharmthera.2024.108592</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR357"><label>357.</label><citation-alternatives><element-citation id="ec-CR357" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jirikowski</surname><given-names>GF</given-names></name><name name-style="western"><surname>Sanna</surname><given-names>PP</given-names></name><name name-style="western"><surname>Maciejewski-Lenoir</surname><given-names>D</given-names></name><name name-style="western"><surname>Bloom</surname><given-names>FE</given-names></name></person-group><article-title>Reversal of diabetes insipidus in Brattleboro rats: intrahypothalamic injection of vasopressin mRNA</article-title><source>Science</source><year>1992</year><volume>255</volume><fpage>996</fpage><lpage>998</lpage><pub-id pub-id-type="doi">10.1126/science.1546298</pub-id><pub-id pub-id-type="pmid">1546298</pub-id></element-citation><mixed-citation id="mc-CR357" publication-type="journal">Jirikowski, G. F., Sanna, P. P., Maciejewski-Lenoir, D. &amp; Bloom, F. E. Reversal of diabetes insipidus in Brattleboro rats: intrahypothalamic injection of vasopressin mRNA. <italic toggle="yes">Science</italic><bold>255</bold>, 996&#8211;998 (1992).<pub-id pub-id-type="pmid">1546298</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.1546298</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR358"><label>358.</label><citation-alternatives><element-citation id="ec-CR358" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>R</given-names></name><name name-style="western"><surname>Shi</surname><given-names>J</given-names></name><name name-style="western"><surname>Wei</surname><given-names>R</given-names></name><name name-style="western"><surname>Li</surname><given-names>J</given-names></name></person-group><article-title>Challenges of insulin-like growth factor-1 testing</article-title><source>Crit. Rev. Clin. Lab. Sci.</source><year>2024</year><volume>61</volume><fpage>388</fpage><lpage>403</lpage><pub-id pub-id-type="doi">10.1080/10408363.2024.2306804</pub-id><pub-id pub-id-type="pmid">38323343</pub-id></element-citation><mixed-citation id="mc-CR358" publication-type="journal">Huang, R., Shi, J., Wei, R. &amp; Li, J. Challenges of insulin-like growth factor-1 testing. <italic toggle="yes">Crit. Rev. Clin. Lab. Sci.</italic><bold>61</bold>, 388&#8211;403 (2024).<pub-id pub-id-type="pmid">38323343</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/10408363.2024.2306804</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR359"><label>359.</label><citation-alternatives><element-citation id="ec-CR359" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>H</given-names></name><etal/></person-group><article-title>Engineered adipose-derived stem cells with IGF-1-modified mRNA ameliorates osteoarthritis development</article-title><source>Stem Cell Res. Ther.</source><year>2022</year><volume>13</volume><fpage>19</fpage><pub-id pub-id-type="doi">10.1186/s13287-021-02695-x</pub-id><pub-id pub-id-type="pmid">35033199</pub-id><pub-id pub-id-type="pmcid">PMC8760691</pub-id></element-citation><mixed-citation id="mc-CR359" publication-type="journal">Wu, H. et al. Engineered adipose-derived stem cells with IGF-1-modified mRNA ameliorates osteoarthritis development. <italic toggle="yes">Stem Cell Res. Ther.</italic><bold>13</bold>, 19 (2022).<pub-id pub-id-type="pmid">35033199</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13287-021-02695-x</pub-id><pub-id pub-id-type="pmcid">PMC8760691</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR360"><label>360.</label><citation-alternatives><element-citation id="ec-CR360" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zangi</surname><given-names>L</given-names></name><etal/></person-group><article-title>Modified mRNA directs the fate of heart progenitor cells and induces vascular regeneration after myocardial infarction</article-title><source>Nat. Biotechnol.</source><year>2013</year><volume>31</volume><fpage>898</fpage><lpage>907</lpage><pub-id pub-id-type="doi">10.1038/nbt.2682</pub-id><pub-id pub-id-type="pmid">24013197</pub-id><pub-id pub-id-type="pmcid">PMC4058317</pub-id></element-citation><mixed-citation id="mc-CR360" publication-type="journal">Zangi, L. et al. Modified mRNA directs the fate of heart progenitor cells and induces vascular regeneration after myocardial infarction. <italic toggle="yes">Nat. Biotechnol.</italic><bold>31</bold>, 898&#8211;907 (2013).<pub-id pub-id-type="pmid">24013197</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nbt.2682</pub-id><pub-id pub-id-type="pmcid">PMC4058317</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR361"><label>361.</label><citation-alternatives><element-citation id="ec-CR361" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Coll&#233;n</surname><given-names>A</given-names></name><etal/></person-group><article-title>VEGFA mRNA for regenerative treatment of heart failure</article-title><source>Nat. Rev. Drug Discov.</source><year>2022</year><volume>21</volume><fpage>79</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1038/s41573-021-00355-6</pub-id><pub-id pub-id-type="pmid">34873303</pub-id><pub-id pub-id-type="pmcid">PMC8646349</pub-id></element-citation><mixed-citation id="mc-CR361" publication-type="journal">Coll&#233;n, A. et al. VEGFA mRNA for regenerative treatment of heart failure. <italic toggle="yes">Nat. Rev. Drug Discov.</italic><bold>21</bold>, 79&#8211;80 (2022).<pub-id pub-id-type="pmid">34873303</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41573-021-00355-6</pub-id><pub-id pub-id-type="pmcid">PMC8646349</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR362"><label>362.</label><citation-alternatives><element-citation id="ec-CR362" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anttila</surname><given-names>V</given-names></name><etal/></person-group><article-title>Synthetic mRNA encoding VEGF-A in patients undergoing coronary artery bypass grafting: design of a phase 2a clinical trial</article-title><source>Mol. Ther. Methods Clin. Dev.</source><year>2020</year><volume>18</volume><fpage>464</fpage><lpage>472</lpage><pub-id pub-id-type="doi">10.1016/j.omtm.2020.05.030</pub-id><pub-id pub-id-type="pmid">32728595</pub-id><pub-id pub-id-type="pmcid">PMC7369517</pub-id></element-citation><mixed-citation id="mc-CR362" publication-type="journal">Anttila, V. et al. Synthetic mRNA encoding VEGF-A in patients undergoing coronary artery bypass grafting: design of a phase 2a clinical trial. <italic toggle="yes">Mol. Ther. Methods Clin. Dev.</italic><bold>18</bold>, 464&#8211;472 (2020).<pub-id pub-id-type="pmid">32728595</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.omtm.2020.05.030</pub-id><pub-id pub-id-type="pmcid">PMC7369517</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR363"><label>363.</label><citation-alternatives><element-citation id="ec-CR363" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Cell-mediated delivery of VEGF modified mRNA enhances blood vessel regeneration and ameliorates murine critical limb ischemia</article-title><source>J. Control Release</source><year>2019</year><volume>310</volume><fpage>103</fpage><lpage>114</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2019.08.014</pub-id><pub-id pub-id-type="pmid">31425721</pub-id></element-citation><mixed-citation id="mc-CR363" publication-type="journal">Yu, Z. et al. Cell-mediated delivery of VEGF modified mRNA enhances blood vessel regeneration and ameliorates murine critical limb ischemia. <italic toggle="yes">J. Control Release</italic><bold>310</bold>, 103&#8211;114 (2019).<pub-id pub-id-type="pmid">31425721</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jconrel.2019.08.014</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR364"><label>364.</label><citation-alternatives><element-citation id="ec-CR364" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nawaz</surname><given-names>M</given-names></name><etal/></person-group><article-title>lipid nanoparticles deliver the therapeutic VEGFA mRNA in vitro and in vivo and transform extracellular vesicles for their functional extensions</article-title><source>Adv. Sci.</source><year>2023</year><volume>10</volume><fpage>2206187</fpage><pub-id pub-id-type="doi">10.1002/advs.202206187</pub-id><pub-id pub-id-type="pmcid">PMC10131815</pub-id><pub-id pub-id-type="pmid">36806740</pub-id></element-citation><mixed-citation id="mc-CR364" publication-type="journal">Nawaz, M. et al. lipid nanoparticles deliver the therapeutic VEGFA mRNA in vitro and in vivo and transform extracellular vesicles for their functional extensions. <italic toggle="yes">Adv. Sci.</italic><bold>10</bold>, 2206187 (2023).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/advs.202206187</pub-id><pub-id pub-id-type="pmcid">PMC10131815</pub-id><pub-id pub-id-type="pmid">36806740</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR365"><label>365.</label><citation-alternatives><element-citation id="ec-CR365" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kapoor</surname><given-names>N</given-names></name><name name-style="western"><surname>Galang</surname><given-names>G</given-names></name><name name-style="western"><surname>Marb&#225;n</surname><given-names>E</given-names></name><name name-style="western"><surname>Cho</surname><given-names>HC</given-names></name></person-group><article-title>Transcriptional suppression of Connexin43 by TBX18 undermines cell-cell electrical coupling in postnatal cardiomyocytes</article-title><source>J. Biol. Chem.</source><year>2011</year><volume>286</volume><fpage>14073</fpage><lpage>14079</lpage><pub-id pub-id-type="doi">10.1074/jbc.M110.185298</pub-id><pub-id pub-id-type="pmid">21205823</pub-id><pub-id pub-id-type="pmcid">PMC3077608</pub-id></element-citation><mixed-citation id="mc-CR365" publication-type="journal">Kapoor, N., Galang, G., Marb&#225;n, E. &amp; Cho, H. C. Transcriptional suppression of Connexin43 by TBX18 undermines cell-cell electrical coupling in postnatal cardiomyocytes. <italic toggle="yes">J. Biol. Chem.</italic><bold>286</bold>, 14073&#8211;14079 (2011).<pub-id pub-id-type="pmid">21205823</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1074/jbc.M110.185298</pub-id><pub-id pub-id-type="pmcid">PMC3077608</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR366"><label>366.</label><mixed-citation publication-type="other">Wolfson, D. W. et al. Transient pacing in pigs with complete heart block via myocardial injection of mRNA coding for the T-box transcription factor 18. <italic toggle="yes">Nat. Biomed. Eng</italic>. 10.1038/s41551-024-01211-9 (2024).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41551-024-01211-9</pub-id><pub-id pub-id-type="pmcid">PMC11410671</pub-id><pub-id pub-id-type="pmid">38698155</pub-id></mixed-citation></ref><ref id="CR367"><label>367.</label><citation-alternatives><element-citation id="ec-CR367" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>T</given-names></name><etal/></person-group><article-title>Therapeutic HNF4A mRNA attenuates liver fibrosis in a preclinical model</article-title><source>J. Hepatol.</source><year>2021</year><volume>75</volume><fpage>1420</fpage><lpage>1433</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2021.08.011</pub-id><pub-id pub-id-type="pmid">34453962</pub-id></element-citation><mixed-citation id="mc-CR367" publication-type="journal">Yang, T. et al. Therapeutic HNF4A mRNA attenuates liver fibrosis in a preclinical model. <italic toggle="yes">J. Hepatol.</italic><bold>75</bold>, 1420&#8211;1433 (2021).<pub-id pub-id-type="pmid">34453962</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jhep.2021.08.011</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR368"><label>368.</label><citation-alternatives><element-citation id="ec-CR368" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shteinberg</surname><given-names>M</given-names></name><name name-style="western"><surname>Haq</surname><given-names>IJ</given-names></name><name name-style="western"><surname>Polineni</surname><given-names>D</given-names></name><name name-style="western"><surname>Davies</surname><given-names>JC</given-names></name></person-group><article-title>Cystic fibrosis</article-title><source>Lancet</source><year>2021</year><volume>397</volume><fpage>2195</fpage><lpage>2211</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)32542-3</pub-id><pub-id pub-id-type="pmid">34090606</pub-id></element-citation><mixed-citation id="mc-CR368" publication-type="journal">Shteinberg, M., Haq, I. J., Polineni, D. &amp; Davies, J. C. Cystic fibrosis. <italic toggle="yes">Lancet</italic><bold>397</bold>, 2195&#8211;2211 (2021).<pub-id pub-id-type="pmid">34090606</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(20)32542-3</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR369"><label>369.</label><citation-alternatives><element-citation id="ec-CR369" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rowe</surname><given-names>SM</given-names></name><etal/></person-group><article-title>Inhaled mRNA therapy for treatment of cystic fibrosis: interim results of a randomized, double&#8208;blind, placebo&#8208;controlled phase 1/2 clinical study</article-title><source>J. Cyst. Fibros.</source><year>2023</year><volume>22</volume><fpage>656</fpage><lpage>664</lpage><pub-id pub-id-type="doi">10.1016/j.jcf.2023.04.008</pub-id><pub-id pub-id-type="pmid">37121795</pub-id><pub-id pub-id-type="pmcid">PMC10524666</pub-id></element-citation><mixed-citation id="mc-CR369" publication-type="journal">Rowe, S. M. et al. Inhaled mRNA therapy for treatment of cystic fibrosis: interim results of a randomized, double&#8208;blind, placebo&#8208;controlled phase 1/2 clinical study. <italic toggle="yes">J. Cyst. Fibros.</italic><bold>22</bold>, 656&#8211;664 (2023).<pub-id pub-id-type="pmid">37121795</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jcf.2023.04.008</pub-id><pub-id pub-id-type="pmcid">PMC10524666</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR370"><label>370.</label><citation-alternatives><element-citation id="ec-CR370" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>P</given-names></name><etal/></person-group><article-title>Co-delivery of NS1 and BMP2 mRNAs to murine pluripotent stem cells leads to enhanced BMP-2 expression and osteogenic differentiation</article-title><source>Acta Biomater.</source><year>2020</year><volume>108</volume><fpage>337</fpage><lpage>346</lpage><pub-id pub-id-type="doi">10.1016/j.actbio.2020.03.045</pub-id><pub-id pub-id-type="pmid">32251783</pub-id></element-citation><mixed-citation id="mc-CR370" publication-type="journal">Wang, P. et al. Co-delivery of NS1 and BMP2 mRNAs to murine pluripotent stem cells leads to enhanced BMP-2 expression and osteogenic differentiation. <italic toggle="yes">Acta Biomater.</italic><bold>108</bold>, 337&#8211;346 (2020).<pub-id pub-id-type="pmid">32251783</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.actbio.2020.03.045</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR371"><label>371.</label><citation-alternatives><element-citation id="ec-CR371" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>P</given-names></name><etal/></person-group><article-title>In Vivo bone tissue induction by freeze-dried collagen-nanohydroxyapatite matrix loaded with BMP2/NS1 mRNAs lipopolyplexes</article-title><source>J. Control Release</source><year>2021</year><volume>334</volume><fpage>188</fpage><lpage>200</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2021.04.021</pub-id><pub-id pub-id-type="pmid">33895201</pub-id></element-citation><mixed-citation id="mc-CR371" publication-type="journal">Wang, P. et al. In Vivo bone tissue induction by freeze-dried collagen-nanohydroxyapatite matrix loaded with BMP2/NS1 mRNAs lipopolyplexes. <italic toggle="yes">J. Control Release</italic><bold>334</bold>, 188&#8211;200 (2021).<pub-id pub-id-type="pmid">33895201</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jconrel.2021.04.021</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR372"><label>372.</label><citation-alternatives><element-citation id="ec-CR372" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Geng</surname><given-names>Y</given-names></name><etal/></person-group><article-title>BMP-2 and VEGF-A modRNAs in collagen scaffold synergistically drive bone repair through osteogenic and angiogenic pathways</article-title><source>Commun. Biol.</source><year>2021</year><volume>4</volume><fpage>82</fpage><pub-id pub-id-type="doi">10.1038/s42003-020-01606-9</pub-id><pub-id pub-id-type="pmid">33469143</pub-id><pub-id pub-id-type="pmcid">PMC7815925</pub-id></element-citation><mixed-citation id="mc-CR372" publication-type="journal">Geng, Y. et al. BMP-2 and VEGF-A modRNAs in collagen scaffold synergistically drive bone repair through osteogenic and angiogenic pathways. <italic toggle="yes">Commun. Biol.</italic><bold>4</bold>, 82 (2021).<pub-id pub-id-type="pmid">33469143</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s42003-020-01606-9</pub-id><pub-id pub-id-type="pmcid">PMC7815925</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR373"><label>373.</label><citation-alternatives><element-citation id="ec-CR373" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>C-Y</given-names></name><etal/></person-group><article-title>Treatment of intervertebral disk disease by the administration of mRNA encoding a cartilage-anabolic transcription factor</article-title><source>Mol. Ther. Nucleic Acids</source><year>2019</year><volume>16</volume><fpage>162</fpage><lpage>171</lpage><pub-id pub-id-type="doi">10.1016/j.omtn.2019.02.012</pub-id><pub-id pub-id-type="pmid">30889482</pub-id><pub-id pub-id-type="pmcid">PMC6424144</pub-id></element-citation><mixed-citation id="mc-CR373" publication-type="journal">Lin, C.-Y. et al. Treatment of intervertebral disk disease by the administration of mRNA encoding a cartilage-anabolic transcription factor. <italic toggle="yes">Mol. Ther. Nucleic Acids</italic><bold>16</bold>, 162&#8211;171 (2019).<pub-id pub-id-type="pmid">30889482</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.omtn.2019.02.012</pub-id><pub-id pub-id-type="pmcid">PMC6424144</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR374"><label>374.</label><citation-alternatives><element-citation id="ec-CR374" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sanger</surname><given-names>HL</given-names></name><name name-style="western"><surname>Klotz</surname><given-names>G</given-names></name><name name-style="western"><surname>Riesner</surname><given-names>D</given-names></name><name name-style="western"><surname>Gross</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Kleinschmidt</surname><given-names>AK</given-names></name></person-group><article-title>Viroids are single-stranded covalently closed circular RNA molecules existing as highly base-paired rod-like structures</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>1976</year><volume>73</volume><fpage>3852</fpage><lpage>3856</lpage><pub-id pub-id-type="doi">10.1073/pnas.73.11.3852</pub-id><pub-id pub-id-type="pmid">1069269</pub-id><pub-id pub-id-type="pmcid">PMC431239</pub-id></element-citation><mixed-citation id="mc-CR374" publication-type="journal">Sanger, H. L., Klotz, G., Riesner, D., Gross, H. J. &amp; Kleinschmidt, A. K. Viroids are single-stranded covalently closed circular RNA molecules existing as highly base-paired rod-like structures. <italic toggle="yes">Proc. Natl. Acad. Sci. USA</italic><bold>73</bold>, 3852&#8211;3856 (1976).<pub-id pub-id-type="pmid">1069269</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.73.11.3852</pub-id><pub-id pub-id-type="pmcid">PMC431239</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR375"><label>375.</label><citation-alternatives><element-citation id="ec-CR375" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>C-Y</given-names></name><etal/></person-group><article-title>Messenger RNA-based therapeutics for brain diseases: an animal study for augmenting clearance of beta-amyloid by intracerebral administration of neprilysin mRNA loaded in polyplex nanomicelles</article-title><source>J. Control Release</source><year>2016</year><volume>235</volume><fpage>268</fpage><lpage>275</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2016.06.001</pub-id><pub-id pub-id-type="pmid">27282413</pub-id></element-citation><mixed-citation id="mc-CR375" publication-type="journal">Lin, C.-Y. et al. Messenger RNA-based therapeutics for brain diseases: an animal study for augmenting clearance of beta-amyloid by intracerebral administration of neprilysin mRNA loaded in polyplex nanomicelles. <italic toggle="yes">J. Control Release</italic><bold>235</bold>, 268&#8211;275 (2016).<pub-id pub-id-type="pmid">27282413</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jconrel.2016.06.001</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR376"><label>376.</label><citation-alternatives><element-citation id="ec-CR376" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>H</given-names></name><etal/></person-group><article-title>Engineering brain-derived neurotrophic factor mRNA delivery for the treatment of Alzheimer&#8217;s disease</article-title><source>Chem. Eng. J.</source><year>2023</year><volume>466</volume><fpage>143152</fpage><pub-id pub-id-type="doi">10.1016/j.cej.2023.143152</pub-id></element-citation><mixed-citation id="mc-CR376" publication-type="journal">Li, H. et al. Engineering brain-derived neurotrophic factor mRNA delivery for the treatment of Alzheimer&#8217;s disease. <italic toggle="yes">Chem. Eng. J.</italic><bold>466</bold>, 143152 (2023).</mixed-citation></citation-alternatives></ref><ref id="CR377"><label>377.</label><citation-alternatives><element-citation id="ec-CR377" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lescan</surname><given-names>M</given-names></name><etal/></person-group><article-title>De novo synthesis of elastin by exogenous delivery of synthetic modified mRNA into skin and elastin-deficient cells</article-title><source>Mol. Ther. Nucleic Acids</source><year>2018</year><volume>11</volume><fpage>475</fpage><lpage>484</lpage><pub-id pub-id-type="doi">10.1016/j.omtn.2018.03.013</pub-id><pub-id pub-id-type="pmid">29858082</pub-id><pub-id pub-id-type="pmcid">PMC5992474</pub-id></element-citation><mixed-citation id="mc-CR377" publication-type="journal">Lescan, M. et al. De novo synthesis of elastin by exogenous delivery of synthetic modified mRNA into skin and elastin-deficient cells. <italic toggle="yes">Mol. Ther. Nucleic Acids</italic><bold>11</bold>, 475&#8211;484 (2018).<pub-id pub-id-type="pmid">29858082</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.omtn.2018.03.013</pub-id><pub-id pub-id-type="pmcid">PMC5992474</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR378"><label>378.</label><citation-alternatives><element-citation id="ec-CR378" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Golombek</surname><given-names>S</given-names></name><etal/></person-group><article-title>Improved tropoelastin synthesis in the skin by codon optimization and nucleotide modification of tropoelastin-encoding synthetic mRNA</article-title><source>Mol. Ther. Nucleic Acids</source><year>2023</year><volume>33</volume><fpage>642</fpage><lpage>654</lpage><pub-id pub-id-type="doi">10.1016/j.omtn.2023.07.035</pub-id><pub-id pub-id-type="pmid">37650117</pub-id><pub-id pub-id-type="pmcid">PMC10462787</pub-id></element-citation><mixed-citation id="mc-CR378" publication-type="journal">Golombek, S. et al. Improved tropoelastin synthesis in the skin by codon optimization and nucleotide modification of tropoelastin-encoding synthetic mRNA. <italic toggle="yes">Mol. Ther. Nucleic Acids</italic><bold>33</bold>, 642&#8211;654 (2023).<pub-id pub-id-type="pmid">37650117</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.omtn.2023.07.035</pub-id><pub-id pub-id-type="pmcid">PMC10462787</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR379"><label>379.</label><citation-alternatives><element-citation id="ec-CR379" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ghazanfari</surname><given-names>S</given-names></name><name name-style="western"><surname>Khademhosseini</surname><given-names>A</given-names></name><name name-style="western"><surname>Smit</surname><given-names>TH</given-names></name></person-group><article-title>Mechanisms of lamellar collagen formation in connective tissues</article-title><source>Biomaterials</source><year>2016</year><volume>97</volume><fpage>74</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2016.04.028</pub-id><pub-id pub-id-type="pmid">27162076</pub-id></element-citation><mixed-citation id="mc-CR379" publication-type="journal">Ghazanfari, S., Khademhosseini, A. &amp; Smit, T. H. Mechanisms of lamellar collagen formation in connective tissues. <italic toggle="yes">Biomaterials</italic><bold>97</bold>, 74&#8211;84 (2016).<pub-id pub-id-type="pmid">27162076</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biomaterials.2016.04.028</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR380"><label>380.</label><citation-alternatives><element-citation id="ec-CR380" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>You</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Intradermally delivered mRNA-encapsulating extracellular vesicles for collagen-replacement therapy</article-title><source>Nat. Biomed. Eng.</source><year>2023</year><volume>7</volume><fpage>887</fpage><lpage>900</lpage><pub-id pub-id-type="doi">10.1038/s41551-022-00989-w</pub-id><pub-id pub-id-type="pmid">36635419</pub-id></element-citation><mixed-citation id="mc-CR380" publication-type="journal">You, Y. et al. Intradermally delivered mRNA-encapsulating extracellular vesicles for collagen-replacement therapy. <italic toggle="yes">Nat. Biomed. Eng.</italic><bold>7</bold>, 887&#8211;900 (2023).<pub-id pub-id-type="pmid">36635419</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41551-022-00989-w</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR381"><label>381.</label><citation-alternatives><element-citation id="ec-CR381" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>N</given-names></name><name name-style="western"><surname>Abil</surname><given-names>Z</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>H</given-names></name></person-group><article-title>Recent advances in targeted genome engineering in mammalian systems</article-title><source>Biotechnol. J.</source><year>2012</year><volume>7</volume><fpage>1074</fpage><lpage>1087</lpage><pub-id pub-id-type="doi">10.1002/biot.201200038</pub-id><pub-id pub-id-type="pmid">22777886</pub-id></element-citation><mixed-citation id="mc-CR381" publication-type="journal">Sun, N., Abil, Z. &amp; Zhao, H. Recent advances in targeted genome engineering in mammalian systems. <italic toggle="yes">Biotechnol. J.</italic><bold>7</bold>, 1074&#8211;1087 (2012).<pub-id pub-id-type="pmid">22777886</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/biot.201200038</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR382"><label>382.</label><citation-alternatives><element-citation id="ec-CR382" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>W</given-names></name><etal/></person-group><article-title>Progress of delivery methods for CRISPR-Cas9</article-title><source>Expert Opin. Drug Deliv.</source><year>2022</year><volume>19</volume><fpage>913</fpage><lpage>926</lpage><pub-id pub-id-type="doi">10.1080/17425247.2022.2100342</pub-id><pub-id pub-id-type="pmid">35818792</pub-id></element-citation><mixed-citation id="mc-CR382" publication-type="journal">Yang, W. et al. Progress of delivery methods for CRISPR-Cas9. <italic toggle="yes">Expert Opin. Drug Deliv.</italic><bold>19</bold>, 913&#8211;926 (2022).<pub-id pub-id-type="pmid">35818792</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/17425247.2022.2100342</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR383"><label>383.</label><citation-alternatives><element-citation id="ec-CR383" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bjurstr&#246;m</surname><given-names>CF</given-names></name><etal/></person-group><article-title>Reactivating fetal hemoglobin expression in human adult erythroblasts through BCL11A knockdown using targeted endonucleases</article-title><source>Mol. Ther. Nucleic Acids</source><year>2016</year><volume>5</volume><fpage>e351</fpage><pub-id pub-id-type="doi">10.1038/mtna.2016.52</pub-id><pub-id pub-id-type="pmid">28131278</pub-id><pub-id pub-id-type="pmcid">PMC5023398</pub-id></element-citation><mixed-citation id="mc-CR383" publication-type="journal">Bjurstr&#246;m, C. F. et al. Reactivating fetal hemoglobin expression in human adult erythroblasts through BCL11A knockdown using targeted endonucleases. <italic toggle="yes">Mol. Ther. Nucleic Acids</italic><bold>5</bold>, e351 (2016).<pub-id pub-id-type="pmid">28131278</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/mtna.2016.52</pub-id><pub-id pub-id-type="pmcid">PMC5023398</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR384"><label>384.</label><citation-alternatives><element-citation id="ec-CR384" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shen</surname><given-names>B</given-names></name><etal/></person-group><article-title>Efficient genome modification by CRISPR-Cas9 nickase with minimal off-target effects</article-title><source>Nat. Methods</source><year>2014</year><volume>11</volume><fpage>399</fpage><lpage>402</lpage><pub-id pub-id-type="doi">10.1038/nmeth.2857</pub-id><pub-id pub-id-type="pmid">24584192</pub-id></element-citation><mixed-citation id="mc-CR384" publication-type="journal">Shen, B. et al. Efficient genome modification by CRISPR-Cas9 nickase with minimal off-target effects. <italic toggle="yes">Nat. Methods</italic><bold>11</bold>, 399&#8211;402 (2014).<pub-id pub-id-type="pmid">24584192</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nmeth.2857</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR385"><label>385.</label><citation-alternatives><element-citation id="ec-CR385" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cho</surname><given-names>SW</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S</given-names></name><name name-style="western"><surname>Kim</surname><given-names>JM</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J-S</given-names></name></person-group><article-title>Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease</article-title><source>Nat. Biotechnol.</source><year>2013</year><volume>31</volume><fpage>230</fpage><lpage>232</lpage><pub-id pub-id-type="doi">10.1038/nbt.2507</pub-id><pub-id pub-id-type="pmid">23360966</pub-id></element-citation><mixed-citation id="mc-CR385" publication-type="journal">Cho, S. W., Kim, S., Kim, J. M. &amp; Kim, J.-S. Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease. <italic toggle="yes">Nat. Biotechnol.</italic><bold>31</bold>, 230&#8211;232 (2013).<pub-id pub-id-type="pmid">23360966</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nbt.2507</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR386"><label>386.</label><citation-alternatives><element-citation id="ec-CR386" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheng</surname><given-names>H</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>F</given-names></name><name name-style="western"><surname>Ding</surname><given-names>Y</given-names></name></person-group><article-title>CRISPR/Cas9 delivery system engineering for genome editing in therapeutic applications</article-title><source>Pharmaceutics</source><year>2021</year><volume>13</volume><fpage>1649</fpage><pub-id pub-id-type="doi">10.3390/pharmaceutics13101649</pub-id><pub-id pub-id-type="pmid">34683943</pub-id><pub-id pub-id-type="pmcid">PMC8538656</pub-id></element-citation><mixed-citation id="mc-CR386" publication-type="journal">Cheng, H., Zhang, F. &amp; Ding, Y. CRISPR/Cas9 delivery system engineering for genome editing in therapeutic applications. <italic toggle="yes">Pharmaceutics</italic><bold>13</bold>, 1649 (2021).<pub-id pub-id-type="pmid">34683943</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/pharmaceutics13101649</pub-id><pub-id pub-id-type="pmcid">PMC8538656</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR387"><label>387.</label><citation-alternatives><element-citation id="ec-CR387" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ling</surname><given-names>S</given-names></name><etal/></person-group><article-title>Lentiviral delivery of co-packaged Cas9 mRNA and a Vegfa-targeting guide RNA prevents wet age-related macular degeneration in mice</article-title><source>Nat. Biomed. Eng.</source><year>2021</year><volume>5</volume><fpage>144</fpage><lpage>156</lpage><pub-id pub-id-type="doi">10.1038/s41551-020-00656-y</pub-id><pub-id pub-id-type="pmid">33398131</pub-id></element-citation><mixed-citation id="mc-CR387" publication-type="journal">Ling, S. et al. Lentiviral delivery of co-packaged Cas9 mRNA and a Vegfa-targeting guide RNA prevents wet age-related macular degeneration in mice. <italic toggle="yes">Nat. Biomed. Eng.</italic><bold>5</bold>, 144&#8211;156 (2021).<pub-id pub-id-type="pmid">33398131</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41551-020-00656-y</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR388"><label>388.</label><citation-alternatives><element-citation id="ec-CR388" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Peng</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zi</surname><given-names>G</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J</given-names></name><name name-style="western"><surname>Peng</surname><given-names>B</given-names></name></person-group><article-title>Co-delivery of Cas9 mRNA and guide RNAs for editing of LGMN gene represses breast cancer cell metastasis</article-title><source>Sci. Rep.</source><year>2024</year><volume>14</volume><fpage>8095</fpage><pub-id pub-id-type="doi">10.1038/s41598-024-58765-6</pub-id><pub-id pub-id-type="pmid">38582932</pub-id><pub-id pub-id-type="pmcid">PMC10998893</pub-id></element-citation><mixed-citation id="mc-CR388" publication-type="journal">Wang, Y., Peng, Y., Zi, G., Chen, J. &amp; Peng, B. Co-delivery of Cas9 mRNA and guide RNAs for editing of LGMN gene represses breast cancer cell metastasis. <italic toggle="yes">Sci. Rep.</italic><bold>14</bold>, 8095 (2024).<pub-id pub-id-type="pmid">38582932</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-024-58765-6</pub-id><pub-id pub-id-type="pmcid">PMC10998893</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR389"><label>389.</label><citation-alternatives><element-citation id="ec-CR389" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yi</surname><given-names>J</given-names></name><etal/></person-group><article-title>Co-delivery of Cas9 mRNA and guide RNAs edits hepatitis B virus episomal and integration DNA in mouse and tree shrew models</article-title><source>Antivir. Res.</source><year>2023</year><volume>215</volume><fpage>105618</fpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2023.105618</pub-id><pub-id pub-id-type="pmid">37142191</pub-id></element-citation><mixed-citation id="mc-CR389" publication-type="journal">Yi, J. et al. Co-delivery of Cas9 mRNA and guide RNAs edits hepatitis B virus episomal and integration DNA in mouse and tree shrew models. <italic toggle="yes">Antivir. Res.</italic><bold>215</bold>, 105618 (2023).<pub-id pub-id-type="pmid">37142191</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.antiviral.2023.105618</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR390"><label>390.</label><citation-alternatives><element-citation id="ec-CR390" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>J</given-names></name><etal/></person-group><article-title>Fast and efficient CRISPR/Cas9 genome editing in vivo enabled by bioreducible lipid and messenger RNA nanoparticles</article-title><source>Adv. Mater.</source><year>2019</year><volume>31</volume><fpage>1902575</fpage><pub-id pub-id-type="doi">10.1002/adma.201902575</pub-id><pub-id pub-id-type="pmcid">PMC6732788</pub-id><pub-id pub-id-type="pmid">31215123</pub-id></element-citation><mixed-citation id="mc-CR390" publication-type="journal">Liu, J. et al. Fast and efficient CRISPR/Cas9 genome editing in vivo enabled by bioreducible lipid and messenger RNA nanoparticles. <italic toggle="yes">Adv. Mater.</italic><bold>31</bold>, 1902575 (2019).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/adma.201902575</pub-id><pub-id pub-id-type="pmcid">PMC6732788</pub-id><pub-id pub-id-type="pmid">31215123</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR391"><label>391.</label><citation-alternatives><element-citation id="ec-CR391" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yadav</surname><given-names>M</given-names></name><name name-style="western"><surname>Atala</surname><given-names>A</given-names></name><name name-style="western"><surname>Lu</surname><given-names>B</given-names></name></person-group><article-title>Developing all-in-one virus-like particles for Cas9 mRNA/single guide RNA co-delivery and aptamer-containing lentiviral vectors for improved gene expression</article-title><source>Int. J. Biol. Macromol.</source><year>2022</year><volume>209</volume><fpage>1260</fpage><lpage>1270</lpage><pub-id pub-id-type="doi">10.1016/j.ijbiomac.2022.04.114</pub-id><pub-id pub-id-type="pmid">35461863</pub-id></element-citation><mixed-citation id="mc-CR391" publication-type="journal">Yadav, M., Atala, A. &amp; Lu, B. Developing all-in-one virus-like particles for Cas9 mRNA/single guide RNA co-delivery and aptamer-containing lentiviral vectors for improved gene expression. <italic toggle="yes">Int. J. Biol. Macromol.</italic><bold>209</bold>, 1260&#8211;1270 (2022).<pub-id pub-id-type="pmid">35461863</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijbiomac.2022.04.114</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR392"><label>392.</label><citation-alternatives><element-citation id="ec-CR392" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gillmore</surname><given-names>JD</given-names></name><etal/></person-group><article-title>CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis</article-title><source>New Engl. J. Med.</source><year>2021</year><volume>385</volume><fpage>493</fpage><lpage>502</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2107454</pub-id><pub-id pub-id-type="pmid">34215024</pub-id></element-citation><mixed-citation id="mc-CR392" publication-type="journal">Gillmore, J. D. et al. CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis. <italic toggle="yes">New Engl. J. Med.</italic><bold>385</bold>, 493&#8211;502 (2021).<pub-id pub-id-type="pmid">34215024</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2107454</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR393"><label>393.</label><citation-alternatives><element-citation id="ec-CR393" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>H-X</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yin</surname><given-names>H</given-names></name></person-group><article-title>Genome editing with mRNA encoding ZFN, TALEN, and Cas9</article-title><source>Mol. Ther.</source><year>2019</year><volume>27</volume><fpage>735</fpage><lpage>746</lpage><pub-id pub-id-type="doi">10.1016/j.ymthe.2019.01.014</pub-id><pub-id pub-id-type="pmid">30803822</pub-id><pub-id pub-id-type="pmcid">PMC6453514</pub-id></element-citation><mixed-citation id="mc-CR393" publication-type="journal">Zhang, H.-X., Zhang, Y. &amp; Yin, H. Genome editing with mRNA encoding ZFN, TALEN, and Cas9. <italic toggle="yes">Mol. Ther.</italic><bold>27</bold>, 735&#8211;746 (2019).<pub-id pub-id-type="pmid">30803822</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ymthe.2019.01.014</pub-id><pub-id pub-id-type="pmcid">PMC6453514</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR394"><label>394.</label><citation-alternatives><element-citation id="ec-CR394" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rizzi</surname><given-names>M</given-names></name><etal/></person-group><article-title>SARS-CoV-2 infection risk is higher in vaccinated patients with inflammatory autoimmune diseases or liver transplantation treated with mycophenolate due to an impaired antiviral immune response: results of the extended follow up of the RIVALSA prospective cohort</article-title><source>Front. Immunol.</source><year>2023</year><volume>14</volume><fpage>1185278</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2023.1185278</pub-id><pub-id pub-id-type="pmid">37545528</pub-id><pub-id pub-id-type="pmcid">PMC10398576</pub-id></element-citation><mixed-citation id="mc-CR394" publication-type="journal">Rizzi, M. et al. SARS-CoV-2 infection risk is higher in vaccinated patients with inflammatory autoimmune diseases or liver transplantation treated with mycophenolate due to an impaired antiviral immune response: results of the extended follow up of the RIVALSA prospective cohort. <italic toggle="yes">Front. Immunol.</italic><bold>14</bold>, 1185278 (2023).<pub-id pub-id-type="pmid">37545528</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2023.1185278</pub-id><pub-id pub-id-type="pmcid">PMC10398576</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR395"><label>395.</label><mixed-citation publication-type="other">Li, B. et al. Enhancing the immunogenicity of lipid-nanoparticle mRNA vaccines by adjuvanting the ionizable lipid and the mRNA. <italic toggle="yes">Nat. Biomed. Eng</italic>. 10.1038/s41551-023-01082-6 (2023).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41551-023-01082-6</pub-id><pub-id pub-id-type="pmid">37679571</pub-id></mixed-citation></ref><ref id="CR396"><label>396.</label><citation-alternatives><element-citation id="ec-CR396" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kon</surname><given-names>E</given-names></name><name name-style="western"><surname>Ad-El</surname><given-names>N</given-names></name><name name-style="western"><surname>Hazan-Halevy</surname><given-names>I</given-names></name><name name-style="western"><surname>Stotsky-Oterin</surname><given-names>L</given-names></name><name name-style="western"><surname>Peer</surname><given-names>D</given-names></name></person-group><article-title>Targeting cancer with mRNA&#8211;lipid nanoparticles: key considerations and future prospects</article-title><source>Nat. Rev. Clin. Oncol.</source><year>2023</year><volume>20</volume><fpage>739</fpage><lpage>754</lpage><pub-id pub-id-type="doi">10.1038/s41571-023-00811-9</pub-id><pub-id pub-id-type="pmid">37587254</pub-id></element-citation><mixed-citation id="mc-CR396" publication-type="journal">Kon, E., Ad-El, N., Hazan-Halevy, I., Stotsky-Oterin, L. &amp; Peer, D. Targeting cancer with mRNA&#8211;lipid nanoparticles: key considerations and future prospects. <italic toggle="yes">Nat. Rev. Clin. Oncol.</italic><bold>20</bold>, 739&#8211;754 (2023).<pub-id pub-id-type="pmid">37587254</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41571-023-00811-9</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR397"><label>397.</label><citation-alternatives><element-citation id="ec-CR397" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nugent</surname><given-names>C</given-names></name><etal/></person-group><article-title>Second monovalent SARS-CoV-2 mRNA booster restores Omicron-specific neutralizing activity in both nursing home residents and health care workers</article-title><source>Vaccine</source><year>2023</year><volume>41</volume><fpage>3403</fpage><lpage>3409</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2023.04.034</pub-id><pub-id pub-id-type="pmid">37117056</pub-id><pub-id pub-id-type="pmcid">PMC10123357</pub-id></element-citation><mixed-citation id="mc-CR397" publication-type="journal">Nugent, C. et al. Second monovalent SARS-CoV-2 mRNA booster restores Omicron-specific neutralizing activity in both nursing home residents and health care workers. <italic toggle="yes">Vaccine</italic><bold>41</bold>, 3403&#8211;3409 (2023).<pub-id pub-id-type="pmid">37117056</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2023.04.034</pub-id><pub-id pub-id-type="pmcid">PMC10123357</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR398"><label>398.</label><citation-alternatives><element-citation id="ec-CR398" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heftdal</surname><given-names>LD</given-names></name><etal/></person-group><article-title>Humoral and cellular immune responses eleven months after the third dose of BNT162b2 an mRNA-based COVID-19 vaccine in people with HIV&#8212;a prospective observational cohort study</article-title><source>EBioMedicine</source><year>2023</year><volume>93</volume><fpage>104661</fpage><pub-id pub-id-type="doi">10.1016/j.ebiom.2023.104661</pub-id><pub-id pub-id-type="pmid">37331161</pub-id><pub-id pub-id-type="pmcid">PMC10272831</pub-id></element-citation><mixed-citation id="mc-CR398" publication-type="journal">Heftdal, L. D. et al. Humoral and cellular immune responses eleven months after the third dose of BNT162b2 an mRNA-based COVID-19 vaccine in people with HIV&#8212;a prospective observational cohort study. <italic toggle="yes">EBioMedicine</italic><bold>93</bold>, 104661 (2023).<pub-id pub-id-type="pmid">37331161</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ebiom.2023.104661</pub-id><pub-id pub-id-type="pmcid">PMC10272831</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR399"><label>399.</label><citation-alternatives><element-citation id="ec-CR399" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Q</given-names></name><etal/></person-group><article-title>Inborn errors of type I IFN immunity in patients with life-threatening COVID-19</article-title><source>Science</source><year>2020</year><volume>370</volume><fpage>eabd4570</fpage><pub-id pub-id-type="doi">10.1126/science.abd4570</pub-id><pub-id pub-id-type="pmid">32972995</pub-id><pub-id pub-id-type="pmcid">PMC7857407</pub-id></element-citation><mixed-citation id="mc-CR399" publication-type="journal">Zhang, Q. et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. <italic toggle="yes">Science</italic><bold>370</bold>, eabd4570 (2020).<pub-id pub-id-type="pmid">32972995</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.abd4570</pub-id><pub-id pub-id-type="pmcid">PMC7857407</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR400"><label>400.</label><citation-alternatives><element-citation id="ec-CR400" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bastard</surname><given-names>P</given-names></name><etal/></person-group><article-title>Vaccine breakthrough hypoxemic COVID-19 pneumonia in patients with auto-Abs neutralizing type I IFNs</article-title><source>Sci. Immunol.</source><year>2022</year><volume>8</volume><fpage>eabp8966</fpage><pub-id pub-id-type="doi">10.1126/sciimmunol.abp8966</pub-id><pub-id pub-id-type="pmcid">PMC9210448</pub-id><pub-id pub-id-type="pmid">35857576</pub-id></element-citation><mixed-citation id="mc-CR400" publication-type="journal">Bastard, P. et al. Vaccine breakthrough hypoxemic COVID-19 pneumonia in patients with auto-Abs neutralizing type I IFNs. <italic toggle="yes">Sci. Immunol.</italic><bold>8</bold>, eabp8966 (2022).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/sciimmunol.abp8966</pub-id><pub-id pub-id-type="pmcid">PMC9210448</pub-id><pub-id pub-id-type="pmid">35857576</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR401"><label>401.</label><citation-alternatives><element-citation id="ec-CR401" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hou</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Insights into vaccines for elderly individuals: from the impacts of immunosenescence to delivery strategies</article-title><source>NPJ Vaccines</source><year>2024</year><volume>9</volume><fpage>77</fpage><pub-id pub-id-type="doi">10.1038/s41541-024-00874-4</pub-id><pub-id pub-id-type="pmid">38600250</pub-id><pub-id pub-id-type="pmcid">PMC11006855</pub-id></element-citation><mixed-citation id="mc-CR401" publication-type="journal">Hou, Y. et al. Insights into vaccines for elderly individuals: from the impacts of immunosenescence to delivery strategies. <italic toggle="yes">NPJ Vaccines</italic><bold>9</bold>, 77 (2024).<pub-id pub-id-type="pmid">38600250</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41541-024-00874-4</pub-id><pub-id pub-id-type="pmcid">PMC11006855</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR402"><label>402.</label><citation-alternatives><element-citation id="ec-CR402" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goronzy</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Weyand</surname><given-names>CM</given-names></name></person-group><article-title>Understanding immunosenescence to improve responses to vaccines</article-title><source>Nat. Immunol.</source><year>2013</year><volume>14</volume><fpage>428</fpage><lpage>436</lpage><pub-id pub-id-type="doi">10.1038/ni.2588</pub-id><pub-id pub-id-type="pmid">23598398</pub-id><pub-id pub-id-type="pmcid">PMC4183346</pub-id></element-citation><mixed-citation id="mc-CR402" publication-type="journal">Goronzy, J. J. &amp; Weyand, C. M. Understanding immunosenescence to improve responses to vaccines. <italic toggle="yes">Nat. Immunol.</italic><bold>14</bold>, 428&#8211;436 (2013).<pub-id pub-id-type="pmid">23598398</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ni.2588</pub-id><pub-id pub-id-type="pmcid">PMC4183346</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR403"><label>403.</label><citation-alternatives><element-citation id="ec-CR403" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aiello</surname><given-names>A</given-names></name><etal/></person-group><article-title>How can we improve vaccination response in old people? Part I: targeting immunosenescence of innate immunity cells</article-title><source>Int. J. Mol. Sci.</source><year>2022</year><volume>23</volume><fpage>9880</fpage><pub-id pub-id-type="doi">10.3390/ijms23179880</pub-id><pub-id pub-id-type="pmid">36077278</pub-id><pub-id pub-id-type="pmcid">PMC9456428</pub-id></element-citation><mixed-citation id="mc-CR403" publication-type="journal">Aiello, A. et al. How can we improve vaccination response in old people? Part I: targeting immunosenescence of innate immunity cells. <italic toggle="yes">Int. J. Mol. Sci.</italic><bold>23</bold>, 9880 (2022).<pub-id pub-id-type="pmid">36077278</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms23179880</pub-id><pub-id pub-id-type="pmcid">PMC9456428</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR404"><label>404.</label><citation-alternatives><element-citation id="ec-CR404" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garnica</surname><given-names>M</given-names></name><etal/></person-group><article-title>How can we improve the vaccination response in older people? Part II: targeting immunosenescence of adaptive immunity cells</article-title><source>Int. J. Mol. Sci.</source><year>2022</year><volume>23</volume><fpage>9797</fpage><pub-id pub-id-type="doi">10.3390/ijms23179797</pub-id><pub-id pub-id-type="pmid">36077216</pub-id><pub-id pub-id-type="pmcid">PMC9456031</pub-id></element-citation><mixed-citation id="mc-CR404" publication-type="journal">Garnica, M. et al. How can we improve the vaccination response in older people? Part II: targeting immunosenescence of adaptive immunity cells. <italic toggle="yes">Int. J. Mol. Sci.</italic><bold>23</bold>, 9797 (2022).<pub-id pub-id-type="pmid">36077216</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms23179797</pub-id><pub-id pub-id-type="pmcid">PMC9456031</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR405"><label>405.</label><citation-alternatives><element-citation id="ec-CR405" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pereira</surname><given-names>B</given-names></name><name name-style="western"><surname>Xu</surname><given-names>X-N</given-names></name><name name-style="western"><surname>Akbar</surname><given-names>AN</given-names></name></person-group><article-title>Targeting inflammation and immunosenescence to improve vaccine responses in the elderly</article-title><source>Front. Immunol.</source><year>2020</year><volume>11</volume><fpage>583019</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2020.583019</pub-id><pub-id pub-id-type="pmid">33178213</pub-id><pub-id pub-id-type="pmcid">PMC7592394</pub-id></element-citation><mixed-citation id="mc-CR405" publication-type="journal">Pereira, B., Xu, X.-N. &amp; Akbar, A. N. Targeting inflammation and immunosenescence to improve vaccine responses in the elderly. <italic toggle="yes">Front. Immunol.</italic><bold>11</bold>, 583019 (2020).<pub-id pub-id-type="pmid">33178213</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2020.583019</pub-id><pub-id pub-id-type="pmcid">PMC7592394</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR406"><label>406.</label><citation-alternatives><element-citation id="ec-CR406" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Puzianowska-Ku&#378;nicka</surname><given-names>M</given-names></name><etal/></person-group><article-title>Interleukin-6 and C-reactive protein, successful aging, and mortality: the PolSenior study</article-title><source>Immun. Ageing</source><year>2016</year><volume>13</volume><fpage>21</fpage><pub-id pub-id-type="doi">10.1186/s12979-016-0076-x</pub-id><pub-id pub-id-type="pmid">27274758</pub-id><pub-id pub-id-type="pmcid">PMC4891873</pub-id></element-citation><mixed-citation id="mc-CR406" publication-type="journal">Puzianowska-Ku&#378;nicka, M. et al. Interleukin-6 and C-reactive protein, successful aging, and mortality: the PolSenior study. <italic toggle="yes">Immun. Ageing</italic><bold>13</bold>, 21 (2016).<pub-id pub-id-type="pmid">27274758</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12979-016-0076-x</pub-id><pub-id pub-id-type="pmcid">PMC4891873</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR407"><label>407.</label><citation-alternatives><element-citation id="ec-CR407" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nakaya</surname><given-names>HI</given-names></name><etal/></person-group><article-title>Systems analysis of immunity to influenza vaccination across multiple years and in diverse populations reveals shared molecular signatures</article-title><source>Immunity</source><year>2015</year><volume>43</volume><fpage>1186</fpage><lpage>1198</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2015.11.012</pub-id><pub-id pub-id-type="pmid">26682988</pub-id><pub-id pub-id-type="pmcid">PMC4859820</pub-id></element-citation><mixed-citation id="mc-CR407" publication-type="journal">Nakaya, H. I. et al. Systems analysis of immunity to influenza vaccination across multiple years and in diverse populations reveals shared molecular signatures. <italic toggle="yes">Immunity</italic><bold>43</bold>, 1186&#8211;1198 (2015).<pub-id pub-id-type="pmid">26682988</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.immuni.2015.11.012</pub-id><pub-id pub-id-type="pmcid">PMC4859820</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR408"><label>408.</label><citation-alternatives><element-citation id="ec-CR408" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tizazu</surname><given-names>AM</given-names></name><name name-style="western"><surname>Mengist</surname><given-names>HM</given-names></name><name name-style="western"><surname>Demeke</surname><given-names>G</given-names></name></person-group><article-title>Aging, inflammaging and immunosenescence as risk factors of severe COVID-19</article-title><source>Immun. Ageing</source><year>2022</year><volume>19</volume><fpage>53</fpage><pub-id pub-id-type="doi">10.1186/s12979-022-00309-5</pub-id><pub-id pub-id-type="pmid">36369012</pub-id><pub-id pub-id-type="pmcid">PMC9650172</pub-id></element-citation><mixed-citation id="mc-CR408" publication-type="journal">Tizazu, A. M., Mengist, H. M. &amp; Demeke, G. Aging, inflammaging and immunosenescence as risk factors of severe COVID-19. <italic toggle="yes">Immun. Ageing</italic><bold>19</bold>, 53 (2022).<pub-id pub-id-type="pmid">36369012</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12979-022-00309-5</pub-id><pub-id pub-id-type="pmcid">PMC9650172</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR409"><label>409.</label><citation-alternatives><element-citation id="ec-CR409" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Salminen</surname><given-names>A</given-names></name></person-group><article-title>Clinical perspectives on the age-related increase of immunosuppressive activity</article-title><source>J. Mol. Med.</source><year>2022</year><volume>100</volume><fpage>697</fpage><lpage>712</lpage><pub-id pub-id-type="doi">10.1007/s00109-022-02193-4</pub-id><pub-id pub-id-type="pmid">35384505</pub-id><pub-id pub-id-type="pmcid">PMC8985067</pub-id></element-citation><mixed-citation id="mc-CR409" publication-type="journal">Salminen, A. Clinical perspectives on the age-related increase of immunosuppressive activity. <italic toggle="yes">J. Mol. Med.</italic><bold>100</bold>, 697&#8211;712 (2022).<pub-id pub-id-type="pmid">35384505</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00109-022-02193-4</pub-id><pub-id pub-id-type="pmcid">PMC8985067</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR410"><label>410.</label><citation-alternatives><element-citation id="ec-CR410" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cunha</surname><given-names>LL</given-names></name><name name-style="western"><surname>Perazzio</surname><given-names>SF</given-names></name><name name-style="western"><surname>Azzi</surname><given-names>J</given-names></name><name name-style="western"><surname>Cravedi</surname><given-names>P</given-names></name><name name-style="western"><surname>Riella</surname><given-names>LV</given-names></name></person-group><article-title>Remodeling of the immune response with aging: immunosenescence and its potential impact on COVID-19 immune response</article-title><source>Front. Immunol.</source><year>2020</year><volume>11</volume><fpage>1748</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2020.01748</pub-id><pub-id pub-id-type="pmid">32849623</pub-id><pub-id pub-id-type="pmcid">PMC7427491</pub-id></element-citation><mixed-citation id="mc-CR410" publication-type="journal">Cunha, L. L., Perazzio, S. F., Azzi, J., Cravedi, P. &amp; Riella, L. V. Remodeling of the immune response with aging: immunosenescence and its potential impact on COVID-19 immune response. <italic toggle="yes">Front. Immunol.</italic><bold>11</bold>, 1748 (2020).<pub-id pub-id-type="pmid">32849623</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2020.01748</pub-id><pub-id pub-id-type="pmcid">PMC7427491</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR411"><label>411.</label><citation-alternatives><element-citation id="ec-CR411" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>M&#252;ller</surname><given-names>L</given-names></name><name name-style="western"><surname>Di Benedetto</surname><given-names>S</given-names></name></person-group><article-title>From aging to long COVID: exploring the convergence of immunosenescence, inflammaging, and autoimmunity</article-title><source>Front. Immunol.</source><year>2023</year><volume>14</volume><fpage>1298004</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2023.1298004</pub-id><pub-id pub-id-type="pmid">37942323</pub-id><pub-id pub-id-type="pmcid">PMC10628127</pub-id></element-citation><mixed-citation id="mc-CR411" publication-type="journal">M&#252;ller, L. &amp; Di Benedetto, S. From aging to long COVID: exploring the convergence of immunosenescence, inflammaging, and autoimmunity. <italic toggle="yes">Front. Immunol.</italic><bold>14</bold>, 1298004 (2023).<pub-id pub-id-type="pmid">37942323</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2023.1298004</pub-id><pub-id pub-id-type="pmcid">PMC10628127</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR412"><label>412.</label><citation-alternatives><element-citation id="ec-CR412" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cisneros</surname><given-names>B</given-names></name><etal/></person-group><article-title>Immune system modulation in aging: molecular mechanisms and therapeutic targets</article-title><source>Front. Immunol.</source><year>2022</year><volume>13</volume><fpage>1059173</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2022.1059173</pub-id><pub-id pub-id-type="pmid">36591275</pub-id><pub-id pub-id-type="pmcid">PMC9797513</pub-id></element-citation><mixed-citation id="mc-CR412" publication-type="journal">Cisneros, B. et al. Immune system modulation in aging: molecular mechanisms and therapeutic targets. <italic toggle="yes">Front. Immunol.</italic><bold>13</bold>, 1059173 (2022).<pub-id pub-id-type="pmid">36591275</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2022.1059173</pub-id><pub-id pub-id-type="pmcid">PMC9797513</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR413"><label>413.</label><citation-alternatives><element-citation id="ec-CR413" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cadar</surname><given-names>AN</given-names></name><name name-style="western"><surname>Martin</surname><given-names>DE</given-names></name><name name-style="western"><surname>Bartley</surname><given-names>JM</given-names></name></person-group><article-title>Targeting the hallmarks of aging to improve influenza vaccine responses in older adults</article-title><source>Immun. Ageing</source><year>2023</year><volume>20</volume><fpage>23</fpage><pub-id pub-id-type="doi">10.1186/s12979-023-00348-6</pub-id><pub-id pub-id-type="pmid">37198683</pub-id><pub-id pub-id-type="pmcid">PMC10189223</pub-id></element-citation><mixed-citation id="mc-CR413" publication-type="journal">Cadar, A. N., Martin, D. E. &amp; Bartley, J. M. Targeting the hallmarks of aging to improve influenza vaccine responses in older adults. <italic toggle="yes">Immun. Ageing</italic><bold>20</bold>, 23 (2023).<pub-id pub-id-type="pmid">37198683</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12979-023-00348-6</pub-id><pub-id pub-id-type="pmcid">PMC10189223</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR414"><label>414.</label><citation-alternatives><element-citation id="ec-CR414" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Valiathan</surname><given-names>R</given-names></name><name name-style="western"><surname>Ashman</surname><given-names>M</given-names></name><name name-style="western"><surname>Asthana</surname><given-names>D</given-names></name></person-group><article-title>Effects of ageing on the immune system: infants to elderly</article-title><source>Scand. J. Immunol.</source><year>2016</year><volume>83</volume><fpage>255</fpage><lpage>266</lpage><pub-id pub-id-type="doi">10.1111/sji.12413</pub-id><pub-id pub-id-type="pmid">26808160</pub-id></element-citation><mixed-citation id="mc-CR414" publication-type="journal">Valiathan, R., Ashman, M. &amp; Asthana, D. Effects of ageing on the immune system: infants to elderly. <italic toggle="yes">Scand. J. Immunol.</italic><bold>83</bold>, 255&#8211;266 (2016).<pub-id pub-id-type="pmid">26808160</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/sji.12413</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR415"><label>415.</label><citation-alternatives><element-citation id="ec-CR415" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anderson</surname><given-names>EJ</given-names></name><etal/></person-group><article-title>Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults</article-title><source>New Engl. J. Med.</source><year>2020</year><volume>383</volume><fpage>2427</fpage><lpage>2438</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2028436</pub-id><pub-id pub-id-type="pmid">32991794</pub-id><pub-id pub-id-type="pmcid">PMC7556339</pub-id></element-citation><mixed-citation id="mc-CR415" publication-type="journal">Anderson, E. J. et al. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. <italic toggle="yes">New Engl. J. Med.</italic><bold>383</bold>, 2427&#8211;2438 (2020).<pub-id pub-id-type="pmid">32991794</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2028436</pub-id><pub-id pub-id-type="pmcid">PMC7556339</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR416"><label>416.</label><citation-alternatives><element-citation id="ec-CR416" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Walsh</surname><given-names>EE</given-names></name><etal/></person-group><article-title>Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates</article-title><source>New Engl. J. Med.</source><year>2020</year><volume>383</volume><fpage>2439</fpage><lpage>2450</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2027906</pub-id><pub-id pub-id-type="pmid">33053279</pub-id><pub-id pub-id-type="pmcid">PMC7583697</pub-id></element-citation><mixed-citation id="mc-CR416" publication-type="journal">Walsh, E. E. et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. <italic toggle="yes">New Engl. J. Med.</italic><bold>383</bold>, 2439&#8211;2450 (2020).<pub-id pub-id-type="pmid">33053279</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2027906</pub-id><pub-id pub-id-type="pmcid">PMC7583697</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR417"><label>417.</label><citation-alternatives><element-citation id="ec-CR417" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>F</given-names></name><etal/></person-group><article-title>Sex differences orchestrated by androgens at single-cell resolution</article-title><source>Nature</source><year>2024</year><volume>629</volume><fpage>193</fpage><lpage>200</lpage><pub-id pub-id-type="doi">10.1038/s41586-024-07291-6</pub-id><pub-id pub-id-type="pmid">38600383</pub-id></element-citation><mixed-citation id="mc-CR417" publication-type="journal">Li, F. et al. Sex differences orchestrated by androgens at single-cell resolution. <italic toggle="yes">Nature</italic><bold>629</bold>, 193&#8211;200 (2024).<pub-id pub-id-type="pmid">38600383</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-024-07291-6</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR418"><label>418.</label><citation-alternatives><element-citation id="ec-CR418" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haitao</surname><given-names>T</given-names></name><etal/></person-group><article-title>COVID-19 and sex differences: mechanisms and biomarkers</article-title><source>Mayo Clin. Proc.</source><year>2020</year><volume>95</volume><fpage>2189</fpage><lpage>2203</lpage><pub-id pub-id-type="doi">10.1016/j.mayocp.2020.07.024</pub-id><pub-id pub-id-type="pmid">33012349</pub-id><pub-id pub-id-type="pmcid">PMC7402208</pub-id></element-citation><mixed-citation id="mc-CR418" publication-type="journal">Haitao, T. et al. COVID-19 and sex differences: mechanisms and biomarkers. <italic toggle="yes">Mayo Clin. Proc.</italic><bold>95</bold>, 2189&#8211;2203 (2020).<pub-id pub-id-type="pmid">33012349</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.mayocp.2020.07.024</pub-id><pub-id pub-id-type="pmcid">PMC7402208</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR419"><label>419.</label><citation-alternatives><element-citation id="ec-CR419" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scully</surname><given-names>EP</given-names></name></person-group><article-title>Sex differences in HIV infection</article-title><source>Curr. HIV/AIDS Rep.</source><year>2018</year><volume>15</volume><fpage>136</fpage><lpage>146</lpage><pub-id pub-id-type="doi">10.1007/s11904-018-0383-2</pub-id><pub-id pub-id-type="pmid">29504062</pub-id><pub-id pub-id-type="pmcid">PMC5882769</pub-id></element-citation><mixed-citation id="mc-CR419" publication-type="journal">Scully, E. P. Sex differences in HIV infection. <italic toggle="yes">Curr. HIV/AIDS Rep.</italic><bold>15</bold>, 136&#8211;146 (2018).<pub-id pub-id-type="pmid">29504062</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11904-018-0383-2</pub-id><pub-id pub-id-type="pmcid">PMC5882769</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR420"><label>420.</label><citation-alternatives><element-citation id="ec-CR420" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cardenas-Garcia</surname><given-names>S</given-names></name><etal/></person-group><article-title>Impact of sex on humoral immunity with live influenza B virus vaccines in mice</article-title><source>NPJ Vaccines</source><year>2024</year><volume>9</volume><fpage>45</fpage><pub-id pub-id-type="doi">10.1038/s41541-024-00827-x</pub-id><pub-id pub-id-type="pmid">38409236</pub-id><pub-id pub-id-type="pmcid">PMC10897209</pub-id></element-citation><mixed-citation id="mc-CR420" publication-type="journal">Cardenas-Garcia, S. et al. Impact of sex on humoral immunity with live influenza B virus vaccines in mice. <italic toggle="yes">NPJ Vaccines</italic><bold>9</bold>, 45 (2024).<pub-id pub-id-type="pmid">38409236</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41541-024-00827-x</pub-id><pub-id pub-id-type="pmcid">PMC10897209</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR421"><label>421.</label><citation-alternatives><element-citation id="ec-CR421" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Forsyth</surname><given-names>KS</given-names></name><name name-style="western"><surname>Jiwrajka</surname><given-names>N</given-names></name><name name-style="western"><surname>Lovell</surname><given-names>CD</given-names></name><name name-style="western"><surname>Toothacre</surname><given-names>NE</given-names></name><name name-style="western"><surname>Anguera</surname><given-names>MC</given-names></name></person-group><article-title>The conneXion between sex and immune responses</article-title><source>Nat. Rev. Immunol.</source><year>2024</year><volume>24</volume><fpage>487</fpage><lpage>502</lpage><pub-id pub-id-type="doi">10.1038/s41577-024-00996-9</pub-id><pub-id pub-id-type="pmid">38383754</pub-id><pub-id pub-id-type="pmcid">PMC11216897</pub-id></element-citation><mixed-citation id="mc-CR421" publication-type="journal">Forsyth, K. S., Jiwrajka, N., Lovell, C. D., Toothacre, N. E. &amp; Anguera, M. C. The conneXion between sex and immune responses. <italic toggle="yes">Nat. Rev. Immunol.</italic><bold>24</bold>, 487&#8211;502 (2024).<pub-id pub-id-type="pmid">38383754</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41577-024-00996-9</pub-id><pub-id pub-id-type="pmcid">PMC11216897</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR422"><label>422.</label><citation-alternatives><element-citation id="ec-CR422" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kanuri</surname><given-names>B</given-names></name><name name-style="western"><surname>Biswas</surname><given-names>P</given-names></name><name name-style="western"><surname>Dahdah</surname><given-names>A</given-names></name><name name-style="western"><surname>Murphy</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Nagareddy</surname><given-names>PR</given-names></name></person-group><article-title>Impact of age and sex on myelopoiesis and inflammation during myocardial infarction</article-title><source>J. Mol. Cell. Cardiol.</source><year>2024</year><volume>187</volume><fpage>80</fpage><lpage>89</lpage><pub-id pub-id-type="doi">10.1016/j.yjmcc.2023.11.011</pub-id><pub-id pub-id-type="pmid">38163742</pub-id><pub-id pub-id-type="pmcid">PMC10922716</pub-id></element-citation><mixed-citation id="mc-CR422" publication-type="journal">Kanuri, B., Biswas, P., Dahdah, A., Murphy, A. J. &amp; Nagareddy, P. R. Impact of age and sex on myelopoiesis and inflammation during myocardial infarction. <italic toggle="yes">J. Mol. Cell. Cardiol.</italic><bold>187</bold>, 80&#8211;89 (2024).<pub-id pub-id-type="pmid">38163742</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.yjmcc.2023.11.011</pub-id><pub-id pub-id-type="pmcid">PMC10922716</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR423"><label>423.</label><citation-alternatives><element-citation id="ec-CR423" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Costa</surname><given-names>AR</given-names></name><etal/></person-group><article-title>The sex bias of cancer</article-title><source>Trends Endocrinol. Metab.</source><year>2020</year><volume>31</volume><fpage>785</fpage><lpage>799</lpage><pub-id pub-id-type="doi">10.1016/j.tem.2020.07.002</pub-id><pub-id pub-id-type="pmid">32900596</pub-id></element-citation><mixed-citation id="mc-CR423" publication-type="journal">Costa, A. R. et al. The sex bias of cancer. <italic toggle="yes">Trends Endocrinol. Metab.</italic><bold>31</bold>, 785&#8211;799 (2020).<pub-id pub-id-type="pmid">32900596</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.tem.2020.07.002</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR424"><label>424.</label><citation-alternatives><element-citation id="ec-CR424" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bhattacharya</surname><given-names>S</given-names></name><name name-style="western"><surname>Sadhukhan</surname><given-names>D</given-names></name><name name-style="western"><surname>Saraswathy</surname><given-names>R</given-names></name></person-group><article-title>Role of sex in immune response and epigenetic mechanisms</article-title><source>Epigenet. Chromatin</source><year>2024</year><volume>17</volume><fpage>1</fpage><pub-id pub-id-type="doi">10.1186/s13072-024-00525-x</pub-id><pub-id pub-id-type="pmcid">PMC10802034</pub-id><pub-id pub-id-type="pmid">38247002</pub-id></element-citation><mixed-citation id="mc-CR424" publication-type="journal">Bhattacharya, S., Sadhukhan, D. &amp; Saraswathy, R. Role of sex in immune response and epigenetic mechanisms. <italic toggle="yes">Epigenet. Chromatin</italic><bold>17</bold>, 1 (2024).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13072-024-00525-x</pub-id><pub-id pub-id-type="pmcid">PMC10802034</pub-id><pub-id pub-id-type="pmid">38247002</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR425"><label>425.</label><citation-alternatives><element-citation id="ec-CR425" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>X</given-names></name><etal/></person-group><article-title>Sex-biased molecular differences in lung adenocarcinoma are ethnic and smoking specific</article-title><source>BMC Pulm. Med.</source><year>2023</year><volume>23</volume><fpage>99</fpage><pub-id pub-id-type="doi">10.1186/s12890-023-02387-7</pub-id><pub-id pub-id-type="pmid">36964522</pub-id><pub-id pub-id-type="pmcid">PMC10039609</pub-id></element-citation><mixed-citation id="mc-CR425" publication-type="journal">Li, X. et al. Sex-biased molecular differences in lung adenocarcinoma are ethnic and smoking specific. <italic toggle="yes">BMC Pulm. Med.</italic><bold>23</bold>, 99 (2023).<pub-id pub-id-type="pmid">36964522</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12890-023-02387-7</pub-id><pub-id pub-id-type="pmcid">PMC10039609</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR426"><label>426.</label><citation-alternatives><element-citation id="ec-CR426" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thompson</surname><given-names>MG</given-names></name><name name-style="western"><surname>Peiffer</surname><given-names>DS</given-names></name><name name-style="western"><surname>Larson</surname><given-names>M</given-names></name><name name-style="western"><surname>Navarro</surname><given-names>F</given-names></name><name name-style="western"><surname>Watkins</surname><given-names>SK</given-names></name></person-group><article-title>FOXO3, estrogen receptor alpha, and androgen receptor impact tumor growth rate and infiltration of dendritic cell subsets differentially between male and female mice</article-title><source>Cancer Immunol. Immunother.</source><year>2017</year><volume>66</volume><fpage>615</fpage><lpage>625</lpage><pub-id pub-id-type="doi">10.1007/s00262-017-1972-4</pub-id><pub-id pub-id-type="pmid">28229217</pub-id><pub-id pub-id-type="pmcid">PMC11028910</pub-id></element-citation><mixed-citation id="mc-CR426" publication-type="journal">Thompson, M. G., Peiffer, D. S., Larson, M., Navarro, F. &amp; Watkins, S. K. FOXO3, estrogen receptor alpha, and androgen receptor impact tumor growth rate and infiltration of dendritic cell subsets differentially between male and female mice. <italic toggle="yes">Cancer Immunol. Immunother.</italic><bold>66</bold>, 615&#8211;625 (2017).<pub-id pub-id-type="pmid">28229217</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00262-017-1972-4</pub-id><pub-id pub-id-type="pmcid">PMC11028910</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR427"><label>427.</label><citation-alternatives><element-citation id="ec-CR427" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xiao</surname><given-names>T</given-names></name><etal/></person-group><article-title>Hallmarks of sex bias in immuno-oncology: mechanisms and therapeutic implications</article-title><source>Nat. Rev. Cancer</source><year>2024</year><volume>24</volume><fpage>338</fpage><lpage>355</lpage><pub-id pub-id-type="doi">10.1038/s41568-024-00680-z</pub-id><pub-id pub-id-type="pmid">38589557</pub-id></element-citation><mixed-citation id="mc-CR427" publication-type="journal">Xiao, T. et al. Hallmarks of sex bias in immuno-oncology: mechanisms and therapeutic implications. <italic toggle="yes">Nat. Rev. Cancer</italic><bold>24</bold>, 338&#8211;355 (2024).<pub-id pub-id-type="pmid">38589557</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41568-024-00680-z</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR428"><label>428.</label><citation-alternatives><element-citation id="ec-CR428" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wallis</surname><given-names>CJD</given-names></name><etal/></person-group><article-title>Association of patient sex with efficacy of immune checkpoint inhibitors and overall survival in advanced cancers: a systematic review and meta-analysis</article-title><source>JAMA Oncol.</source><year>2019</year><volume>5</volume><fpage>529</fpage><lpage>536</lpage><pub-id pub-id-type="doi">10.1001/jamaoncol.2018.5904</pub-id><pub-id pub-id-type="pmid">30605213</pub-id><pub-id pub-id-type="pmcid">PMC6459215</pub-id></element-citation><mixed-citation id="mc-CR428" publication-type="journal">Wallis, C. J. D. et al. Association of patient sex with efficacy of immune checkpoint inhibitors and overall survival in advanced cancers: a systematic review and meta-analysis. <italic toggle="yes">JAMA Oncol.</italic><bold>5</bold>, 529&#8211;536 (2019).<pub-id pub-id-type="pmid">30605213</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamaoncol.2018.5904</pub-id><pub-id pub-id-type="pmcid">PMC6459215</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR429"><label>429.</label><citation-alternatives><element-citation id="ec-CR429" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pinto</surname><given-names>JA</given-names></name><name name-style="western"><surname>Araujo</surname><given-names>JM</given-names></name><name name-style="western"><surname>G&#243;mez</surname><given-names>HL</given-names></name></person-group><article-title>Sex, immunity, and cancer</article-title><source>Biochim. Biophys. Acta Rev. Cancer</source><year>2022</year><volume>1877</volume><fpage>188647</fpage><pub-id pub-id-type="doi">10.1016/j.bbcan.2021.188647</pub-id><pub-id pub-id-type="pmid">34767966</pub-id></element-citation><mixed-citation id="mc-CR429" publication-type="journal">Pinto, J. A., Araujo, J. M. &amp; G&#243;mez, H. L. Sex, immunity, and cancer. <italic toggle="yes">Biochim. Biophys. Acta Rev. Cancer</italic><bold>1877</bold>, 188647 (2022).<pub-id pub-id-type="pmid">34767966</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbcan.2021.188647</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR430"><label>430.</label><citation-alternatives><element-citation id="ec-CR430" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dodd</surname><given-names>KC</given-names></name><name name-style="western"><surname>Menon</surname><given-names>M</given-names></name></person-group><article-title>Sex bias in lymphocytes: implications for autoimmune diseases</article-title><source>Front. Immunol.</source><year>2022</year><volume>13</volume><fpage>945762</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2022.945762</pub-id><pub-id pub-id-type="pmid">36505451</pub-id><pub-id pub-id-type="pmcid">PMC9730535</pub-id></element-citation><mixed-citation id="mc-CR430" publication-type="journal">Dodd, K. C. &amp; Menon, M. Sex bias in lymphocytes: implications for autoimmune diseases. <italic toggle="yes">Front. Immunol.</italic><bold>13</bold>, 945762 (2022).<pub-id pub-id-type="pmid">36505451</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2022.945762</pub-id><pub-id pub-id-type="pmcid">PMC9730535</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR431"><label>431.</label><citation-alternatives><element-citation id="ec-CR431" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xing</surname><given-names>E</given-names></name><name name-style="western"><surname>Billi</surname><given-names>AC</given-names></name><name name-style="western"><surname>Gudjonsson</surname><given-names>JE</given-names></name></person-group><article-title>Sex bias and autoimmune diseases</article-title><source>J. Investig. Dermatol.</source><year>2022</year><volume>142</volume><fpage>857</fpage><lpage>866</lpage><pub-id pub-id-type="doi">10.1016/j.jid.2021.06.008</pub-id><pub-id pub-id-type="pmid">34362556</pub-id></element-citation><mixed-citation id="mc-CR431" publication-type="journal">Xing, E., Billi, A. C. &amp; Gudjonsson, J. E. Sex bias and autoimmune diseases. <italic toggle="yes">J. Investig. Dermatol.</italic><bold>142</bold>, 857&#8211;866 (2022).<pub-id pub-id-type="pmid">34362556</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jid.2021.06.008</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR432"><label>432.</label><citation-alternatives><element-citation id="ec-CR432" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wilkinson</surname><given-names>NM</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H-C</given-names></name><name name-style="western"><surname>Lechner</surname><given-names>MG</given-names></name><name name-style="western"><surname>Su</surname><given-names>MA</given-names></name></person-group><article-title>Sex differences in immunity</article-title><source>Annu. Rev. Immunol.</source><year>2022</year><volume>40</volume><fpage>75</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1146/annurev-immunol-101320-125133</pub-id><pub-id pub-id-type="pmid">34985929</pub-id><pub-id pub-id-type="pmcid">PMC9805670</pub-id></element-citation><mixed-citation id="mc-CR432" publication-type="journal">Wilkinson, N. M., Chen, H.-C., Lechner, M. G. &amp; Su, M. A. Sex differences in immunity. <italic toggle="yes">Annu. Rev. Immunol.</italic><bold>40</bold>, 75&#8211;94 (2022).<pub-id pub-id-type="pmid">34985929</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1146/annurev-immunol-101320-125133</pub-id><pub-id pub-id-type="pmcid">PMC9805670</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR433"><label>433.</label><citation-alternatives><element-citation id="ec-CR433" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moulton</surname><given-names>VR</given-names></name></person-group><article-title>Sex hormones in acquired immunity and autoimmune disease</article-title><source>Front. Immunol.</source><year>2018</year><volume>9</volume><fpage>2279</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2018.02279</pub-id><pub-id pub-id-type="pmid">30337927</pub-id><pub-id pub-id-type="pmcid">PMC6180207</pub-id></element-citation><mixed-citation id="mc-CR433" publication-type="journal">Moulton, V. R. Sex hormones in acquired immunity and autoimmune disease. <italic toggle="yes">Front. Immunol.</italic><bold>9</bold>, 2279 (2018).<pub-id pub-id-type="pmid">30337927</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2018.02279</pub-id><pub-id pub-id-type="pmcid">PMC6180207</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR434"><label>434.</label><citation-alternatives><element-citation id="ec-CR434" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Sex hormones influence the intestinal microbiota composition in mice</article-title><source>Front. Microbiol.</source><year>2022</year><volume>13</volume><fpage>964847</fpage><pub-id pub-id-type="doi">10.3389/fmicb.2022.964847</pub-id><pub-id pub-id-type="pmid">36386696</pub-id><pub-id pub-id-type="pmcid">PMC9659915</pub-id></element-citation><mixed-citation id="mc-CR434" publication-type="journal">Wu, Y. et al. Sex hormones influence the intestinal microbiota composition in mice. <italic toggle="yes">Front. Microbiol.</italic><bold>13</bold>, 964847 (2022).<pub-id pub-id-type="pmid">36386696</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fmicb.2022.964847</pub-id><pub-id pub-id-type="pmcid">PMC9659915</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR435"><label>435.</label><mixed-citation publication-type="other">Natl. Inst. Health. NOT-OD-15-102: consideration of sex as a biological variable in NIH-funded research. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://grants.nih.gov/grants/guide/notice-files/not-od-15-102.html">https://grants.nih.gov/grants/guide/notice-files/not-od-15-102.html</ext-link> (2015).</mixed-citation></ref><ref id="CR436"><label>436.</label><citation-alternatives><element-citation id="ec-CR436" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arumugam</surname><given-names>GS</given-names></name><name name-style="western"><surname>Damodharan</surname><given-names>K</given-names></name><name name-style="western"><surname>Doble</surname><given-names>M</given-names></name><name name-style="western"><surname>Thennarasu</surname><given-names>S</given-names></name></person-group><article-title>Significant perspectives on various viral infections targeted antiviral drugs and vaccines including COVID-19 pandemicity</article-title><source>Mol. Biomed.</source><year>2022</year><volume>3</volume><fpage>21</fpage><pub-id pub-id-type="doi">10.1186/s43556-022-00078-z</pub-id><pub-id pub-id-type="pmid">35838929</pub-id><pub-id pub-id-type="pmcid">PMC9283561</pub-id></element-citation><mixed-citation id="mc-CR436" publication-type="journal">Arumugam, G. S., Damodharan, K., Doble, M. &amp; Thennarasu, S. Significant perspectives on various viral infections targeted antiviral drugs and vaccines including COVID-19 pandemicity. <italic toggle="yes">Mol. Biomed.</italic><bold>3</bold>, 21 (2022).<pub-id pub-id-type="pmid">35838929</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s43556-022-00078-z</pub-id><pub-id pub-id-type="pmcid">PMC9283561</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR437"><label>437.</label><citation-alternatives><element-citation id="ec-CR437" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Levin</surname><given-names>EG</given-names></name><etal/></person-group><article-title>Waning immune humoral response to BNT162b2 Covid-19 vaccine over 6 months</article-title><source>N. Engl. J. Med.</source><year>2021</year><volume>385</volume><fpage>e84</fpage><pub-id pub-id-type="doi">10.1056/NEJMoa2114583</pub-id><pub-id pub-id-type="pmid">34614326</pub-id><pub-id pub-id-type="pmcid">PMC8522797</pub-id></element-citation><mixed-citation id="mc-CR437" publication-type="journal">Levin, E. G. et al. Waning immune humoral response to BNT162b2 Covid-19 vaccine over 6 months. <italic toggle="yes">N. Engl. J. Med.</italic><bold>385</bold>, e84 (2021).<pub-id pub-id-type="pmid">34614326</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2114583</pub-id><pub-id pub-id-type="pmcid">PMC8522797</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR438"><label>438.</label><citation-alternatives><element-citation id="ec-CR438" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Furer</surname><given-names>V</given-names></name><etal/></person-group><article-title>Immunogenicity induced by two and three doses of the BNT162b2 mRNA vaccine in patients with autoimmune inflammatory rheumatic diseases and immunocompetent controls: a longitudinal multicentre study</article-title><source>Ann. Rheum. Dis.</source><year>2022</year><volume>81</volume><fpage>1594</fpage><lpage>1602</lpage><pub-id pub-id-type="doi">10.1136/ard-2022-222550</pub-id><pub-id pub-id-type="pmid">35868846</pub-id></element-citation><mixed-citation id="mc-CR438" publication-type="journal">Furer, V. et al. Immunogenicity induced by two and three doses of the BNT162b2 mRNA vaccine in patients with autoimmune inflammatory rheumatic diseases and immunocompetent controls: a longitudinal multicentre study. <italic toggle="yes">Ann. Rheum. Dis.</italic><bold>81</bold>, 1594&#8211;1602 (2022).<pub-id pub-id-type="pmid">35868846</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/ard-2022-222550</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR439"><label>439.</label><citation-alternatives><element-citation id="ec-CR439" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leston</surname><given-names>M</given-names></name><etal/></person-group><article-title>Disparities in COVID-19 mortality amongst the immunosuppressed: a systematic review and meta-analysis for enhanced disease surveillance</article-title><source>J. Infect.</source><year>2024</year><volume>88</volume><fpage>106110</fpage><pub-id pub-id-type="doi">10.1016/j.jinf.2024.01.009</pub-id><pub-id pub-id-type="pmid">38302061</pub-id><pub-id pub-id-type="pmcid">PMC10943183</pub-id></element-citation><mixed-citation id="mc-CR439" publication-type="journal">Leston, M. et al. Disparities in COVID-19 mortality amongst the immunosuppressed: a systematic review and meta-analysis for enhanced disease surveillance. <italic toggle="yes">J. Infect.</italic><bold>88</bold>, 106110 (2024).<pub-id pub-id-type="pmid">38302061</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jinf.2024.01.009</pub-id><pub-id pub-id-type="pmcid">PMC10943183</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR440"><label>440.</label><citation-alternatives><element-citation id="ec-CR440" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Meeraus</surname><given-names>W</given-names></name><etal/></person-group><article-title>AZD1222 effectiveness against severe COVID-19 in individuals with comorbidity or frailty: the RAVEN cohort study</article-title><source>J. Infect.</source><year>2024</year><volume>88</volume><fpage>106129</fpage><pub-id pub-id-type="doi">10.1016/j.jinf.2024.106129</pub-id><pub-id pub-id-type="pmid">38431156</pub-id></element-citation><mixed-citation id="mc-CR440" publication-type="journal">Meeraus, W. et al. AZD1222 effectiveness against severe COVID-19 in individuals with comorbidity or frailty: the RAVEN cohort study. <italic toggle="yes">J. Infect.</italic><bold>88</bold>, 106129 (2024).<pub-id pub-id-type="pmid">38431156</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jinf.2024.106129</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR441"><label>441.</label><citation-alternatives><element-citation id="ec-CR441" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Obeid</surname><given-names>M</given-names></name><etal/></person-group><article-title>Humoral responses against variants of concern by COVID-19 mRNA vaccines in immunocompromised patients</article-title><source>JAMA Oncol.</source><year>2022</year><volume>8</volume><fpage>e220446</fpage><pub-id pub-id-type="doi">10.1001/jamaoncol.2022.0446</pub-id><pub-id pub-id-type="pmid">35271706</pub-id><pub-id pub-id-type="pmcid">PMC8914885</pub-id></element-citation><mixed-citation id="mc-CR441" publication-type="journal">Obeid, M. et al. Humoral responses against variants of concern by COVID-19 mRNA vaccines in immunocompromised patients. <italic toggle="yes">JAMA Oncol.</italic><bold>8</bold>, e220446 (2022).<pub-id pub-id-type="pmid">35271706</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamaoncol.2022.0446</pub-id><pub-id pub-id-type="pmcid">PMC8914885</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR442"><label>442.</label><citation-alternatives><element-citation id="ec-CR442" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mbonde</surname><given-names>AA</given-names></name><etal/></person-group><article-title>Neuroinvasive West Nile virus infection in immunosuppressed and immunocompetent adults</article-title><source>JAMA Netw. Open</source><year>2024</year><volume>7</volume><fpage>e244294</fpage><pub-id pub-id-type="doi">10.1001/jamanetworkopen.2024.4294</pub-id><pub-id pub-id-type="pmid">38546642</pub-id><pub-id pub-id-type="pmcid">PMC10979308</pub-id></element-citation><mixed-citation id="mc-CR442" publication-type="journal">Mbonde, A. A. et al. Neuroinvasive West Nile virus infection in immunosuppressed and immunocompetent adults. <italic toggle="yes">JAMA Netw. Open</italic><bold>7</bold>, e244294 (2024).<pub-id pub-id-type="pmid">38546642</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamanetworkopen.2024.4294</pub-id><pub-id pub-id-type="pmcid">PMC10979308</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR443"><label>443.</label><citation-alternatives><element-citation id="ec-CR443" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liao</surname><given-names>C</given-names></name><etal/></person-group><article-title>Siglec-F<sup>+</sup> neutrophils in the spleen induce immunosuppression following acute infection</article-title><source>Theranostics</source><year>2024</year><volume>14</volume><fpage>2589</fpage><lpage>2604</lpage><pub-id pub-id-type="doi">10.7150/thno.93812</pub-id><pub-id pub-id-type="pmid">38646647</pub-id><pub-id pub-id-type="pmcid">PMC11024851</pub-id></element-citation><mixed-citation id="mc-CR443" publication-type="journal">Liao, C. et al. Siglec-F<sup>+</sup> neutrophils in the spleen induce immunosuppression following acute infection. <italic toggle="yes">Theranostics</italic><bold>14</bold>, 2589&#8211;2604 (2024).<pub-id pub-id-type="pmid">38646647</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7150/thno.93812</pub-id><pub-id pub-id-type="pmcid">PMC11024851</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR444"><label>444.</label><citation-alternatives><element-citation id="ec-CR444" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Suk-Ouichai</surname><given-names>C</given-names></name><etal/></person-group><article-title>A clinical overview of people living with HIV and genitourinary cancer care</article-title><source>Nat. Rev. Urol.</source><year>2024</year><volume>21</volume><fpage>373</fpage><lpage>383</lpage><pub-id pub-id-type="doi">10.1038/s41585-023-00846-8</pub-id><pub-id pub-id-type="pmid">38238527</pub-id></element-citation><mixed-citation id="mc-CR444" publication-type="journal">Suk-Ouichai, C. et al. A clinical overview of people living with HIV and genitourinary cancer care. <italic toggle="yes">Nat. Rev. Urol.</italic><bold>21</bold>, 373&#8211;383 (2024).<pub-id pub-id-type="pmid">38238527</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41585-023-00846-8</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR445"><label>445.</label><citation-alternatives><element-citation id="ec-CR445" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gianesin</surname><given-names>K</given-names></name><etal/></person-group><article-title>Premature aging and immune senescence in HIV-infected children</article-title><source>AIDS</source><year>2016</year><volume>30</volume><fpage>1363</fpage><lpage>1373</lpage><pub-id pub-id-type="doi">10.1097/QAD.0000000000001093</pub-id><pub-id pub-id-type="pmid">26990630</pub-id><pub-id pub-id-type="pmcid">PMC4867984</pub-id></element-citation><mixed-citation id="mc-CR445" publication-type="journal">Gianesin, K. et al. Premature aging and immune senescence in HIV-infected children. <italic toggle="yes">AIDS</italic><bold>30</bold>, 1363&#8211;1373 (2016).<pub-id pub-id-type="pmid">26990630</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/QAD.0000000000001093</pub-id><pub-id pub-id-type="pmcid">PMC4867984</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR446"><label>446.</label><citation-alternatives><element-citation id="ec-CR446" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vergori</surname><given-names>A</given-names></name><etal/></person-group><article-title>Immunogenicity to COVID-19 mRNA vaccine third dose in people living with HIV</article-title><source>Nat. Commun.</source><year>2022</year><volume>13</volume><fpage>4922</fpage><pub-id pub-id-type="doi">10.1038/s41467-022-32263-7</pub-id><pub-id pub-id-type="pmid">35995780</pub-id><pub-id pub-id-type="pmcid">PMC9395398</pub-id></element-citation><mixed-citation id="mc-CR446" publication-type="journal">Vergori, A. et al. Immunogenicity to COVID-19 mRNA vaccine third dose in people living with HIV. <italic toggle="yes">Nat. Commun.</italic><bold>13</bold>, 4922 (2022).<pub-id pub-id-type="pmid">35995780</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-022-32263-7</pub-id><pub-id pub-id-type="pmcid">PMC9395398</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR447"><label>447.</label><citation-alternatives><element-citation id="ec-CR447" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kachikis</surname><given-names>A</given-names></name><etal/></person-group><article-title>Timing of maternal COVID-19 vaccine and antibody concentrations in infants born preterm</article-title><source>JAMA Netw. Open</source><year>2024</year><volume>7</volume><fpage>e2352387</fpage><pub-id pub-id-type="doi">10.1001/jamanetworkopen.2023.52387</pub-id><pub-id pub-id-type="pmid">38241046</pub-id><pub-id pub-id-type="pmcid">PMC10799259</pub-id></element-citation><mixed-citation id="mc-CR447" publication-type="journal">Kachikis, A. et al. Timing of maternal COVID-19 vaccine and antibody concentrations in infants born preterm. <italic toggle="yes">JAMA Netw. Open</italic><bold>7</bold>, e2352387 (2024).<pub-id pub-id-type="pmid">38241046</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamanetworkopen.2023.52387</pub-id><pub-id pub-id-type="pmcid">PMC10799259</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR448"><label>448.</label><citation-alternatives><element-citation id="ec-CR448" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Johnston</surname><given-names>MS</given-names></name><name name-style="western"><surname>Galan</surname><given-names>A</given-names></name><name name-style="western"><surname>Watsky</surname><given-names>KL</given-names></name><name name-style="western"><surname>Little</surname><given-names>AJ</given-names></name></person-group><article-title>Delayed localized hypersensitivity reactions to the Moderna COVID-19 vaccine</article-title><source>JAMA Dermatol</source><year>2021</year><volume>157</volume><fpage>716</fpage><lpage>720</lpage><pub-id pub-id-type="doi">10.1001/jamadermatol.2021.1214</pub-id><pub-id pub-id-type="pmid">33978670</pub-id><pub-id pub-id-type="pmcid">PMC8117061</pub-id></element-citation><mixed-citation id="mc-CR448" publication-type="journal">Johnston, M. S., Galan, A., Watsky, K. L. &amp; Little, A. J. Delayed localized hypersensitivity reactions to the Moderna COVID-19 vaccine. <italic toggle="yes">JAMA Dermatol</italic><bold>157</bold>, 716&#8211;720 (2021).<pub-id pub-id-type="pmid">33978670</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamadermatol.2021.1214</pub-id><pub-id pub-id-type="pmcid">PMC8117061</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR449"><label>449.</label><citation-alternatives><element-citation id="ec-CR449" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cappelletti-Montano</surname><given-names>B</given-names></name><name name-style="western"><surname>Demuru</surname><given-names>G</given-names></name><name name-style="western"><surname>Laconi</surname><given-names>E</given-names></name><name name-style="western"><surname>Musio</surname><given-names>M</given-names></name></person-group><article-title>A comparative analysis on serious adverse events reported for COVID-19 vaccines in adolescents and young adults</article-title><source>Front. Public Health</source><year>2023</year><volume>11</volume><fpage>1145645</fpage><pub-id pub-id-type="doi">10.3389/fpubh.2023.1145645</pub-id><pub-id pub-id-type="pmid">37377545</pub-id><pub-id pub-id-type="pmcid">PMC10291619</pub-id></element-citation><mixed-citation id="mc-CR449" publication-type="journal">Cappelletti-Montano, B., Demuru, G., Laconi, E. &amp; Musio, M. A comparative analysis on serious adverse events reported for COVID-19 vaccines in adolescents and young adults. <italic toggle="yes">Front. Public Health</italic><bold>11</bold>, 1145645 (2023).<pub-id pub-id-type="pmid">37377545</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fpubh.2023.1145645</pub-id><pub-id pub-id-type="pmcid">PMC10291619</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR450"><label>450.</label><citation-alternatives><element-citation id="ec-CR450" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heil</surname><given-names>M</given-names></name></person-group><article-title>Self-DNA driven inflammation in COVID-19 and after mRNA-based vaccination: lessons for non-COVID-19 pathologies</article-title><source>Front. Immunol.</source><year>2024</year><volume>14</volume><fpage>1259879</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2023.1259879</pub-id><pub-id pub-id-type="pmid">38439942</pub-id><pub-id pub-id-type="pmcid">PMC10910434</pub-id></element-citation><mixed-citation id="mc-CR450" publication-type="journal">Heil, M. Self-DNA driven inflammation in COVID-19 and after mRNA-based vaccination: lessons for non-COVID-19 pathologies. <italic toggle="yes">Front. Immunol.</italic><bold>14</bold>, 1259879 (2024).<pub-id pub-id-type="pmid">38439942</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2023.1259879</pub-id><pub-id pub-id-type="pmcid">PMC10910434</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR451"><label>451.</label><citation-alternatives><element-citation id="ec-CR451" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pettini</surname><given-names>E</given-names></name><etal/></person-group><article-title>Spike-specific memory B cell response in hematopoietic cell transplantation recipients following multiple mRNA-1273 vaccinations: a longitudinal observational study</article-title><source>Vaccines</source><year>2024</year><volume>12</volume><fpage>368</fpage><pub-id pub-id-type="doi">10.3390/vaccines12040368</pub-id><pub-id pub-id-type="pmid">38675750</pub-id><pub-id pub-id-type="pmcid">PMC11054563</pub-id></element-citation><mixed-citation id="mc-CR451" publication-type="journal">Pettini, E. et al. Spike-specific memory B cell response in hematopoietic cell transplantation recipients following multiple mRNA-1273 vaccinations: a longitudinal observational study. <italic toggle="yes">Vaccines</italic><bold>12</bold>, 368 (2024).<pub-id pub-id-type="pmid">38675750</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/vaccines12040368</pub-id><pub-id pub-id-type="pmcid">PMC11054563</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR452"><label>452.</label><citation-alternatives><element-citation id="ec-CR452" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mawson</surname><given-names>AR</given-names></name><name name-style="western"><surname>Croft</surname><given-names>AM</given-names></name></person-group><article-title>Multiple vaccinations and the enigma of vaccine injury</article-title><source>Vaccines</source><year>2020</year><volume>8</volume><fpage>676</fpage><pub-id pub-id-type="doi">10.3390/vaccines8040676</pub-id><pub-id pub-id-type="pmid">33198395</pub-id><pub-id pub-id-type="pmcid">PMC7712358</pub-id></element-citation><mixed-citation id="mc-CR452" publication-type="journal">Mawson, A. R. &amp; Croft, A. M. Multiple vaccinations and the enigma of vaccine injury. <italic toggle="yes">Vaccines</italic><bold>8</bold>, 676 (2020).<pub-id pub-id-type="pmid">33198395</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/vaccines8040676</pub-id><pub-id pub-id-type="pmcid">PMC7712358</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR453"><label>453.</label><mixed-citation publication-type="other">BioNTech SE. A Phase Ib/IIa two-part, randomized, placebo-controlled, observer-blind, dose-finding evaluation trial to describe the safety, reactogenicity, and immunogenicity of two investigational vaccines against tuberculosis in BCG vaccinated, HIV-negative subjects and people living with HIV. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/study/NCT05547464">https://clinicaltrials.gov/study/NCT05547464</ext-link> (2024).</mixed-citation></ref><ref id="CR454"><label>454.</label><citation-alternatives><element-citation id="ec-CR454" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Park</surname><given-names>JK</given-names></name><name name-style="western"><surname>Lee</surname><given-names>EB</given-names></name><name name-style="western"><surname>Winthrop</surname><given-names>KL</given-names></name></person-group><article-title>What rheumatologists need to know about mRNA vaccines: current status and future of mRNA vaccines in autoimmune inflammatory rheumatic diseases</article-title><source>Ann. Rheum. Dis.</source><year>2024</year><volume>83</volume><fpage>687</fpage><lpage>695</lpage><pub-id pub-id-type="doi">10.1136/ard-2024-225492</pub-id><pub-id pub-id-type="pmid">38413167</pub-id></element-citation><mixed-citation id="mc-CR454" publication-type="journal">Park, J. K., Lee, E. B. &amp; Winthrop, K. L. What rheumatologists need to know about mRNA vaccines: current status and future of mRNA vaccines in autoimmune inflammatory rheumatic diseases. <italic toggle="yes">Ann. Rheum. Dis.</italic><bold>83</bold>, 687&#8211;695 (2024).<pub-id pub-id-type="pmid">38413167</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/ard-2024-225492</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR455"><label>455.</label><citation-alternatives><element-citation id="ec-CR455" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mendon&#231;a</surname><given-names>MCP</given-names></name><name name-style="western"><surname>Kont</surname><given-names>A</given-names></name><name name-style="western"><surname>Kowalski</surname><given-names>PS</given-names></name><name name-style="western"><surname>O&#8217;Driscoll</surname><given-names>CM</given-names></name></person-group><article-title>Design of lipid-based nanoparticles for delivery of therapeutic nucleic acids</article-title><source>Drug Discov. Today</source><year>2023</year><volume>28</volume><fpage>103505</fpage><pub-id pub-id-type="doi">10.1016/j.drudis.2023.103505</pub-id><pub-id pub-id-type="pmid">36708760</pub-id></element-citation><mixed-citation id="mc-CR455" publication-type="journal">Mendon&#231;a, M. C. P., Kont, A., Kowalski, P. S. &amp; O&#8217;Driscoll, C. M. Design of lipid-based nanoparticles for delivery of therapeutic nucleic acids. <italic toggle="yes">Drug Discov. Today</italic><bold>28</bold>, 103505 (2023).<pub-id pub-id-type="pmid">36708760</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.drudis.2023.103505</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR456"><label>456.</label><citation-alternatives><element-citation id="ec-CR456" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bitounis</surname><given-names>D</given-names></name><name name-style="western"><surname>Jacquinet</surname><given-names>E</given-names></name><name name-style="western"><surname>Rogers</surname><given-names>MA</given-names></name><name name-style="western"><surname>Amiji</surname><given-names>MM</given-names></name></person-group><article-title>Strategies to reduce the risks of mRNA drug and vaccine toxicity</article-title><source>Nat. Rev. Drug Discov.</source><year>2024</year><volume>23</volume><fpage>281</fpage><lpage>300</lpage><pub-id pub-id-type="doi">10.1038/s41573-023-00859-3</pub-id><pub-id pub-id-type="pmid">38263456</pub-id></element-citation><mixed-citation id="mc-CR456" publication-type="journal">Bitounis, D., Jacquinet, E., Rogers, M. A. &amp; Amiji, M. M. Strategies to reduce the risks of mRNA drug and vaccine toxicity. <italic toggle="yes">Nat. Rev. Drug Discov.</italic><bold>23</bold>, 281&#8211;300 (2024).<pub-id pub-id-type="pmid">38263456</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41573-023-00859-3</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR457"><label>457.</label><citation-alternatives><element-citation id="ec-CR457" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tursi</surname><given-names>NJ</given-names></name><name name-style="western"><surname>Weiner</surname><given-names>DB</given-names></name></person-group><article-title>Modified messenger-RNA components alter the encoded protein</article-title><source>Nature</source><year>2024</year><volume>625</volume><fpage>37</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1038/d41586-023-03787-9</pub-id><pub-id pub-id-type="pmid">38093050</pub-id></element-citation><mixed-citation id="mc-CR457" publication-type="journal">Tursi, N. J. &amp; Weiner, D. B. Modified messenger-RNA components alter the encoded protein. <italic toggle="yes">Nature</italic><bold>625</bold>, 37&#8211;38 (2024).<pub-id pub-id-type="pmid">38093050</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/d41586-023-03787-9</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR458"><label>458.</label><citation-alternatives><element-citation id="ec-CR458" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mulroney</surname><given-names>TE</given-names></name><etal/></person-group><article-title>N1-methylpseudouridylation of mRNA causes +1 ribosomal frameshifting</article-title><source>Nature</source><year>2024</year><volume>625</volume><fpage>189</fpage><lpage>194</lpage><pub-id pub-id-type="doi">10.1038/s41586-023-06800-3</pub-id><pub-id pub-id-type="pmid">38057663</pub-id><pub-id pub-id-type="pmcid">PMC10764286</pub-id></element-citation><mixed-citation id="mc-CR458" publication-type="journal">Mulroney, T. E. et al. N1-methylpseudouridylation of mRNA causes +1 ribosomal frameshifting. <italic toggle="yes">Nature</italic><bold>625</bold>, 189&#8211;194 (2024).<pub-id pub-id-type="pmid">38057663</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-023-06800-3</pub-id><pub-id pub-id-type="pmcid">PMC10764286</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR459"><label>459.</label><citation-alternatives><element-citation id="ec-CR459" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ni</surname><given-names>L</given-names></name></person-group><article-title>Advances in mRNA-based cancer vaccines</article-title><source>Vaccines</source><year>2023</year><volume>11</volume><fpage>1599</fpage><pub-id pub-id-type="doi">10.3390/vaccines11101599</pub-id><pub-id pub-id-type="pmid">37897001</pub-id><pub-id pub-id-type="pmcid">PMC10611059</pub-id></element-citation><mixed-citation id="mc-CR459" publication-type="journal">Ni, L. Advances in mRNA-based cancer vaccines. <italic toggle="yes">Vaccines</italic><bold>11</bold>, 1599 (2023).<pub-id pub-id-type="pmid">37897001</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/vaccines11101599</pub-id><pub-id pub-id-type="pmcid">PMC10611059</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR460"><label>460.</label><citation-alternatives><element-citation id="ec-CR460" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xie</surname><given-names>C</given-names></name><name name-style="western"><surname>Yao</surname><given-names>R</given-names></name><name name-style="western"><surname>Xia</surname><given-names>X</given-names></name></person-group><article-title>The advances of adjuvants in mRNA vaccines</article-title><source>NPJ Vaccines</source><year>2023</year><volume>8</volume><fpage>162</fpage><pub-id pub-id-type="doi">10.1038/s41541-023-00760-5</pub-id><pub-id pub-id-type="pmid">37884526</pub-id><pub-id pub-id-type="pmcid">PMC10603121</pub-id></element-citation><mixed-citation id="mc-CR460" publication-type="journal">Xie, C., Yao, R. &amp; Xia, X. The advances of adjuvants in mRNA vaccines. <italic toggle="yes">NPJ Vaccines</italic><bold>8</bold>, 162 (2023).<pub-id pub-id-type="pmid">37884526</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41541-023-00760-5</pub-id><pub-id pub-id-type="pmcid">PMC10603121</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR461"><label>461.</label><citation-alternatives><element-citation id="ec-CR461" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Buschmann</surname><given-names>MD</given-names></name><etal/></person-group><article-title>Nanomaterial delivery systems for mRNA vaccines</article-title><source>Vaccines</source><year>2021</year><volume>9</volume><fpage>65</fpage><pub-id pub-id-type="doi">10.3390/vaccines9010065</pub-id><pub-id pub-id-type="pmid">33478109</pub-id><pub-id pub-id-type="pmcid">PMC7836001</pub-id></element-citation><mixed-citation id="mc-CR461" publication-type="journal">Buschmann, M. D. et al. Nanomaterial delivery systems for mRNA vaccines. <italic toggle="yes">Vaccines</italic><bold>9</bold>, 65 (2021).<pub-id pub-id-type="pmid">33478109</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/vaccines9010065</pub-id><pub-id pub-id-type="pmcid">PMC7836001</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR462"><label>462.</label><citation-alternatives><element-citation id="ec-CR462" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Melamed</surname><given-names>JR</given-names></name><etal/></person-group><article-title>Lipid nanoparticle chemistry determines how nucleoside base modifications alter mRNA delivery</article-title><source>J. Control Release</source><year>2022</year><volume>341</volume><fpage>206</fpage><lpage>214</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2021.11.022</pub-id><pub-id pub-id-type="pmid">34801660</pub-id><pub-id pub-id-type="pmcid">PMC8905090</pub-id></element-citation><mixed-citation id="mc-CR462" publication-type="journal">Melamed, J. R. et al. Lipid nanoparticle chemistry determines how nucleoside base modifications alter mRNA delivery. <italic toggle="yes">J. Control Release</italic><bold>341</bold>, 206&#8211;214 (2022).<pub-id pub-id-type="pmid">34801660</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jconrel.2021.11.022</pub-id><pub-id pub-id-type="pmcid">PMC8905090</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR463"><label>463.</label><citation-alternatives><element-citation id="ec-CR463" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Swetha</surname><given-names>K</given-names></name><etal/></person-group><article-title>Recent advances in the lipid nanoparticle-mediated delivery of mRNA vaccines</article-title><source>Vaccines</source><year>2023</year><volume>11</volume><fpage>658</fpage><pub-id pub-id-type="doi">10.3390/vaccines11030658</pub-id><pub-id pub-id-type="pmid">36992242</pub-id><pub-id pub-id-type="pmcid">PMC10059764</pub-id></element-citation><mixed-citation id="mc-CR463" publication-type="journal">Swetha, K. et al. Recent advances in the lipid nanoparticle-mediated delivery of mRNA vaccines. <italic toggle="yes">Vaccines</italic><bold>11</bold>, 658 (2023).<pub-id pub-id-type="pmid">36992242</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/vaccines11030658</pub-id><pub-id pub-id-type="pmcid">PMC10059764</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR464"><label>464.</label><citation-alternatives><element-citation id="ec-CR464" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhuang</surname><given-names>L</given-names></name><name name-style="western"><surname>Ye</surname><given-names>Z</given-names></name><name name-style="western"><surname>Li</surname><given-names>L</given-names></name><name name-style="western"><surname>Yang</surname><given-names>L</given-names></name><name name-style="western"><surname>Gong</surname><given-names>W</given-names></name></person-group><article-title>Next-generation TB vaccines: progress, challenges, and prospects</article-title><source>Vaccines</source><year>2023</year><volume>11</volume><fpage>1304</fpage><pub-id pub-id-type="doi">10.3390/vaccines11081304</pub-id><pub-id pub-id-type="pmid">37631874</pub-id><pub-id pub-id-type="pmcid">PMC10457792</pub-id></element-citation><mixed-citation id="mc-CR464" publication-type="journal">Zhuang, L., Ye, Z., Li, L., Yang, L. &amp; Gong, W. Next-generation TB vaccines: progress, challenges, and prospects. <italic toggle="yes">Vaccines</italic><bold>11</bold>, 1304 (2023).<pub-id pub-id-type="pmid">37631874</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/vaccines11081304</pub-id><pub-id pub-id-type="pmcid">PMC10457792</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR465"><label>465.</label><citation-alternatives><element-citation id="ec-CR465" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pulendran</surname><given-names>B</given-names></name><name name-style="western"><surname>Arunachalam</surname><given-names>PS</given-names></name><name name-style="western"><surname>O&#8217;Hagan</surname><given-names>DT</given-names></name></person-group><article-title>Emerging concepts in the science of vaccine adjuvants</article-title><source>Nat. Rev. Drug Discov.</source><year>2021</year><volume>20</volume><fpage>454</fpage><lpage>475</lpage><pub-id pub-id-type="doi">10.1038/s41573-021-00163-y</pub-id><pub-id pub-id-type="pmid">33824489</pub-id><pub-id pub-id-type="pmcid">PMC8023785</pub-id></element-citation><mixed-citation id="mc-CR465" publication-type="journal">Pulendran, B., Arunachalam, P. S. &amp; O&#8217;Hagan, D. T. Emerging concepts in the science of vaccine adjuvants. <italic toggle="yes">Nat. Rev. Drug Discov.</italic><bold>20</bold>, 454&#8211;475 (2021).<pub-id pub-id-type="pmid">33824489</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41573-021-00163-y</pub-id><pub-id pub-id-type="pmcid">PMC8023785</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR466"><label>466.</label><citation-alternatives><element-citation id="ec-CR466" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gu</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Incorporation of a Toll-like receptor 2/6 agonist potentiates mRNA vaccines against cancer and infectious diseases</article-title><source>Signal Transduct. Target. Ther.</source><year>2023</year><volume>8</volume><fpage>273</fpage><pub-id pub-id-type="doi">10.1038/s41392-023-01479-4</pub-id><pub-id pub-id-type="pmid">37455272</pub-id><pub-id pub-id-type="pmcid">PMC10350459</pub-id></element-citation><mixed-citation id="mc-CR466" publication-type="journal">Gu, Y. et al. Incorporation of a Toll-like receptor 2/6 agonist potentiates mRNA vaccines against cancer and infectious diseases. <italic toggle="yes">Signal Transduct. Target. Ther.</italic><bold>8</bold>, 273 (2023).<pub-id pub-id-type="pmid">37455272</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41392-023-01479-4</pub-id><pub-id pub-id-type="pmcid">PMC10350459</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR467"><label>467.</label><citation-alternatives><element-citation id="ec-CR467" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Coffman</surname><given-names>RL</given-names></name><name name-style="western"><surname>Sher</surname><given-names>A</given-names></name><name name-style="western"><surname>Seder</surname><given-names>RA</given-names></name></person-group><article-title>Vaccine adjuvants: putting innate immunity to work</article-title><source>Immunity</source><year>2010</year><volume>33</volume><fpage>492</fpage><lpage>503</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2010.10.002</pub-id><pub-id pub-id-type="pmid">21029960</pub-id><pub-id pub-id-type="pmcid">PMC3420356</pub-id></element-citation><mixed-citation id="mc-CR467" publication-type="journal">Coffman, R. L., Sher, A. &amp; Seder, R. A. Vaccine adjuvants: putting innate immunity to work. <italic toggle="yes">Immunity</italic><bold>33</bold>, 492&#8211;503 (2010).<pub-id pub-id-type="pmid">21029960</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.immuni.2010.10.002</pub-id><pub-id pub-id-type="pmcid">PMC3420356</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR468"><label>468.</label><citation-alternatives><element-citation id="ec-CR468" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>W</given-names></name><etal/></person-group><article-title>cGAMP-adjuvanted multivalent influenza mRNA vaccines induce broadly protective immunity through cutaneous vaccination in mice</article-title><source>Mol. Ther. Nucleic Acids</source><year>2022</year><volume>30</volume><fpage>421</fpage><lpage>437</lpage><pub-id pub-id-type="doi">10.1016/j.omtn.2022.10.024</pub-id><pub-id pub-id-type="pmid">36420215</pub-id><pub-id pub-id-type="pmcid">PMC9668623</pub-id></element-citation><mixed-citation id="mc-CR468" publication-type="journal">Zhu, W. et al. cGAMP-adjuvanted multivalent influenza mRNA vaccines induce broadly protective immunity through cutaneous vaccination in mice. <italic toggle="yes">Mol. Ther. Nucleic Acids</italic><bold>30</bold>, 421&#8211;437 (2022).<pub-id pub-id-type="pmid">36420215</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.omtn.2022.10.024</pub-id><pub-id pub-id-type="pmcid">PMC9668623</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR469"><label>469.</label><citation-alternatives><element-citation id="ec-CR469" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Du</surname><given-names>J</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X</given-names></name><name name-style="western"><surname>Ye</surname><given-names>Y</given-names></name><name name-style="western"><surname>Sun</surname><given-names>H</given-names></name></person-group><article-title>A comparative study on the mechanisms of innate immune responses in mice induced by Alum and <italic toggle="yes">Actinidia eriantha</italic> polysaccharide</article-title><source>Int. J. Biol. Macromol.</source><year>2020</year><volume>156</volume><fpage>1202</fpage><lpage>1216</lpage><pub-id pub-id-type="doi">10.1016/j.ijbiomac.2019.11.158</pub-id><pub-id pub-id-type="pmid">31758993</pub-id></element-citation><mixed-citation id="mc-CR469" publication-type="journal">Du, J., Chen, X., Ye, Y. &amp; Sun, H. A comparative study on the mechanisms of innate immune responses in mice induced by Alum and <italic toggle="yes">Actinidia eriantha</italic> polysaccharide. <italic toggle="yes">Int. J. Biol. Macromol.</italic><bold>156</bold>, 1202&#8211;1216 (2020).<pub-id pub-id-type="pmid">31758993</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijbiomac.2019.11.158</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR470"><label>470.</label><citation-alternatives><element-citation id="ec-CR470" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kimura</surname><given-names>S</given-names></name><name name-style="western"><surname>Harashima</surname><given-names>H</given-names></name></person-group><article-title>Nano&#8211;bio interactions: exploring the biological behavior and the fate of lipid-based gene delivery systems</article-title><source>BioDrugs</source><year>2024</year><volume>38</volume><fpage>259</fpage><lpage>273</lpage><pub-id pub-id-type="doi">10.1007/s40259-024-00647-4</pub-id><pub-id pub-id-type="pmid">38345754</pub-id></element-citation><mixed-citation id="mc-CR470" publication-type="journal">Kimura, S. &amp; Harashima, H. Nano&#8211;bio interactions: exploring the biological behavior and the fate of lipid-based gene delivery systems. <italic toggle="yes">BioDrugs</italic><bold>38</bold>, 259&#8211;273 (2024).<pub-id pub-id-type="pmid">38345754</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40259-024-00647-4</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR471"><label>471.</label><citation-alternatives><element-citation id="ec-CR471" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>H</given-names></name><etal/></person-group><article-title>Stimuli-responsive nanotechnology for RNA delivery</article-title><source>Adv. Sci.</source><year>2023</year><volume>10</volume><fpage>2303597</fpage><pub-id pub-id-type="doi">10.1002/advs.202303597</pub-id><pub-id pub-id-type="pmcid">PMC10754096</pub-id><pub-id pub-id-type="pmid">37915127</pub-id></element-citation><mixed-citation id="mc-CR471" publication-type="journal">Zhou, H. et al. Stimuli-responsive nanotechnology for RNA delivery. <italic toggle="yes">Adv. Sci.</italic><bold>10</bold>, 2303597 (2023).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/advs.202303597</pub-id><pub-id pub-id-type="pmcid">PMC10754096</pub-id><pub-id pub-id-type="pmid">37915127</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR472"><label>472.</label><citation-alternatives><element-citation id="ec-CR472" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sato</surname><given-names>Y</given-names></name><name name-style="western"><surname>Nakamura</surname><given-names>T</given-names></name><name name-style="western"><surname>Yamada</surname><given-names>Y</given-names></name><name name-style="western"><surname>Harashima</surname><given-names>H</given-names></name></person-group><article-title>The impact of, and expectations for, lipid nanoparticle technology: from cellular targeting to organelle targeting</article-title><source>J. Control Release</source><year>2024</year><volume>370</volume><fpage>516</fpage><lpage>527</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2024.05.006</pub-id><pub-id pub-id-type="pmid">38718875</pub-id></element-citation><mixed-citation id="mc-CR472" publication-type="journal">Sato, Y., Nakamura, T., Yamada, Y. &amp; Harashima, H. The impact of, and expectations for, lipid nanoparticle technology: from cellular targeting to organelle targeting. <italic toggle="yes">J. Control Release</italic><bold>370</bold>, 516&#8211;527 (2024).<pub-id pub-id-type="pmid">38718875</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jconrel.2024.05.006</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR473"><label>473.</label><citation-alternatives><element-citation id="ec-CR473" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khare</surname><given-names>P</given-names></name><name name-style="western"><surname>Edgecomb</surname><given-names>SX</given-names></name><name name-style="western"><surname>Hamadani</surname><given-names>CM</given-names></name><name name-style="western"><surname>Tanner</surname><given-names>EEL</given-names></name><name name-style="western"><surname>Manickam</surname><given-names>DS</given-names></name></person-group><article-title>Lipid nanoparticle-mediated drug delivery to the brain</article-title><source>Adv. Drug Deliv. Rev.</source><year>2023</year><volume>197</volume><fpage>114861</fpage><pub-id pub-id-type="doi">10.1016/j.addr.2023.114861</pub-id><pub-id pub-id-type="pmid">37150326</pub-id></element-citation><mixed-citation id="mc-CR473" publication-type="journal">Khare, P., Edgecomb, S. X., Hamadani, C. M., Tanner, E. E. L. &amp; Manickam, D. S. Lipid nanoparticle-mediated drug delivery to the brain. <italic toggle="yes">Adv. Drug Deliv. Rev.</italic><bold>197</bold>, 114861 (2023).<pub-id pub-id-type="pmid">37150326</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.addr.2023.114861</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR474"><label>474.</label><citation-alternatives><element-citation id="ec-CR474" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>J</given-names></name><etal/></person-group><article-title>Targeted and equally distributed delivery of mRNA to organs with pentaerythritol-based one-component ionizable amphiphilic Janus dendrimers</article-title><source>J. Am. Chem. Soc.</source><year>2023</year><volume>145</volume><fpage>18760</fpage><lpage>18766</lpage><pub-id pub-id-type="doi">10.1021/jacs.3c07337</pub-id><pub-id pub-id-type="pmid">37606244</pub-id></element-citation><mixed-citation id="mc-CR474" publication-type="journal">Lu, J. et al. Targeted and equally distributed delivery of mRNA to organs with pentaerythritol-based one-component ionizable amphiphilic Janus dendrimers. <italic toggle="yes">J. Am. Chem. Soc.</italic><bold>145</bold>, 18760&#8211;18766 (2023).<pub-id pub-id-type="pmid">37606244</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/jacs.3c07337</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR475"><label>475.</label><citation-alternatives><element-citation id="ec-CR475" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Design of PD-L1-targeted lipid nanoparticles to turn on PTEN for efficient cancer therapy</article-title><source>Adv. Sci.</source><year>2024</year><volume>11</volume><fpage>2309917</fpage><pub-id pub-id-type="doi">10.1002/advs.202309917</pub-id><pub-id pub-id-type="pmcid">PMC11165541</pub-id><pub-id pub-id-type="pmid">38520717</pub-id></element-citation><mixed-citation id="mc-CR475" publication-type="journal">Kim, Y. et al. Design of PD-L1-targeted lipid nanoparticles to turn on PTEN for efficient cancer therapy. <italic toggle="yes">Adv. Sci.</italic><bold>11</bold>, 2309917 (2024).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/advs.202309917</pub-id><pub-id pub-id-type="pmcid">PMC11165541</pub-id><pub-id pub-id-type="pmid">38520717</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR476"><label>476.</label><citation-alternatives><element-citation id="ec-CR476" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tang</surname><given-names>X</given-names></name><etal/></person-group><article-title>Simultaneous dendritic cells targeting and effective endosomal escape enhance sialic acid-modified mRNA vaccine efficacy and reduce side effects</article-title><source>J. Control Release</source><year>2023</year><volume>364</volume><fpage>529</fpage><lpage>545</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2023.11.008</pub-id><pub-id pub-id-type="pmid">37949317</pub-id></element-citation><mixed-citation id="mc-CR476" publication-type="journal">Tang, X. et al. Simultaneous dendritic cells targeting and effective endosomal escape enhance sialic acid-modified mRNA vaccine efficacy and reduce side effects. <italic toggle="yes">J. Control Release</italic><bold>364</bold>, 529&#8211;545 (2023).<pub-id pub-id-type="pmid">37949317</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jconrel.2023.11.008</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR477"><label>477.</label><citation-alternatives><element-citation id="ec-CR477" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>Y</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X</given-names></name><name name-style="western"><surname>Wang</surname><given-names>K</given-names></name><name name-style="western"><surname>Liang</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H</given-names></name></person-group><article-title>An overview of nanoparticle-based delivery platforms for mRNA vaccines for treating cancer</article-title><source>Vaccines</source><year>2024</year><volume>12</volume><fpage>727</fpage><pub-id pub-id-type="doi">10.3390/vaccines12070727</pub-id><pub-id pub-id-type="pmid">39066365</pub-id><pub-id pub-id-type="pmcid">PMC11281455</pub-id></element-citation><mixed-citation id="mc-CR477" publication-type="journal">Lin, Y., Chen, X., Wang, K., Liang, L. &amp; Zhang, H. An overview of nanoparticle-based delivery platforms for mRNA vaccines for treating cancer. <italic toggle="yes">Vaccines</italic><bold>12</bold>, 727 (2024).<pub-id pub-id-type="pmid">39066365</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/vaccines12070727</pub-id><pub-id pub-id-type="pmcid">PMC11281455</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR478"><label>478.</label><citation-alternatives><element-citation id="ec-CR478" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lorentzen</surname><given-names>CL</given-names></name><name name-style="western"><surname>Haanen</surname><given-names>JB</given-names></name><name name-style="western"><surname>Met</surname><given-names>&#214;</given-names></name><name name-style="western"><surname>Svane</surname><given-names>IM</given-names></name></person-group><article-title>Clinical advances and ongoing trials of mRNA vaccines for cancer treatment</article-title><source>Lancet Oncol.</source><year>2022</year><volume>23</volume><fpage>e450</fpage><lpage>e458</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(22)00372-2</pub-id><pub-id pub-id-type="pmid">36174631</pub-id><pub-id pub-id-type="pmcid">PMC9512276</pub-id></element-citation><mixed-citation id="mc-CR478" publication-type="journal">Lorentzen, C. L., Haanen, J. B., Met, &#214;. &amp; Svane, I. M. Clinical advances and ongoing trials of mRNA vaccines for cancer treatment. <italic toggle="yes">Lancet Oncol.</italic><bold>23</bold>, e450&#8211;e458 (2022).<pub-id pub-id-type="pmid">36174631</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1470-2045(22)00372-2</pub-id><pub-id pub-id-type="pmcid">PMC9512276</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR479"><label>479.</label><citation-alternatives><element-citation id="ec-CR479" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>GL</given-names></name><etal/></person-group><article-title>234. Safety and immunogenicity of mRNA-1345, an mRNA-based RSV vaccine in younger and older adult cohorts: results from a phase 1, randomized clinical trial</article-title><source>Open Forum Infect. Dis.</source><year>2022</year><volume>9</volume><fpage>ofac492.312</fpage><pub-id pub-id-type="doi">10.1093/ofid/ofac492.312</pub-id></element-citation><mixed-citation id="mc-CR479" publication-type="journal">Chen, G. L. et al. 234. Safety and immunogenicity of mRNA-1345, an mRNA-based RSV vaccine in younger and older adult cohorts: results from a phase 1, randomized clinical trial. <italic toggle="yes">Open Forum Infect. Dis.</italic><bold>9</bold>, ofac492.312 (2022).</mixed-citation></citation-alternatives></ref><ref id="CR480"><label>480.</label><citation-alternatives><element-citation id="ec-CR480" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bruch</surname><given-names>A</given-names></name><name name-style="western"><surname>Kelani</surname><given-names>AA</given-names></name><name name-style="western"><surname>Blango</surname><given-names>MG</given-names></name></person-group><article-title>RNA-based therapeutics to treat human fungal infections</article-title><source>Trends Microbiol</source><year>2022</year><volume>30</volume><fpage>411</fpage><lpage>420</lpage><pub-id pub-id-type="doi">10.1016/j.tim.2021.09.007</pub-id><pub-id pub-id-type="pmid">34635448</pub-id><pub-id pub-id-type="pmcid">PMC8498853</pub-id></element-citation><mixed-citation id="mc-CR480" publication-type="journal">Bruch, A., Kelani, A. A. &amp; Blango, M. G. RNA-based therapeutics to treat human fungal infections. <italic toggle="yes">Trends Microbiol</italic><bold>30</bold>, 411&#8211;420 (2022).<pub-id pub-id-type="pmid">34635448</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.tim.2021.09.007</pub-id><pub-id pub-id-type="pmcid">PMC8498853</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR481"><label>481.</label><citation-alternatives><element-citation id="ec-CR481" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khattak</surname><given-names>A</given-names></name><etal/></person-group><article-title>Distant metastasis-free survival results from the randomized, phase 2 mRNA-4157-P201/KEYNOTE-942 trial</article-title><source>J. Clin. Oncol.</source><year>2023</year><volume>41</volume><fpage>LBA9503</fpage><pub-id pub-id-type="doi">10.1200/JCO.2023.41.17_suppl.LBA9503</pub-id></element-citation><mixed-citation id="mc-CR481" publication-type="journal">Khattak, A. et al. Distant metastasis-free survival results from the randomized, phase 2 mRNA-4157-P201/KEYNOTE-942 trial. <italic toggle="yes">J. Clin. Oncol.</italic><bold>41</bold>, LBA9503 (2023).</mixed-citation></citation-alternatives></ref><ref id="CR482"><label>482.</label><citation-alternatives><element-citation id="ec-CR482" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>L</given-names></name><etal/></person-group><article-title>Lipid nanoparticle (LNP) delivery carrier-assisted targeted controlled release mRNA vaccines in tumor immunity</article-title><source>Vaccines</source><year>2024</year><volume>12</volume><fpage>186</fpage><pub-id pub-id-type="doi">10.3390/vaccines12020186</pub-id><pub-id pub-id-type="pmid">38400169</pub-id><pub-id pub-id-type="pmcid">PMC10891594</pub-id></element-citation><mixed-citation id="mc-CR482" publication-type="journal">Wu, L. et al. Lipid nanoparticle (LNP) delivery carrier-assisted targeted controlled release mRNA vaccines in tumor immunity. <italic toggle="yes">Vaccines</italic><bold>12</bold>, 186 (2024).<pub-id pub-id-type="pmid">38400169</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/vaccines12020186</pub-id><pub-id pub-id-type="pmcid">PMC10891594</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR483"><label>483.</label><citation-alternatives><element-citation id="ec-CR483" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kowalski</surname><given-names>PS</given-names></name><name name-style="western"><surname>Rudra</surname><given-names>A</given-names></name><name name-style="western"><surname>Miao</surname><given-names>L</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>DG</given-names></name></person-group><article-title>Delivering the messenger: advances in technologies for therapeutic mRNA delivery</article-title><source>Mol. Ther.</source><year>2019</year><volume>27</volume><fpage>710</fpage><lpage>728</lpage><pub-id pub-id-type="doi">10.1016/j.ymthe.2019.02.012</pub-id><pub-id pub-id-type="pmid">30846391</pub-id><pub-id pub-id-type="pmcid">PMC6453548</pub-id></element-citation><mixed-citation id="mc-CR483" publication-type="journal">Kowalski, P. S., Rudra, A., Miao, L. &amp; Anderson, D. G. Delivering the messenger: advances in technologies for therapeutic mRNA delivery. <italic toggle="yes">Mol. Ther.</italic><bold>27</bold>, 710&#8211;728 (2019).<pub-id pub-id-type="pmid">30846391</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ymthe.2019.02.012</pub-id><pub-id pub-id-type="pmcid">PMC6453548</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR484"><label>484.</label><citation-alternatives><element-citation id="ec-CR484" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dong</surname><given-names>Y</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>DG</given-names></name></person-group><article-title>Opportunities and challenges in mRNA therapeutics</article-title><source>Acc. Chem. Res.</source><year>2022</year><volume>55</volume><fpage>1</fpage><pub-id pub-id-type="doi">10.1021/acs.accounts.1c00739</pub-id><pub-id pub-id-type="pmid">34979806</pub-id></element-citation><mixed-citation id="mc-CR484" publication-type="journal">Dong, Y. &amp; Anderson, D. G. Opportunities and challenges in mRNA therapeutics. <italic toggle="yes">Acc. Chem. Res.</italic><bold>55</bold>, 1 (2022).<pub-id pub-id-type="pmid">34979806</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.accounts.1c00739</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR485"><label>485.</label><citation-alternatives><element-citation id="ec-CR485" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>C</given-names></name><etal/></person-group><article-title>mRNA-based cancer therapeutics</article-title><source>Nat. Rev. Cancer</source><year>2023</year><volume>23</volume><fpage>526</fpage><lpage>543</lpage><pub-id pub-id-type="doi">10.1038/s41568-023-00586-2</pub-id><pub-id pub-id-type="pmid">37311817</pub-id></element-citation><mixed-citation id="mc-CR485" publication-type="journal">Liu, C. et al. mRNA-based cancer therapeutics. <italic toggle="yes">Nat. Rev. Cancer</italic><bold>23</bold>, 526&#8211;543 (2023).<pub-id pub-id-type="pmid">37311817</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41568-023-00586-2</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR486"><label>486.</label><citation-alternatives><element-citation id="ec-CR486" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baden</surname><given-names>LR</given-names></name><etal/></person-group><article-title>Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine</article-title><source>New Engl. J. Med.</source><year>2021</year><volume>384</volume><fpage>403</fpage><lpage>416</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2035389</pub-id><pub-id pub-id-type="pmid">33378609</pub-id><pub-id pub-id-type="pmcid">PMC7787219</pub-id></element-citation><mixed-citation id="mc-CR486" publication-type="journal">Baden, L. R. et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. <italic toggle="yes">New Engl. J. Med.</italic><bold>384</bold>, 403&#8211;416 (2021).<pub-id pub-id-type="pmid">33378609</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2035389</pub-id><pub-id pub-id-type="pmcid">PMC7787219</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR487"><label>487.</label><citation-alternatives><element-citation id="ec-CR487" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thomas</surname><given-names>SJ</given-names></name><etal/></person-group><article-title>Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months</article-title><source>New Engl. J. Med.</source><year>2021</year><volume>385</volume><fpage>1761</fpage><lpage>1773</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2110345</pub-id><pub-id pub-id-type="pmid">34525277</pub-id><pub-id pub-id-type="pmcid">PMC8461570</pub-id></element-citation><mixed-citation id="mc-CR487" publication-type="journal">Thomas, S. J. et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months. <italic toggle="yes">New Engl. J. Med.</italic><bold>385</bold>, 1761&#8211;1773 (2021).<pub-id pub-id-type="pmid">34525277</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2110345</pub-id><pub-id pub-id-type="pmcid">PMC8461570</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR488"><label>488.</label><citation-alternatives><element-citation id="ec-CR488" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Soens</surname><given-names>M</given-names></name><etal/></person-group><article-title>1639. A review of clinical safety, reactogenicity, and immunogenicity of an mRNA-based seasonal influenza vaccine (mRNA-1010) in adults</article-title><source>Open Forum Infect. Dis.</source><year>2023</year><volume>10</volume><fpage>ofad500.1473</fpage><pub-id pub-id-type="doi">10.1093/ofid/ofad500.1473</pub-id></element-citation><mixed-citation id="mc-CR488" publication-type="journal">Soens, M. et al. 1639. A review of clinical safety, reactogenicity, and immunogenicity of an mRNA-based seasonal influenza vaccine (mRNA-1010) in adults. <italic toggle="yes">Open Forum Infect. Dis.</italic><bold>10</bold>, ofad500.1473 (2023).</mixed-citation></citation-alternatives></ref><ref id="CR489"><label>489.</label><citation-alternatives><element-citation id="ec-CR489" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Panther</surname><given-names>L</given-names></name><etal/></person-group><article-title>2892. Safety and immunogenicity of mRNA-1647, an mRNA-based cytomegalovirus vaccine in healthy adults: results of a phase 2, randomized, observer-blind, placebo-controlled, dose-finding trial</article-title><source>Open Forum Infect. Dis.</source><year>2023</year><volume>10</volume><fpage>ofad500.2475</fpage><pub-id pub-id-type="doi">10.1093/ofid/ofad500.2475</pub-id></element-citation><mixed-citation id="mc-CR489" publication-type="journal">Panther, L. et al. 2892. Safety and immunogenicity of mRNA-1647, an mRNA-based cytomegalovirus vaccine in healthy adults: results of a phase 2, randomized, observer-blind, placebo-controlled, dose-finding trial. <italic toggle="yes">Open Forum Infect. Dis.</italic><bold>10</bold>, ofad500.2475 (2023).</mixed-citation></citation-alternatives></ref><ref id="CR490"><label>490.</label><citation-alternatives><element-citation id="ec-CR490" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Essink</surname><given-names>B</given-names></name><etal/></person-group><article-title>The safety and immunogenicity of two Zika virus mRNA vaccine candidates in healthy flavivirus baseline seropositive and seronegative adults: the results of two randomised, placebo-controlled, dose-ranging, phase 1 clinical trials</article-title><source>Lancet Infect. Dis.</source><year>2023</year><volume>23</volume><fpage>621</fpage><lpage>633</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(22)00764-2</pub-id><pub-id pub-id-type="pmid">36682364</pub-id></element-citation><mixed-citation id="mc-CR490" publication-type="journal">Essink, B. et al. The safety and immunogenicity of two Zika virus mRNA vaccine candidates in healthy flavivirus baseline seropositive and seronegative adults: the results of two randomised, placebo-controlled, dose-ranging, phase 1 clinical trials. <italic toggle="yes">Lancet Infect. Dis.</italic><bold>23</bold>, 621&#8211;633 (2023).<pub-id pub-id-type="pmid">36682364</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1473-3099(22)00764-2</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR491"><label>491.</label><citation-alternatives><element-citation id="ec-CR491" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shaw</surname><given-names>CA</given-names></name><etal/></person-group><article-title>A phase 1, randomized, placebo-controlled, dose-ranging study to evaluate the safety and immunogenicity of an mRNA-based chikungunya virus vaccine in healthy adults</article-title><source>Vaccine</source><year>2023</year><volume>41</volume><fpage>3898</fpage><lpage>3906</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2023.04.064</pub-id><pub-id pub-id-type="pmid">37210308</pub-id></element-citation><mixed-citation id="mc-CR491" publication-type="journal">Shaw, C. A. et al. A phase 1, randomized, placebo-controlled, dose-ranging study to evaluate the safety and immunogenicity of an mRNA-based chikungunya virus vaccine in healthy adults. <italic toggle="yes">Vaccine</italic><bold>41</bold>, 3898&#8211;3906 (2023).<pub-id pub-id-type="pmid">37210308</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2023.04.064</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR492"><label>492.</label><citation-alternatives><element-citation id="ec-CR492" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Feldman</surname><given-names>RA</given-names></name><etal/></person-group><article-title>mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials</article-title><source>Vaccine</source><year>2019</year><volume>37</volume><fpage>3326</fpage><lpage>3334</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2019.04.074</pub-id><pub-id pub-id-type="pmid">31079849</pub-id></element-citation><mixed-citation id="mc-CR492" publication-type="journal">Feldman, R. A. et al. mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials. <italic toggle="yes">Vaccine</italic><bold>37</bold>, 3326&#8211;3334 (2019).<pub-id pub-id-type="pmid">31079849</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2019.04.074</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR493"><label>493.</label><citation-alternatives><element-citation id="ec-CR493" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aldrich</surname><given-names>C</given-names></name><etal/></person-group><article-title>Proof-of-concept of a low-dose unmodified mRNA-based rabies vaccine formulated with lipid nanoparticles in human volunteers: a phase 1 trial</article-title><source>Vaccine</source><year>2021</year><volume>39</volume><fpage>1310</fpage><lpage>1318</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2020.12.070</pub-id><pub-id pub-id-type="pmid">33487468</pub-id><pub-id pub-id-type="pmcid">PMC7825876</pub-id></element-citation><mixed-citation id="mc-CR493" publication-type="journal">Aldrich, C. et al. Proof-of-concept of a low-dose unmodified mRNA-based rabies vaccine formulated with lipid nanoparticles in human volunteers: a phase 1 trial. <italic toggle="yes">Vaccine</italic><bold>39</bold>, 1310&#8211;1318 (2021).<pub-id pub-id-type="pmid">33487468</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2020.12.070</pub-id><pub-id pub-id-type="pmcid">PMC7825876</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR494"><label>494.</label><citation-alternatives><element-citation id="ec-CR494" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Parhiz</surname><given-names>H</given-names></name><name name-style="western"><surname>Atochina-Vasserman</surname><given-names>EN</given-names></name><name name-style="western"><surname>Weissman</surname><given-names>D</given-names></name></person-group><article-title>mRNA-based therapeutics: looking beyond COVID-19 vaccines</article-title><source>Lancet</source><year>2024</year><volume>403</volume><fpage>1192</fpage><lpage>1204</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(23)02444-3</pub-id><pub-id pub-id-type="pmid">38461842</pub-id></element-citation><mixed-citation id="mc-CR494" publication-type="journal">Parhiz, H., Atochina-Vasserman, E. N. &amp; Weissman, D. mRNA-based therapeutics: looking beyond COVID-19 vaccines. <italic toggle="yes">Lancet</italic><bold>403</bold>, 1192&#8211;1204 (2024).<pub-id pub-id-type="pmid">38461842</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(23)02444-3</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR495"><label>495.</label><mixed-citation publication-type="other">International AIDS Vaccine Initiative. A phase 1, randomized, first-in-human, open-label study to evaluate the safety and immunogenicity of eOD-GT8 60mer mRNA Vaccine (mRNA-1644) and Core-g28v2 60mer mRNA vaccine (mRNA-1644v2-Core) in HIV-1 uninfected adults in good general health. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/study/NCT05001373">https://clinicaltrials.gov/study/NCT05001373</ext-link> (2024).</mixed-citation></ref><ref id="CR496"><label>496.</label><mixed-citation publication-type="other">Peng, X. A phase I study of mRNA vaccine for patients with EBV-positive advanced malignant tumors. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/study/NCT05714748">https://clinicaltrials.gov/study/NCT05714748</ext-link> (2023).</mixed-citation></ref><ref id="CR497"><label>497.</label><citation-alternatives><element-citation id="ec-CR497" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Klinghammer</surname><given-names>K</given-names></name><etal/></person-group><article-title>155P BNT113 + pembrolizumab as first-line treatment in patients with unresectable recurrent/metastatic HNSCC: preliminary safety data from AHEAD-MERIT</article-title><source>Immuno-Oncol. Technol.</source><year>2022</year><volume>16</volume><fpage>100267</fpage><pub-id pub-id-type="doi">10.1016/j.iotech.2022.100267</pub-id></element-citation><mixed-citation id="mc-CR497" publication-type="journal">Klinghammer, K. et al. 155P BNT113 + pembrolizumab as first-line treatment in patients with unresectable recurrent/metastatic HNSCC: preliminary safety data from AHEAD-MERIT. <italic toggle="yes">Immuno-Oncol. Technol.</italic><bold>16</bold>, 100267 (2022).</mixed-citation></citation-alternatives></ref><ref id="CR498"><label>498.</label><mixed-citation publication-type="other">Peng, X. A phase I study of mRNA vaccine for patients with HBV-positive advanced hepatocellular carcinoma. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/study/NCT05738447">https://clinicaltrials.gov/study/NCT05738447</ext-link> (2023).</mixed-citation></ref><ref id="CR499"><label>499.</label><citation-alternatives><element-citation id="ec-CR499" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Linch</surname><given-names>M</given-names></name><etal/></person-group><article-title>421 A first-in-human (FIH) phase I/IIa clinical trial assessing a ribonucleic acid lipoplex (RNA-LPX) encoding shared tumor antigens for immunotherapy of prostate cancer; preliminary analysis of PRO-MERIT</article-title><source>J. Immunother. Cancer</source><year>2021</year><volume>9</volume><fpage>A451</fpage></element-citation><mixed-citation id="mc-CR499" publication-type="journal">Linch, M. et al. 421 A first-in-human (FIH) phase I/IIa clinical trial assessing a ribonucleic acid lipoplex (RNA-LPX) encoding shared tumor antigens for immunotherapy of prostate cancer; preliminary analysis of PRO-MERIT. <italic toggle="yes">J. Immunother. Cancer</italic><bold>9</bold>, A451 (2021).</mixed-citation></citation-alternatives></ref><ref id="CR500"><label>500.</label><mixed-citation publication-type="other">BioNTech SE. LuCa-MERIT-1: first-in-human, open label, phase I dose confirmation trial evaluating the safety, tolerability and preliminary efficacy of BNT116 alone and in combinations in patients with advanced non-small cell lung cancer. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/study/NCT05142189">https://clinicaltrials.gov/study/NCT05142189</ext-link> (2024).</mixed-citation></ref><ref id="CR501"><label>501.</label><citation-alternatives><element-citation id="ec-CR501" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Killock</surname><given-names>D</given-names></name></person-group><article-title>Personalized neoantigen mRNA vaccine mitigates melanoma recurrence</article-title><source>Nat. Rev. Clin. Oncol.</source><year>2024</year><volume>21</volume><fpage>168</fpage><pub-id pub-id-type="doi">10.1038/s41571-024-00867-1</pub-id><pub-id pub-id-type="pmid">38302646</pub-id></element-citation><mixed-citation id="mc-CR501" publication-type="journal">Killock, D. Personalized neoantigen mRNA vaccine mitigates melanoma recurrence. <italic toggle="yes">Nat. Rev. Clin. Oncol.</italic><bold>21</bold>, 168 (2024).<pub-id pub-id-type="pmid">38302646</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41571-024-00867-1</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR502"><label>502.</label><citation-alternatives><element-citation id="ec-CR502" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rojas</surname><given-names>LA</given-names></name><etal/></person-group><article-title>Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer</article-title><source>Nature</source><year>2023</year><volume>618</volume><fpage>144</fpage><lpage>150</lpage><pub-id pub-id-type="doi">10.1038/s41586-023-06063-y</pub-id><pub-id pub-id-type="pmid">37165196</pub-id><pub-id pub-id-type="pmcid">PMC10171177</pub-id></element-citation><mixed-citation id="mc-CR502" publication-type="journal">Rojas, L. A. et al. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. <italic toggle="yes">Nature</italic><bold>618</bold>, 144&#8211;150 (2023).<pub-id pub-id-type="pmid">37165196</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-023-06063-y</pub-id><pub-id pub-id-type="pmcid">PMC10171177</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR503"><label>503.</label><mixed-citation publication-type="other">Shanghai Zhongshan Hospital. Clinical study of mRNA personalized tumor vaccine encoding neonatal antigen combined with Sintilimab injection liver cancer. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/study/NCT05761717">https://clinicaltrials.gov/study/NCT05761717</ext-link> (2023).</mixed-citation></ref><ref id="CR504"><label>504.</label><mixed-citation publication-type="other">Stemirna Therapeutics. Clinical trial on the safety and efficacy of neoantigen antigen mRNA tumor vaccine in the treatment of advanced esophageal cancer and non-small cell lung cancer. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/study/NCT03908671">https://clinicaltrials.gov/study/NCT03908671</ext-link> (2023).</mixed-citation></ref><ref id="CR505"><label>505.</label><citation-alternatives><element-citation id="ec-CR505" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Palmer</surname><given-names>CD</given-names></name><etal/></person-group><article-title>Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results</article-title><source>Nat. Med.</source><year>2022</year><volume>28</volume><fpage>1619</fpage><lpage>1629</lpage><pub-id pub-id-type="doi">10.1038/s41591-022-01937-6</pub-id><pub-id pub-id-type="pmid">35970920</pub-id></element-citation><mixed-citation id="mc-CR505" publication-type="journal">Palmer, C. D. et al. Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results. <italic toggle="yes">Nat. Med.</italic><bold>28</bold>, 1619&#8211;1629 (2022).<pub-id pub-id-type="pmid">35970920</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-022-01937-6</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR506"><label>506.</label><citation-alternatives><element-citation id="ec-CR506" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>August</surname><given-names>A</given-names></name><etal/></person-group><article-title>A phase 1 trial of lipid-encapsulated mRNA encoding a monoclonal antibody with neutralizing activity against Chikungunya virus</article-title><source>Nat. Med.</source><year>2021</year><volume>27</volume><fpage>2224</fpage><lpage>2233</lpage><pub-id pub-id-type="doi">10.1038/s41591-021-01573-6</pub-id><pub-id pub-id-type="pmid">34887572</pub-id><pub-id pub-id-type="pmcid">PMC8674127</pub-id></element-citation><mixed-citation id="mc-CR506" publication-type="journal">August, A. et al. A phase 1 trial of lipid-encapsulated mRNA encoding a monoclonal antibody with neutralizing activity against Chikungunya virus. <italic toggle="yes">Nat. Med.</italic><bold>27</bold>, 2224&#8211;2233 (2021).<pub-id pub-id-type="pmid">34887572</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-021-01573-6</pub-id><pub-id pub-id-type="pmcid">PMC8674127</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR507"><label>507.</label><citation-alternatives><element-citation id="ec-CR507" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Papadopoulos</surname><given-names>KP</given-names></name><etal/></person-group><article-title>A phase I/II dose escalation and expansion trial to evaluate safety and preliminary efficacy of BNT141 in patients with claudin-18.2-positive solid tumors</article-title><source>J. Clin. Oncol.</source><year>2023</year><volume>41</volume><fpage>TPS2670</fpage><pub-id pub-id-type="doi">10.1200/JCO.2023.41.16_suppl.TPS2670</pub-id></element-citation><mixed-citation id="mc-CR507" publication-type="journal">Papadopoulos, K. P. et al. A phase I/II dose escalation and expansion trial to evaluate safety and preliminary efficacy of BNT141 in patients with claudin-18.2-positive solid tumors. <italic toggle="yes">J. Clin. Oncol.</italic><bold>41</bold>, TPS2670 (2023).</mixed-citation></citation-alternatives></ref><ref id="CR508"><label>508.</label><citation-alternatives><element-citation id="ec-CR508" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yap</surname><given-names>TA</given-names></name><etal/></person-group><article-title>A phase I/II dose escalation trial with expansion cohorts to evaluate safety and preliminary efficacy of BNT142 in patients with prospectively confirmed claudin 6-positive solid tumors</article-title><source>J. Clin. Oncol.</source><year>2023</year><volume>41</volume><fpage>TPS2669</fpage><pub-id pub-id-type="doi">10.1200/JCO.2023.41.16_suppl.TPS2669</pub-id></element-citation><mixed-citation id="mc-CR508" publication-type="journal">Yap, T. A. et al. A phase I/II dose escalation trial with expansion cohorts to evaluate safety and preliminary efficacy of BNT142 in patients with prospectively confirmed claudin 6-positive solid tumors. <italic toggle="yes">J. Clin. Oncol.</italic><bold>41</bold>, TPS2669 (2023).</mixed-citation></citation-alternatives></ref><ref id="CR509"><label>509.</label><citation-alternatives><element-citation id="ec-CR509" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Patel</surname><given-names>MR</given-names></name><etal/></person-group><article-title>A phase I study of mRNA-2752, a lipid nanoparticle encapsulating mRNAs encoding human OX40L, IL-23, and IL-36&#947;, for intratumoral (iTu) injection alone and in combination with durvalumab</article-title><source>J. Clin. Oncol.</source><year>2020</year><volume>38</volume><fpage>3092</fpage><pub-id pub-id-type="doi">10.1200/JCO.2020.38.15_suppl.3092</pub-id></element-citation><mixed-citation id="mc-CR509" publication-type="journal">Patel, M. R. et al. A phase I study of mRNA-2752, a lipid nanoparticle encapsulating mRNAs encoding human OX40L, IL-23, and IL-36&#947;, for intratumoral (iTu) injection alone and in combination with durvalumab. <italic toggle="yes">J. Clin. Oncol.</italic><bold>38</bold>, 3092 (2020).</mixed-citation></citation-alternatives></ref><ref id="CR510"><label>510.</label><citation-alternatives><element-citation id="ec-CR510" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Berraondo</surname><given-names>P</given-names></name><name name-style="western"><surname>Gomis</surname><given-names>G</given-names></name><name name-style="western"><surname>Melero</surname><given-names>I</given-names></name></person-group><article-title>The liver as a cytokine factory working on mRNA blueprints for cancer immunotherapy</article-title><source>Cancer Cell</source><year>2024</year><volume>42</volume><fpage>502</fpage><lpage>504</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2024.02.015</pub-id><pub-id pub-id-type="pmid">38490214</pub-id></element-citation><mixed-citation id="mc-CR510" publication-type="journal">Berraondo, P., Gomis, G. &amp; Melero, I. The liver as a cytokine factory working on mRNA blueprints for cancer immunotherapy. <italic toggle="yes">Cancer Cell</italic><bold>42</bold>, 502&#8211;504 (2024).<pub-id pub-id-type="pmid">38490214</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ccell.2024.02.015</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR511"><label>511.</label><mixed-citation publication-type="other">ModernaTX, Inc. A Phase 1, Dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of mRNA-6231, encoding for a human serum albumin&#8211; interleukin-2 mutein fusion protein (HSA-IL2m), in healthy adults. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/study/NCT04916431">https://clinicaltrials.gov/study/NCT04916431</ext-link> (2022).</mixed-citation></ref><ref id="CR512"><label>512.</label><mixed-citation publication-type="other">Universitair Ziekenhuis Brussel. A phase i study on the safety and immune-modulatory effect of intratumoral (i.t.) administration of mRNA (messenger RNA) encoding dendritic cell activating proteins in patients with early, resectable breast cancer. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/study/NCT03788083">https://clinicaltrials.gov/study/NCT03788083</ext-link> (2022).</mixed-citation></ref><ref id="CR513"><label>513.</label><citation-alternatives><element-citation id="ec-CR513" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>W</given-names></name><etal/></person-group><article-title>273 phase I study of LioCyx-M, autologous hepatitis B virus (HBV)-specific T cell receptor (TCR) T-cells, in recurrent HBV-related hepatocellular carcinoma (HCC) post-liver transplantation</article-title><source>J. Immunother. Cancer</source><year>2020</year><volume>8</volume><fpage>A167</fpage></element-citation><mixed-citation id="mc-CR513" publication-type="journal">Chen, W. et al. 273 phase I study of LioCyx-M, autologous hepatitis B virus (HBV)-specific T cell receptor (TCR) T-cells, in recurrent HBV-related hepatocellular carcinoma (HCC) post-liver transplantation. <italic toggle="yes">J. Immunother. Cancer</italic><bold>8</bold>, A167 (2020).</mixed-citation></citation-alternatives></ref><ref id="CR514"><label>514.</label><mixed-citation publication-type="other">Argos Therapeutics. A phase II study testing the activity and safety of AGS-004 as an immunotherapeutic in successfully ART-treated subjects infected with HIV-1 in combination with ART followed by ART interruption. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/study/NCT00672191">https://clinicaltrials.gov/study/NCT00672191</ext-link> (2013).</mixed-citation></ref><ref id="CR515"><label>515.</label><citation-alternatives><element-citation id="ec-CR515" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Van Acker</surname><given-names>HH</given-names></name><etal/></person-group><article-title>Dendritic cell-based immunotherapy of acute myeloid leukemia</article-title><source>J. Clin. Med.</source><year>2019</year><volume>8</volume><fpage>579</fpage><pub-id pub-id-type="doi">10.3390/jcm8050579</pub-id><pub-id pub-id-type="pmid">31035598</pub-id><pub-id pub-id-type="pmcid">PMC6572115</pub-id></element-citation><mixed-citation id="mc-CR515" publication-type="journal">Van Acker, H. H. et al. Dendritic cell-based immunotherapy of acute myeloid leukemia. <italic toggle="yes">J. Clin. Med.</italic><bold>8</bold>, 579 (2019).<pub-id pub-id-type="pmid">31035598</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/jcm8050579</pub-id><pub-id pub-id-type="pmcid">PMC6572115</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR516"><label>516.</label><mixed-citation publication-type="other">Svane, I. M. Evaluation of dendritic cells transfected with Survivin, hTERT and p53 mRNA as a treatment for patients with metastatic breast cancer or malignant melanoma. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/study/NCT00978913">https://clinicaltrials.gov/study/NCT00978913</ext-link> (2015).</mixed-citation></ref><ref id="CR517"><label>517.</label><citation-alternatives><element-citation id="ec-CR517" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sampson</surname><given-names>JH</given-names></name><etal/></person-group><article-title>Reproducibility of outcomes in sequential trials using CMV-targeted dendritic cell vaccination for glioblastoma</article-title><source>J. Clin. Oncol.</source><year>2022</year><volume>40</volume><fpage>2005</fpage><pub-id pub-id-type="doi">10.1200/JCO.2022.40.16_suppl.2005</pub-id></element-citation><mixed-citation id="mc-CR517" publication-type="journal">Sampson, J. H. et al. Reproducibility of outcomes in sequential trials using CMV-targeted dendritic cell vaccination for glioblastoma. <italic toggle="yes">J. Clin. Oncol.</italic><bold>40</bold>, 2005 (2022).</mixed-citation></citation-alternatives></ref><ref id="CR518"><label>518.</label><citation-alternatives><element-citation id="ec-CR518" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lockard</surname><given-names>RE</given-names></name><name name-style="western"><surname>Lingrel</surname><given-names>JB</given-names></name></person-group><article-title>The synthesis of mouse hemoglobin chains in a rabbit reticulocyte cell-free system programmed with mouse reticulocyte 9S RNA</article-title><source>Biochem. Biophys. Res. Commun.</source><year>1969</year><volume>37</volume><fpage>204</fpage><lpage>212</lpage><pub-id pub-id-type="doi">10.1016/0006-291X(69)90720-7</pub-id><pub-id pub-id-type="pmid">5823930</pub-id></element-citation><mixed-citation id="mc-CR518" publication-type="journal">Lockard, R. E. &amp; Lingrel, J. B. The synthesis of mouse hemoglobin chains in a rabbit reticulocyte cell-free system programmed with mouse reticulocyte 9S RNA. <italic toggle="yes">Biochem. Biophys. Res. Commun.</italic><bold>37</bold>, 204&#8211;212 (1969).<pub-id pub-id-type="pmid">5823930</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0006-291x(69)90720-7</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR519"><label>519.</label><citation-alternatives><element-citation id="ec-CR519" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Muthukrishnan</surname><given-names>S</given-names></name><name name-style="western"><surname>Both</surname><given-names>GW</given-names></name><name name-style="western"><surname>Furuichi</surname><given-names>Y</given-names></name><name name-style="western"><surname>Shatkin</surname><given-names>AJ</given-names></name></person-group><article-title>5&#8242;-Terminal 7-methylguanosine in eukaryotic mRNA is required for translation</article-title><source>Nature</source><year>1975</year><volume>255</volume><fpage>33</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1038/255033a0</pub-id><pub-id pub-id-type="pmid">165427</pub-id></element-citation><mixed-citation id="mc-CR519" publication-type="journal">Muthukrishnan, S., Both, G. W., Furuichi, Y. &amp; Shatkin, A. J. 5&#8242;-Terminal 7-methylguanosine in eukaryotic mRNA is required for translation. <italic toggle="yes">Nature</italic><bold>255</bold>, 33&#8211;37 (1975).<pub-id pub-id-type="pmid">165427</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/255033a0</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR520"><label>520.</label><citation-alternatives><element-citation id="ec-CR520" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Steinle</surname><given-names>H</given-names></name><etal/></person-group><article-title>Delivery of synthetic mRNAs for tissue regeneration</article-title><source>Adv. Drug Deliv. Rev.</source><year>2021</year><volume>179</volume><fpage>114007</fpage><pub-id pub-id-type="doi">10.1016/j.addr.2021.114007</pub-id><pub-id pub-id-type="pmid">34710530</pub-id></element-citation><mixed-citation id="mc-CR520" publication-type="journal">Steinle, H. et al. Delivery of synthetic mRNAs for tissue regeneration. <italic toggle="yes">Adv. Drug Deliv. Rev.</italic><bold>179</bold>, 114007 (2021).<pub-id pub-id-type="pmid">34710530</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.addr.2021.114007</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR521"><label>521.</label><citation-alternatives><element-citation id="ec-CR521" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sahin</surname><given-names>U</given-names></name><etal/></person-group><article-title>Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer</article-title><source>Nature</source><year>2017</year><volume>547</volume><fpage>222</fpage><lpage>226</lpage><pub-id pub-id-type="doi">10.1038/nature23003</pub-id><pub-id pub-id-type="pmid">28678784</pub-id></element-citation><mixed-citation id="mc-CR521" publication-type="journal">Sahin, U. et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. <italic toggle="yes">Nature</italic><bold>547</bold>, 222&#8211;226 (2017).<pub-id pub-id-type="pmid">28678784</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature23003</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR522"><label>522.</label><mixed-citation publication-type="other">BioNTech RNA Pharmaceuticals GmbH. First-in-human study evaluating the safety, tolerability and immunogenicity of i.n. administration of a personalized vaccination with IVAC MUTANOME vaccine w/o initial treatment with RBL001/RBL002 vaccine in patients with advanced melanoma. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/study/NCT02035956">https://clinicaltrials.gov/study/NCT02035956</ext-link> (2020).</mixed-citation></ref><ref id="CR523"><label>523.</label><citation-alternatives><element-citation id="ec-CR523" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>N</given-names></name><etal/></person-group><article-title>Modified VEGF-A mRNA induces sustained multifaceted microvascular response and accelerates diabetic wound healing</article-title><source>Sci. Rep.</source><year>2018</year><volume>8</volume><fpage>17509</fpage><pub-id pub-id-type="doi">10.1038/s41598-018-35570-6</pub-id><pub-id pub-id-type="pmid">30504800</pub-id><pub-id pub-id-type="pmcid">PMC6269526</pub-id></element-citation><mixed-citation id="mc-CR523" publication-type="journal">Sun, N. et al. Modified VEGF-A mRNA induces sustained multifaceted microvascular response and accelerates diabetic wound healing. <italic toggle="yes">Sci. Rep.</italic><bold>8</bold>, 17509 (2018).<pub-id pub-id-type="pmid">30504800</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-018-35570-6</pub-id><pub-id pub-id-type="pmcid">PMC6269526</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR524"><label>524.</label><citation-alternatives><element-citation id="ec-CR524" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Deng</surname><given-names>Z</given-names></name><name name-style="western"><surname>Tian</surname><given-names>Y</given-names></name><name name-style="western"><surname>Song</surname><given-names>J</given-names></name><name name-style="western"><surname>An</surname><given-names>G</given-names></name><name name-style="western"><surname>Yang</surname><given-names>P</given-names></name></person-group><article-title>mRNA vaccines: the dawn of a new era of cancer immunotherapy</article-title><source>Front. Immunol.</source><year>2022</year><volume>13</volume><fpage>887125</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2022.887125</pub-id><pub-id pub-id-type="pmid">35720301</pub-id><pub-id pub-id-type="pmcid">PMC9201022</pub-id></element-citation><mixed-citation id="mc-CR524" publication-type="journal">Deng, Z., Tian, Y., Song, J., An, G. &amp; Yang, P. mRNA vaccines: the dawn of a new era of cancer immunotherapy. <italic toggle="yes">Front. Immunol.</italic><bold>13</bold>, 887125 (2022).<pub-id pub-id-type="pmid">35720301</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2022.887125</pub-id><pub-id pub-id-type="pmcid">PMC9201022</pub-id></mixed-citation></citation-alternatives></ref></ref-list></back></article></pmc-articleset>